

12° CONGRESSO NAZIONALE

**ICAR**

**Italian Conference on  
AIDS and Antiviral Research**

*Reach out  
for including all*

 12-16  
ottobre 2020  
**DIGITAL EDITION**

*Presidenza del Congresso*  
Massimo Clementi, Milano  
Sandro Mattioli, Bologna  
Cristina Mussini, Modena  
Guido Silvestri, Atlanta  
Marcello Tavio, Ancona

## SCIENTIFIC PROGRAMME



Promosso da



e da

**INMI**, Istituto Nazionale per le Malattie Infettive

**ISS**, Istituto Superiore di Sanità

**AMCLI**, Associazione Microbiologi Clinici Italiani

**SIICA**, Società Italiana di Immunologia, Immunologia Clinica e Allergologia

**SIMaST**, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili

**SITA**, Società Italiana per la Terapia Antinfettiva

**SIV-ISV**, Società Italiana di Virologia - Italian Society for Virology

**ANLAIDS**, Associazione Nazionale per la lotta all'AIDS

**ARCIGAY**, Associazione LGBT Italiana

**ASA Onlus**, Associazione Solidarietà AIDS Onlus

**EpaC Onlus**, Associazione EpaC Onlus

**LILA**, Lega Italiana per la lotta contro l'AIDS

**MARIO MIELI**, Circolo di Cultura Omosessuale

**NADIR**, Associazione Nadir Onlus

**NPS Italia Onlus**, Network Persone Sieropositive

**PLUS**, Rete persone LGBT+ sieropositive Aps

Con il Patrocinio di





12° CONGRESSO NAZIONALE  
**Italian Conference on AIDS and Antiviral Research**  
12-16 ottobre 2020 **DIGITAL EDITION**

Reach out  
for including all

## Endorsements

Con il Patrocinio di

### INSTITUTIONS



### INSTITUTES



**UNIMORE**  
UNIVERSITÀ DEGLI STUDI DI  
MODENA E REGGIO EMILIA



**UniSR**  
UNIVERSITÀ  
VITA-SALUTE  
SAN RAFFAELE

### FOUNDATIONS

**Aviralia**, Fondazione Aviralia Onlus

**Icona**, Fondazione Icona

**Villa Maraini**, Fondazione Villa Maraini

### SCIENTIFIC SOCIETIES

**AISF**, Associazione Italiana per lo Studio del Fegato

**PTS**, Patto Trasversale per la Scienza

**SIM**, Società Italiana di Microbiologia

**SIMET**, Società Italiana di Medicina Tropicale

### ASSOCIATIONS

**Arcobaleno AIDS**

**Bergamo Fast-Track City**

**C.I.C.A.** Coordinamento Italiano delle Case Alloggio per persone con HIV/AIDS

**Esedomani Terni**

**Gay Center**

**Milano Check Point**

**MIT**, Movimento Identità Transessuale

**Omphalos**



SCIENTIFIC  
PROGRAMME



12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research  
12-16 ottobre 2020 **DIGITAL EDITION**

Reach out  
for including all

## Scientific Committee

### Chairs



**Massimo Clementi**, Milano



**Sandro Mattioli**, Bologna



**Cristina Mussini**, Modena



**Guido Silvestri**, Atlanta



**Marcello Tavio**, Ancona

### Abstract Coordinator

**Franco Maggiolo**, Bergamo

### Scientific Secretariat

**Chiara Agrati**, Roma  
**Guido Antonelli**, Roma  
**Patrizia Bagnarelli**, Ancona  
**Alessandra Bandera**, Milano  
**Mara Biasin**, Milano  
**Marco Borderi**, Bologna  
**Vanni Borghi**, Modena  
**Luca Butini**, Ancona  
**Andrea Calcagno**, Torino  
**Leonardo Calza**, Bologna  
**Arnaldo Caruso**, Brescia  
**Dario Cattaneo**, Milano  
**Rossana Cavallo**, Torino  
**Francesca Ceccherini-Silberstein**, Roma  
**Stefania Cicalini**, Roma  
**Antonella Cingolani**, Roma  
**Paola Cinque**, Milano  
**Nicola Coppola**, Napoli  
**Giulio Maria Corbelli**, Bologna  
**Andrea Cossarizza**, Modena

**Gabriella d'Ettorre**, Roma  
**Andrea De Maria**, Genova  
**Antonio Di Biagio**, Genova  
**Simona Di Giambenedetto**, Roma  
**Cristina Gervasoni**, Milano  
**Enrico Girardi**, Roma  
**Giovanni Guaraldi**, Modena  
**Giuseppe Lapadula**, Monza  
**Sergio Lo Caputo**, Foggia  
**Lucia Lopalco**, Milano  
**Giordano Madeddu**, Sassari  
**Paolo Maggi**, Napoli  
**Giulia Marchetti**, Milano  
**Alberto Matteelli**, Brescia  
**Stefano Menzo**, Ancona  
**Ada Moznich**, Pordenone  
**Silvia Nozza**, Milano  
**Giuseppe Nunnari**, Messina  
**Mauro Pistello**, Pisa  
**Tullio Prestileo**, Palermo  
**Diego Ripamonti**, Bergamo  
**Stefano Rusconi**, Milano  
**Annalisa Saracino**, Bari  
**Laura Sighinolfi**, Ferrara  
**Elisa Vicenzi**, Milano

### Pre-Conference Courses Secretariat

**Lorenzo Badia**, Bologna  
**Isabella Bon**, Bologna  
**Erika Bruni**, Ferrara  
**Gianluca Cuomo**, Modena  
**Manuela Gatti**, Lecco  
**Annalisa Mondì**, Roma  
**Barbara Rossetti**, Siena  
**Roberto Rossotti**, Milano  
**Camilla Tincati**, Milano

### Annual Programme Committee

**Andrea Antinori**, Roma  
**Valeria Calvino**, Roma  
**Antonella Castagna**, Milano  
**Massimo Clementi**, Milano  
**Maria Luisa Cosmaro**, Milano  
**Antonella d'Arminio Monforte**, Milano  
**Sandro Mattioli**, Bologna  
**Cristina Mussini**, Modena  
**Guido Silvestri**, Atlanta USA  
**Marcello Tavio**, Ancona





12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research  
12-16 ottobre 2020 **DIGITAL EDITION**

Reach out  
for including all

## Government Bodies

### ICAR Government

**Massimo Andreoni**, Roma  
**Andrea Antinori**, Roma  
**Massimo Clementi**, Milano  
**Antonella d'Arminio Monforte**, Milano  
(Coordinator)  
**Massimo Farinella**, Roma  
**Enrico Girardi**, Roma  
**Franco Maggiolo**, Bergamo  
**Michele Manfredini**, Milano  
**Cristina Mussini**, Modena  
**Massimo Puoti**, Milano  
**Maria Carla Re**, Bologna  
**Marcello Tavio**, Ancona

### SPC

(Scientific Programme Committee)

**Massimo Andreoni**, Roma  
**Andrea Antinori**, Roma  
**Guido Antonelli**, Roma  
**Matteo Bassetti**, Udine  
**Alberto Bignardi**, Bologna  
**Paolo Bonfanti**, Monza  
**Stefano Bonora**, Torino  
**Maria Rosaria Capobianchi**, Roma  
**Antonella Castagna**, Milano  
**Francesco Castelli**, Brescia  
**Anna Maria Cattelan**, Padova  
**Benedetto Maurizio Celesia**, Catania  
**Antonella Cingolani**, Roma  
**Massimo Clementi**, Milano  
**Giulio Maria Corbelli**, Bologna

**Andrea Cossarizza**, Modena  
**Antonella d'Arminio Monforte**, Milano  
**Maria Grazia Di Benedetto**, Catania  
**Antonio Di Biagio**, Genova  
**Giovanni Di Perri**, Torino  
**Massimo Di Pietro**, Pistoia  
**Margherita Errico**, Milano  
**Vincenzo Esposito**, Napoli  
**Massimo Farinella**, Roma  
**Massimo Galli**, Milano  
**Ivan Gardini**, Vercate MB  
**Enrico Girardi**, Roma  
**Andrea Gori**, Milano  
**Giuseppe Ippolito**, Roma  
**Sergio Lo Caputo**, Foggia  
**Paolo Maggi**, Napoli  
**Franco Maggiolo**, Bergamo  
**Michele Manfredini**, Milano  
**Bruno Marchini**, Roma  
**Claudio Maria Mastroianni**, Roma  
**Giovanni Mazzola**, Palermo  
**Cristina Mussini**, Modena  
**Silvia Nozza**, Milano  
**Giuseppe Nunnari**, Messina  
**Giustino Parruti**, Pescara  
**Carlo Federico Perno**, Roma  
**Massimo Puoti**, Milano  
**Maria Carla Re**, Bologna  
**Giovanni Rezza**, Roma  
**Giuliano Rizzardini**, Milano  
**Stefano Rusconi**, Milano  
**Filippo von Schloesser**, Roma  
**Laura Sighinolfi**, Ferrara  
**Guido Silvestri**, Atlanta USA

**Barbara Suligoj**, Roma  
**Gloria Taliani**, Roma  
**Marcello Tavio**, Ancona  
**Carlo Torti**, Catanzaro  
**Stefano Vella**, Roma  
**Maurizio Zazzi**, Siena

### CsC

(Community sub-Committee)

**Alberto Bignardi**, Bologna  
(ARCIGAY)  
**Giulio Maria Corbelli**, Bologna  
(PLUS)  
**Maria Grazia Di Benedetto**, Catania  
(LILA)  
**Margherita Errico**, Milano  
(NPS Italia Onlus)  
**Massimo Farinella**, Roma  
(Circolo Mario Mieli)  
**Ivan Gardini**, Vercate MB  
(EpaC onlus)  
**Michele Manfredini**, Milano  
(ASA onlus)  
**Bruno Marchini**, Roma  
(ANLAIDS)  
**Filippo von Schloesser**, Roma  
(NADIR onlus)



12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research  
12-16 ottobre 2020 **DIGITAL EDITION**

*Reach out  
for including all*

## Faculty

**Roberto Accolla**, Varese  
**Chiara Agrati**, Roma  
**Massimo Andreoni**, Roma  
**Gioacchino Angarano**, Bari  
**Andrea Antinori**, Roma  
**Guido Antonelli**, Roma  
**Orlando Armignacco**, Roma  
**Bertrand Audoin**, Paris F  
**Sergio Babudieri**, Sassari  
**Lorenzo Badia**, Bologna  
**Patrizia Bagnarelli**, Ancona  
**Alessandra Bandera**, Milano  
**Ramona Bella**, Brussels BE  
**Rita Bellagamba**, Roma  
**Michela Belli**, Modena  
**Mara Biasin**, Milano  
**Alberto Bignardi**, Modena  
**Teresa Bini**, Milano  
**Isabella Bon**, Bologna  
**Paolo Bonfanti**, Monza  
**Stefano Bonora**, Torino  
**Marco Borderi**, Bologna  
**Paolo Boscolo Rizzo**, Padova  
**Michele Breveglieri**, Bologna  
**Erika Bruni**, Ferrara  
**Raffaele Bruno**, Pavia  
**Luca Butini**, Ancona  
**Francesca Caccuri**, Brescia  
**Andrea Calcagno**, Torino  
**Valeria Calvino**, Roma  
**Leonardo Calza**, Bologna  
**Daniele Calzavara**, Milano  
**Maria Rosaria Capobianchi**, Roma  
**Anna Caraglia**, Roma  
**Federica Carli**, Modena  
**Arnaldo Caruso**, Brescia  
**Antonio Cascio**, Palermo  
**Mario Cascio**, Palermo  
**Antonella Castagna**, Milano  
**Francesco Castelli**, Brescia  
**Dario Cattaneo**, Milano  
**Anna Maria Cattelan**, Padova  
**Roberto Cauda**, Roma  
**Rossana Cavallo**, Torino  
**Francesca Ceccherini – Silberstein**, Roma  
**Benedetto Maurizio Celesia**, Catania  
**Giovanni Cenderello**, Sanremo IM  
**Massimo Cernuschi**, Milano

**Stefania Cicalini**, Roma  
**Arturo Ciccullo**, Roma  
**Antonella Cingolani**, Roma  
**Paola Cinque**, Milano  
**Massimo Clementi**, Milano  
**Nicola Clementi**, Milano  
**Mario Clerici**, Milano  
**Nicola Coppola**, Napoli  
**Giulio Maria Corbelli**, Bologna  
**Maddalena Cordioli**, Verona  
**Maria Luisa Cosmaro**, Milano  
**Andrea Cossarizza**, Modena  
**Alessandro Cozzi-Lepri**, London UK  
**Gianluca Cuomo**, Modena  
**Antonella d'Arminio Monforte**, Milano  
**Gabriella d'Etto**, Roma  
**Andrea De Maria**, Genova  
**Anita De Rossi**, Padova  
**Maria Grazia Di Benedetto**, Catania  
**Antonio Di Biagio**, Genova  
**Cesare Di Feliciano**, Manchester UK  
**Simona Di Giambenedetto**, Roma  
**Giovanni Di Perri**, Torino  
**Massimo Di Pietro**, Pistoia  
**Margherita Digaetano**, Modena  
**Brinda Emu**, New Haven USA  
**Margherita Errico**, Milano  
**Massimo Farinella**, Roma  
**Daniela Francisci**, Perugia  
**Antonina Franco**, Siracusa  
**Massimo Galli**, Milano  
**José M. Gatell**, Barcelona E  
**Manuela Gatti**, Lecco  
**Cristina Gervasoni**, Milano  
**Vania Giacomet**, Milano  
**Nicola Gianotti**, Milano  
**Enrico Girardi**, Roma  
**Massimo Giuliani**, Roma  
**Delia Goletti**, Roma  
**Andrea Gori**, Milano  
**Costantino Grana**, Modena  
**Giovanni Guaraldi**, Modena  
**Maria Rosaria Iardino**, Milano  
**Angela Infante**, Roma  
**Giuseppe Ippolito**, Roma  
**Giuseppe Lapadula**, Monza  
**Adriano Lazzarin**, Milano  
**Ricardo Baptista Leite**, Lisbon PT  
**Mathias Lichterfeld**, Boston USA  
**Miriam Lichtner**, Latina

**Giuseppina Liuzzi**, Roma  
**Sergio Lo Caputo**, Foggia  
**Lucia Lopalco**, Milano  
**Giordano Madeddu**, Sassari  
**Paolo Maggi**, Napoli  
**Franco Maggiolo**, Bergamo  
**Ivana Maida**, Sassari  
**Donatella Mainieri**, Milano  
**Marina Malena**, Verona  
**Michele Manfredini**, Milano  
**Giulia Marchetti**, Milano  
**Renato Maserati**, Pavia  
**Marco Massari**, Reggio Emilia  
**Claudio Maria Mastroianni**, Roma  
**Alberto Matteelli**, Brescia  
**Sandro Mattioli**, Bologna  
**Salvatore Maugeri**, Bologna  
**Giovanni Mazzola**, Palermo  
**Adriana Meda**, Monza  
**Stefano Menzo**, Ancona  
**Maria Cristina Moiola**, Milano  
**José Moltò**, Badalona E  
**Ada Moznich**, Pordenone  
**Cristina Mussini**, Modena  
**Milena Nasi**, Modena  
**Paola Nasta**, Brescia  
**Silvia Negri**, Milano  
**Silvia Nozza**, Milano  
**Giuseppe Nunnari**, Messina  
**Nneka Nwokolo**, London UK  
**Massimo Oldrini**, Como  
**Silvia Ondedei**, Roma  
**Giancarlo Orofino**, Torino  
**Mirko Paiardini**, Atlanta USA  
**Saverio Parisi**, Padova  
**Giustino Parruti**, Pescara  
**Stefano Patrucco**, Torino  
**Carlo Federico Perno**, Roma  
**Stefania Piconi**, Lecco  
**Mauro Pistello**, Pisa  
**Guido Poli**, Milano  
**Anton Pozniak**, London UK  
**Tullio Prestileo**, Palermo  
**Massimo Puoti**, Milano  
**Vincenzo Puro**, Roma  
**Laura Rancilio**, Milano  
**Maria Carla Re**, Bologna  
**Diego Ripamonti**, Bergamo  
**Giuliano Rizzardini**, Milano  
**Paolo Rizzini**, Verona



Reach out  
for including all

**Luca Rizzo Nervo**, Bologna  
**Barbara Rossetti**, Siena  
**Giada Rossini**, Bologna  
**Roberto Rossotti**, Milano  
**Alessandro Ruggieri**, Piacenza  
**Stefano Rusconi**, Milano  
**Francesca Sabbatini**, Monza  
**Caterina Sagnelli** Napoli  
**Teresa Santantonio**, Foggia  
**Maria Santoro**, Roma  
**Annalisa Saracino**, Bari  
**Loredana Sarmati**, Roma  
**Gabriella Scarlati**, Milano  
**Giada Sebastiani**, Montreal CA  
**Laura Sighinolfi**, Ferrara  
**Guido Silvestri**, Atlanta USA  
**Francesco R. Simonetti**, Baltimore USA  
**Sophie Strachan**, London UK  
**Barbara Suligoj**, Roma  
**Valentina Svicher**, Roma  
**Gloria Taliani**, Roma  
**Marcello Tavio**, Ancona  
**Elisabetta Teti**, Roma  
**Camilla Tincati**, Milano  
**Carlo Torti**, Catanzaro  
**Ombretta Turriziani**, Roma  
**Emanuela Vaccher**, Aviano PN  
**Stefano Vella**, Roma  
**Serena Venturelli**, Bergamo  
**Gabriella Verucchi**, Bologna  
**Pierluigi Viale**, Bologna  
**Elisa Vicenzi**, Milano  
**Francesca Vichi**, Firenze  
**Filippo von Schloesser**, Roma  
**Maurizio Zazzi**, Siena

### Abstract Reviewers

**Chiara Agrati**, Roma  
**Claudia Alteri**, Milano  
**Guido Antonelli**, Roma  
**Lorenzo Badia**, Bologna  
**Patrizia Bagnarelli**, Ancona  
**Francesca Bai**, Milano  
**Alessandra Bandera**, Milano  
**Dario Bartolozzi**, Firenze  
**Mara Biasin**, Milano  
**Teresa Bini**, Milano  
**Isabella Bon**, Bologna  
**Paolo Bonfanti**, Monza

**Stefano Bonora**, Torino  
**Marco Borderi**, Bologna  
**Vanni Borghi**, Modena  
**Luca Butini**, Ancona  
**Andrea Calcagno**, Torino  
**Anna Paola Callegaro**, Bergamo  
**Leonardo Calza**, Bologna  
**Maria Rosaria Capobianchi**, Roma  
**Antonella Castagna**, Milano  
**Francesco Castelli**, Brescia  
**Dario Cattaneo**, Milano  
**Anna Maria Cattelan**, Padova  
**Rossana Cavallo**, Torino  
**Francesca Ceccherini - Silberstein**, Roma  
**Benedetto Maurizio Celesia**, Catania  
**Valeria Cento**, Milano  
**Massimo Cernuschi**, Milano  
**Stefania Cicalini**, Roma  
**Antonella Cingolani**, Roma  
**Paola Cinque**, Milano  
**Mario Clerici**, Milano  
**Laura Comi**, Bergamo  
**Nicola Coppola**, Napoli  
**Giulio Maria Corbelli**, Bologna  
**Maria Luisa Cosmaro**, Milano  
**Andrea Cossarizza**, Modena  
**Alessandro Cozzi-Lepri**, London UK  
**Gianluca Cuomo**, Modena  
**Gabriella d'Ettore**, Roma  
**Gianpiero D'Offizi**, Roma  
**Andrea De Maria**, Genova  
**Antonio Di Biagio**, Genova  
**Simona Di Giambenedetto**, Roma  
**Giovanni Di Perri**, Torino  
**Margherita Errico**, Milano  
**Massimo Farinella**, Roma  
**Massimo Fasano**, Triggiano BA  
**Micol Ferrara**, Torino  
**Carlo Ferrari**, Parma  
**Giovanni Battista Gaeta**, Napoli  
**Laura Galli**, Milano  
**Cristina Gervasoni**, Milano  
**Nicola Gianotti**, Milano  
**Enrico Girardi**, Roma  
**Andrea Gori**, Milano  
**Giovanni Guaraldi**, Modena  
**Giuseppe Lapadula**, Monza  
**Miriam Lichtner**, Latina  
**Giuseppina Liuzzi**, Roma  
**Sergio Lo Caputo**, Foggia

**Lucia Lopalco**, Milano  
**Giordano Madeddu**, Sassari  
**Gaetano Maffongelli**, Roma  
**Paolo Maggi**, Napoli  
**Franco Maggiolo**, Bergamo  
**Giulia Marchetti**, Milano  
**Renato Maserati**, Pavia  
**Claudio Maria Mastroianni**, Roma  
**Alberto Matteelli**, Brescia  
**Stefano Menzo**, Ancona  
**Annalisa Mondì**, Roma  
**Laura Monno**, Bari  
**Ada Moznich**, Pordenone  
**Antonio Muscatello**, Milano  
**Emanuele Nicastrì**, Roma  
**Silvia Nozza**, Milano  
**Giuseppe Nunnari**, Messina  
**Giancarlo Orofino**, Torino  
**Saverio Parisi**, Padova  
**Stefania Piconi**, Lecco  
**Carmela Pinnetti**, Roma  
**Mauro Pistello**, Pisa  
**Tullio Prestileo**, Palermo  
**Massimo Puoti**, Milano  
**Vincenzo Puro**, Roma  
**Diego Ripamonti**, Bergamo  
**Giuliano Rizzardini**, Milano  
**Barbara Rossetti**, Siena  
**Roberto Rossotti**, Milano  
**Stefano Rusconi**, Milano  
**Francesco Saladini**, Siena  
**Maria Santoro**, Roma  
**Annalisa Saracino**, Bari  
**Loredana Sarmati**, Roma  
**Laura Sighinolfi**, Ferrara  
**Alessandro Soria**, Monza  
**Vincenzo Spagnuolo**, Milano  
**Nicola Squillace**, Monza  
**Valentina Svicher**, Roma  
**Gloria Taliani**, Roma  
**Lucia Taramasso**, Genova  
**Elisabetta Teti**, Roma  
**Camilla Tincati**, Milano  
**Carlo Torti**, Catanzaro  
**Daria Trabattoni**, Milano  
**Elisa Vicenzi**, Milano  
**Francesca Vichi**, Firenze





12° CONGRESSO NAZIONALE  
Italian Conference on **AIDS** and **Antiviral Research**  
12-16 ottobre 2020 **DIGITAL EDITION**

Reach out  
for including all

## Dear Colleagues,

It is our great pleasure to welcome you to this particular **12<sup>th</sup> edition of ICAR, the Italian Conference on AIDS and Antiviral Research** which takes place this year online by high-performance platforms that will allow to follow the conference works through a highly stimulating digital and educational experience.

The objectives and the characteristics that have always distinguished **ICAR** remain intact: **abstract-driven congress**, strong **interaction** between basic, translational and clinical research, inspired by the need for a common language between the scientific community and the patients, particular attention towards **young researchers, non-medical health personnel, the Community, the civil society**.

**ICAR 2020** is aimed to promote the visibility of young clinicians and basic researchers in addition to nurses, social workers and volunteers through **Young Investigators** and **Community Scholarships**. Other crucial moments of ICAR as **ICAR-CROI Awards, Special Awards** of ICAR and **SIMIT** and the 6<sup>th</sup> edition of the **RaccontART** art competition are reconfirmed even with the online format.

Special thanks go to the **Scientific and Course Secretariats**, to the **Abstract Reviewers** for their commitment, to our **Faculty Members**, to the **ICAR Governing Board**, to **SIMIT, Institutions, Scientific Societies and Patient Associations**, to the **schools** and students, to our **Sponsors** who enabled us to involve hundreds of young researchers and representatives of the Community of patient associations despite the moment of global health emergency due to COVID-19 epidemic.

*Welcome to the Digital Edition of ICAR 2020!*

### The Chairs

Massimo Clementi

Sandro Mattioli

Cristina Mussini

Guido Silvestri

Marcello Tavio

12° CONGRESSO NAZIONALE



**Italian Conference on  
AIDS and Antiviral Research**

*Reach out  
for including all*

 12-16  
ottobre 2020  
DIGITAL EDITION

*Presidenza del Congresso*

*Massimo Clementi, Milano*

*Sandro Mattioli, Bologna*

*Cristina Mussini, Modena*

*Guido Silvestri, Atlanta*

*Marcello Tavio, Ancona*

# PROGRAMME AT A GLANCE







PROGRAMME  
AT A GLANCE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 **DIGITAL EDITION**

| 12 OTTOBRE 2020 |   |  |
|-----------------|---|--|
|                 | PLENARY ROOM  | ROOM 2   |
| 14.00<br>15.00  | PRE-CONFERENCE ADVANCED COURSE<br><b>New frontiers in medical virology</b><br><i>pag. 15</i>  |  |
| 15.00<br>16.00  | PRE-CONFERENCE ADVANCED COURSE<br><b>New challenges in sexually transmitted infections:<br/>sexual health, prevention and more</b><br><i>pag. 15</i>  | PRE-CONFERENCE ADVANCED COURSE<br><b>Nurse management of patients<br/>with comorbidities</b><br><i>pag. 16</i> |
|                 | PLENARY ROOM  |  |
| 16.00<br>16.45  | SATELLITE SYMPOSIUM<br><b>Durable treatment success in HIV</b><br><i>pag. 18</i>  |  |
| 16.45<br>18.30  | <b>ICAR 2020 OPENING SESSION</b><br><i>pag. 18</i><br>16.45-17.00 <b>Introducing ICAR 2020</b><br>17.00-17.15 <b>RaccontART HIV contest Awards</b><br>17.15-18.15 <b>Keynote Lectures</b><br>18.15-18.30 <b>Closing Remarks</b> |  |





**PROGRAMME  
AT A GLANCE**

| 13 OTTOBRE 2020 |  |  |  |
|-----------------|--|--|--|
| PLENARY ROOM    |  |  |  |
| 14.30<br>14.50  | KEYNOTE LECTURE<br><b>Visions of ART - Anton Pozniak, London UK</b><br><i>pag. 19</i>  |  |  |
|                 | PLENARY ROOM   | ROOM 2   | ROOM 3   |
| 15.00<br>16.00  | SYMPOSIUM<br><b>Virus persistence and host interactions</b><br><i>pag. 19</i>  | EXPERT MEETING<br><b>Hepatitis C Elimination: the winning challenge of the 8-weeks treatment</b><br><i>pag. 19</i> |  |
| 16.00<br>17.00  | SATELLITE SYMPOSIUM<br><b>Fighting multi drug resistance - the right moment, the right drugs</b><br><i>pag. 20</i>                                   | ORAL COMMUNICATIONS<br><b>Social Science</b><br><i>pag. 20</i>   |  |
| PLENARY ROOM    |  |  |  |
| 17.00<br>17.20  | KEYNOTE LECTURE<br><b>Genomics and proteomics approaches for studies of HIV eradication - Mathias Lichterfeld, Boston USA</b><br><i>pag. 21</i>      |  |  |
| 17.30<br>18.30  | SYMPOSIUM<br><b>New metabolic challenges in comorbidities</b><br><i>pag. 21</i>  | ORAL COMMUNICATIONS<br><b>Antiretroviral Therapy</b><br><i>pag. 21</i>   | SPECIAL SESSION <br><b>MEET THE EXPERT Antiretroviral Therapy Transgender</b><br><i>pag. 22</i> |
| 18.30<br>19.30  | SPONSORED SYMPOSIUM<br><b>Streamline ART from the start: the novel approach of 2DR single pill regimen dolutegravir/lamivudine</b><br><i>pag. 23</i> | ORAL COMMUNICATIONS<br><b>HIV Prevention</b><br><i>pag. 23</i>   |  |
| PLENARY ROOM    |  |  |  |
| 19.30<br>20.30  | <b>ICAR-CROI Awards 2020 for young Italian HIV investigators</b><br><i>pag. 24</i>   |  |  |





PROGRAMME  
AT A GLANCE

| 14 OTTOBRE 2020 |   |   |  |
|-----------------|---|---|--|
| PLENARY ROOM    |   |   |  |
| 14.30<br>14.50  | KEYNOTE LECTURE<br><b>Orientating in a maze. The Arianna's thread to partner notification - Maria Luisa Cosmaro, Milano</b><br><i>pag. 25</i>               |   |  |
|                 | PLENARY ROOM  | ROOM 2  | ROOM 3   |
| 15.00<br>16.00  | SPONSORED SYMPOSIUM<br><b>POP ART (population on ART): from patient to <i>personas</i> - A new approach to fulfill PLHIV expectations</b><br><i>pag. 25</i> | ORAL COMMUNICATIONS<br><b>Virology</b><br><i>pag. 25</i>  |  |
| 16.00<br>17.00  | SYMPOSIUM<br><b>Reaching out: same models for different infections</b><br><i>pag. 26</i>  | SATELLITE SYMPOSIUM<br><b>Recent advances in the management of Gram positive infections: the evolving role of long acting therapy</b><br><i>pag. 27</i> |  |
| PLENARY ROOM    |   |   |  |
| 17.00<br>17.20  | KEYNOTE LECTURE<br><b>New challenges in virology: SARS-CoV-2 - Maria Rosanna Capobianchi, Roma</b><br><i>pag. 27</i>  |   |  |
| 17.30<br>18.30  | SATELLITE SYMPOSIUM<br><b>Committed globally to fight HIV and other severe infections</b><br><i>pag. 27</i>   | ORAL COMMUNICATIONS<br><b>Comorbidities</b><br><i>pag. 28</i>   | SPECIAL SESSION <br><b>MEET THE EXPERT<br/>Chemsex<br/>Drug-Drug Interactions</b><br><i>pag. 28</i> |
| 18.30<br>19.30  | SYMPOSIUM<br><b>Lights and shadows in HIV clinical research</b><br><i>pag. 29</i>   | ORAL COMMUNICATIONS<br><b>Clinical Hepatitis and Coinfections</b><br><i>pag. 29</i>   |  |







**PROGRAMME  
AT A GLANCE**

| <b>15 OTTOBRE 2020</b> |  |   |   |
|------------------------|--|---|---|
| <b>PLENARY ROOM</b>    |  |   |   |
| 14.30<br>15.15         | ROUND TABLE<br><b>HIV in COVID-19 era: how to ensure quality of care and outpatient management</b><br><i>pag. 31</i> |   |   |
|                        | <b>PLENARY ROOM</b>  | <b>ROOM 2</b>   | <b>ROOM 3</b>   |
| 15.20<br>16.20         | SATELLITE SYMPOSIUM<br><b>HIV: understanding the real burdens of the diseases</b><br><i>pag. 31</i>                  | ORAL COMMUNICATIONS<br><b>Basic Science and Immunology</b><br><i>pag. 31</i>  |   |
| 16.20<br>17.20         | SYMPOSIUM<br><b>Immune control over HIV reservoir</b><br><i>pag. 32</i>  | EXPERT MEETING<br><b>Enhancing care for people living with HIV: current and future of monitoring approaches</b><br><i>pag. 33</i> |   |
| 17.20<br>18.20         | SYMPOSIUM<br><b>Challenges in PrEP implementation and TasP confidence</b><br><i>pag. 33</i>                          | ORAL COMMUNICATIONS<br><b>Clinical HIV</b><br><i>pag. 34</i>  | SPECIAL SESSION <br><b>MEET THE EXPERT Immunological Update Cure</b><br><i>pag. 35</i> |
| 18.20<br>19.20         | SYMPOSIUM<br><b>HIV and Coinfections: new challenges for 2020</b><br><i>pag. 35</i>                                  | EXPERT MEETING<br><b>Urgent global challenges in infectious diseases: fight together against HIV and AMR</b><br><i>pag. 35</i>    |   |





**PROGRAMME  
AT A GLANCE**

| 16 OTTOBRE 2020 |   |              |        |                |  |   |                |   |                |  |
|-----------------|---|--------------|--------|----------------|--|---|----------------|---|----------------|--|
| PLENARY ROOM    |   |              |        |                |  |   |                |   |                |  |
| 14.30<br>15.15  | <p>SYMPOSIUM</p> <p><b>The Fast-Track Cities initiative and the Italian state of the art</b><br/><i>pag. 36</i></p>   |              |        |                |  |   |                |   |                |  |
|                 | <table border="1"> <thead> <tr> <th>PLENARY ROOM</th> <th>ROOM 2</th> </tr> </thead> <tbody> <tr> <td rowspan="2">15.20<br/>15.50</td> <td> <p>ORAL COMMUNICATIONS</p> <p><b>Immunopathogenesis</b><br/><i>pag. 36</i></p> </td> </tr> <tr> <td> <p>ORAL COMMUNICATIONS</p> <p><b>Hepatitis and Clinical Virology</b><br/><i>pag. 37</i></p> </td> </tr> <tr> <td>15.50<br/>16.20</td> <td> <p>ORAL COMMUNICATIONS</p> <p><b>Social Science and Epidemiology</b><br/><i>pag. 38</i></p> </td> </tr> <tr> <td>16.20<br/>17.20</td> <td> <p>ORAL COMMUNICATIONS</p> <p><b>Pharmacology</b><br/><i>pag. 39</i></p> </td> </tr> </tbody> </table> | PLENARY ROOM | ROOM 2 | 15.20<br>15.50 | <p>ORAL COMMUNICATIONS</p> <p><b>Immunopathogenesis</b><br/><i>pag. 36</i></p> | <p>ORAL COMMUNICATIONS</p> <p><b>Hepatitis and Clinical Virology</b><br/><i>pag. 37</i></p> | 15.50<br>16.20 | <p>ORAL COMMUNICATIONS</p> <p><b>Social Science and Epidemiology</b><br/><i>pag. 38</i></p> | 16.20<br>17.20 | <p>ORAL COMMUNICATIONS</p> <p><b>Pharmacology</b><br/><i>pag. 39</i></p> |
| PLENARY ROOM    | ROOM 2  |              |        |                |  |   |                |   |                |  |
| 15.20<br>15.50  | <p>ORAL COMMUNICATIONS</p> <p><b>Immunopathogenesis</b><br/><i>pag. 36</i></p>  |              |        |                |  |   |                |   |                |  |
|                 | <p>ORAL COMMUNICATIONS</p> <p><b>Hepatitis and Clinical Virology</b><br/><i>pag. 37</i></p>   |              |        |                |  |   |                |   |                |  |
| 15.50<br>16.20  | <p>ORAL COMMUNICATIONS</p> <p><b>Social Science and Epidemiology</b><br/><i>pag. 38</i></p>   |              |        |                |  |   |                |   |                |  |
| 16.20<br>17.20  | <p>ORAL COMMUNICATIONS</p> <p><b>Pharmacology</b><br/><i>pag. 39</i></p>  |              |        |                |  |   |                |   |                |  |
|                 | <p>SPECIAL EVENT</p> <p><b>Special Session on HIV and COVID in Italy</b><br/><i>pag. 36</i></p>   |              |        |                |  |   |                |   |                |  |
|                 | <p>SYMPOSIUM</p> <p><b>ART treatment: when the patient's journey becomes difficult</b><br/><i>pag. 38</i></p>   |              |        |                |  |   |                |   |                |  |
|                 | <p>SYMPOSIUM</p> <p><b>Proud to be women, proud to fight HIV</b><br/><i>pag. 39</i></p>   |              |        |                |  |   |                |   |                |  |
| PLENARY ROOM    |   |              |        |                |  |   |                |   |                |  |
| 18.20<br>18.35  | <p><b>ICAR 2020 Special Awards</b><br/><i>pag. 40</i></p>   |              |        |                |  |   |                |   |                |  |
| 18.35<br>18.45  | <p><b>Closing remarks</b><br/><i>pag. 40</i></p>  |              |        |                |  |   |                |   |                |  |



12° CONGRESSO NAZIONALE



**Italian Conference on  
AIDS and Antiviral Research**

*Reach out  
for including all*

 12-16  
ottobre 2020  
DIGITAL EDITION

*Presidenza del Congresso  
Massimo Clementi, Milano  
Sandro Mattioli, Bologna  
Cristina Mussini, Modena  
Guido Silvestri, Atlanta  
Marcello Tavio, Ancona*

PRE-CONFERENCE  
ADVANCED COURSES



LUNEDÌ  
12 OTTOBRE





LUNEDI'  
12 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 **DIGITAL EDITION**

**PRE-CONFERENCE ADVANCED COURSE** 14.00-15.00

**PLENARY ROOM**

**New frontiers in medical virology**

Chairs: I. Bon (Bologna), B. Rossetti (Siena), C. Tincati (Milano)

*Infectious diseases are of public interest because of their impact on human, animal, and plant health. In this context, viruses play a central role in all aspects of medical research, ranging from molecular biology and immunology to evolution and epidemiology. The course will offer insight into the laboratory tools for the surveillance, diagnosis and monitoring of viral infections. It will also focus on novel aspects of viral pathogenesis and elaboration of therapeutic strategies.*

|             |   |                            |
|-------------|---|----------------------------|
| 14.00-14.10 | <b>Next-generation sequencing: a methodology changing the way to understand genome sequencing, evolution, ecology and discovery viruses</b> | Nicola Clementi, Milano    |
| 14.10-14.20 | <b>Serological and molecular tools for detection of emerging viruses</b>  | Giada Rossini, Bologna     |
| 14.20-14.30 | <b>Role of HIV-1 protein variants in lymphoma pathogenesis</b>  | Francesca Caccuri, Brescia |
| 14.30-14.40 | <b>New frontiers of antiviral strategies</b>  | Ombretta Turriziani, Roma  |
| 14.40-15.00 | <b>Discussion and conclusions</b>   |                            |

**PRE-CONFERENCE ADVANCED COURSE** 15.00-16.00

**PLENARY ROOM**

**New challenges in sexually transmitted infections: sexual health, prevention and more**

Chairs: L. Badia (Bologna), G. Cuomo (Modena), R. Rossotti (Milano)

*The consequences of sexually transmitted infections (STIs) on both individual and public health can be severe. The increasing incidence of STIs demands a call to action to ensure that populations at risk have access to comprehensive STIs prevention and care, especially in the context of expanded use of pre-exposure prophylaxis (PrEP) for HIV prevention. Integration of STIs services and PrEP is challenging but also provides a unique opportunity to optimize broader sexual and reproductive health services.*

|             |  |                              |
|-------------|--|------------------------------|
| 15.00-15.10 | <b>Beyond PrEP: from a clinical management of STIs to a broader approach to sexual health</b>                      | Maddalena Cordioli, Verona   |
| 15.10-15.20 | <b>Test and Same Day Treatment in HIV: the role of screening and early ART initiation in the management of HIV</b> | Arturo Ciccullo, Roma        |
| 15.20-15.30 | <b>Empowering people for their sexual health: how U=U changed the sexual lives of people living with HIV</b>       | Daniele Calzavara, Milano    |
| 15.30-15.40 | <b>Focus on vaccinations: are they an effective tool of sexual prevention?</b>                                     | Margherita Digaetano, Modena |
| 15.40-16.00 | <b>Discussion and conclusions</b>  |                              |



LUNEDI'  
12 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

**PRE-CONFERENCE ADVANCED COURSE** 15.00-16.00

**ROOM 2**

## **Nurse management of patients with comorbidities**

*Chairs:* E. Bruni (Ferrara), M. Gatti (Lecco), S. Patrucco (Torino)

*Achieving an undetectable viral load is no longer the sole endpoint in treating HIV. Today's challenge is to guide patients towards a proactive management of HIV-associated comorbidities. Therapies have improved notably: nowadays patients diagnosed with HIV and treated with the latest antiretrovirals have a life expectancy comparable to the general population. A recent study showed that in 2010 patients' mean age was 43.9 years, whereas in 2030 is expected to be 56.6 years, with patients aged over 50 increasing from 28% to 73%. Nonetheless, there are more challenges to face: aging with HIV puts patients to an increased risk of developing HIV-related illnesses, such as osteoporosis, hepatic, cardiovascular and neurological disease. It is therefore necessary for the nursing staff to be able to lead patients to a successful management of their comorbidities through a learning process based on efficient means of communication aimed at patients' empowerment.*

|             |  |                       |
|-------------|--|-----------------------|
| 15.00-15.10 | <b>Cardiovascular risk factors</b>   | Michela Belli, Modena |
| 15.10-15.20 | <b>Nurse management of frail and elderly HIV-positive patients</b>                 | Manuela Gatti, Lecco  |
| 15.20-15.30 | <b>Therapeutic Patient Education in subjects with neurocognitive disorders</b>     | Silvia Ondedei, Roma  |
| 15.30-15.40 | <b>Nurse management of cancer patients</b>   | Adriana Meda, Monza   |
| 15.40-15.50 | <b>The nurse's role in managing the risk of infection in HIV-positive patients</b> | Erika Bruni, Ferrara  |
| 15.50-16.00 | <b>Discussion</b>  |                       |



SCIENTIFIC  
PROGRAMME

12° CONGRESSO NAZIONALE



**Italian Conference on  
AIDS and Antiviral Research**

*Reach out  
for including all*



12-16  
ottobre 2020

DIGITAL EDITION

*Presidenza del Congresso*

*Massimo Clementi, Milano*

*Sandro Mattioli, Bologna*

*Cristina Mussini, Modena*

*Guido Silvestri, Atlanta*

*Marcello Tavio, Ancona*

# SCIENTIFIC PROGRAMME







LUNEDI'  
12 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

## SATELLITE SYMPOSIUM 16.00-16.45

Con la sponsorizzazione non condizionante di Gilead Sciences

### Durable treatment success in HIV

Chair: C. Mussini (Modena)

Thanks to the advent of increasingly effective antiretroviral drugs and the additional knowledge/experience gained, HIV infection is now a manageable chronic condition, in which the achievement of immune-viral control has become a reality for the majority of treated patients. Therefore, it becomes essential to "update" the clinicians' and patients' perspectives of the disease, targeting not only the mere control of the virus (both at the population and patient level) but also the global health of current PLWHIV. This latter aspect becomes even more crucial since patients still are vulnerable due to a residual disease driven by non-AIDS defined comorbidities. Reflecting on current challenges and available strategies to fill these gaps will be essential, also with the support of real-life data. These themes will be addressed in an interactive way, through a direct dialogue between physicians and patients..

16.00-16.15

#### Global Health in HIV

Stefano Vella, Roma

16.15-16.45

#### Round Table "Strategies for durable treatment success"

M. Andreoni (Roma), G.M. Corbelli (Bologna), A. d'Arminio Monforte (Milano), G. Di Perri (Torino)

PLENARY ROOM

## ICAR 2020 OPENING SESSION

PLENARY ROOM

### Introducing ICAR 2020 16.45-17.00

M. Clementi (Milano), S. Mattioli (Bologna), C. Mussini (Modena), G. Silvestri (Atlanta), M. Tavio (Ancona)

### RaccontART HIV contest Awards 17.00-17.15

Chairs: A. Caraglia (Roma), M. Errico (Milano), A. Lazzarin (Milano)

### Keynote Lectures 17.15-18.15

Chairs: V. Calvino (Roma), A. Cossarizza (Modena), C.F. Perno (Roma), S. Vella (Roma)

17.15-17.35

#### Mauro Moroni Memorial Lecture "Immune control to reservoir: commencing countdown, control on"

Mirko Paiardini, Atlanta USA

17.35-17.55

#### Transgender, non-binary and HIV people: peculiarities of a key population between stigma and retaining in care

Ottavia Voza, Salerno

17.55-18.15

#### The public health response to new and future pandemics: lights and shadows from COVID-19

Giuseppe Ippolito, Roma

### Closing Remarks 18.15-18.30

M. Clementi (Milano), S. Mattioli (Bologna), C. Mussini (Modena), G. Silvestri (Atlanta), M. Tavio (Ancona)



SCIENTIFIC  
PROGRAMME



**MARTEDI'**  
**13 OTTOBRE**

**12° CONGRESSO NAZIONALE**  
**Italian Conference on AIDS and Antiviral Research**

**12-16 ottobre 2020** **DIGITAL EDITION**

**KEYNOTE LECTURE** 14.30-14.50

Chairs: M. Farinella (Roma), C. Mussini (Modena)

**PLENARY ROOM**

14.30-14.50 **Visions of ART**

Anton Pozniak, London UK

**SYMPOSIUM** 15.00-15.55

**Virus persistence and host interactions**

Chairs: G. Antonelli (Roma), P. Bagnarelli (Ancona), S. Rusconi (Milano)

**PLENARY ROOM**

*Antiretroviral therapy (ART) has gained a great deal of success in recent years and succeeded in suppressing viral replication in people infected with HIV. Nevertheless, infected cells persist for decades on ART and HIV-RNA comes back if ART is stopped. Persistence has been attributed to viral replication in cellular/anatomical reservoirs and long-lived and/or proliferating latently infected cells. This symposium aims at shedding light on the fine mechanisms of persistence of retroviruses and their crosstalk with the host immune system.*

15.00-15.10 **Restriction factors and the peculiar function of CIITA**

Roberto Accolla, Varese

15.10-15.20 **The persistence of memory: HIV reservoir and adaptive immunity**

Francesco Simonetti,  
Baltimore USA

15.20-15.30 **Gene editing: from the virus side**

Ramona Bella, Brussels BE

15.30-15.40 **Gene editing: from the cell side**

Mauro Pistello, Pisa

15.40-15.55 **Discussion on Symposium issues**

**EXPERT MEETING** 15.00-16.00

**ROOM 2**

Con la sponsorizzazione di AbbVie

**Hepatitis C Elimination: the winning challenge of the 8-weeks treatment**

*Thanks to the DAAs, the WHO's goal of HCV elimination by 2030 could be achieved more easily. The high efficacy of these antiviral drugs, characterized by great power, few DDIs and short treatment make the patient's journey less onerous and heavy. Clinical trials and RWE data demonstrate not only the high SVR rate of the short therapies but also the improvement of adherence to the treatment. This last aspect is fundamental for the special populations (PWIDs and patients from SERD) because the briefer the therapy, the less burdensome it is for them.*

*The Expert Meeting will focus precisely of the opportunity of the short therapy in the challenge against HCV. In this context, it represents an important step towards the efforts for eliminating the hepatitis C because it evaluates a brief antiviral regimen in untreated patients without cirrhosis and with compensated cirrhosis, across HCV genotypes 1-6.*

*Through a talk show session, the two Professors will explain and convey the main data and results of this HCV turning point to the audience. The latter will be able to intervene in the session thanks to an interactive platform that will allow the physicians to answer the questions formulated by the speakers.*

15.00-16.00 **Hepatitis C Elimination: the winning challenge of the 8-weeks treatment**

Massimo Andreoni, Roma  
Massimo Puoti, Milano



MARTEDI'  
13 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

**SATELLITE SYMPOSIUM** 16.00-17.00

**PLENARY ROOM**

**Fighting multi drug resistance - the right moment, the right drugs**

Patients with Multi Drug Resistant (MDR) HIV infection and few residual antiretroviral options are very likely to experience progression of the disease and death. To address this important unmet need, new antiretroviral agents are needed with novel mechanisms of action, good safety profile, no drug-drug interactions and no cross-resistance to other HIV drugs. The Symposium will focus on new modes of action currently in development and share latest clinical data conducted so far with ibalizumab, a new humanized IgG4 monoclonal antibody which blocks the entry of HIV by non-competitive binding to CD4. The Italian experience with the use of ibalizumab will also be presented.

|             |  |                            |
|-------------|--|----------------------------|
| 16.00-16.05 | <b>Speaker's introduction and scientific rationale</b>                             | Cristina Mussini, Modena   |
| 16.05-16.15 | <b>New treatments, new options</b>   | Andrea Antinori, Roma      |
| 16.15-16.25 | <b>Resistance to Long-Acting Antivirals</b>  | Maurizio Zazzi, Siena      |
| 16.25-16.45 | <b>Building a fully suppressive regimen for patients with MDR –lessons learned</b> | Antonella Castagna, Milano |
| 16.45-16.55 | <b>The Italian experience</b>  | Brinda Emu, New Haven USA  |
| 16.55-17.00 | <b>Discussion on Symposium issues</b>  |                            |

**ORAL COMMUNICATIONS** 16.00-17.00

**ROOM 2**

**Social Science**

Chairs: G. Liuzzi (Roma), A. Matteelli (Brescia), L. Rancilio (Milano)

**OC 1 16.00-16.10 Awareness and perception of accuracy of the U = U message in people living with HIV (PLWHIV), in Italy and correlation with the level of confidence in reference physicians**

A. Cingolani<sup>1</sup>, A. Tavelli<sup>2</sup>, V. Calvino<sup>3</sup>, F. Maggiolo<sup>4</sup>, E. Girardi<sup>5</sup>, A. Cozzi Lepri<sup>6</sup>, A. Perziano<sup>7</sup>, A. Camposeragna<sup>8</sup>, R. Gagliardini<sup>9</sup>, S. Nozza<sup>9</sup>, A. Antinori<sup>5</sup>, A. d'Arminio Monforte<sup>10</sup> for Icona Foundation Study Group

<sup>1</sup>Fondazione Policlinico A. Gemelli, Università Cattolica S. Cuore, <sup>2</sup>ICONA Foundation, Milano, <sup>3</sup>ANLAIDS, Roma, <sup>4</sup>ASST Giovanni XXIII, Bergamo, <sup>5</sup>INMI L.Spallanzani, Roma, <sup>6</sup>UCL, London, <sup>7</sup>Arcovaleno AIDS, Torino, <sup>8</sup>CNCA, Roma, <sup>9</sup>HSR San Raffaele, Milano, <sup>10</sup>ASST San Paolo e Carlo, Università di Milano

**OC 2 16.10-16.20 Hepatitis C, HIV and Tuberculosis among vulnerable populations in an out-of-hospital setting: a seroprevalence analysis from "The week of the poor" experience**

G. De Simone, E. Teti, L. Foroghi, T. Mulas, V. Malagnino, C. Stingone, M. De Masi, L. Campogiani, M. Compagno, L. Coppola, P. Vitale, I. Spalliera, L. Ferrari, S. Tedde, F. Caldara, B. Rossi, A. Crea, D. Checchi, M. Ortelli, A. Lodi, P. Pace, M. Zordan, L. Ansaldo, F. Barreca, A. Di Lorenzo, A. Buoso, A. Salvati, M. Iannetta, L. Sarmati, M. Andreoni

Infectious Diseases Clinic, Tor Vergata Hospital, Rome, Italy

**OC 3 16.20-16.30 Engagement of younger generations in the fight against HIV/AIDS**

P. Meli<sup>1</sup>, C. Pellegrini<sup>1</sup>, P. Adamini<sup>1</sup>, I. Falceri<sup>1</sup>, F. Maggiolo<sup>2</sup>, A. Giannellini<sup>3</sup>

<sup>1</sup>Comunità Emmaus & Caritas Bergamasca, <sup>2</sup>ASST Papa Giovanni XXIII, Bergamo, <sup>3</sup>Ufficio Scolastico Territoriale Bergamo

**OC 4 16.30-16.40 Post-migration HIV infection in the foreign-born population enrolled in the ICONA cohort**

A. Saracino<sup>1</sup>, P. Lorenzini<sup>2</sup>, M.M. Santoro<sup>3</sup>, A. Tavelli<sup>4</sup>, S. Rusconi<sup>5</sup>, N. Bobbio<sup>6</sup>, A. Mondì<sup>7</sup>, S. Lo Caputo<sup>7</sup>, A. Antinori<sup>8</sup>, E. Girardi<sup>9</sup>, A. d'Arminio Monforte<sup>9</sup>, L. Monno<sup>1</sup>

<sup>1</sup>Clinic of Infectious Diseases, Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy, <sup>2</sup>HIV/AIDS Unit, INMI "L. Spallanzani" IRCCS, Rome, Italy, <sup>3</sup>University of Rome "Tor Vergata", Department of Experimental Medicine, Rome, Italy, <sup>4</sup>Icona Foundation, Milan, Italy, <sup>5</sup>Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy, <sup>6</sup>Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, <sup>7</sup>Clinic of Infectious Diseases, University of Foggia, Foggia, Italy, <sup>8</sup>Clinical Epidemiology Unit, INMI "L. Spallanzani" IRCCS, Rome, Italy, <sup>9</sup>Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy

**OC 5 16.40-16.50 BLQ Checkpoint: characteristics of users and services offered. A 5 years review**

S. Mattioli, M. Bonanni, P. Gorgoni, P. Tomasi, G.M. Corbelli

Plus, rete persone LGBT+ sieropositivo



SCIENTIFIC  
PROGRAMME





**MARTEDI'**  
**13 OTTOBRE**

**12° CONGRESSO NAZIONALE**  
**Italian Conference on AIDS and Antiviral Research**

**12-16 ottobre 2020** **DIGITAL EDITION**

**OC 6 16.50-17.00 Sexual behaviour and associated risk for sexual health among men who have sex with men (MSM in Italy: data from the EMIS 2017 survey**

M. Cordioli<sup>1</sup>, L. Gios<sup>1</sup>, M.L. Cosmaro<sup>2</sup>, M. Breveglieri<sup>3</sup>, F.M. Nimbi<sup>4</sup>, G.M. Corbelli<sup>5</sup>, N. Sherriff<sup>6</sup>, M. Mirandola<sup>1,6</sup>

<sup>1</sup>UOC di Malattie Infettive e Tropicali, Dipartimento di Diagnostica e Sanità Pubblica, Università di Verona / Infectious Diseases Section, Diagnostic and Public Health Department, University of Verona, <sup>2</sup>Fondazione Lega Italiana per la Lotta contro l'AIDS – LILA Milano, <sup>3</sup>Arcigay – Associazione LGBT+ Italiana, <sup>4</sup>Dept of Dynamic and Clinical Psychology, Sapienza University of Rome, <sup>5</sup>Plus Network persone LGBT sieropositive, <sup>6</sup>School of Health Sciences, University of Brighton, Brighton, UK

**KEYNOTE LECTURE 17.00-17.20**

Chairs: F. Ceccherini-Silberstein (Roma), A. De Rossi (Padova)

**PLENARY ROOM**

17:00-17:20 **Genomics and proteomics approaches for studies of HIV eradication**

Mathias Lichterfeld, Boston USA

**SYMPOSIUM 17.30-18.25**

**New metabolic challenges in comorbidities**

Chairs: A. Bandera (Milano), P. Bonfanti (Monza), F. Castelli (Brescia)

*HIV ad cART comorbidities are continuously changing their presentations, in parallel with the evolving spectrum of antiretroviral treatment regimens and the demographic and clinical features of people with HIV (PWH). At present, the current scenario of metabolic comorbidities seems to reflect, on one hand, the extended use of potent antiretroviral drugs with a very high safety profile, and, on another hand, the increasing age of PWH and the persisting immune activation. This symposium discusses emerging issues in the field, including prevalence and impact of these complications and explore the potential of old and new tools for their definition and management.*

**PLENARY ROOM**

17.30-17.40 **The growing burden of nonalcoholic fatty liver disease in people aging with HIV**

Giada Sebastiani, Montreal CA

17.40-17.50 **Weight gain and new antiretrovirals: is a real issue?**

Stefania Cicalini, Roma

17.50-18.00 **Immune-metabolic interventions as geroprotective agents in HIV**

Giovanni Guaraldi, Modena

18.00-18.10 **Artificial intelligence in aging: from data collection to data analytics**

Costantino Grana, Modena

18.10-18.25 **Discussion on Symposium issues**

**ORAL COMMUNICATIONS 17.30-18.30**

**ROOM 2**

**Antiretroviral Therapy**

Chairs: M. Malena (Verona), C. Torti (Catanzaro)

**OC 7 17.30-17.40 Durability of dolutegravir-based regimens after the first year of therapy**

L. Taramasso<sup>1,2</sup>, A. De Vito<sup>3</sup>, E. Ricci<sup>4</sup>, N. Squillace<sup>5</sup>, R. Gulminetti<sup>6</sup>, G. De Socio<sup>7</sup>, B. Menzaghi<sup>8</sup>, G. Orofino<sup>9</sup>, G.F. Pellicano<sup>10</sup>, B.M. Celesia<sup>11</sup>, C. Martinelli<sup>12</sup>, S. Rusconi<sup>13</sup>, A. Cascio<sup>14</sup>, L. Valsecchi<sup>15</sup>, L. Calza<sup>16</sup>, C. Bellacosa<sup>17</sup>, C. Dentone<sup>18</sup>, G. Angioni<sup>19</sup>, K. Falasca<sup>20</sup>, E. Sarchi<sup>21</sup>, P. Bonfanti<sup>22</sup>, A. Di Biagio<sup>23</sup>, G. Madeddu<sup>3</sup>

<sup>1</sup>Department of Pathophysiology and Transplantation, Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Italy, <sup>2</sup>Multidisciplinary Research in Health Science (MACH), Milan, Italy, <sup>3</sup>Unit of Infectious and Tropical Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>4</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>5</sup>Infectious Diseases Clinic, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, <sup>6</sup>Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia Italy, <sup>7</sup>Unit of Infectious Diseases, Department of Medicine 2, Azienda Ospedaliera di Perugia, Santa Maria Hospital, Perugia, <sup>8</sup>Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, Busto Arsizio, Italy, <sup>9</sup>Unit of Infectious Diseases, "Divisione A", Amedeo di Savoia Hospital, Torino, Italy, <sup>10</sup>Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", Unit of Infectious Diseases, University of Messina, <sup>11</sup>Department of Clinical and Molecular Biomedicine, Division of Infectious Diseases, University of Catania, Catania, Italy, <sup>12</sup>SOD Malattie Infettive e Tropicali AOU Careggi, Florence, Italy, <sup>13</sup>Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy, <sup>14</sup>Department of Health



MARTEDI'  
13 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy, <sup>15</sup>Infectious Disease Unit (I Divisione), ASST Fatebenefratelli Sacco, Milan, Italy, <sup>16</sup>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna, Bologna, Italy, <sup>17</sup>Infectious Diseases Clinic, University of Bari, Bari, Italy, <sup>18</sup>Infectious Disease Unit, Sanremo Hospital, Sanremo, Italy, <sup>19</sup>Infectious Disease Unit, SS Trinità Hospital, Cagliari, Italy, <sup>20</sup>Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy, <sup>21</sup>Infectious Diseases Unit, SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, <sup>22</sup>Infectious Disease Unit, Ospedale A. Manzoni, Lecco, Italy, <sup>23</sup>Infectious Diseases Clinic, Dept. of Health Sciences, University of Genoa, San Martino Hospital-IRCCS, Genoa, Italy

**OC 8 17.40-17.50 Switch to RPV+DRV/cobi: 48week results of the PROBE 2 study**

*E. Maggiolo<sup>1</sup>, L. Comi<sup>1</sup>, E. Di Filippo<sup>1</sup>, L. Fumagalli<sup>2</sup>, N. Gianotti<sup>2</sup>, S. Nozza<sup>2</sup>, D. Valenti<sup>1</sup>, A. Castagna<sup>2</sup>*

<sup>1</sup>ASST PG-23, Bergamo, <sup>2</sup>HSR Milano2, Italy

**OC 9 17.50-18.00 Predictors of virological failure among HIV-1 infected patients switching from an effective first line antiretroviral regimen. A preliminary analysis**

*L. Magnasco<sup>1</sup>, R. Pincino<sup>1</sup>, G. Pasculli<sup>2,3</sup>, R. Yagai Bouba<sup>4</sup>, F. Saladini<sup>5</sup>, D. Fiore Bavaro<sup>6</sup>, A. De Vito<sup>7</sup>, R. Lattanzio<sup>6</sup>, R. Corsini<sup>8</sup>, S. Arima<sup>2</sup>, F. Incardona<sup>3,9</sup>, B. Rossetti<sup>10</sup>, A. Bezenchek<sup>9</sup>, V. Borghi<sup>11</sup>, A. Di Biagio<sup>1</sup>*

<sup>1</sup>Department of Health's Sciences, University of Genoa, Genoa, Italy, <sup>2</sup>Department of Computer, Control, and Management Engineering Antonio Ruberti (DIAG), La Sapienza University, Rome, Italy, <sup>3</sup>EuResist Network, Rome, Italy, <sup>4</sup>Department of experimental medicine, University of Rome "Tor Vergata", Rome, Italy, <sup>5</sup>Department of Medical Biotechnologies, University of Siena, Italy, <sup>6</sup>Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari, Bari, Italy, <sup>7</sup>Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>8</sup>Infectious Diseases Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, <sup>9</sup>INFORMAPRO Srl, Rome, Italy, <sup>10</sup>Infectious Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy, <sup>11</sup>Clinic of Infectious Diseases, Azienda Ospedaliero Universitaria di Modena, Modena, Italy

**OC 10 18.00-18.10 Long term efficacy of dolutegravir + lamivudine as simplification cART in patients with suppressed HIV-RNA**

*E. Maggiolo<sup>1</sup>, R. Gulminetti<sup>2</sup>, L. Pagnucco<sup>2</sup>, M. Digaetano<sup>3</sup>, D. Valenti<sup>1</sup>, M. Rizzi<sup>1</sup>, C. Mussini<sup>3</sup>*

<sup>1</sup>Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, <sup>2</sup>Division of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, <sup>3</sup>Division of Infectious Diseases, University of Modena, Modena, Italy

**OC 11 18.10-18.20 Lamivudine+dolutegravir (3TC+DTG) switch strategy compared with the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically suppressed HIV patients: preliminary results from an Italian center**

*G. Baldin<sup>1,2</sup>, A. Ciccullo<sup>2</sup>, A. Borghetti<sup>3</sup>, A. D'Angelillo<sup>2</sup>, A. Dusina<sup>2</sup>, A. Emiliozzi<sup>2,4</sup>, D. Farinacci<sup>2</sup>, D. Moschese<sup>2</sup>, C. Picarelli<sup>2</sup>, R. Cauda<sup>2,3</sup>, S. Di Giambenedetto<sup>2,3</sup>*

<sup>1</sup>Mater Olbia Hospital, Olbia, Italia, <sup>2</sup>Dipartimento di Sicurezza e Bioetica, Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italia, <sup>3</sup>Fondazione Policlinico Agostino Gemelli IRCCS, UOC Malattie Infettive, Roma, Italia, <sup>4</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italia

**OC 12 18.20-18.30 Durability of F/TAF regimens in the era of integrase inhibitors in a large cohort of PLWH seen for care in Italy**

*A. Vergori<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, N. Gianotti<sup>3</sup>, A. Calcagno<sup>4</sup>, G. Guaraldi<sup>5</sup>, G. Orofino<sup>6</sup>, M.C. Moioli<sup>7</sup>, I. Gentile<sup>8</sup>, L. Sarmati<sup>9</sup>, S. Cicalini<sup>1</sup>, A. d'Arminio Monforte<sup>10</sup>, A. Antinori<sup>1</sup> on behalf of Icona Foundation Study Group*

<sup>1</sup>HIV/AIDS Unit, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, <sup>2</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, <sup>3</sup>Infectious Diseases Department, San Raffaele Scientific Institute, IRCCS, Milan, Italy, <sup>4</sup>Unit of Infectious Diseases, Amedeo di Savoia Hospital, Department of Medical Sciences, University of Turin, Turin, Italy, <sup>5</sup>Infectious Diseases Clinic, Department of Medical Specialties, University of Modena and Reggio Emilia, Modena, Italy, <sup>6</sup>Unit A of Infectious Diseases, Amedeo di Savoia Hospital, Turin, Italy, <sup>7</sup>Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>8</sup>Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples "Federico II", Naples, Italy, <sup>9</sup>Clinical Infectious Diseases, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy, <sup>10</sup>Institute of Infectious and Tropical Diseases, Department of Health Sciences, Santi Paolo e Carlo Hospital, University of Milan, Milan, Italy

**SPECIAL SESSION 17.30-18.30**

**Meet the Expert**

Chairs: M. Cascio (Palermo), S. Mattioli (Bologna)

During these Sessions, participants will have the opportunity to informally discuss with top ICAR Experts and exchange with them personal views, receive practical insights about specific topics. Guided by Facilitators, these sessions represent an important opportunity for all delegates to sit down and converse on a more one-to-one level.

**ROOM 3**



17.30-18.00 **Antiretroviral therapy**

Anton Pozniak, London UK

18.00-18.30 **Transgender**

Ottavia Voza, Salerno



MARTEDI'  
13 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

**SPONSORED SYMPOSIUM** 18.30-19.30

Con il supporto di ViiV Healthcare

**PLENARY ROOM**

**Streamline ART from the start: the novel approach of 2DR single pill regimen dolutegravir/lamivudine**

Chair: P. Rizzini (Verona)

Remarkable advances in drug development for the treatment of HIV-1 infection have been achieved in recent years. From the coformulation of combination antiretroviral therapy (cART) into single-tablet regimens to the development new antiretroviral drugs, the treatment of HIV has and will become much more tolerable and less complicated for people living with HIV (PLWH).

Moreover, there is a focus on reducing short- and long-term toxicities of treatment while maintaining robust efficacy and good tolerability.

In this scenario, one of the most recently options considered is 2-drug regimen (2DR) containing highly effective ARV compounds while excluding components that have relatively unfavorable toxicity profiles, with the potential additional advantage to minimize antiretroviral medication burden for improving effectiveness.

In this novel therapeutic context, the 2DR consisting of the INSTI dolutegravir (DTG) and the NRTI lamivudine (3TC), represents today the unique regimen extensively studied versus standard 3- or 4-drug regimens both in naïve and virologically suppressed patients. Aim of the symposium is to highlight important considerations for the use of 2DR single tablet DTG/3TC in the context of existing and emerging ARV options.

|               |   |                             |
|---------------|---|-----------------------------|
| 18.30 - 18.45 | <b>The robustness of the evidences up to date: challenging the use of 3 drug regimens</b> | José M. Gatell, Barcelona E |
| 18.45-19.00   | <b>How dolutegravir/lamivudine meets the patient needs</b>                                | Nneka Nwokolo, London UK    |
| 19.00-19.30   | <b>Discussion on Symposium issues</b>   |                             |

**ORAL COMMUNICATIONS** 18.30-19.30

**ROOM 2**

**HIV Prevention**

Chairs: A. Bignardi (Modena), T. Prestileo (Palermo), B. Suligoi (Roma)

**OC 13 18.30-18.40 Engagement, adherence and rate of discontinuation in an Italian access program of HIV pre-exposure prophylaxis (ItaPrEP)**

V. Mazzotta<sup>1</sup>, P. Vinti<sup>2</sup>, F. De Zottis<sup>1</sup>, P. Lorenzini<sup>1</sup>, A. Tavelli<sup>3</sup>, A. De Bona<sup>3</sup>, S. Nappi<sup>4</sup>, S. Mattioli<sup>5</sup>, A. Bianchi<sup>6</sup>, G. De Carli<sup>7</sup>, G. Mulè<sup>3</sup>, L. Badia<sup>5</sup>, S. Bossolasco<sup>2</sup>, R. Bellagamba<sup>1</sup>, D. Tesoro<sup>3</sup>, R. Rossotti<sup>8</sup>, D. Calzavara<sup>2</sup>, M. Pedone<sup>5</sup>, S. Nozza<sup>9</sup>, P. Tomasi<sup>8</sup>, G. Ancona<sup>3</sup>, F. Gili<sup>7</sup>, G. Lapadula<sup>10</sup>, B.M. Ghisi<sup>11</sup>, F. Niero<sup>12</sup>, M. Bonanni<sup>5</sup>, C. Stingone<sup>13</sup>, G. D'Ettore<sup>14</sup>, R. Esvan<sup>7</sup>, A. Castagna<sup>2</sup>, A. Gori<sup>10</sup>, M. Puoti<sup>8</sup>, M. Galli<sup>11</sup>, G. Rizzardini<sup>12</sup>, M. Andreoni<sup>13</sup>, C. Mastroianni<sup>14</sup>, M. Tavio<sup>15</sup>, R. Cauda<sup>4</sup>, V. Puro<sup>7</sup>, A. Cingolani<sup>4</sup>, G.M. Corbelli<sup>5</sup>, M. Cernuschi<sup>2,6</sup>, A. d'Arminio Monforte<sup>3</sup>, A. Antinori<sup>1</sup>

<sup>1</sup>HIV/AIDS Unit, INMI L. Spallanzani IRCCS, Roma, <sup>2</sup>Milano Checkpoint, Milano, <sup>3</sup>ASST Santi Paolo e Carlo, University of Milano, <sup>4</sup>Fondazione Policlinico A. Gemelli, Catholic University, Roma, <sup>5</sup>PLUS ops (BLQ Checkpoint), Bologna, <sup>6</sup>ASA Onlus, Milano, <sup>7</sup>CRAIDS, INMI L. Spallanzani IRCCS, Roma, <sup>8</sup>ASST Niguarda Hospital, Milano, <sup>9</sup>HSR San Raffaele Scientific Institute, Milano, <sup>10</sup>IRCCS Policlinico Ospedale Maggiore, Milano, <sup>11</sup>ASST L. Sacco Hospital, University of Milano, <sup>12</sup>ASST L. Sacco Hospital, Milano, <sup>13</sup>Tor Vergata University, Roma, <sup>14</sup>Sapienza University, Roma, <sup>15</sup>AOU Ospedali Riuniti, Ancona

**OC 14 18.40-18.50 Pre-Exposure Prophylaxis (PrEP) use at five Infectious Diseases Units in northern Italy (PrEP-Italy study)**

S. Venturilli<sup>1</sup>, R. Rossotti<sup>2</sup>, M. Puoti<sup>2</sup>, G. Cuomo<sup>3</sup>, C. Mussini<sup>3</sup>, N. Squillace<sup>4</sup>, G. Migliorino<sup>4</sup>, S. Cavinato<sup>5</sup>, A.M. Cattelan<sup>5</sup>, D. Ripamonti<sup>1</sup>

<sup>1</sup>ASST Papa Giovanni XXIII, Bergamo, <sup>2</sup>ASST Grande Ospedale Metropolitano Niguarda, Milano, <sup>3</sup>Policlinico di Modena, Modena, <sup>4</sup>ASST Monza Ospedale San Gerardo, Monza, <sup>5</sup>Azienda Ospedaliera di Padova, Padova

**OC 15 18.50-19.00 Uptake and effects on sexual behaviour in a cohort of PrEP users**

P. Vinti<sup>1,2</sup>, A. Tavelli<sup>3</sup>, A. De Bona<sup>3</sup>, A. Bianchi<sup>1,2</sup>, S. Bossolasco<sup>4</sup>, E. Suardi<sup>3</sup>, G. Ancona<sup>3</sup>, D. Tesoro<sup>3</sup>, D. Canetti<sup>4</sup>, A. Antonino<sup>1,2</sup>, F. Rossi<sup>1,2</sup>, D. Calzavara<sup>1</sup>, C. Ferrara<sup>1,2</sup>, V. Polgati<sup>1</sup>, R. Repossi<sup>1,2</sup>, D. Zagato<sup>1,2</sup>, A. d'Arminio Monforte<sup>3</sup>, M. Cernuschi<sup>1,2,4</sup> on behalf of the Milano Checkpoint Group

<sup>1</sup>Milano Checkpoint, Milano, <sup>2</sup>ASA Onlus, Milano, <sup>3</sup>ASST Santi Paolo e Carlo, Milano, <sup>4</sup>IRCCS San Raffaele, Milano

**OC 16 19.00-19.10 Preventive measures against HIV and sexually transmitted infections among key populations referring to a counseling and testing center in the metropolitan area of Rome**

R. Esvan<sup>1</sup>, F. Gili<sup>1</sup>, G. De Carli<sup>1</sup>, N. Orchi<sup>1</sup>, S. Pittalis<sup>2</sup>, F. De Zottis<sup>3</sup>, V. Mazzotta<sup>3</sup>, R. Bellagamba<sup>3</sup>, O. Bruzzi<sup>1</sup>, E. Piscitelli<sup>1</sup>, A. Navarra<sup>2</sup>, G. Nurra<sup>1</sup>, A. Antinori<sup>3</sup>, V. Puro<sup>1</sup>

<sup>1</sup>AIDS Reference Center, INMI "Lazzaro Spallanzani" IRCCS, Rome, Italy, <sup>2</sup>Clinical Epidemiology Unit, INMI "Lazzaro Spallanzani" IRCCS, Rome, Italy, <sup>3</sup>HIV/AIDS Unit, INMI "Lazzaro Spallanzani" IRCCS, Rome, Italy





MARTEDI'  
13 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 **DIGITAL EDITION**

**OC 17 19.10-19.20 Incidence of STIs and HIV in a cohort of MSM and MtF with high prevalence of risk factors for HIV acquisition evaluated in a PrEP community-based service in Italy: one-year follow-up data from SEX-CHECK study**

*D. Testi<sup>1</sup>, L. Badia<sup>1</sup>, E. Rosselli Del Turco<sup>1</sup>, P. Malosso<sup>1</sup>, B. Granozzi<sup>1</sup>, R. Pascale<sup>1</sup>, P. Viale<sup>1</sup>, M. Pedone<sup>2</sup>, S. Mattioli<sup>2</sup>, G. Verucchi<sup>1</sup>*

<sup>1</sup>Alma Mater Studiorum University of Bologna, Infectious Disease Department, S.Orsola-Malpighi Hospital, <sup>2</sup>Plus APS Bologna

**OC 18 19.20-19.30 HIV and motherhood – A survey on women's experiences in the U=U era**

*M.G. Di Benedetto<sup>1</sup>, M.L. Cosmaro<sup>1</sup>, S. Delzero<sup>2</sup>, G. Giupponi<sup>1</sup>, P. Perone<sup>1</sup>, F. Sabbatini<sup>3</sup>, F. Von Schloesser<sup>4</sup>, M. Oldrini<sup>1</sup>*

<sup>1</sup>Lila Onlus, Como, <sup>2</sup>Asst Santi Paolo e Carlo, Ospedale San Paolo Clinica ostetrica e ginecologica, Milano, <sup>3</sup>Clinica di Malattie Infettive, Ospedale San Gerardo dei Tintori, Monza, <sup>4</sup>Nadir Onlus, Roma

**ICAR-CROI Awards 2020 for young Italian HIV investigators**

19.30-20.30

Chairs: R. Cauda (Roma), G. d'Ettore (Roma), G. Rizzardini (Milano)

**PLENARY ROOM**

19.30-19.40 **Introduction**

Guido Silvestri, Atlanta USA

**Oral Presentations of the best selected abstracts 19.40-20.30**

- **NAFLD and liver fibrosis predict high cardiovascular risk in HIV-monoinfected patient**
- **PRO 140 in vitro activity in HTE subjects with a 4-class drugresistant HIV-1 virus**
- **Effect of past virological failure on dolutegravir+lamivudine as maintenance regimen**
- **Persistent poor clinical outcomes for AIDS presentation in Italy over the last decade**
- **Prevotella is related to a dysregulation of IFN and T-CELL response in HIV infection**
- **Liver pathology in HIV-positive subjects undergoing liver transplantation**
- **Functional restoring of gut barrier after modulation of intestinal microbiota**
- **No evidence of clinical impact of STIs on seminal HIV burden during successful ART**
- **Plasma rams in reverse transcriptase gene associate with CSF HIV-1 escape**
- **NK cells are preserved by early ART in HIV-infected children with lower reservoir**

Adriana Cervo, Palermo  
Arianna Gabrieli, Milano  
Roberta Gagliardini, Roma  
Annalisa Mondì, Roma  
Claudia Pinacchio, Roma  
Roberto Rossotti, Milano  
Letizia Santinelli, Roma  
Rossana Scutari, Roma  
Mattia G.C. Trunfio, Torino  
Sonia Zicari, Roma



SCIENTIFIC  
PROGRAMME



MERCOLEDÌ  
14 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

## KEYNOTE LECTURE 14.30-14.50

Chairs: S. Di Giambenedetto (Roma), F. von Schloesser (Roma)

## PLENARY ROOM

14.30-14.50 **Orientating in a maze. The Arianna's thread to partner notification**

Maria Luisa Cosmaro, Milano

## SPONSORED SYMPOSIUM 15.00-16.00

Con la sponsorizzazione di Gilead Sciences

## PLENARY ROOM

### POP ART (population on ART): from patient to *personas* A new approach to fulfill PLHIV expectations

Chairs: A. d'Arminio Monforte, C.F. Perno

*The advent of the new antiretroviral drugs has permitted to obtain virological success in the majority of treated patients. This achievement has allowed the clinicians to focus on HRQoL (4th 90) to guarantee a long-term well-being. In this new context, populations defined by clinical conditions are now obsolete: to achieve the 4th 90 goal we need to consider PLHIV lifestyles by moving from patient profile to personas concept. Each persona is different and has different expectations, therefore is crucial to contemplate all the key factors that contribute to obtain a better quality of life. In this evolving scenario, therapy still has a critical role in controlling the virus, but how can it fulfill doctors' and patients' needs to reach the HRQoL (4th 90)?*

15.00-15.30 **PLHIV in 2020: interactive discussion on *personas***

Cristina Gervasoni, Milano

15.30-15.45 **How therapy can meet patients' needs**

Giordano Madeddu, Sassari

15.45-16.00 **Discussion on Symposium issues**

Stefano Bonora, Torino

## ORAL COMMUNICATIONS 15.00-16.00

## ROOM 2

### Virology

Chairs: S. Menzo (Ancona), M.C. Re (Bologna)

#### OC 19 15.00-15.10 Defining stable reference genes to analyze cell associated HIV RNA induced by latency reversing agents

C. Ceriani<sup>1,2</sup>, K.J. Lemu<sup>1</sup>, K.S. James<sup>1,2</sup>, S. Ghofrani<sup>1,2</sup>, B. Allard<sup>1,2</sup>, D.M. Margolis<sup>1,2,3</sup>, N.M. Archin<sup>1,2</sup>

<sup>1</sup>UNC HIV Cure Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, <sup>2</sup>Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, <sup>3</sup>Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

#### OC 20 15.10-15.20 Prevalence of drug resistance mutations to rilpivirine and doravirine among NNRTI-experienced patients in Italy: a cross-sectional study

A. Lazzaro<sup>1</sup>, A. Lai<sup>2</sup>, M. Franzetti<sup>3</sup>, F. Lombardi<sup>4</sup>, L. Taramasso<sup>5</sup>, M. Siano<sup>2</sup>, F. Saladini<sup>6</sup>, S. Di Giambenedetto<sup>4</sup>, S.T. Kiroso<sup>7</sup>, P. Bagnarelli<sup>8</sup>, E. Barchi<sup>9</sup>, W. Gennari<sup>10</sup>, A. Gabrieli<sup>2</sup>, A. Shallvari<sup>11</sup>, S. Rusconi<sup>2</sup>

<sup>1</sup>Università degli Studi di Torino, Dipartimento di Scienze Mediche, Unità di Malattie Infettive, Torino, <sup>2</sup>Divisione Clinicizzata di Malattie Infettive, DIBIC Luigi Sacco, Università degli Studi di Milano, Milano, <sup>3</sup>Divisione di Malattie Infettive, Ospedale "Alessandro Manzoni", Lecco, <sup>4</sup>Università Cattolica del Sacro Cuore, Istituto di Clinica Malattie Infettive, Roma, <sup>5</sup>Divisione Clinicizzata di Malattie Infettive, Dipartimento di Medicina Interna, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, <sup>6</sup>Laboratorio di Virologia, Università degli Studi di Siena, Siena, <sup>7</sup>Divisione Clinicizzata di Malattie Infettive, Ospedale Careggi, Firenze, <sup>8</sup>Laboratorio di Virologia, Università Politecnica delle Marche, Ancona, <sup>9</sup>Divisione di Malattie Infettive, Azienda Ospedaliera Santa Maria Nuova, Reggio Emilia, <sup>10</sup>Laboratorio di Virologia, Azienda Ospedaliera-Universitaria di Modena, Modena, <sup>11</sup>InformaPRO S.r.l., Roma

#### OC 21 15.20-15.30 HIV-DNA from rectal GALT is a valid marker to characterize the viral reservoir

C. Stingone<sup>1</sup>, R. Scutari<sup>2</sup>, C. Matteucci<sup>2</sup>, L. Piermatteo<sup>2</sup>, M. Compagno<sup>1</sup>, E. Cavazzoni<sup>3</sup>, K.Y. La Rosa<sup>2</sup>, A. De Nicolò<sup>4</sup>, G. Di Perri<sup>4</sup>, V. Malagnino<sup>1</sup>, A. Bertoli<sup>2,6</sup>, V. Vicher<sup>2</sup>, C. Alteri<sup>5</sup>, S. Grelli<sup>2</sup>, L. Sarmati<sup>1</sup>, F. Ceccherini-Silberstein<sup>2</sup>, M. Andreoni<sup>1</sup>

<sup>1</sup>Department of System Medicine, Clinical Infectious Diseases, Tor Vergata University, Rome, <sup>2</sup>Department of Experimental Medicine, Tor Vergata University, Rome, <sup>3</sup>Department of Surgical Sciences, University of Perugia, <sup>4</sup>Department of Medical Sciences, University of Turin, <sup>5</sup>Department of Oncology and Hemato-oncology, University of Milan, <sup>6</sup>Virology Unit, Tor Vergata University Hospital, Rome



SCIENTIFIC  
PROGRAMME



MERCOLEDÌ  
14 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

**OC 22 15.30-15.40 Evaluation of HIV-1 tropism in multidrug-resistant cART failing patients**

Y. Boubou<sup>1</sup>, D. Armenia<sup>1,2</sup>, F. Forbici<sup>3</sup>, A. Bertoli<sup>1,4</sup>, V. Borghi<sup>5</sup>, R. Gagliardini<sup>6</sup>, A. Vergori<sup>6</sup>, S. Cicalini<sup>6</sup>, V. Mazzotta<sup>6</sup>, V. Malagnino<sup>7</sup>, M. Lichtner<sup>8</sup>, M. Colafigli<sup>9</sup>, M. Andreoni<sup>7</sup>, A. Antinori<sup>6</sup>, C.F. Perno<sup>3</sup>, F. Ceccherini-Silberstein<sup>1</sup>, M.M. Santoro<sup>1</sup>

<sup>1</sup>Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, <sup>2</sup>Saint Camillus International University of Health Sciences, Rome, Italy, <sup>3</sup>Laboratory of Virology, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy, <sup>4</sup>Laboratory of Virology, University Hospital "Tor Vergata", Rome, Italy, <sup>5</sup>Clinic of Infectious Diseases, University Hospital, University of Modena and Reggio Emilia, Modena, Italy, <sup>6</sup>Clinical Department, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy, <sup>7</sup>Clinical Infectious Diseases, University Hospital "Tor Vergata", Rome, Italy, <sup>8</sup>Infectious Diseases Unit, "Sapienza" University, Polo Pontino, Latina, Italy, <sup>9</sup>Unit of Dermatology and Sexually Transmitted Diseases, San Gallicano Dermatological Institute IRCCS, Rome, Italy

**OC 23 15.40-15.50 Does dual therapy have an impact on HIV-DNA decay in virologically-suppressed patients compared to triple therapy? Results from a multicentric study**

A. Emiliozzi<sup>1</sup>, F. Lombardi<sup>2</sup>, B. Rossetti<sup>3</sup>, C. Spertilli Raffaelli<sup>1</sup>, S. Belmonti<sup>2</sup>, A. Ciccullo<sup>2</sup>, A. Dusina<sup>2</sup>, A. D'Angelillo<sup>2</sup>, M. D. Di Trapani<sup>1</sup>, G. Zanelli<sup>1</sup>, F. Montagnani<sup>1</sup>, F. Saladini<sup>5</sup>, M. Zazzi<sup>5</sup>, S. Di Giambenedetto<sup>2,4</sup>, M. Fabbiani<sup>3</sup>

<sup>1</sup>UOC Malattie Infettive e Tropicali, Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italy, <sup>2</sup>Università Cattolica del Sacro Cuore, Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive, Roma, Italy, <sup>3</sup>UOC Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Senese, Siena, Italy, <sup>4</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, UOC Malattie Infettive, <sup>5</sup>UOC Microbiologia e Virologia, Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italy

**OC 24 15.50-16.00 Prevalence of high-risk HPV genotypes and HPV genotypes targeted by the nine-valent vaccine Gardasil-9 and the associated risk factors**

E. Bruzzesi<sup>1</sup>, L. Galli<sup>2</sup>, A. Poli<sup>2</sup>, S. Bossolasco<sup>2</sup>, M. Cernuschi<sup>2</sup>, V. Spagnuolo<sup>1,2</sup>, A.M. Tamburini<sup>2</sup>, D. Canetti<sup>2</sup>, E. Messina<sup>2</sup>, N. Gianotti<sup>2</sup>, A. Lazzarin<sup>2</sup>, A. Castagna<sup>1,2</sup>, S. Nozza<sup>2</sup>

<sup>1</sup>Vita-Salute San Raffaele University, Milan, Italy, <sup>2</sup>Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

**SYMPOSIUM 16.00-16.55**

**PLENARY ROOM**

**Reaching out: same models for different infections**

Chairs: S. Negri (Milano), V. Puro (Roma), E. Vaccher (Aviano PN)

The first of the United Nations' 90-90-90 targets to end the HIV epidemic is for 90% of people living with HIV to learn their HIV status. HIV testing is therefore essential to achieving "the first 90". The only way to determine a person's HIV status is for them to have an HIV test. What is the best way?

HIV testing in healthcare services is the traditional approach. Good results have been accomplished through it but there are some obstacles as limited access and usability of the healthcare structures and the difficulty of people to undergo the test in the hospital.

In recent years, the Point of Care (POC) have been successful to overcome some difficulties and to make easier the access to the test especially for populations who showed reluctance to go to the hospital.

The European POC has also created a network to facilitate access to the hospital and to make access to care simpler and faster. It already has the result to accelerate the United Nations' 90-90-90 campaign.

Discussing and finding further solutions requires reflection on the experiences that have been carried out by NGOs. Looking for concrete collaborations and new intervention strategies between POC and hospital can bring us closer to the WHO objectives and reinforce the equation Undetectable = Untransmittable (U=U) message.

There is an opportunity to improve prevention, testing services and ensure high-quality well-adhered treatment and care for all.

|             |  |                                |
|-------------|--|--------------------------------|
| 16.00-16.10 | <b>Amending missed opportunities for HIV testing in healthcare services</b>            | Silvia Nozza, Milano           |
| 16.10-16.20 | <b>Testing, prevention and treatment outside of the hospital: the checkpoint model</b> | Giulio Maria Corbelli, Bologna |
| 16.20-16.30 | <b>"We are not hard to reach" - Bringing people to the hospital and vice versa</b>     | Elisabetta Teti, Roma          |
| 16.30-16.40 | <b>Integrated health policies: barriers, challenges and opportunities</b>              | Luca Rizzo Nervo, Bologna      |
| 16.40-16.55 | <b>Discussion on Symposium issues</b>  |                                |



SCIENTIFIC  
PROGRAMME



MERCOLEDÌ  
14 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

## SATELLITE SYMPOSIUM 16.00-17.00

Con la sponsorizzazione non condizionante di Angelini

ROOM 2

### Recent advances in the management of Gram positive infections: the evolving role of long acting therapy

Chair: M. Tavio (Ancona)

Gram positive infections are a continuing challenge for clinicians: while classic pathogens still persist and evolve acquiring new mechanisms of resistance, new pathogens emerge with intrinsic multiple antibiotics resistance profiles, causing life-threatening infections as nosocomial pneumonia and intravascular device associated bloodstream infections. Not less important, the population at risk, i.e. elderly with multiple comorbidities or recipients of various foreign bodies, is increasing. New therapy options are required, with increased bactericidal activity and antibacterial spectrum that includes multiple resistant pathogens. Recently, the antimicrobial armamentarium has been enriched by a lipoglycopeptide with a very prolonged half-life (dalbavancin) enabling treatment with a single intravenous administration. Pharmacokinetic profile and convenient single dosing make dalbavancin an interesting option for other serious Gram positive infections requiring prolonged treatment courses, for example bone infections, endocarditis and intravascular line associated infections. The aim of this workshop is to focus on new pharmacological, clinical and pharmacoeconomical data with dalbavancin in order to provide an up-to-date of the actual and potential future role of this options for serious Gram positive infections.

|             |   |                          |
|-------------|---|--------------------------|
| 16.00-16.15 | <b>Gram+ subacute infections</b>  | Pierluigi Viale, Bologna |
| 16.15-16.30 | <b>The evolving role of long acting therapy in the management of Gram positive infections</b> | Massimo Andreoni, Roma   |
| 16.30-16.45 | <b>Dalbavancin: pharmacokinetical data</b>  | Pierluigi Viale, Bologna |
| 16.45-17.00 | <b>Dalbavancin: pharmacoeconomical data</b>   | Massimo Andreoni, Roma   |

## KEYNOTE LECTURE 17.00-17.20

Chairs: M. Galli (Milano), E. Girardi (Roma)

PLENARY ROOM

|             |   |                                 |
|-------------|---|---------------------------------|
| 17.00-17.20 | <b>New challenges in virology: SARS-CoV-2</b> | Maria Rosaria Capobianchi, Roma |
|-------------|---|---------------------------------|

## SATELLITE SYMPOSIUM 17.30-18.30

Con la sponsorizzazione non condizionante di Janssen

PLENARY ROOM

### Committed globally to fight HIV and other severe infections

Chair: C. Mussini (Modena)

Since the introduction of cART there has been increased survival in HIV-infected persons, so nowadays it is important to answer to individual HIV patients needs, going beyond viral suppression, as antiretroviral therapy is a life-long commitment. Furthermore, with the availability of two or three drugs combinations is becoming more crucial the physician's role in choosing and adapting the ART to treat population living with HIV (PLWH) avoiding issues about adherence, potential drug-drug interactions, long-term toxicities given that the PLWH is ageing with increasing comorbidities such as osteoporosis, renal, cardiovascular, metabolic and liver diseases, which need additional drugs.

The aim of the symposium is to examine how current antiretroviral agents may be better incorporated into management strategies in daily practice to benefit patient's individuality now and to preserve the future.

In this changing scenario, is interesting to show how the well-known NNRTI rilpivirine (RPV) has remained central to several key therapeutic innovations due to its proven durable efficacy & tolerability that delivers multiple benefits for HIV patients.

Furthermore, while the global genetic diversity of HIV poses a considerable scientific challenge, the symposium will be an opportunity to discuss on the Infectivologists & pharma company's commitment to HIV and other infections vaccine research, aiming to address these problems.

|             |   |                            |
|-------------|---|----------------------------|
| 17.30-17.45 | <b>Individuality: beyond viral suppression</b>                            | Giordano Madeddu, Sassari  |
| 17.45-18.00 | <b>The rilpivirine perspective: present and future</b>                    | Sergio Lo Caputo, Foggia   |
| 18.00-18.15 | <b>Back to basic: paving the way to HIV and other infections vaccines</b> | Antonella Castagna, Milano |
| 18.15-18.30 | <b>Discussion on Symposium issues</b>                                     |                            |



SCIENTIFIC  
PROGRAMME





MERCOLEDÌ  
14 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

## ORAL COMMUNICATIONS 17.30-18.30

ROOM 2

### Comorbidities

Chairs: D. Francisci (Perugia), G. Parruti (Pescara)

#### OC 25 17.30-17.40 Fat distribution and density in PLWH with ≥5% weight gain

G. Guaraldi<sup>1</sup>, S. Draisci<sup>1</sup>, M. Menozzi<sup>1</sup>, J. Milic<sup>1</sup>, A. Malagoli<sup>1</sup>, F. Carli<sup>1</sup>, G. Besutti<sup>1</sup>, C. Bassoli<sup>1</sup>, A. Raimondi<sup>1</sup>, G. Ciusa<sup>1</sup>, G. Ligabue<sup>1</sup>, C. Mussini<sup>1</sup>, K. Erlandson<sup>2</sup>, T.T. Brown<sup>3</sup>, J.E. Lake<sup>4</sup>

<sup>1</sup>Università degli studi di Modena e Reggio Emilia, <sup>2</sup>University of Colorado, Department of Medicine, Aurora, CO, <sup>3</sup>Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, <sup>4</sup>University of Texas Health Sciences Center, Houston, Texas, USA

#### OC 26 17.40-17.50 Statin Eligibility in People living with HIV: are we using the right tools to identify patients at risk of developing major cardiovascular disease?

M. Mazzitelli<sup>1,2</sup>, B. Pereira<sup>1</sup>, A. Milinkovic<sup>1</sup>, A. Pozniak<sup>1,3</sup>, D. Asboe<sup>1</sup>, G. Moyle<sup>1</sup>, A. Al-Hussaini<sup>4</sup>, M. Boffito<sup>1,3</sup>

<sup>1</sup>HIV/GUM Directorate, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, <sup>2</sup>Magna Graecia University, Catanzaro, Italy, <sup>3</sup>Imperial College London, London, UK, <sup>4</sup>Cardiology Department, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK

#### OC 27 17.50-18.00 Prevalence, predictors and evolution of lean non-alcoholic fatty liver disease in HIV mono-infected patients

A. Cervo<sup>1,2</sup>, J. Milic<sup>3</sup>, G. Mazzola<sup>2</sup>, F. Schepis<sup>3</sup>, S. Petta<sup>2</sup>, T. Krahn<sup>1</sup>, B. Lebouche<sup>1</sup>, M. Deschenes<sup>1</sup>, A. Cascio<sup>2</sup>, G. Guaraldi<sup>3</sup>, G. Sebastiani<sup>1</sup>

<sup>1</sup>McGill University Health Centre, Montreal, Canada, <sup>2</sup>University of Palermo, Palermo, Italy, <sup>3</sup>University of Modena and Reggio Emilia, Modena, Italy

#### OC 28 18.00-18.10 NAFLD with significant fibrosis in PLWH informs the natural history of cardiovascular disease

G. Guaraldi<sup>1</sup>, J. Milic<sup>1</sup>, A. Cervo<sup>2</sup>, A. Malagoli<sup>1</sup>, M. Menozzi<sup>1</sup>, G. Dolci<sup>1</sup>, G. Ciusa<sup>1</sup>, F. Carli<sup>1</sup>, G. Mazzola<sup>2</sup>, G. Sebastiani<sup>3</sup>, C. Mussini<sup>1</sup>

<sup>1</sup>University of Modena and Reggio Emilia, Italy, <sup>2</sup>Infectious Diseases Unit, PROMISE, University of Palermo, Palermo, Italy, <sup>3</sup>Chronic Viral Illness Service, McGill University Health Centre, Montreal, Canada

#### OC 29 18.10-18.20 Decline of metabolic syndrome and increase in overweight in HIV infected patients from 2005-2015

G.V. De Socio<sup>1</sup>, E. Ricci<sup>2</sup>, L. Taramasso<sup>3</sup>, P. Maggi<sup>4</sup>, G. Orofino<sup>5</sup>, N. Squillace<sup>6</sup>, B. Menzaghi<sup>7</sup>, G. Madeddu<sup>8</sup>, A. Di Biagio<sup>9</sup>, C. Molteni<sup>10</sup>, F. Vichi<sup>11</sup>, E. Riguccini<sup>1</sup>, C. Santoro<sup>12</sup>, M. Guastavigna<sup>5</sup>, A. De Vito<sup>8</sup>, D. Francisci<sup>1</sup>, P. Bonfanti<sup>10, 6</sup>, For the CISA study group

<sup>1</sup>Infectious Diseases Clinic, Azienda Ospedaliera di Perugia and University of Perugia, Santa Maria Hospital, Perugia, Italy, <sup>2</sup>Department of Woman, Newborn and Child, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>3</sup>Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>4</sup>Infectious Diseases Clinic, University of Campania "Luigi Vanvitelli", Naples, Italy, <sup>5</sup>Unit of Infectious Diseases, "Divisione A", Amedeo di Savoia Hospital, Torino, Italy, <sup>6</sup>Infectious Diseases Clinic, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, <sup>7</sup>Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, Busto Arsizio, Italy, <sup>8</sup>Unit of Infectious and Tropical Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>9</sup>Infectious Diseases Clinic, Dept. of Health Sciences, University of Genoa, San Martino Hospital-IRCCS, Genoa, Italy, <sup>10</sup>Infectious Disease Unit, Ospedale A. Manzoni, Lecco, Italy, <sup>11</sup>Infectious Diseases Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy, <sup>12</sup>Infectious Diseases Clinic, University of Bari, Italy

#### OC 30 18.20-18.30 Progression of anal/cervical dysplasia is associated with Human Papillomavirus (HPV) and Syphilis coinfection in HIV-infected patients

C. Tinca<sup>1</sup>, F. Bai<sup>1</sup>, D. Mondatore<sup>1</sup>, A. Liparoti<sup>1</sup>, M. Augello<sup>1</sup>, M. Giovenzana<sup>2</sup>, A. Pisani Ceretti<sup>2</sup>, E. Opocher<sup>2</sup>, A. d'Arminio Monforte<sup>1</sup>, G. Marchetti<sup>1</sup>

<sup>1</sup>Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, Italy, <sup>2</sup>Department of Health Sciences, Hepatobiliopancreatic and Digestive Surgery, ASST Santi Paolo e Carlo, University of Milan, Italy

## SPECIAL SESSION 17.30-18.30

ROOM 3

### Meet the Expert

Chairs: M. Breveglieri (Bologna), S. Mattioli (Bologna)

During these Sessions, participants will have the opportunity to informally discuss with top ICAR Experts and exchange with them personal views, receive practical insights about specific topics.

Guided by Facilitators, these sessions represent an important opportunity for all delegates to sit down and converse on a more one-to-one level.



17.30-18.00

**Chemsex**

Cesare Di Felicianantonio, Manchester UK

18.00-18.30

**Drug-Drug Interactions**

Dario Cattaneo, Milano



SCIENTIFIC  
PROGRAMME



MERCOLEDÌ  
14 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

**SYMPOSIUM** 18.30-19.25

**PLENARY ROOM**

## Lights and shadows in HIV clinical research

Chairs: P. Cinque (Milano), N. Gianotti (Milano), A. Gori (Milano)

Evidence based medicine relies on well conducted clinical trials and comprehensive cohort data to draw its indications. However, no experimental design is completely free of drawbacks and limitations. Therefore, the results of different clinical experiences must be read in a critical way understanding which is the right field of application. The problem is further complicated in a constantly expanding field as HIV/AIDS by the need to adequate outcomes and measures to newly defined goals. The symposium will offer a comprehensive discussion about all these critical aspects of clinical management of HIV/AIDS.

- 18.30-18.40 **What trials did not show**
- 18.40-18.50 **What we cannot expect from clinical cohorts**
- 18.50-19.00 **Innovative outcomes: what surrogate outcomes**
- 19.00-19.10 **Unconventional innovative outcomes**
- 19.10-19.25 **Discussion on Symposium issues**

Franco Maggiolo, Bergamo  
Alessandro Cozzi-Lepri, London UK  
Maria Santoro, Roma  
Antonella Cingolani, Roma

**ORAL COMMUNICATIONS** 18.30-19.30

**ROOM 2**

## Clinical Hepatitis and Coinfections

Chairs: G. Mazzola (Palermo), T. Santantonio (Foggia)

### OC 31 18.30-18.40 The contribution of late presentation and late ART initiation to TB-HIV occurrence across four countries

Y. Caro-Vega, E. Girardi, J. Musaaazi, A. Cozzi-Lepri, G. Carriquiry, B. Castelnuevo, A. Gori, Y.C. Manabe, E. Gotuzzo, A. D'Arminio Monforte, B. Crabtree-Ramirez, C. Mussini for the ICoNA, IMT AvH, INNSZ and IDI Cohorts

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Departamento de Infectología, Mexico City, Mexico; National Institute for Infectious Diseases Lazzaro Spallanzani -IRCCS, Roma, Italy; Infectious Disease Institute, Kampala, Uganda; University College London, London, United Kingdom; Universidad Peruana Cayetano Heredia, Lima, Peru; University of Milan, Milan, Italy; Johns Hopkins University, Baltimore, United States; University of Modena and Reggio Emilia, Modena, Italy

### OC 32 18.40-18.50 HPV 16 and 18 infections contribute to development of anal cytological abnormalities in a cohort of PLWH

N. Squillace<sup>1</sup>, D.P. Bernasconi<sup>2</sup>, G. Lapadula<sup>1</sup>, A. Soria<sup>1</sup>, F. Sabbatini<sup>1</sup>, E. Colella<sup>1</sup>, V. Cogliandro<sup>1</sup>, P. Vitiello<sup>1</sup>, M. Rossi<sup>1</sup>, B.E. Leone<sup>3</sup>, A. Brenna<sup>3</sup>, S. Malandrini<sup>4</sup>, A. Cavallero<sup>4</sup>, A. Di Lucia<sup>5</sup>, M. Braga<sup>5</sup>, G.M. Migliorino<sup>1</sup>

<sup>1</sup>Azienda Socio Sanitaria Territoriale Monza, Ospedale San Gerardo, Unità Operativa di Malattie infettive, Monza, <sup>2</sup>Center of Biostatistics for Clinical Epidemiology School of Medicine and Surgery University of Milano-Bicocca, Monza, <sup>3</sup>Pathology, Department of Medicine and Surgery, University of Milano-Bicocca, Ospedale San Gerardo, Monza, <sup>4</sup>Azienda Socio Sanitaria Territoriale Monza, Ospedale San Gerardo, Struttura Complessa di Microbiologia, Monza, <sup>5</sup>Azienda Socio Sanitaria Territoriale Monza, Ospedale San Gerardo, Chirurgia generale e d'urgenza I, Monza

### OC 33 18.50-19.00 Impact of syphilis on the risk of HIV viral rebound in HIV positive patients under effective antiretroviral treatment: data from the ICONA cohort

A. Giacomelli<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, A. Cingolani<sup>3</sup>, A. Tavelli<sup>4</sup>, V. Mazzotta<sup>5</sup>, D. Tesoro<sup>6</sup>, M. Bassetti<sup>7</sup>, A. Castagna<sup>8</sup>, A. Di Biagio<sup>7</sup>, M. Lichter<sup>9</sup>, A. d'Arminio Monforte<sup>6</sup>, S. Rusconi<sup>1</sup> on behalf of the ICONA Foundation Study Group

<sup>1</sup>III Infectious Diseases Unit, ASST-FBF-Sacco, Department of Biomedical and Clinical Sciences DIBIC Luigi Sacco, University of Milan, <sup>2</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, <sup>3</sup>Infectious Diseases Unit, Fondazione Policlinico Universitario A. Gemelli - Università Cattolica Del Sacro Cuore, Rome, Italy, <sup>4</sup>ICONA Foundation, Milan, Italy, <sup>5</sup>HIV/AIDS Unit, INMI "Lazzaro Spallanzani" IRCCS, Rome, Italy, <sup>6</sup>Clinic of Infectious and Tropical Diseases, ASST Santi Paolo e Carlo, University of Milan Department of Health Sciences, Milan, Italy, <sup>7</sup>Infectious Diseases Clinic, Policlinico San Martino Hospital, Department of Health Sciences, University of Genoa, Genova, Italy, <sup>8</sup>Infectious Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, <sup>9</sup>Infectious Diseases Unit, Sapienza University of Rome, Santa Maria Goretti Hospital, Latina, Italy

### OC 34 19.00-19.10 Decrease of prevalence of subjects harboring replicating HCV among PLWHIV in Italy: results from the NoCo study

A. d'Arminio Monforte<sup>1</sup>, A. Tavelli<sup>2</sup>, A. Cozzi-Lepri<sup>3</sup>, A. Vergori<sup>4</sup>, E. Quiros-Roldan<sup>5</sup>, R. Rossotti<sup>6</sup>, B.M. Ceslasia<sup>7</sup>, F. Bai<sup>1</sup>, F. Maggiolo<sup>8</sup>, E. Girardi<sup>9</sup>, A. Antinori<sup>4</sup>, M. Puoti<sup>6</sup> for the NoCo Study of the Icona cohort

<sup>1</sup>Clinic of Infectious and Tropical Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, <sup>2</sup>Icona Foundation, Milan, Italy, <sup>3</sup>Institute for Global Health, University College of London, London, UK, <sup>4</sup>Clinical Division of HIV/AIDS, INMI "L. Spallanzani" IRCCS, Rome, Italy, <sup>5</sup>Department of Infectious and Tropical Diseases, University of Brescia, ASST Spedali Civili Hospital, Brescia, Italy, <sup>6</sup>Division of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan Italy, <sup>7</sup>Division of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital, University of Catania, Catania, Italy, <sup>8</sup>Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>9</sup>Clinical Epidemiology Unit, INMI "L. Spallanzani" IRCCS, Rome, Italy



SCIENTIFIC  
PROGRAMME



MERCOLEDÌ  
14 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

**OC 35 19.10-19.20 Innovative procedures for micro-elimination of HCV infection in a high-risk population of undocumented migrants and low income refugees**

*M. Macera<sup>1,3</sup>, L. Alessio<sup>2,3</sup>, S. De Pascalis<sup>1</sup>, V. Messina<sup>2</sup>, L. Onorato<sup>1,4</sup>, C. Sagnelli<sup>1,5</sup>, E. Sagnelli<sup>1</sup>, G. Di Caprio<sup>2,3</sup>, M. Pisaturo<sup>1,4</sup>, N. Coppola<sup>1,2</sup>*

<sup>1</sup>Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Italy, <sup>2</sup>InfectiousDiseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, <sup>3</sup>Medical Center, Centro Sociale ex Canapificio, Caserta; Italy, <sup>4</sup>Medical Center, Centro di Accoglienza "La tenda di Abramo", Caserta, Italy, <sup>5</sup>Medical Center, Centro per la Tutela della Salute degli Immigrati, Naples, Italy, <sup>6</sup>Medical center, Centro Suore Missionarie della Carità, Naples, Italy

**OC 36 19.20-19.30 HCV treatment and reinfection risk in injecting drug users in Residential Treatment Setting for drug addiction. San Patrignano HCV-free**

*P. Piselli<sup>1</sup>, A. Boschini<sup>2</sup>, R. Poletti<sup>2</sup>, M. Begnini<sup>2</sup>, P. Ottogalli<sup>2</sup>, C. Cimaglia<sup>1</sup>, M.P. Parracino<sup>1</sup>, E. Girardi<sup>1</sup>*

<sup>1</sup>INMI "L. Spallanzani" IRCCS, Rome, <sup>2</sup>Comunità San Patrignano, Rimini



SCIENTIFIC  
PROGRAMME





GIOVEDÌ  
15 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

**ROUND TABLE** 14.30-15.15

**PLENARY ROOM**

## HIV in COVID-19 era: how to ensure quality of care and outpatient management

Chairs: M. Andreoni (Roma), A.M. Cattelan (Padova)

2020 has been so far very challenging for infectious disease specialists around the world especially for new coronavirus. The aim of the round table is to discuss how this emergency impacted on the outpatient management of HIV infected patients and, more generally, on their quality of care. Clinicians will talk about clinic experiences, recommendations and organizational models on management and security, diagnosis, screening, telemedicine while patients will relate about their perception on the quality of care with a focus on PrEP and STI management.

14.30-15.15

### Participants:

M.G. Di Benedetto (Catania), M. Lichtner (Roma), S. Mattioli (Bologna), S. Rusconi (Milano)

**SATELLITE SYMPOSIUM** 15.20-16.20

**PLENARY ROOM**

Con il supporto incondizionato di ViiV Healthcare

## HIV: understanding the real burdens of the disease

Chair: C. Mussini (Modena)

The today new standards of highly virologically effective antiretroviral regimens fully authorize clinicians to move the attention from pursuing viro-immunological outcomes, namely efficacy, to also considering in the clinical practice concrete strategies for preserving both quality of life and long-term well-being, namely effectiveness. Reducing all kind of medication burdens, both pharmacological and taking medicine ones, suggest a patient-centered approach.

15.20-15.35

**Reducing ARV and taking medicines burdens for improving effectiveness**

Massimo Andreoni, Roma

15.35-15.50

**The evaluation of patient complexity in the setting of ARV deprescribing**

Giovanni Guaraldi, Modena

15.50-16.15

**Discussion on Symposium issues**

16.15-16.20

**Closing remarks**

Cristina Mussini, Modena

**ORAL COMMUNICATIONS** 15.20-16.20

**ROOM 2**

## Basic Science and Immunology

Chairs: C. Agrati (Roma), C.M. Mastroianni (Roma)

### OC 37 15.20-15.30 Reduced probability of achieving optimal viro-immunological condition in subjects with vertical transmission of HIV reaching adult age with unsuppressed HIV RNA or incomplete immunological recovery

A. Celotti<sup>1</sup>, S. Calza<sup>2</sup>, A. Di Biagio<sup>3</sup>, C. Mussini<sup>4</sup>, S. Rusconi<sup>5</sup>, S. Bonora<sup>6</sup>, S. Di Giambenedetto<sup>7</sup>, E. Quiros Roldan<sup>1</sup>, G. Sarteschi<sup>3</sup>, M. Menozzi<sup>4</sup>, M. Ferrara<sup>6</sup>, A. Ciccullo<sup>8</sup>, V. Giacomel<sup>9</sup>, A. Ferrari<sup>10</sup>, R. Badolato<sup>10</sup>, I. Izzo<sup>1</sup>, F. Castelli<sup>1</sup>, E. Focà<sup>1</sup>

<sup>1</sup>Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, <sup>2</sup>Unit of Biostatistics, Department of Molecular and Translational Medicine, University of Brescia, Italy, <sup>3</sup>Clinic of Infectious and Tropical Diseases, University of Genova and "San Martino" Hospital, Genoa, Italy, <sup>4</sup>Department of Infectious Diseases, University of Modena and Reggio Emilia and Modena Polyclinic, Modena, Italy, <sup>5</sup>Unit of Infectious Diseases, University of Milano and ASST Fatebenefratelli "L. Sacco" Hospital, Milan, Italy, <sup>6</sup>Department of Infectious Diseases, University of Torino and "Amedeo di Savoia" Hospital, Turin, Italy, <sup>7</sup>Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, <sup>8</sup>Department of safety and bioethics, section of infectious diseases, Catholic University of the Sacred Heart, Rome, Italy, <sup>9</sup>Unit of Pediatrics, University of Milano and ASST Fatebenefratelli "L. Sacco" Hospital, Milan, Italy, <sup>10</sup>Unit of Pediatrics, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy

### OC 38 15.30-15.40 Immunological recovery in T-cell activation after DAA treatment and SVR in HIV positive subjects with chronic hepatitis C

F. Maggiolo, A. Callegaro, D. Valenti, E. Di Filippo, L. Comi, M. Rizzi

ASST Papa Giovanni XXIII, Bergamo



SCIENTIFIC  
PROGRAMME



GIOVEDÌ  
15 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

**OC 39 15.40-15.50 Higher frequency of CD4+PD1+ T cells and Interferon-Stimulate Genes are associated to a decrease in CD4+ Treg levels in HIV-1 infected patients**

*F. Frasca<sup>1</sup>, M. Scordio<sup>1</sup>, L. Santinelli<sup>1</sup>, G. Ceccarelli<sup>2</sup>, C. Mastroianni<sup>2</sup>, G. Antonelli<sup>1</sup>, I. Mezzaroma<sup>3</sup>, G. d'Ettore<sup>2</sup>, C. Scagnolari<sup>1</sup>*

<sup>1</sup>Department of Molecular Medicine, Laboratory of Virology, Affiliated to Istituto Pasteur Italia - Cenci Bolognietti Foundation, Sapienza University of Rome, <sup>2</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, <sup>3</sup>Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy

**OC 40 15.50-16.00 Macrophage transcriptome profiling upon CCL2 neutralization identifies an association between activation of antiviral responses and HIV-1 restriction**

*D.A. Covino<sup>1</sup>, K. Kaczor Urbanowicz<sup>2</sup>, J. Lu<sup>2</sup>, M.V. Chiantore<sup>3</sup>, G. Fiorucci<sup>3,4</sup>, L. Catapano<sup>1</sup>, C. Purificato<sup>1</sup>, C.M. Galluzzo<sup>1</sup>, R. Amici<sup>1</sup>, M. Andreotti<sup>1</sup>, M. C. Gauzzi<sup>1</sup>, M. Pellegrini<sup>2</sup>, L. Fantuzzi<sup>1</sup>*

<sup>1</sup>National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy, <sup>2</sup>Department of Molecular, Cell, and Developmental Biology, University of California Los Angeles, Los Angeles, CA, USA, <sup>3</sup>Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy, <sup>4</sup>Institute of Molecular Biology and Pathology, CNR, Rome, Italy

**OC 41 16.00-16.10 High frequency of Myeloid Derived Suppressor Cells in Immunological Non Responders: possible involvement in CD4 T cell recovery**

*A. Sacchi, G. Grassi, S. Cicalini, V. Mazzotta, V. Bordoni, R. Casetti, E. Cimini, A. Antinori, C. Agrati*

National Institute for Infectious Diseases Lazzaro Spallanzani

**OC 42 16.10-16.20 HIV-binding specificity and -neutralizing potency after ART interruption in chronically HIV-1 infected subjects with long-lasting virological suppression (APACHE study).**

*G. Siracusano, L. Galli, C. Pastori, A. Bigoloni, A. Galli, C. Muccini, A. Mastrangelo, E. Bruzzesi, A. Lazzarin, V. Spagnuolo, A. Castagna, L. Lopalco*

IRCCS San Raffaele Scientific Institute, Milan

**SYMPOSIUM 16.20-17.15**

**PLENARY ROOM**

**Immune control over HIV reservoir**

*Chairs: A. Caruso (Brescia), M. Clerici (Milano), L. Sarmati (Roma)*

*Despite full control over HIV replication by cART, HIV has been shown to persist in lymphoid tissues, and represent a major obstacle to HIV eradication. The symposium will review the major immunologic pathways behind immune control over HIV, alongside the distinguishing features of patients with progressive versus non-progressive disease.*

- 16.20-16.30 **Models of natural protection against HIV infection and progression**
- 16.30-16.40 **Innate immunity: don't forget the macrophages!**
- 16.40-16.50 **Inflammatory stem cells**
- 16.50-17.00 **Killing HIV by bNABs: apocalypse, now?**
- 17.00-17.15 **Discussion on Symposium issues**

- Mara Biasin, Milano
- Guido Poli, Milano
- Andrea De Maria, Genova
- Lucia Lopalco, Milano



GIOVEDÌ  
15 OTTOBRE

**EXPERT MEETING** 16.20-17.20

Con la sponsorizzazione non condizionante di Gilead Sciences

**ROOM 2**

**Enhancing care for people living with HIV:  
current and future of monitoring approaches**

Chairs: A. Di Biagio (Genova), F. Maggiolo (Bergamo)

The most significant advance in the medical management of HIV-1 infection has been the treatment of patients with antiretroviral (ART) drugs, which can suppress HIV-1 replication to undetectable levels. Despite this HIV cannot currently be eradicated from the body, and antiretroviral treatment thus has to be indefinitely maintained. People living with HIV will have to go a long way and only CD4+ lymphocytes count and HIV-RNA load will not be able to adequately inform the doctor and the researcher about the real benefit of the ART. New approaches need to be defined for monitoring people with HIV infection, including clinical, virological, immunological parameters and also the point of view of people living with HIV.

The purpose of this Expert Meeting is to highlight the evidence on different biomarkers or innovative approach use in research and clinical settings, to better define the management of HIV infection.

|              |  |                           |
|--------------|--|---------------------------|
| 16.20-16.25  | <b>Introduction</b>  | Franco Maggiolo, Bergamo  |
| 16.25 -16.35 | <b>Virology</b>  | Stefano Rusconi, Milano   |
|              | <b>Gruppo di lavoro:</b> N. Gianotti, R. Maserati, S. Rusconi, M. Zazzi      |                           |
| 16.35-16.45  | <b>Immunology and inflammation</b>   | Giulia Marchetti, Milano  |
|              | <b>Gruppo di lavoro:</b> A. Bandera, A. Calcagno, M. Lichtner, G. Marchetti  |                           |
| 16.45-16.55  | <b>Comorbidities</b>   | Giordano Madeddu, Sassari |
|              | <b>Gruppo di lavoro:</b> S. Bonora, G. Madeddu, M. Borderi, P. Maggi         |                           |
| 16.55-17.05  | <b>PROs, Patient-reported outcomes</b>                                       | Antonella Cingolani, Roma |
|              | <b>Gruppo di lavoro:</b> A.M. Cattelan, A. Cingolani, S. Lo Caputo, S. Nozza |                           |
| 17.05-17.15  | <b>Discussion</b>  |                           |
| 17.15-17.20  | <b>Closing remarks</b>   | Antonio Di Biagio, Genova |

**SYMPOSIUM** 17.20-18.15

**PLENARY ROOM**

**Challenges in PrEP implementation and TasP confidence**

Chairs: S. Maugeri (Bologna), D. Ripamonti (Bergamo), L. Sighinolfi (Ferrara)

Pre-exposure prophylaxis (PrEP) for HIV has proven effective in reducing the number of new infections in several trials and in different settings, while treatment as prevention (TasP) is one of the major advancements in the HIV field, becoming a major argument for supporting both the universal treatment and test and treatment strategies. However, issues are arising in PrEP implementation in clinical practice, while the trust in TasP may be challenging when it comes to the real world, as both patients and clinicians may have different interpretations, expectations and confidence.

|             |   |                            |
|-------------|---|----------------------------|
| 17.20-17.30 | <b>PrEParing providers</b>                | Serena Venturelli, Bergamo |
| 17.30-17.40 | <b>Challenges in becoming a PrEP user</b> | Angela Infante, Roma       |
| 17.40-17.50 | <b>How much trust in TasP?</b>            | Serena Venturelli, Bergamo |
| 17.50-18.00 | <b>Consequences of TasP</b>               | Angela Infante, Roma       |
| 18.00-18.15 | <b>Discussion on Symposium issues</b>     |                            |





GIOVEDÌ  
15 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

ORAL COMMUNICATIONS 17.20-18.20

ROOM 2

## Clinical HIV

Chairs: A. Calcagno (Torino), M.C. Moiola (Milano)

### OC 43 17.20-17.30 Machine learning statistical approach to identify HIV co-infected patients with asymptomatic neurosyphilis

*L. Celani, C. Borrazzo, L. Battistini, S. Valeri, P. Vassalini, M. Ridolfi, E.N. Cavallari, G.P. Innocenti, L. Santinelli, C. Pinacchio, G. Ceccarelli, C.M. Mastroianni, G. d'Ettorre*

Department of Public Health and Infectious Diseases – “Sapienza” University of Rome

### OC 44 17.30-17.40 Body composition changes in HIV: do INSTI matter?

*G. Guaraldi<sup>1</sup>, J. Milic<sup>1,2</sup>, A. Malagoli<sup>1</sup>, C. Bassoli<sup>3</sup>, F. Carli<sup>1</sup>, A. Raimondi<sup>1</sup>, C. Mussini<sup>1</sup>*

<sup>1</sup>Modena HIV Metabolic Clinic, University of Modena and Reggio Emilia, Italy, <sup>2</sup>Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy, <sup>3</sup>University of Modena and Reggio Emilia, Modena, Italy

### OC 45 17.40-17.50 Risk of weight gain (WG) according to type of switching strategy in a large cohort of HIV-infected individuals with stable suppressed HIV-RNA

*S. Cicalini<sup>1</sup>, P. Lorenzini<sup>1</sup>, A. Di Biagio<sup>2</sup>, L. Taramasso<sup>3</sup>, A. Cozzi-Lepri<sup>4</sup>, D. Canetti<sup>5</sup>, A. Saracino<sup>6</sup>, G. Lapadula<sup>7</sup>, R. Rossotti<sup>8</sup>, G. Guaraldi<sup>9</sup>, G. Madeddu<sup>10</sup>, A. d'Armino Monforte<sup>11</sup>, A. Antinori<sup>1</sup> on behalf of the ICONA Foundation Study Group*

<sup>1</sup>National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, <sup>2</sup>Infectious Diseases Clinic, Policlinico San Martino Hospital, Department of Health Sciences (DISSAL), University of Genoa, Genova, <sup>3</sup>Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, <sup>4</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, <sup>5</sup>Clinic of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, <sup>6</sup>Department of Infectious Diseases, Policlinic Hospital, University of Bari 'Aldo Moro', Bari, <sup>7</sup>Clinic of Infectious Diseases, ASST Monza San Gerardo Hospital, University Milano-Bicocca, Monza, <sup>8</sup>Infectious Diseases Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, <sup>9</sup>Department of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, <sup>10</sup>Infectious and Tropical Diseases Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, <sup>11</sup>ASST Santi Paolo e Carlo, University of Milan, Clinic of Infectious and Tropical Diseases, Department of Health Sciences, Milan

### OC 46 17.50-18.00 Impact of antiretroviral therapy on gut CD4 T cells activation: differences between naïve and long-term treated HIV-1 infected patients

*G.P. Innocenti, C. Pinacchio, L. Santinelli, E.N. Cavallari, L. Bonato, L. Celani, G. Ceccarelli, C.M. Mastroianni, G. d'Ettorre*

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome

### OC 47 18.00-18.10 Residual Inflammation and CD4/CD8 Recovery After Switching to Dual Therapy

*E. Merlini<sup>1</sup>, P. Lorenzini<sup>2</sup>, C. Mussini<sup>3</sup>, A. Cozzi-Lepri<sup>4</sup>, S. Truffa<sup>5</sup>, E. Quiros Roldan<sup>6</sup>, C. Muccini<sup>7</sup>, E.S. Cannizzo<sup>1</sup>, M. Lichtner<sup>8</sup>, A. Antinori<sup>9</sup>, A. d'Armino Monforte<sup>1</sup>, G. Marchetti<sup>1</sup> for Icona Study Group*

<sup>1</sup>ASST Santi Paolo e Carlo, University of Milan, Clinic of Infectious and Tropical Diseases, Department of Health Sciences, Milan, Italy, <sup>2</sup>HIV/AIDS Clinical Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>3</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME) Institute for Global Health UCL, London, UK, <sup>4</sup>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy, <sup>5</sup>University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>6</sup>Division of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>7</sup>Department of Infectious Diseases, La Sapienza University, Polo Pontino, Latina, Italy

### OC 48 18.10-18.20 Evaluation of the impact of resistance on virological efficacy of STR regimens and emergence of resistance at virological failure

*G. Stella<sup>1,2</sup>, L. Volpicelli<sup>3</sup>, D. Di Carlo<sup>4</sup>, I. Vicenti<sup>1</sup>, L. Celani<sup>5</sup>, F. Maggiolo<sup>6</sup>, A.P. Callegaro<sup>7</sup>, W. Gennari<sup>8</sup>, D. Francisci<sup>9</sup>, F. Lombardi<sup>10</sup>, L. Piermatteo<sup>11</sup>, A. Bezenchek<sup>12</sup>, V. Micheli<sup>13</sup>, B. Rossetti<sup>2</sup>, M. M. Santoro<sup>11</sup>*

<sup>1</sup>Medical Biotechnology Department, University of Siena, Siena, <sup>2</sup>UOC Infectious and Tropical Diseases, Siena University Hospital, Siena, <sup>3</sup>Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, <sup>4</sup>CRC Pediatric "Romeo and Enrica Invernizzi", Department of Biosciences, University of Milan, Milan, <sup>5</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, <sup>6</sup>Department of Infectious Diseases, Papa Giovanni XXIII Hospital, Bergamo, <sup>7</sup>Department of Laboratory Medicine, ASST Papa Giovanni XXIII, Bergamo, <sup>8</sup>Unit of Virology and Molecular Microbiology, University Hospital, Modena, <sup>9</sup>Clinical Infectious Diseases, University of Perugia, Perugia, <sup>10</sup>Department of Safety and Bioethics Section of Infectious Diseases, Catholic University of the Sacred Heart, Rome, <sup>11</sup>Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, <sup>12</sup>IPRO - InformaPRO S.r.l., Rome, <sup>13</sup>Department of Clinical Microbiology Virology and Diagnosis of Bioemergency, Luigi Sacco University Hospital, Milan



GIOVEDÌ  
15 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

## SPECIAL SESSION 17.20-18.20

### Meet the Expert

Chairs: D. Calzavara (Milano), S. Mattioli (Bologna)

During these Sessions, participants will have the opportunity to informally discuss with top ICAR Experts and exchange with them personal views, receive practical insights about specific topics.

Guided by Facilitators, these sessions represent an important opportunity for all delegates to sit down and converse on a more one-to-one level.

## ROOM 3



17.20-17.50 **Immunological update**  
17.50-18.20 **Cure**

Guido Silvestri, Atlanta USA  
Francesco Simonetti, Baltimore USA

## SYMPOSIUM 18.20-19.25

### HIV and Coinfections: new challenges for 2020

Chairs: R. Bruno (Pavia), G. Taliani (Roma)

In the last years the control of HIV replication obtained excellent results with more than 90% of patients being undetectable. However, clinical challenges in the management of HIV infected patients still remain, such as the presence of co-infections with viruses such as HBV and HPV, both involved in cancer development, as well as with tuberculosis. The symposium will focus on such pathogens, discussing the challenges in terms of clinical history, diagnosis and treatment.

## PLENARY ROOM

18.20-18.30 **Critical epidemiological and virological insights on HBV coinfection**  
18.30-18.40 **HBV: from new drugs to functional cure**  
18.40-18.50 **HPV-associated ano-genital lesions in HIV patients**  
18.50-19.00 **HPV-driven oropharyngeal cancer in the HIV/AIDS patient**  
19.00-19.10 **Which is the best approach to screen HIV-infected individuals for latent tuberculosis infection in Italy?**  
19.10-19.25 **Discussion on Symposium issues**

Valentina Svicher, Roma  
Massimo Puoti, Milano  
Massimo Giuliani, Roma  
Paolo Boscolo Rizzo, Padova  
Delia Goletti, Roma

## EXPERT MEETING 18.20-19.20

Con la sponsorizzazione non condizionante di MSD Italia

### Urgent global challenges in infectious diseases: fight together against HIV and AMR

Chair: G. Di Perri (Torino)

The objective of this expert meeting is to give an update on the current global health challenges in infectious diseases, giving a clear picture on how HIV and AMR are impacting our country and patients' life. Prevention and protection of future generations is becoming increasingly important in HIV: awareness, innovative drugs and quality of life are essential to ensure the achievement of Global UNAIDS objectives.

Together with HIV, the fight against drug resistance is a priority at worldwide level with Antimicrobial resistance (AMR) as the most important infectious disease threat of our time. The impact of AMR on patients' life creates the need to accelerate the fight in hospital setting and to ensure the dissemination of strategies and tools for an appropriate management.

## ROOM 2

18.20-18.30 **Introduction**  
18.30-18.50 **Objective: Future HIV free generations**  
18.50-19.10 **AMR: impact on patients' life and strategies for an appropriate management**  
19.10-19.20 **Discussion on Expert Meeting issues**

Andrea Antinori, Roma  
Pierluigi Viale, Bologna



SCIENTIFIC  
PROGRAMME



VENERDI'  
16 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

## SYMPOSIUM 14.30-15.15

## PLENARY ROOM

Con la sponsorizzazione non condizionante di Gilead Sciences, MSD Italia e ViiV Healthcare

### The Fast-Track Cities initiative and the Italian state of the art

Chair: B. Audoin (Paris F)

Discussants: A. d'Arminio Monforte (Milano), M.R. Iardino (Milano)

The Fast-Track Cities initiative is a global partnership between cities and municipalities around the world and four core partners – the International Association of Providers of AIDS Care (IAPAC), the Joint United Nations Programme on HIV/AIDS (UNAIDS), the United Nations Human Settlements Programme (UN-Habitat), and the City of Paris. Launched on World AIDS Day 2014, the network has grown to include more than 300 cities and municipalities that are committed to attain the UNAIDS 90-90-90 targets by 2020.

The aim of the symposium is to discuss the global initiatives and to focus on the Italian Fast-Track Cities state of the art, in a round table involving the different Italian Fast-Track Cities' stakeholders.

14.30-14.35

**Introduction**

Bertrand Audoin, Paris F

14.35-14.45

**The Global Network**

Ricardo Baptista Leite, Lisbon PT

14.45-15.15

**Round Table "The Italian Fast-Track Cities"**

**Participants:** A. Cascio (Palermo), G. Cenderello (Sanremo), A.Di Biagio (Genova), M. Di Pietro (Pistoia), F. Maggiolo (Bergamo), D. Mainieri (Milano), F. Vichi (Firenze)

## SPECIAL EVENT 15.20-16.20

## PLENARY ROOM

### Special Session on HIV and COVID in Italy

Chairs: G. Angarano (Bari), E. Vicenzi (Milano)

**Participants:** C. Gervasoni (Milano), F. Gili (Roma), F. Maggiolo (Bergamo), E. Schiaroli (Perugia), C. Vanetti (Milano)

## ORAL COMMUNICATIONS 15.20-15.50

## ROOM 2

### Immunopathogenesis

Chairs: M. Nasi (Modena), G. Nunnari (Messina)

#### OC 54 15.20-15.30 **Psycosexual health and systemic, mucosal immune activation and in hiv-infected ART suppressed and uninfected women: evaluation of biomarkers and environmental stimuli**

P. Nijhawan<sup>1</sup>, A. Carraro<sup>1</sup>, R. Marocco<sup>2</sup>, C. Mascia<sup>1</sup>, F. Mengoni<sup>1</sup>, B. Kertusha<sup>2</sup>, L. Fondaco<sup>2</sup>, P. Ianiri<sup>3</sup>, M. Immacolata<sup>3</sup>, V. Mercurio<sup>2</sup>, G. Masci<sup>1</sup>, M. D'Achille<sup>2</sup>, C. Del Borgo<sup>2</sup>, C.M. Mastroianni<sup>1</sup>, S. Vita<sup>2</sup>, M. Lichtner<sup>1,2</sup>

<sup>1</sup>Department of Public health and Infectious disease, Sapienza, University of Rome, <sup>2</sup>Infectious Disease Unit, SM Goretti Hospital Latina, <sup>3</sup>Gynaecology Unit, SM Goretti Hospital Latina

#### OC 55 15.30-15.40 **Inflammatory burden in people living with four-class drug resistant HIV: data from the PRESTIGIO registry**

T. Clemente<sup>1</sup>, R. Caccia<sup>2</sup>, V. Spagnuolo<sup>1,2</sup>, L. Galli<sup>2</sup>, A. Poli<sup>2</sup>, A. Galli<sup>2</sup>, G. Marchetti<sup>3</sup>, M. Andreoni<sup>4</sup>, A. Bandera<sup>5</sup>, M. Puoti<sup>6</sup>, M. Zazzi<sup>7</sup>, M.M. Santoro<sup>8</sup>, P. Cinque<sup>2</sup>, A. Castagna<sup>1,2</sup> on the behalf of the PRESTIGIO Study Group

<sup>1</sup>School of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy, <sup>2</sup>Division of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy, <sup>3</sup>Clinica di Malattie Infettive, San Paolo Hospital, University of Milan, Milan, Italy, <sup>4</sup>Department of Clinical Infectious Diseases, University Hospital of Rome "Tor Vergata", Rome, Italy, <sup>5</sup>Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>6</sup>Infectious Diseases Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>7</sup>Department of Medical Biotechnology, University of Siena, Siena, Italy, <sup>8</sup>Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy



VENERDI'  
16 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

**OC 56 15.40-15.50 Gut microbial dysbiosis is linked to immune-reconstitution and CD4+ T-cell skewing in MSM with high Framingham Risk Score**

G. Ancona<sup>1</sup>, C. Tincati<sup>1</sup>, N. Nusbacher<sup>2</sup>, S. Li<sup>2</sup>, A. d'Arminio Monforte<sup>1</sup>, C.A. Lozupone<sup>2</sup>, B.E. Palmer<sup>2</sup>, G. Marchetti<sup>1</sup>

<sup>1</sup>Department of Health Sciences-University of Milan, Clinic of Infectious Diseases, San Paolo Hospital, Italy, <sup>2</sup>Department of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, USA

**ORAL COMMUNICATIONS 15.50-16.20**

**ROOM 2**

**Hepatitis and Clinical Virology**

Chairs: N. Coppola (Napoli), G. Verucchi (Bologna)

**OC 57 15.50-16.00 Unexpected rising in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies**

L. Piermatteo<sup>1</sup>, M. Alkhatib<sup>1</sup>, A. Bertoli<sup>1</sup>, E. Di Giulio<sup>1</sup>, L. Fabeni<sup>2</sup>, M. Lichtner<sup>3</sup>, C. Mastroianni<sup>3</sup>, G. De Sanctis<sup>4</sup>, M. Marignani<sup>5</sup>, C. Pasquazzi<sup>5</sup>, N. Iapadre<sup>6</sup>, G. Parruti<sup>7</sup>, S. Romano<sup>8</sup>, M. Visca<sup>8</sup>, G. Cappiello<sup>8</sup>, I. Vecchiet<sup>9</sup>, M. Andreoni<sup>10</sup>, L. Sarmati<sup>10</sup>, M. Angelico<sup>11</sup>, C.F. Perno<sup>12</sup>, F. Ceccherini-Silberstein<sup>1</sup>, V. Svicher<sup>1</sup>, R. Salpini<sup>1</sup>

<sup>1</sup>Tor Vergata University, Department of Experimental Medicine, Rome, Italy, <sup>2</sup>National Institute for Infectious Disease, IRCCS L. Spallanzani, Virology and Biosafety Laboratories Unit, Rome, Italy, <sup>3</sup>"Sapienza" University, Department of Public Health and Infectious Disease, Rome, Italy, <sup>4</sup>"Umberto I" University Hospital, Rome, Italy, <sup>5</sup>Infectious diseases, S. Andrea Hospital, "La Sapienza", Rome, Italy, <sup>6</sup>"San Salvatore Hospital", L'Aquila, Italy, <sup>7</sup>Infectious Disease Unit, Pescara General Hospital, Pescara, Italy, <sup>8</sup>Microbiology and Virology Unit, "S. Pertini" Hospital, Rome, Italy, <sup>9</sup>Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy, <sup>10</sup>Tor Vergata University Hospital, Infectious Diseases Unit, Rome, Italy, <sup>11</sup>Tor Vergata University Hospital, Hepatology Unit, Rome, Italy, <sup>12</sup>University of Milan, Oncology and Haematology, Milan, Italy

**OC 58 16.00-16.10 HCV genetic variability in patients with related hepatocellular carcinoma**

A. Di Fraia<sup>1</sup>, M. Pisaturo<sup>1</sup>, C. Minichini<sup>1</sup>, M. Starace<sup>1</sup>, L. Occhiello<sup>1</sup>, N. Farella<sup>2</sup>, G. De Stefano<sup>2</sup>, V. Iodice<sup>2</sup>, N. Coppola<sup>1,3</sup>

<sup>1</sup>Department of Mental Health and Public Medicine, Division of Infectious Diseases, University of Campania, Luigi Vanvitelli, Naples, Italy, <sup>2</sup>AORN dei Colli, Cotugno Hospital, Naples, Italy, <sup>3</sup>AORN S. Anna S. Sebastiano, Caserta, Italy

**OC 59 16.10-16.20 Prevalence and Resistance Analysis of "Unusual" Hepatitis C Virus (HCV) Subtypes within the Italian Resistance Network VIRONET-C**

Y.C. Di Maio<sup>1</sup>, S. Barbaliscia<sup>1</sup>, E. Teti<sup>2</sup>, S. Paolucci<sup>3</sup>, C. Minichini<sup>4</sup>, K. Yu La Rosa<sup>1</sup>, M. Aragri<sup>1</sup>, L. Foroghi<sup>2</sup>, G. Fiorentino<sup>5</sup>, F. Novazzi<sup>3</sup>, M. Milana<sup>6</sup>, T. Pollicino<sup>7</sup>, V. Di Marco<sup>8</sup>, A. Pieri<sup>9</sup>, V. Pace Palitti<sup>10</sup>, B. Bruzzone<sup>11</sup>, V. Micheli<sup>12</sup>, A. Bertoli<sup>1</sup>, L. Campogiani<sup>2</sup>, A.P. Callegaro<sup>13</sup>, A. Pellicelli<sup>14</sup>, F. Morisco<sup>15</sup>, R. Gulminetti<sup>16</sup>, S. Novati<sup>16</sup>, M. Lichtner<sup>17</sup>, C. Mastroianni<sup>18</sup>, F. Di Lorenzo<sup>19</sup>, P. Andreone<sup>20</sup>, B. Rossetti<sup>21</sup>, S. Marengo<sup>22</sup>, G. Taliani<sup>23</sup>, E. Boeri<sup>24</sup>, H. Hasson<sup>25</sup>, L. Monna<sup>26</sup>, L.A. Nicolini<sup>27</sup>, S. Landonio<sup>28</sup>, C. Paternoster<sup>29</sup>, A. Licata<sup>30</sup>, S. Babudieri<sup>31</sup>, L. Carioti<sup>1</sup>, M. Ciotti<sup>32</sup>, G. De Simone<sup>2</sup>, I. Lenci<sup>6</sup>, A. Bosa<sup>6</sup>, T. Mulas<sup>2</sup>, E. Degasperis<sup>33</sup>, L. Ippolito<sup>34</sup>, M. Quartini<sup>35</sup>, N. Iapadre<sup>36</sup>, R. Cozzolongo<sup>37</sup>, V. Sangiovanni<sup>38</sup>, R. Schiavo<sup>39</sup>, A. Soria<sup>40</sup>, C. Caudai<sup>41</sup>, P. Lampertico<sup>33</sup>, G. arruti<sup>9</sup>, L. Sarmati<sup>2</sup>, N. Coppola<sup>4</sup>, M. Puoti<sup>42</sup>, G. Raimondo<sup>7</sup>, C. Pasquazzi<sup>5</sup>, F. Baldanti<sup>3</sup>, M. Angelico<sup>6</sup>, M. Zazzi<sup>43</sup>, C.F. Perno<sup>44</sup>, A. Craxi<sup>8</sup>, M. Andreoni<sup>2</sup>, F. Ceccherini-Silberstein<sup>1</sup> on behalf of HCV Virology Italian Resistance Network (Vironet C)

<sup>1</sup>Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>2</sup>Infectious Diseases, University Hospital of Rome Tor Vergata, Rome, Italy, <sup>3</sup>Molecular Virology Unit, Microbiology and Virology department, IRCCS Policlinic Foundation San Matteo, Pavia, Italy, <sup>4</sup>Infectious Diseases Unit, University of Campania L. Vanvitelli, Naples, Italy, <sup>5</sup>Infectious Diseases, Sant'Andrea Hospital - "La Sapienza", Rome, Italy, <sup>6</sup>Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy, <sup>7</sup>Department of Human Pathology, University Hospital of Messina, Messina, Italy, <sup>8</sup>Gastroenterology, "P. Giaccone" University Hospital, Palermo, Italy, <sup>9</sup>Infectious Disease Unit, Pescara General Hospital, Pescara, Italy, <sup>10</sup>Hepatology Unit, Pescara General Hospital, Pescara, Italy, <sup>11</sup>Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, <sup>12</sup>Clinical Microbiology, Virology and Bioemergencies Diagnosis, L. Sacco University Hospital, Milan, Italy, <sup>13</sup>Department of Laboratory Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>14</sup>Hepatology Unit, San Camillo Forlanini Hospital, Rome, Italy, <sup>15</sup>Department of Clinical Medicine and Surgery, University "Federico II" of Naples, Naples, Italy, <sup>16</sup>Institute of Infectious Diseases, University of Pavia, Pavia, Italy, <sup>17</sup>Infectious Diseases Unit, Sapienza University, Polo Pontino, Latina, Italy, <sup>18</sup>Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, <sup>19</sup>Infectious Diseases Unit, ARNAS Civico-Di Cristina-Beneffratelli, Palermo, Italy, <sup>20</sup>Department of Medical and Surgical Sciences, Maternal-Infantile and Adult Sciences, University of Modena and Reggio Emilia, Modena, Italy, <sup>21</sup>Infectious Diseases, Siena University Hospital, Siena, Italy, <sup>22</sup>Division of Hepatology, University of Genoa-AOU IRCCS San Martino-IST, Genoa, Italy, <sup>23</sup>Department of Clinical Medicine, Clinic of Tropical Medicine, Sapienza University of Rome, Rome, Italy, <sup>24</sup>Laboratory of Virology and Microbiology, Vita-Salute San Raffaele University, Milan, Italy, <sup>25</sup>Division of Infectious Diseases, IRCCS, Ospedale San Raffaele, Milan, Italy, <sup>26</sup>Clinic of Infectious Diseases, University of Bari, Bari, Italy, <sup>27</sup>Department of Health Sciences (DISSAL), University of Genoa; Genoa, Italy, <sup>28</sup>Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy, <sup>29</sup>Infectious Disease Unit, Ospedale di Trento, Trento, Italy, <sup>30</sup>Internal Medicine and Hepatology, Di.Bi. M.I.S. University of Palermo, Palermo, Italy, <sup>31</sup>Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>32</sup>Virology unit, University Hospital of Rome Tor Vergata, Rome, Italy, <sup>33</sup>CRC "A.M. e A. Migliavacca" Center for Liver Diseases, Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy, <sup>34</sup>Laboratory of Clinical Chemistry and Haematology, Department of Pathology and Laboratory Medicine, Academic Hospital of Parma, <sup>35</sup>Hepatology Unit, Santa Maria Hospital, Terni, Italy, <sup>36</sup>Infectious Diseases Unit, "S Salvatore" Hospital, L'Aquila, Italy, <sup>37</sup>Division of Gastroenterology, National Institute of Gastroenterology S De Bellis, Castellana Grotte (Bari), Italy, <sup>38</sup>Hospital Cotugno, Naples, Italy, <sup>39</sup>Hospital "Guglielmo da Saliceto" Piacenza, Italy, <sup>40</sup>Infectious Diseases, San Gerardo Hospital - ASST Monza, Italy, <sup>41</sup>Microbiology and Virology Unit, Siena University Hospital, Siena, Italy, <sup>42</sup>Division of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>43</sup>Department of Medical Biotechnology, University of Siena, Siena, Italy, <sup>44</sup>Department of Oncology and Oncohematology, University of Milan, Milan, Italy





VENERDI'  
16 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

## SYMPOSIUM 16.20-17.15

## PLENARY ROOM

### ART treatment: when the patient's journey becomes difficult

Chairs: T. Bini (Milano), L. Calza (Bologna), M. Cernuschi (Milano)

The high efficacy and tolerability of antiretroviral drugs nowadays available might give the impression that treating HIV infection is today an easy task. That could even be true in a fairly large proportion of patients but, as in every population, ties exist and these extremes of the Gaussian curve are the challenging patients. The symposium will offer a comprehensive overlook on different "difficult to treat" patients offering hints to an optimized clinical management in these specific situations. "When the play gets tough, tough guys start to play".

|             |                                       |
|-------------|---------------------------------------|
| 16.20-16.30 | <b>Advanced naives</b>                |
| 16.30-16.40 | <b>Multi-drug resistant</b>           |
| 16.40-16.50 | <b>Fragile-social disparities</b>     |
| 16.50-17.00 | <b>Addressing personal barriers</b>   |
| 17.00-17.15 | <b>Discussion on Symposium issues</b> |

Andrea Antinori, Roma  
Antonella Castagna, Milano  
Annalisa Saracino, Bari  
Massimo Oldrini, Como

## ORAL COMMUNICATIONS 16.20-17.20

## ROOM 2

### Social Science and Epidemiology

Chairs: A. Franco (Siracusa), M. Manfredini (Milano), G. Orofino (Torino)

#### OC 60 16.20-16.30 A less recent diagnosis is associated with local transmission clusters among HIV-1 primary infections in Rome

L. Fabeni<sup>1</sup>, G. Rozera<sup>1</sup>, G. Bero<sup>1</sup>, C. Gori<sup>1</sup>, N. Orchi<sup>2</sup>, G. De Carli<sup>2</sup>, S. Pittalis<sup>2</sup>, V. Puro<sup>2</sup>, C. Pinnetti<sup>3</sup>, A. Mondì<sup>3</sup>, M. Camici<sup>3</sup>, A. Antinori<sup>3</sup>, M.R. Capobianchi<sup>1</sup>, I. Abbate<sup>1</sup>

<sup>1</sup>National Institute for Infectious Diseases, IRCCS L. Spallanzani, Virology and Biosafety Laboratories Unit, Rome, Italy, <sup>2</sup>National Institute for Infectious Diseases, IRCCS L. Spallanzani, AIDS Referral Center, Rome, Italy, <sup>3</sup>National Institute for Infectious Diseases, IRCCS L. Spallanzani, HIV/AIDS Clinical Department, Rome, Italy

#### OC 61 16.30-16.40 High HIV Prevalence following Screening of Subjects with HIV Indicator Conditions in a Hospital Setting

C. Tincati<sup>1</sup>, D. Barbanotti<sup>1</sup>, T. Bini<sup>1</sup>, A. Tavelli<sup>1</sup>, M. Ravizza<sup>2</sup>, A.M. Marconi<sup>2</sup>, M. Cattaneo<sup>3</sup>, M. Zuin<sup>4</sup>, D.A. Chiumello<sup>5</sup>, A. Cerri<sup>6</sup>, A. Priori<sup>7</sup>, D. Ferrari<sup>8</sup>, A. d'Arminio Monforte<sup>1</sup>

<sup>1</sup>Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, Italy, <sup>2</sup>Department of Health Sciences, Clinic of Gynecology and Obstetrics, ASST Santi Paolo e Carlo, University of Milan, Italy, <sup>3</sup>Department of Health Sciences, Clinic of Internal Medicine and Hematology, ASST Santi Paolo e Carlo, University of Milan, Italy, <sup>4</sup>Department of Health Sciences, Clinic of Gastroenterology and Hepatology, ASST Santi Paolo e Carlo, University of Milan, Italy, <sup>5</sup>Department of Health Sciences, Clinic of Anaesthesia and Intensive Care Medicine, ASST Santi Paolo e Carlo, University of Milan, Italy, <sup>6</sup>Department of Health Sciences, Clinic of Dermatology, ASST Santi Paolo e Carlo, University of Milan, Italy, <sup>7</sup>Department of Health Sciences, Clinic of Neurology, ASST Santi Paolo e Carlo, University of Milan, Italy, <sup>8</sup>Clinic of Oncology, ASST Santi Paolo e Carlo, San Paolo Hospital, Milan, Italy

#### OC 62 16.40-16.50 The cascade of care as tool to promote a more effective city-wide program against HIV/AIDS

F. Maggiolo<sup>1</sup>, R. Teocchi<sup>1</sup>, P. Meli<sup>2</sup>, L. Trezzi<sup>3</sup>, M. Riglietta<sup>1</sup>, C.A. Tersalvi<sup>3</sup>, M. Rizzi<sup>1</sup>

<sup>1</sup>ASST Papa Giovanni XXIII, <sup>2</sup>Comunità Emmaus & Caritas Bergamasca, <sup>3</sup>Agenzia di Tutela della Salute, Bergamo

#### OC 63 16.50-17.00 Causes and incidence of hospitalization in patients enrolled in the ICONA cohort

S. Nozza<sup>1</sup>, L. Timelli<sup>2</sup>, A. Saracino<sup>3</sup>, N. Gianotti<sup>1</sup>, C. Lazzarelli<sup>6</sup>, A. Tavelli<sup>4</sup>, M. Puoti<sup>5</sup>, S. Lo Caputo<sup>3</sup>, A. Antinori<sup>2</sup>, A. d'Arminio Monforte<sup>4</sup>, C. Mussini<sup>6</sup>, E. Girardi<sup>2</sup>, on behalf of ICONA Foundation Study Group

<sup>1</sup>Ospedale San Raffaele, IRCCS, Milano, Italy, <sup>2</sup>National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>3</sup>Università degli Studi di Bari, Bari, Italy, <sup>4</sup>Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, Italy, <sup>5</sup>ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, <sup>6</sup>Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Italy



VENERDI'  
16 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

**OC 64 17.00-17.10 The 4th Ninety in the 4th Decade**

A. Bove, F. von Schloesser, D. Osorio, M. Martini, L. Giacomi  
Nadir onlus, Rome

**OC 65 17.10-17.20 General Practitioners and PLWH: what do patients think?**

S.R. Bruno<sup>1</sup>, M. Poliseo<sup>2</sup>, F. Vichi<sup>3</sup>, G. Po<sup>4</sup>, D. Anzalone<sup>4</sup>, S. Ferrara<sup>1</sup>, L. Pisan<sup>5</sup>, A. Saracino<sup>2</sup>, T. Santantonio<sup>1</sup>, S. Lo Caputo<sup>1</sup>

<sup>1</sup>Clinica Malattie Infettive, Università degli Studi di Foggia - Foggia, Italy, <sup>2</sup>Clinica di Malattie Infettive, Università degli Studi "Aldo Moro" - Bari, Italy, <sup>3</sup>U.O. Malattie Infettive, Ospedale Santa Maria Annunziata - Bagno a Ripoli (Firenze) Italy, <sup>4</sup>Clinica di Malattie Infettive e Tropicali, Ospedale Policlinico San Martino - Genova, Italy, <sup>5</sup>Department of Intensive Care, Amsterdam University Medical Centers - Location AMC, Amsterdam, the Netherlands

**SYMPOSIUM 17.20-18.15**

**PLENARY ROOM**

**Proud to be women, proud to fight HIV**

Chairs: G. Lapadula (Monza), A. Moznich (Pordenone), G. Scarlatti (Milano)

The efforts made so far in terms of controlling the HIV epidemic on a global level have left women behind compared to the achievement of the objectives set by the WHO. This is because a tailored approach specifically aimed at the female population is far from being applied both in terms of implementation of prevention tools and of clinical and psychological management of women.

The objective of this symposium is to focus attention and reflect on peculiar aspects of women's health to ensure that this gap is quickly bridged.

|             |  |                            |
|-------------|--|----------------------------|
| 17.20-17.30 | <b>Gender differences in HIV bio-medical prevention</b>                      | Sophie Strachan, London UK |
| 17.30-17.40 | <b>Gender gaps in Italian cascade-of-care</b>                                | Margherita Errico, Milano  |
| 17.40-17.50 | <b>Women well-being and safe childbearing: updated management strategies</b> | Francesca Sabbatini, Monza |
| 17.50-18.00 | <b>"Women are from Venus" - Implications for prevention and cure</b>         | Giulia Marchetti, Milano   |
| 18.00-18.15 | <b>Discussion on Symposium issues</b>  |                            |

**ORAL COMMUNICATIONS 17.20-18.20**

**ROOM 2**

**Pharmacology**

Chairs: S. Bonora (Torino), C. Gervasoni (Milano)

17.20-17.30 **The importance of deprescribing in HIV** José Moltò, Badalona E

**OC 66 17.30-17.40 Use of direct oral anticoagulants in people living with HIV: a single-center experience**

D. Cattaneo, T. Formenti, A. Gidaro, A. Merlo, C. Gervasoni  
ASST Fatebenefratelli Sacco University Hospital, Milan, Italy

**OC 67 17.40-17.50 Pharmacokinetics of once-daily doravirine over 72 hours following drug cessation**

M. Mazzitelli<sup>1,2</sup>, X. Wang<sup>1</sup>, A. Milinkovic<sup>2</sup>, B. Pereira<sup>2</sup>, S. Fedele<sup>2</sup>, L. Thomas<sup>2</sup>, D. Yener<sup>2</sup>, S. Connolly<sup>2</sup>, M. McClure<sup>1</sup>, M. Boffito<sup>1,2</sup>  
<sup>1</sup>Chelsea and Westminster Hospital, London UK, <sup>2</sup>Magna Graecia University, Catanzaro, Italy, <sup>3</sup>Imperial College London, London UK



SCIENTIFIC  
PROGRAMME



VENERDI'  
16 OTTOBRE

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

**OC 68 17.50-18.00 Inflammation Affects Antiretrovirals Plasma and Intracellular Exposure**

*M. Ferrara<sup>1</sup>, A. Trentalange<sup>1</sup>, E.S. Cannizzo<sup>2</sup>, G. Marchetti<sup>2</sup>, S. Nozza<sup>3</sup>, A. De Nicolò<sup>1</sup>, V. Avataneo<sup>1</sup>, A. Ianniello<sup>1</sup>, E. De Vivo<sup>1</sup>, A. D'Avolio<sup>1</sup>, G. Di Perri<sup>1</sup>, S. Bonora<sup>1</sup>, A. Calcagno<sup>1</sup>*

<sup>1</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, <sup>2</sup>Department of Health Sciences, Clinic of Infectious Diseases, ASST, Santi Paolo e Carlo, University of Milano, Milano, <sup>3</sup>Department of Infectious Diseases, San Raffaele Scientific Institute, Milano

**OC 69 18.00-18.10 Bictegravir plasma and intracellular pharmacokinetics in in the clinical setting**

*M. Ferrara, C. Alcantarini, A. Lazzaro, S. Biffi, A. Di Stefano, M. Trunfo, M.C. Tettoni, V. Avataneo, A. Ianniello, E. De Vivo, A. De Nicolò, A. D'Avolio, A. Calcagno, G. Di Perri, S. Bonora*

Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino

**OC 70 18.10-18.20 Generic pre-exposure prophylaxis formulations: a comparison of tenofovir trough concentrations**

*D. Cattaneo<sup>1</sup>, C. Gervasoni<sup>1</sup>, P. Vinti<sup>2,3</sup>, S. Baldelli<sup>1</sup>, M. Fusi<sup>1</sup>, D. Zagato<sup>2</sup>, A. De Bona<sup>4</sup>, E. Suardi<sup>4</sup>, S. Bossolasco<sup>5</sup>, G. Ancona<sup>4</sup>, R. Rossotti<sup>6</sup>, D. Canetti<sup>5</sup>, M. Cernuschi<sup>2,3,5</sup>*

<sup>1</sup>ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, <sup>2</sup>Associazione Solidarietà AIDS Onlus, Milan, Italy, <sup>3</sup>Milano Checkpoint, Milan, Italy, <sup>4</sup>ASST Santi Paolo e Carlo, Milan, Italy, <sup>5</sup>IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>6</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

**ICAR 2020 Special Awards 18.20-18.35**

Chairs: M. Clementi (Milano), S. Mattioli (Bologna), C. Mussini (Modena), G. Silvestri (Atlanta), M. Tavio (Ancona)

**PLENARY ROOM**

**Closing remarks 18.35-18.45**

M. Clementi (Milano), S. Mattioli (Bologna), C. Mussini (Modena), G. Silvestri (Atlanta), M. Tavio (Ancona)



SCIENTIFIC  
PROGRAMME

12° CONGRESSO NAZIONALE



**Italian Conference on  
AIDS and Antiviral Research**

*Reach out  
for including all*

 12-16  
ottobre 2020  
DIGITAL EDITION

*Presidenza del Congresso*

*Massimo Clementi, Milano*

*Sandro Mattioli, Bologna*

*Cristina Mussini, Modena*

*Guido Silvestri, Atlanta*

*Marcello Tavio, Ancona*

ORAL POSTER







ORAL  
POSTER

## Antiretroviral Therapy

Chairs: R. Maserati (Pavia), P. Nasta (Brescia)

- OP 1 Evaluation of total HIV-DNA and residual viremia in HIV-1 infected patients who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-OnE Study**  
M.M. Santoro<sup>1</sup>, N. Gianotti<sup>2</sup>, L. Galli<sup>2</sup>, R. Scutari<sup>1</sup>, C. Alteri<sup>3</sup>, A. Poli<sup>2</sup>, L. Piermatteo<sup>1</sup>, A. Bigoloni<sup>2</sup>, C.F. Perno<sup>3</sup>, A. Lazzarin<sup>2</sup>, F. Ceccherini-Silberstein<sup>1</sup>, A. Castagna<sup>2,4</sup>  
<sup>1</sup>University of Rome "Tor Vergata", Rome, <sup>2</sup>Infectious Diseases, IRCCS San Raffaele, Milan, <sup>3</sup>University of Milan, Milan, <sup>4</sup>Vita-Salute San Raffaele University, Milan
- OP 2 Durability and liver safety of INSTI-based regimens in HIV-infected patients with advanced liver fibrosis or cirrhosis: data from the ODOACRE cohort**  
A. Lanari<sup>1</sup>, B. Rossetti<sup>2</sup>, A. Ciccullo<sup>3,4</sup>, V. Borghi<sup>5</sup>, A. Dusina<sup>3,4</sup>, C. Cassol<sup>1</sup>, G. Cuomo<sup>5</sup>, A. D'Angelillo<sup>3,4</sup>, F. Montagnani<sup>1</sup>, C. Mussini<sup>5</sup>, S. Di Giambenedetto<sup>3,4</sup>, M. Fabbiani<sup>2</sup>  
<sup>1</sup>UOC Malattie Infettive e Tropicali, Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, <sup>2</sup>UOC Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Senese, Siena, <sup>3</sup>Università Cattolica del Sacro Cuore, Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive, Roma, <sup>4</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, <sup>5</sup>Clinica Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria di Modena, Modena
- OP 3 Prevalence of transmitted resistance mutations to rilpivirine and doravirine in treatment-naïve patients in a large clinical and resistance database**  
F. Lombardi<sup>1</sup>, V. Costabile<sup>2</sup>, A. Lai<sup>3</sup>, L. Taramasso<sup>4</sup>, M. Siano<sup>3</sup>, B. Bruzzone<sup>5</sup>, V. Micheli<sup>6</sup>, A. Callegaro<sup>7</sup>, E. Paolini<sup>8</sup>, F. Maggiolo<sup>9</sup>, G. Colao<sup>10</sup>, P. Meraviglia<sup>6</sup>, P. Bagnarelli<sup>11</sup>, A. Shallvari<sup>12</sup>, S. Rusconi<sup>3</sup>  
<sup>1</sup>Università Cattolica del Sacro Cuore, Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive, Roma, Italy, <sup>2</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>3</sup>Infectious Disease Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy, <sup>4</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>5</sup>Hygiene Unit, IRCCSAOU San Martino-IST, Genoa, Italy, <sup>6</sup>Laboratorio Microbiologia Ospedale L. Sacco, Seconda Divisione Malattie Infettive, Milan, Italy, <sup>7</sup>Department of Laboratory Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>8</sup>Servizio Immunoematologia e Medicina Trasfusionale, Cremona Hospital, Cremona, Italy, <sup>9</sup>Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>10</sup>Laboratory of Virology, Careggi Hospital, Firenze, Italy, <sup>11</sup>Virology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy, <sup>12</sup>IPRO - InformaPRO S.r.l., Rome
- OP 4 Efficacy and tolerability of bictegravir/ tenofovir alafenamide/ emtricitabine as a switch strategy in a cohort of antiretroviral therapy treatment-experienced HIV-1-infected patients**  
F. Lagi<sup>1</sup>, A. Botta<sup>1</sup>, M. Trotta<sup>2</sup>, B. Borchini<sup>2</sup>, P. Rogasi<sup>2</sup>, P. Nizzoli<sup>3</sup>, A. Bartoloni<sup>1,2</sup>, G. Sterrantino<sup>1</sup>  
<sup>1</sup>Department of Experimental and Clinical Medicine, University of Florence, Florence Italy, <sup>2</sup>Infectious and Tropical Diseases Unit, Careggi University and Hospital, Florence, Italy, <sup>3</sup>Department of Pharmaceuticals, USL Toscana Centro, Careggi - Pharmacy, Florence, Italy
- OP 5 Viral rebound in pts with suppressed HIV-RNA on a 2 or 3-drug regimen: a comparison**  
A. Borghetti<sup>1</sup>, A. Giacomelli<sup>2,3</sup>, M. Colafigli<sup>4</sup>, A. Lanari<sup>5</sup>, L. Celani<sup>6</sup>, V. Borghi<sup>7</sup>, A. Ciccullo<sup>8</sup>, S. Rusconi<sup>2,3</sup>, A. Latini<sup>4</sup>, F. Lombardi<sup>9</sup>, L. Oreni<sup>2,3</sup>, C. Mussini<sup>7</sup>, S. Di Giambenedetto<sup>1,8</sup>  
<sup>1</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, UOC malattie infettive, <sup>2</sup>III Infectious Disease Unit, ASST-FBF-Sacco, Milan, Italy, <sup>3</sup>Department of Biomedical and Clinical Sciences DIBIC L. Sacco, University of Milan, Milan, Italy, <sup>4</sup>Infectious Dermatology and Allergology, IFO San Gallicano, Rome, Italy, <sup>5</sup>Hospital Department of Specialized and Internal Medicine, Infectious Diseases Unit, University Hospital of Siena, Siena, Italy, <sup>6</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, <sup>7</sup>Clinica delle Malattie Infettive e Tropicali dell'Università di Modena e Reggio Emilia, Modena, Italy, <sup>8</sup>Università Cattolica del Sacro Cuore, Roma Italia, Istituto di Clinica Malattie Infettive
- OP 6 Optically traceable PLGA Nanoparticles improve the ability of darunavir to cross the blood brain barrier and inhibit MMP-9. Implications for the Treatment of HIV-Associated Neurological Disorders**  
S. Milella<sup>1</sup>, N. Depalo<sup>2</sup>, A. Panniello<sup>2</sup>, F. Rizzzi<sup>2</sup>, V. Laquintana<sup>3</sup>, N. Denora<sup>3</sup>, C.M. Mastroianni<sup>4</sup>, G.M. Liuzzi<sup>1</sup>, M.L. Curri<sup>5</sup>, T. Latronico<sup>1</sup>  
<sup>1</sup>Dipartimento di Bioscienze, Biotecnologie e Biofarmaceutica, Università degli Studi di Bari Aldo Moro, Italy, <sup>2</sup>Consiglio Nazionale delle Ricerche, Istituto per i Processi Chimico-Fisici, Bari, Italy, <sup>3</sup>Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Bari, Italy, <sup>4</sup>Dipartimento di Sanità Pubblica e Malattie Infettive della Facoltà di Farmacia e Medicina, Università degli Studi di Roma "La Sapienza", Roma, Italy, <sup>5</sup>Dipartimento di Chimica, Università degli Studi di Bari Aldo Moro, Bari, Italy
- OP 7 Effectiveness and long-term durability of rilpivirine-based single tablet regimens in a large cohort of HIV-infected patients. A preliminary analysis**  
L. Magnasco<sup>1</sup>, R. Pincino<sup>1</sup>, G. Sarteschi<sup>1</sup>, S. Lo Caputo<sup>2</sup>, S. Bruno<sup>2</sup>, S. Ferrara<sup>2</sup>, F. Briano<sup>1</sup>, D. Malucelli<sup>3</sup>, S. Beltrami<sup>4</sup>, E. Sasso<sup>4</sup>, A. Di Biagio<sup>1</sup>  
<sup>1</sup>U.O. Clinica Malattie Infettive, University of Genoa (DISSAL) and Ospedale Policlinico San Martino-IRCCS per l'Oncologia, Genova, <sup>2</sup>U.O. Clinica Malattie Infettive, University of Foggia, <sup>3</sup>SANTALUCIA PHARMA APPS<sup>®</sup>, Località Groganino, Groganino Trebbianese, <sup>4</sup>U.O. Farmacia, Ospedale Policlinico San Martino-IRCCS per l'Oncologia, Genova
- OP 8 Increase in body weight after a year of INI-exposure in a multicenter italian cohort**  
A. Ciccullo<sup>1</sup>, G. Baldin<sup>1,2</sup>, G. Sterrantino<sup>3</sup>, M. Colafigli<sup>4</sup>, G. d'Ettore<sup>5</sup>, A. Lanari<sup>6</sup>, G. Greco<sup>7</sup>, A. De Vito<sup>8</sup>, L. Celani<sup>9</sup>, A. Giacomelli<sup>9</sup>, F. Lagi<sup>3</sup>, S. Rusconi<sup>9</sup>, S. Di Giambenedetto<sup>1,10</sup>, G. Madeddu<sup>8</sup>  
<sup>1</sup>Section of Infectious Diseases, Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy, <sup>2</sup>Mater Olbia Hospital, Olbia, Italy, <sup>3</sup>Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy, <sup>4</sup>Infectious Dermatology and Allergology Unit, S. Galliciano Institute IRCCS, Rome, Italy, <sup>5</sup>Department of Public Health and Infectious Diseases, Azienda Policlinico Umberto I, Rome, Italy, <sup>6</sup>Infectious Diseases Unit, Siena University Hospital, Siena, Italy, <sup>7</sup>Department of Medical and Surgical Sciences, Unit of Infectious and Tropical Diseases, "Magna Graecia" University, Catanzaro, Italy, <sup>8</sup>Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>9</sup>Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy, <sup>10</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italia



## ORAL POSTER

**OP 9 Treatment outcome among HIV-1 infected patients who started first-line ART pending GRT results from 2015 to 2018**

D.F. Bavaro<sup>1</sup>, G. Pasculli<sup>2,3</sup>, A. De Vito<sup>4</sup>, R. Lattanzio<sup>1</sup>, F. Saladini<sup>5</sup>, L. Magnasco<sup>6</sup>, R. Yagai Bouba<sup>7</sup>, R. Pincino<sup>6</sup>, R. Corsini<sup>8</sup>, S. Arima<sup>9</sup>, F. Incardona<sup>3,10</sup>, B. Rossetti<sup>11</sup>, A. Bezenchek<sup>10</sup>, V. Borghi<sup>12</sup>, A. Di Biagio<sup>6</sup>

<sup>1</sup>Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari, Bari, Italy, <sup>2</sup>Department of Computer, Control, and Management Engineering Antonio Ruberti (DIAG), La Sapienza University, Rome, Italy, <sup>3</sup>EuResist Network, Rome, Italy, <sup>4</sup>Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>5</sup>Department of Medical Biotechnologies, University of Siena, Italy, <sup>6</sup>Department of Health's Sciences, University of Genoa, Genoa, Italy, <sup>7</sup>Department of experimental medicine, University of Rome "Tor Vergata", Rome, Italy, <sup>8</sup>Infectious Diseases Unit, Azienda USL-IRCCS di Reggio Emilia, <sup>9</sup>Department of Methods and Model for Economy Territory and Finance, University of Rome "La Sapienza", Rome, Italy, <sup>10</sup>INFORMAPRO Srl, Rome, Italy, <sup>11</sup>Infectious Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy, <sup>12</sup>Clinic of Infectious Disease, Azienda Ospedaliero Universitaria di Modena

**OP 10 Retrospective analysis of reasons and characteristics of switches in a cohort of women affected by HIV infection referring to "D. Cotugno" Hospital, Naples, period 2017-2019**

F.M. Fusco<sup>1</sup>, V. Rizzo<sup>2</sup>, M.A. Carleo<sup>2</sup>, S. Mascolo<sup>2</sup>, R. Viglietti<sup>1</sup>, M. D'Abbraccio<sup>2</sup>, V. Esposito<sup>2</sup>

<sup>1</sup>UOC Infezioni Sistemiche e dell'Immunodepresso, P.O. "D. Cotugno", Azienda Ospedaliera dei Colli, Naples, Italy, <sup>2</sup>UOC Immunodeficienze e Malattie Infettive di Genere, P.O. "D. Cotugno", Azienda Ospedaliera dei Colli, Naples, Italy

**OP 11 Assessing the feasibility of 2-drug regimens as switch strategies in a multicenter cohort**

A. Borghetti<sup>1,2</sup>, A. Ciccullo<sup>2</sup>, M. Colafigli<sup>3</sup>, E. Anzalone<sup>4</sup>, A. Pennica<sup>5</sup>, A. Dusina<sup>2</sup>, D. Farinacci<sup>2</sup>, A. Latini<sup>3</sup>, F. Di Sora<sup>6</sup>, S. Di Giambenedetto<sup>1,2</sup>

<sup>1</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Malattie Infettive, Roma, Italy, <sup>2</sup>Dipartimento di Sicurezza e Bioetica, Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, <sup>3</sup>Dermatologia Infettivologica ed Allergologica, Istituto Dermatologico San Gallicano IRCCS, Roma, Italy, <sup>4</sup>UOSD AIDS, Presidio Ospedaliero Frosinone, Italy, <sup>5</sup>Facoltà di Medicina e Psicologia "La Sapienza", Presidio Ospedaliero S. Andrea, Roma, Italy, <sup>6</sup>Dipartimento di Malattie Infettive, Ospedale S. Giovanni Addolorata, Roma, Italy

**OP 12 Risk of failure in dual vs triple therapy in naïve HIV-patients: a meta-analysis**

A. Russo, M. Pisaturo, L. Onorato, S. Martini, S. Simona, P. Maggi, N. Coppola

University of Campania Luigi Vanvitelli, Naples, Italy

## Basic Science and Immunology

Chairs: L. Butini (Ancona), S. Piconi (Lecco)

**OP 13 DAA treatment fails to restore the inflammatory profile both in HCV/HIV and in HCV infected patients**

V. Bordoni, A. Vergori, S. Notari, C. Gruber, C. Montaldo, M. Tripodi, E. Cimini, R. Casetti, G. Grassi, A. Sacchi, E. Tartaglia, R. Lionetti, M. Bibas, G. D'Offizi, E. Grilli, A. Antinori, C. Agrati

National Institute for Infectious Diseases L. Spallanzani - IRCCS - Rome

**OP 14 Sterol metabolism modulates susceptibility to HIV-1 Infection**

I. Saulle<sup>1</sup>, S.V. Ibba<sup>1</sup>, C. Vittori<sup>1</sup>, C. Fenizia<sup>1</sup>, V. Mercurio<sup>1</sup>, F. Vichi<sup>2</sup>, S. Lo Caputo<sup>3</sup>, D. Trabattoni<sup>1</sup>, M. Clerici<sup>1,4</sup>, M. Biasini<sup>1</sup>

<sup>1</sup>Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy, <sup>2</sup>S. Maria Annunziata Hospital, Florence, Italy, <sup>3</sup>Clinica delle Malattie Infettive dell'Azienda Ospedaliero Universitaria Consorziata Policlinico di Bari, <sup>4</sup>Don C. Gnocchi Foundation ONLUS, IRCCS, Milan, Italy

**OP 15 Different amounts of activated or exhausted effector memory T cells among differentiated CD4+ or CD8+ T lymphocytes during primary, acute HIV infection**

D. Lo Tartaro<sup>1</sup>, A. Camiro-Zúñiga<sup>2</sup>, S. Perez-Patrigeon<sup>2</sup>, A. Paolini<sup>1</sup>, M. Nasi<sup>1</sup>, C. Mussini<sup>1</sup>, A. Cossarizza<sup>1</sup>, S. De Biasi<sup>1</sup>

<sup>1</sup>Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>National Institute for Medical Sciences and Nutrition "Salvador Zubirán", Tlalpan, Mexico City, Mexico

**OP 16 HIV+ patients: modulating effects of antiretroviral therapy on cytokines' profile and microbiota composition**

G. Nannini<sup>1</sup>, E. Russo<sup>1</sup>, V. Di Pilato<sup>2</sup>, M. Coppi<sup>1</sup>, F. Ricci<sup>3</sup>, E. Niccolai<sup>1</sup>, S. Tekle Kiroso<sup>4</sup>, S. Baldi<sup>1</sup>, A. Bartoloni<sup>4,5</sup>, G.M. Rossolini<sup>1,6</sup>, A. Amedei<sup>1</sup>

<sup>1</sup>Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy, <sup>2</sup>Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy, <sup>3</sup>Department of Biomedical, Experimental and Clinical Sciences "Mario Serio" University of Florence, Florence, Italy, <sup>4</sup>Infectious Disease Unit, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, <sup>5</sup>Infectious and Tropical Disease Unit, Azienda Ospedaliero - Universitaria Careggi, Florence, Italy, <sup>6</sup>Department of Experimental and Clinical Medicine, University of Florence, Italy; Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy

**OP 17 Association between subclinical atherosclerosis and IFN-1 response in HIV-1 infected patients**

G. De Girolamo<sup>1</sup>, L. Santinelli<sup>1</sup>, C. Borrazzo<sup>1</sup>, C. Pinocchio<sup>1</sup>, G.P. Innocenti<sup>1</sup>, P. Vassalini<sup>1</sup>, E. Nelson Cavallari<sup>1</sup>, M. Statzu<sup>2</sup>, F. Frasca<sup>2</sup>, M. Scordio<sup>2</sup>, M. Mancone<sup>3</sup>, G. Antonelli<sup>2</sup>, G. d'Ettore<sup>1</sup>, C. Scagnolari<sup>2</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, <sup>2</sup>Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy, <sup>3</sup>Department of Cardiovascular, Respiratory, Nephrologic and Geriatric Sciences, Sapienza University of Rome, Rome, Italy

**OP 18 p53/mir34a/SIRT1 loop and immune reconstitution relationship during chronic HIV infection**

V. Bordoni, E. Tartaglia, A. Sacchi, A. Vergori, R. Gagliardini, A. Antinori, C. Agrati

National Institute for Infectious Diseases "L. Spallanzani" IRCCS



ORAL  
POSTER

**OP 19 Lower Immune Activation in Perinatally than in Horizontally HIV-Infected Adults**

L. Taramasso<sup>1,2</sup>, D. Fenoglio<sup>3,4</sup>, A. Parodi<sup>5</sup>, F. Kalli<sup>3</sup>, A. Bandera<sup>1,2</sup>, C. Dentone<sup>6</sup>, T. Altosole<sup>3</sup>, M. Berruti<sup>6</sup>, S. Mora<sup>7</sup>, M. Giacomini<sup>3,7</sup>, G. Filaci<sup>3,5</sup>, A. Di Biagio<sup>6</sup>

<sup>1</sup>Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy, <sup>2</sup>Multidisciplinary Research in Health Science (MACH), Milan, Italy, <sup>3</sup>Centre of Excellence for Biomedical Research (CEBR), University of Genova, Genoa, Italy, <sup>4</sup>Department of Internal Medicine, University of Genova- IRCCS Ospedale Policlinico San Martino, Genoa, Italy, <sup>5</sup>Biotherapy Unit, IRCCS Policlinico San Martino Hospital, Genoa Italy, <sup>6</sup>Department of Health Science (DISSAL), University of Genova and Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, <sup>7</sup>Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), University of Genova, Genoa, Italy

**OP 20 Microbiota Composition in HIV-Positive and HIV-Exposed Uninfected Pediatric Subjects**

E. Merlini<sup>1</sup>, M. Ficara<sup>2</sup>, E.S. Cannizzo<sup>1</sup>, F. Ferrari<sup>2</sup>, C. Tincati<sup>1</sup>, L. Dotta<sup>3</sup>, C. Tagliabue<sup>4</sup>, A. Diana<sup>5</sup>, V. Camelli<sup>6</sup>, L. Iughetti<sup>2,7</sup>, A. d'Arminio Monforte<sup>1</sup>, M. Cellini<sup>2</sup>, G. Marchetti<sup>1</sup> for the MIRROR Study Group

<sup>1</sup>Clinic of Infectious Diseases, Dept Health Sciences, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy, <sup>2</sup>Division of Paediatric Oncology-Haematology, Policlinico Hospital, Modena, Italy, <sup>3</sup>Clinica Pediatrica and "A. Nocivelli" Institute for Molecular Medicine, Department of Clinical and Experimental Sciences, University of Brescia, Spedali Civili Hospital, Brescia, <sup>4</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>5</sup>Department of Translational Medical Science, Section of Pediatrics, University Federico II, Naples, Italy, <sup>6</sup>Dept of Sciences of Public Health and Pediatrics, University of Turin, Italy, <sup>7</sup>Pediatric Unit, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy

**OP 21 Switching to integrase inhibitors is not linked to weight increase in young adults and adolescents perinatally infected with HIV, results from a 10-years observational study**

L. Taramasso<sup>1,2</sup>, A. Di Biagio<sup>3</sup>, F. Bovis<sup>4</sup>, F. Forlanini<sup>5</sup>, E. Albani<sup>5</sup>, R. Papaioannu<sup>3</sup>, V. Giacomet<sup>5</sup>

<sup>1</sup>Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy, <sup>2</sup>Multidisciplinary Research in Health Science (MACH), Milan, Italy, <sup>3</sup>Infectious Diseases Clinic, Department of Health Sciences (DISSAL), University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, <sup>4</sup>Biostatistics Unit, Department of Health Sciences (DISSAL), University of Genova, Italy, <sup>5</sup>Clinic of Paediatrics, ASST Fatebenefratelli-Sacco, Milan, Italy

**OP 22 An atypical case of HIV-1 elite controller: 15 years of follow up**

C. Fimiani<sup>1</sup>, F. Falasca<sup>2</sup>, C. Cerboni<sup>2</sup>, H. Stabile<sup>2</sup>, C. Scagnolari<sup>2</sup>, O. Turriziani<sup>2</sup>

<sup>1</sup>Department of Internal Medicine and Infectious Disease, University Hospital Policlinico Umberto I, Rome, <sup>2</sup>Department of Molecular Medicine, Sapienza University of Rome

**Clinical HIV**

Chairs: M. Borderi (Bologna), A. Ruggieri (Piacenza)

**OP 23 Newly diagnosed HIV infected patients in Brescia, Northern Italy: epidemiological and clinical characteristics and possible targets of prevention and early diagnosis campaign**

I. Izzo, G. Zuglian, C. Carriero, A. Celotti, E. Focà, M.A. Forleo, I. El Hamad, P. Nasta, M.C. Pezzoli, E. Quiros-Roldan, F. Castelli

University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy

**OP 24 Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in HIV-infected patients with metabolic syndrome**

L. Calza, V. Colangeli, M. Borderi, D. Testi, A. Amedeo, M.A. Di Bari, C. Fulgaro, P. Viale

Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola-Malpighi Hospital, University of Bologna

**OP 25 Durability of InSTI-based regimen in geriatric people living with HIV. Data from the Italian Multicenter GEPPCO Cohort**

E. Focà<sup>1</sup>, A. Calcagno<sup>2</sup>, S. Calza<sup>3</sup>, S. Renzetti<sup>3</sup>, A. Riva<sup>4</sup>, G.V. De Socio<sup>5</sup>, S. Piconi<sup>6</sup>, G. Orofino<sup>7</sup>, A. Chiesa<sup>1</sup>, G. Madeddu<sup>8</sup>, A. Cattelan<sup>9</sup>, S. Nozza<sup>10</sup>, J. Milic<sup>11</sup>, B.M. Celesia<sup>12</sup>, F. Castelli<sup>1</sup>, G. Di Perri<sup>2</sup>, G. Guaraldi<sup>11</sup>

<sup>1</sup>Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, <sup>2</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, <sup>3</sup>Unit of Biostatistics and Biomathematics & Unit of Bioinformatics, Department of Molecular and Translational Medicine, Università degli Studi di Brescia – Italy, <sup>4</sup>3<sup>rd</sup> Division of Infectious Diseases, University of Milano, Ospedale L. Sacco, Milano, Italy, <sup>5</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy, <sup>6</sup>1<sup>st</sup> Division of Infectious Diseases Unit, University of Milano, Ospedale L. Sacco, Milano, Italy, <sup>7</sup>Unit of Infectious Diseases, "Divisione A", Ospedale Amedeo di Savoia, ASLTO2, Torino, Italy, <sup>8</sup>Infectious and Tropical Diseases Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>9</sup>Unit of Infectious Diseases, Department of Internal Medicine, Azienda Ospedaliero-Universitaria di Padova, Padova, Italy, <sup>10</sup>Department of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy, <sup>11</sup>University of Modena and Reggio Emilia, Department of Mother, Child and Adult Medicine and Surgical Science, Infectious Disease Clinic, Modena, Italy, <sup>12</sup>Department of Clinical and Molecular Biomedicine, Division of Infectious Diseases, University of Catania, ARNAS Garibaldi, Catania, Italy

**OP 26 Weight gain and body composition changes in people living with HIV treated with Integrase Strand Transfer Inhibitors: a longitudinal assessment with Bioimpedance Vectorial Analysis**

M. Polisenio<sup>1</sup>, D.F. Bavaro<sup>1</sup>, P. Laghetti<sup>1</sup>, G. De Vita, N. de Gennaro<sup>1</sup>, S. Lo Caputo<sup>2</sup>, L. Monno<sup>1</sup>, G. Angarano<sup>1</sup>, A. Saracino<sup>1</sup>

<sup>1</sup>Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari Medical School, Bari, Italy, <sup>2</sup>Clinic of Infectious Diseases University of Foggia, Foggia, Italy

**OP 27 Transmitted drug resistance in newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy**

L. Calza<sup>2</sup>, M. Tamburello<sup>1</sup>, M. Borderi<sup>2</sup>, V. Colangeli<sup>2</sup>, D. Testi<sup>2</sup>, A. Amedeo<sup>2</sup>, M.C. Re<sup>1</sup>, I. Bon<sup>1</sup>

<sup>1</sup>Unit of Microbiology, University of Bologna (Italy), <sup>2</sup>Unit of Infectious Diseases, University of Bologna (Italy)



ORAL  
POSTER

**OP 28 Same day treatment and rapid antiretroviral therapy introduction in a cohort of unselected newly-diagnosed HIV-positive individuals**

G. Lapadula, M. Rossi, P. Vitiello, N. Squillace, A. Soria, P. Columpsi, F. Sabbatini, E. Colella, V. Cogliandro, A. Spolti, I. Beretta, A. Gambaro, G.M. Migliorino

Clinic of Infectious Diseases, "San Gerardo" Hospital, ASST-Monza, University of Milan-Bicocca, Italy

**OP 29 Changes in homeostatic model assessment for insulin resistance (HOMA-IR) index in treated HIV-1 infected people on virological suppression**

C. Muccini<sup>1</sup>, L. Galli<sup>2</sup>, A. Poli<sup>2</sup>, S. Bossolasco<sup>2</sup>, P. Cinque<sup>2</sup>, L. Fumagalli<sup>2</sup>, D. Canetti<sup>2</sup>, H. Hasson<sup>2</sup>, M. Ranzenigo<sup>1</sup>, M. Chiurlo<sup>1</sup>, A. Lazzarin<sup>2</sup>, A. Castagna<sup>1,2</sup>

<sup>1</sup>Vita-Salute San Raffaele University, Milan, Italy, <sup>2</sup>Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

**OP 30 A descriptive analysis on dual regimens' discontinuations in a multicentre Italian cohort**

D. Farinacci<sup>1</sup>, A. Ciccullo<sup>1</sup>, A. Dusina<sup>1</sup>, A. D'Angelillo<sup>1</sup>, D. Moschese<sup>1</sup>, A. Borghetti<sup>2</sup>, V. Borghi<sup>3</sup>, C. Mussini<sup>3</sup>, S. Di Giambenedetto<sup>1,2</sup>

<sup>1</sup>Istituto di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, <sup>2</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy, <sup>3</sup>Azienda Ospedaliero Universitaria di Modena, Clinica Malattie Infettive e Tropicali, Modena, Italy

**OP 31 Virological response and resistance profile in highly treatment-experienced HIV-1 infected patients switching to dolutegravir plus boosted-darunavir in clinical practice**

D. Armenia<sup>1,2</sup>, L. Fabeni<sup>3</sup>, R. Gagliardini<sup>4</sup>, V. Borghi<sup>5</sup>, G. Berno<sup>3</sup>, A. Vergori<sup>4</sup>, S. Cicalini<sup>4</sup>, C. Mussini<sup>5</sup>, A. Antinori<sup>4</sup>, F. Ceccherini-Silberstein<sup>1</sup>, C.F. Perno<sup>3</sup>, M.M. Santoro<sup>1</sup>

<sup>1</sup>Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, <sup>2</sup>Saint Camillus International University of Health Sciences, Rome, Italy, <sup>3</sup>Laboratory of Virology, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy, <sup>4</sup>Clinical Department, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy, <sup>5</sup>Clinic of Infectious Diseases, University Hospital, University of Modena and Reggio Emilia, Modena, Italy

**OP 32 Does rapid initiation of ART at HIV diagnosis impact on virological response and retention in care? A single center experience (Brescia, Northern Italy)**

A. Comelli, N. Gregori, A. Celotti, S. Renzetti, S. Calza, I. Izzo, C. Pezzoli, I. El Hamad, P. Nasta, M. Properzi, A. Chiesa, M. Degli Antoni, G. Faletti, B. Fumarola, E. Quiros-Roldan, F. Castelli, E. Focà

University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy

**OP 33 Efficacy and durability of dolutegravir- or darunavir-based regimens in ART-naïve AIDS- or late-presenter patients**

M. Masini<sup>1</sup>, B. Rossetti<sup>2</sup>, A. Ciccullo<sup>3,4</sup>, V. Borghi<sup>5</sup>, F. Lagi<sup>6</sup>, A. Capetti<sup>7</sup>, M. Colafigli<sup>8</sup>, D. Moschese<sup>3,4</sup>, C. Mussini<sup>5</sup>, G. Sterrantino<sup>6</sup>, C. Picarelli<sup>3,4</sup>, F. Montagnani<sup>1</sup>, S. Di Giambenedetto<sup>3,4</sup>, M. Fabbiani<sup>2</sup>

<sup>1</sup>UOC Malattie Infettive e Tropicali, Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italy, <sup>2</sup>UOC Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Senese, Siena, Italy, <sup>3</sup>Università Cattolica del Sacro Cuore, Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive, Rome, Italy, <sup>4</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, <sup>5</sup>Azienda Ospedaliero Universitaria di Modena, Clinica Malattie Infettive e Tropicali, Modena, Italy, <sup>6</sup>Department of Experimental and Clinical Medicine, University of Florence, Florence Italy, <sup>7</sup>Divisione di Malattie Infettive, Dipartimento di Malattie Infettive, Ospedale Universitario Luigi Sacco, Milano, Italy, <sup>8</sup>Unità di Dermatologia Infettiva e Allergologia, Istituto S. Gallicano IRCCS, Roma, Italy

**OP 34 Efficacy Safety and Tolerability of the switch from efavirenz/emtricitabine/tenofovir disoproxil on alternate days or continuous treatment to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV+ (EBONY Study)**

M. Camici, A. Mondì, F. De Zottis, G. Passavanti, E. Grilli, A. Vergori, R. Gagliardini, S. Ottou, M.M. Plazzi, S. Cicalini, A. Antinori, R. Bellagamba

HIV/AIDS Clinical Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy

**Clinical HIV II**

Chairs: R. Bellagamba (Roma), V. Giacomet (Milano)

**OP 35 Allogenic hematopoietic stem cell transplantation in HIV-positive recipients: a case series**

C. Oltolini<sup>1</sup>, S. Piemontese<sup>2</sup>, R. Greco<sup>2</sup>, D. Clerici<sup>2</sup>, F. Giglio<sup>2</sup>, L. Galli<sup>1</sup>, M. Ripa<sup>1,3</sup>, B. Castiglioni<sup>1</sup>, C. Tassan Din<sup>1</sup>, S. Nozza<sup>1</sup>, C. Corti<sup>2</sup>, M. Bernardi<sup>2</sup>, J. Peccatori<sup>2</sup>, P. Scarpellini<sup>1</sup>, A. Lazzarin<sup>1</sup>, F. Ciceri<sup>2,3</sup>, A. Castagna<sup>1,3</sup>

<sup>1</sup>Clinic of Infectious Diseases, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>2</sup>Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>3</sup>University Vita-Salute San Raffaele, Milan, Italy

**OP 36 Italian survey on clinicians' approach to Latent Tubercular Infection in people living with HIV**

L. Caiazzo<sup>1,2</sup>, A. Calcagno<sup>3</sup>, F. Vignale<sup>1</sup>, M. Pontolillo<sup>1,4</sup>, A. Brandimarte<sup>4</sup>, A. Auricchio<sup>1,4</sup>, K. Falasca<sup>1,4</sup>, J. Vecchiet<sup>1,4</sup>

<sup>1</sup>Clinica di Malattie infettive, Chieti, <sup>2</sup>Scuola di specializzazione in Malattie infettive e tropicali, Università politecnica delle Marche, Ancona, <sup>3</sup>Unità di Malattie Infettive, Università di Torino, Torino, <sup>4</sup>Scuola di specializzazione in Malattie infettive e tropicali, Università D'Annunzio, Chieti





## ORAL POSTER

- OP 37 A poor immunological recovery is associated with non-AIDS-defining cancers in the era of HAART: a case-control study**  
A. Emiliozzi<sup>1,2</sup>, A. Ciccullo<sup>1</sup>, A. Dusina<sup>1</sup>, D. Moschese<sup>1</sup>, D. Farinacci<sup>1</sup>, C. Picarelli<sup>1</sup>, A. D'Angelillo<sup>1</sup>, S. Lamonica<sup>1</sup>, F. Lombardi<sup>1</sup>, G. Baldin<sup>1</sup>, A. Borghetti<sup>3</sup>, M. Fabbiani<sup>4</sup>, S. Di Giambenedetto<sup>1,3</sup>  
<sup>1</sup>Università Cattolica del Sacro Cuore, Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive, Roma, Italy, <sup>2</sup>UOC Malattie Infettive e Tropicali, Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italy, <sup>3</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, UOC Malattie Infettive, <sup>4</sup>UOC Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Senese, Siena, Italy
- OP 38 HPV infection in HIV+, MSM patients followed at a large HIV Clinic in Northern Italy**  
E. Asperges, V. Zuccaro, L. Pagnucco, R. Gulminetti, R. Maserati, R. Bruno  
Infectious Disease Dept, Foundation IRCCS Policlinico "San Matteo" and University of Pavia
- OP 39 Risk of multiple primary neoplasms and impact on survival of person living with HIV (PLWH)**  
V. Mazzotta<sup>1</sup>, P. Lorenzini<sup>1</sup>, A. Bandera<sup>2</sup>, A. Gori<sup>2</sup>, L. Sighinolfi<sup>3</sup>, S. Rusconi<sup>4</sup>, P. Bonfanti<sup>5</sup>, A. Cingolani<sup>6</sup>, G. Marchetti<sup>7</sup>, C. Mussini<sup>8</sup>, A. d'Arminio Monforte<sup>7</sup>, A. Antinori<sup>1</sup> ICONA FOUNDATION STUDY GROUP  
<sup>1</sup>HIV/AIDS Unit, INMI L. Spallanzani IRCCS, Roma, <sup>2</sup>IRCCS Policlinico Ospedale Maggiore, University of Milano, <sup>3</sup>Division of Infectious Disease, Hospital of Ferrara, Ferrara, <sup>4</sup>ASST L. Sacco Hospital, University of Milano, <sup>5</sup>Division of Infectious Disease, ASST Lecco, Lecco, <sup>6</sup>Fondazione Policlinico A. Gemelli, Catholic University, Roma, <sup>7</sup>ASST Santi Paolo e Carlo, University of Milano, <sup>8</sup>Clinic of Infectious Disease, University hospital of Modena, Modena
- OP 40 Development and standardization of a real time PCR for the quantification of HTLV-1 proviral load**  
A. Primavera<sup>1</sup>, A. Bertoldi<sup>1</sup>, I. Bon<sup>1</sup>, V. D'Urbano<sup>1</sup>, M. Tamburello<sup>1</sup>, L. Calza<sup>2</sup>, M.C. Re<sup>1</sup>, G. Gallinella<sup>3</sup>  
<sup>1</sup>Microbiology Section, Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, University of Bologna, Italy, <sup>2</sup>Clinics of Infectious Diseases, Department of Medical and Surgical Sciences, School of Medicine, University of Bologna, Italy, <sup>3</sup>Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
- OP 41 Is pretreatment HIV-1 integrase resistance increasing? A large Italian centre experience**  
D. Canetti<sup>1,2</sup>, L. Galli<sup>1</sup>, A. Poli<sup>1</sup>, N. Gianotti<sup>1</sup>, M. Ripa<sup>1,2</sup>, S. Nozza<sup>1</sup>, A. Bigoloni<sup>1</sup>, M. Guffanti<sup>1</sup>, L. Fumagalli<sup>1</sup>, M. Sampaolo<sup>1</sup>, E. Boeri<sup>1</sup>, A. Lazzarin<sup>1</sup>, A. Castagna<sup>1,2</sup>  
<sup>1</sup>Clinic of Infectious Diseases, IRCCS San Raffaele, Milano, Italy, <sup>2</sup>Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Milano, Italy
- OP 42 Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection**  
C. Muccini<sup>1</sup>, L. Galli<sup>2</sup>, A. Poli<sup>2</sup>, A. Bigoloni<sup>2</sup>, A. Mastrangelo<sup>1</sup>, E. Bruzzesi<sup>1</sup>, C. Uberti Foppa<sup>2</sup>, M. Guffanti<sup>2</sup>, G. Tambussi<sup>2</sup>, M. Cernuschi<sup>1</sup>, A. Lazzarin<sup>1</sup>, A. Castagna<sup>1,2</sup>  
<sup>1</sup>Vita-Salute San Raffaele University, Milan, Italy, <sup>2</sup>Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy
- OP 43 Evolving epidemiology of HIV/AIDS in Campania Region, 2008-19: is HIV/AIDS population in Campania different?**  
F.M. Fusco<sup>1</sup>, A. Menna<sup>2</sup>, A. Galano<sup>2</sup>, L. Anna<sup>2</sup>, A. Mariniello<sup>2</sup>, M. De Cenzo<sup>2</sup>, S. Mascolo<sup>3</sup>, M. Sardo<sup>4</sup>, R. Viglietti<sup>1</sup>, G. Parrella<sup>1</sup>, O. Tambaro<sup>1</sup>, V. Iodice<sup>1</sup>, M.A. Pisaturo<sup>1</sup>, G. Di Flumeri<sup>1</sup>, E. Manzillo<sup>4</sup>, V. Esposito<sup>3</sup>, A. Chirianni<sup>1</sup>, V. Sangiovanni<sup>1</sup>  
<sup>1</sup>UOC Infezioni Sistemiche e dell'Immunodepressione, P.O. "D. Cotugno", Azienda Ospedaliera dei Colli, Naples, Italy, <sup>2</sup>Servizio Ospedalizzazione Domiciliare, P.O. "D. Cotugno", Azienda Ospedaliera dei Colli, Naples, Italy, <sup>3</sup>UOC Immunodeficienze e Malattie Infettive di Genere, P.O. "D. Cotugno", Azienda Ospedaliera dei Colli, Naples, Italy, <sup>4</sup>U.O.C. Immunodeficienze e malattie dell'immigrazione, P.O. "D. Cotugno", Azienda Ospedaliera dei Colli, Naples, Italy
- OP 44 Impact of boosted vs unboosted antiretroviral regimen on Dolutegravir plasma and intracellular pharmacokinetics**  
M. Ferrara, C. Alcantarini, A. Lazzaro, A. Di Stefano, S. Biffi, M. Trunfio, M. Tettoni, V. Avataneo, A. Ianniello, E. De Vivo, A. De Nicolò, A. D'Avolio, A. Calcagno, G.D. Perri, S. Bonora  
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino

## Comorbidities

Chairs: F. Carli (Modena), P. Maggi (Napoli), I. Maida (Sassari)

- OP 45 Inflammatory and neurometabolite changes among patients switching away from efavirenz and their correlation with neurotoxicity: results from the sub-study of a randomized controlled trial**  
I. Baldisserotto<sup>1</sup>, E. Bresciani<sup>1</sup>, D.P. Bernasconi<sup>1</sup>, M. Rossi<sup>2</sup>, E. Focà<sup>3</sup>, A. di Biagio<sup>4</sup>, F. Bai<sup>5</sup>, F. Castelli<sup>6</sup>, A. Calcagno<sup>6</sup>, A. d'Arminio Monforte<sup>7</sup>, A. Torsello<sup>1</sup>, G.M. Migliorino<sup>2</sup>, G. Lapadula<sup>2</sup> for the Swear Study Group  
<sup>1</sup>University of Milan-Bicocca, Milan, Italy, <sup>2</sup>San Gerardo Hospital, Monza, Italy, <sup>3</sup>University of Brescia, Brescia, Italy, <sup>4</sup>San Martino Hospital, Genoa, Italy, <sup>5</sup>San Paolo Hospital, Milan, Italy, <sup>6</sup>University of Turin, Turin, Italy, <sup>7</sup>University of Milan, Milan, Italy
- OP 46 Contribution of INSTI, BMI, physical activity or caloric intake to weight gain in PLWH**  
G. Guaraldi<sup>1</sup>, J. Milic<sup>1</sup>, G. Dolci<sup>1</sup>, A. Malagoli<sup>1</sup>, F. Carli<sup>1</sup>, M. Menozzi<sup>1</sup>, I. Franconi<sup>1</sup>, A. Raimondi<sup>1</sup>, G. Ciusa<sup>1</sup>, V. Masi<sup>1</sup>, M. Belli<sup>1</sup>, S. Guaraldi<sup>1</sup>, C. Mussini<sup>1</sup>, T.T. Brown<sup>2</sup>, J.E. Lake<sup>3</sup>, K. Erlandson<sup>4</sup>  
<sup>1</sup>Infectious Disease Unit, University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, <sup>3</sup>David Geffen School of Medicine, University of California, Los Angeles, CA, USA, <sup>4</sup>University of Colorado-Anschutz Medical Center, Aurora, Colorado



ORAL  
POSTER

**OP 47 Cerebrospinal Fluid CXCL13 as a marker of Intrathecal Immunoglobulin Synthesis and Immune-activation in treatment-naïve People Living with HIV**

M. Trunfio<sup>1</sup>, L. Mighetto<sup>2</sup>, E. Borgogno<sup>1</sup>, C. Atzori<sup>3</sup>, A. Di Stefano<sup>1</sup>, M. Nigra<sup>2</sup>, D. Imperiale<sup>3</sup>, S. Bonora<sup>1</sup>, G. Di Perri<sup>1</sup>, A. Calcagno<sup>1</sup>

<sup>1</sup>Infectious Diseases unit, Amedeo di Savoia hospital, University of Torino, Torino, Italy, <sup>2</sup>Diagnostic Laboratory unit, Maria Vittoria hospital, ASL Città di Torino, Torino, Italy, <sup>3</sup>Neurology unit, Maria Vittoria hospital, ASL Città di Torino, Torino, Italy

**OP 48 Evaluation of the association between cognitive performance and HAND diagnosis with the cognitive reserve in naïve HIV-infected patients**

A.C. Brita, A. Vergori, G. Passavanti, P. Lorenzini, S. Cicalini, R. Gagliardini, R. Bellagamba, E. Grilli, A. Mondì, S. Grisetti, V. Mazzotta, F. Baldini, A. Giannetti, A. Antinori, C. Pinnetti

National Institute for Infectious Diseases, IRCCS, L. Spallanzani-HIV/AIDS Unit, Rome, Italy

**OP 49 Are Low vitamin D plasma levels associated with intrathecal immuneactivation in PLWH?**

A. Vergori<sup>1</sup>, V. Bordon<sup>2</sup>, P. Lorenzini<sup>1</sup>, G. Passavanti<sup>1</sup>, S. Notari<sup>2</sup>, V. Mazzotta<sup>1</sup>, S. Cicalini<sup>1</sup>, A. Giannetti<sup>1</sup>, F. Forbici<sup>3</sup>, C. Agrati<sup>2</sup>, A. Antinori<sup>1</sup>, C. Pinnetti<sup>1</sup>

<sup>1</sup>HIV/AIDS Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, <sup>2</sup>Cellular immunology and Pharmacology Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, <sup>3</sup>Virology Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS

**OP 50 Gender differences in neurocognitive functions in PLWK**

V. Delle Donne<sup>1</sup>, N. Ciccarelli<sup>2</sup>, V. Massaroni<sup>1</sup>, F. Lombardi<sup>1</sup>, C. Picarelli<sup>1</sup>, A. Borghetti<sup>1</sup>, A. Emiliozzi<sup>1</sup>, A. Dusina<sup>1</sup>, A. Ciccullo<sup>1</sup>, D. Moschese<sup>1</sup>, G. Baldini<sup>1,5</sup>, D. Farinacci<sup>1</sup>, S. Di Giambenedetto<sup>1,4</sup>, M. Fabbiani<sup>3</sup>

<sup>1</sup>Università Cattolica del Sacro Cuore, Roma Italia, Istituto di Clinica Malattie Infettive, <sup>2</sup>Dipartimento di Psicologia, Università Cattolica di Milano, <sup>3</sup>UOC Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Senese, Siena, Italy, <sup>4</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, UOC malattie infettive, <sup>5</sup>Mater Olbia Hospital, Olbia, Italy

**OP 51 Menopause in aging women living with HIV: changes in bone mineral density and trabecular bone score**

D. Morini<sup>1</sup>, A. Malagoli<sup>2</sup>, J. Milic<sup>2,3</sup>, F. Carli<sup>2</sup>, A. Raimondi<sup>2</sup>, I. Franconi<sup>2</sup>, C. Mussini<sup>2</sup>, V. Rochira<sup>4</sup>, G. Guaraldi<sup>2</sup>

<sup>1</sup>University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>Modena HIV Metabolic Clinic, University of Modena and Reggio Emilia, Italy, <sup>3</sup>Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy, <sup>4</sup>Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

**OP 52 NAFLD phenotype and prevalence across the menopause spectrum in women with HIV**

J. Milic<sup>1</sup>, A. Cervo<sup>2</sup>, A. Malagoli<sup>1</sup>, V. Menozzi<sup>1</sup>, D. Morini<sup>1</sup>, F. Carli<sup>1</sup>, A. Raimondi<sup>1</sup>, M. Menozzi<sup>1</sup>, I. Franconi<sup>1</sup>, C. Mussini<sup>1</sup>, G. Sebastiani<sup>3</sup>, G. Guaraldi<sup>1</sup>

<sup>1</sup>University of Modena and Reggio Emilia, <sup>2</sup>Infectious Diseases Unit, PROMISE, University of Palermo, Palermo, Italy, <sup>3</sup>Chronic Viral Illness Service, McGill University Health Centre, Montreal, Canada

**OP 53 Incidence of diabetes in a cohort of PLWH people living with HIV in Perugia**

M. Nofri<sup>1</sup>, E. Schiaroli<sup>1</sup>, S. Parretti<sup>2</sup>, M. Cavallo<sup>2</sup>, V. Bianconi<sup>3</sup>, V.G. De Socio<sup>1</sup>, R. Calafiore<sup>2</sup>, D. Francisci<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, Department of Medicine, University of Perugia, Perugia, Italy, <sup>2</sup>Division of Endocrinology and Metabolism, Department of Medicine, University of Perugia, Perugia, Italy, <sup>3</sup>Unit of Internal Medicine, Department of Medicine, University of Perugia, Perugia, Italy

**OP 54 Standard vs higher dose of Rifampicin in patients with tuberculosis: a meta-analysis**

V. Gentile<sup>1</sup>, L. Onorato<sup>1</sup>, A. Russo<sup>1</sup>, L. Alessio<sup>2</sup>, G. DiCaprio<sup>2</sup>, N. Coppola<sup>1</sup>

<sup>1</sup>Department of Mental Health and Public Medicine – Infectious Diseases Unit, University of Campania Luigi Vanvitelli; Napoli, <sup>2</sup>Infectious Diseases Unit, Sant' Anna e San Sebastiano Hospital; Caserta

## Hepatitis and Coinfections

Chairs: O. Armignacco (Roma), M. Massari (Reggio Emilia), C. Sagnelli (Napoli)

**OP 55 Rapid Detection of Mycobacterium tuberculosis DNA in pulmonary and extrapulmonary paraffinized samples by ddPCR**

M. Antonello<sup>1</sup>, R. Scutari<sup>2</sup>, C. Lauricella<sup>3</sup>, S. Renica<sup>1</sup>, V. Motta<sup>3</sup>, S. Torri<sup>4</sup>, S.M. Veronese<sup>3</sup>, L.R. Codecasa<sup>5</sup>, E. Bonoldi<sup>3</sup>, C. Vismara<sup>4</sup>, A. Bandera<sup>6</sup>, E. Mazzola<sup>4</sup>, A. Gori<sup>6</sup>, C.F. Perno<sup>1,4</sup>, C. Alteri<sup>1</sup> on behalf of IFALT study group

<sup>1</sup>Department of Oncology and Hemato-Oncology, University of Milan, Milan, <sup>2</sup>Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, <sup>3</sup>Department of Pathology, ASST Grande Ospedale Metropolitano Niguarda, Milan, <sup>4</sup>Unit of Microbiology, Department of Chemical-clinical and Microbiology Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, <sup>5</sup>Regional TB Reference Centre, Villa Marelli Institute, ASST Grande Ospedale Metropolitano Niguarda, Milan, <sup>6</sup>Infectious Unit, IRCCS Policlinico Maggiore, Milan

**OP 56 Pharyngeal contamination is a major driver for sexually transmitted infections epidemic in Men who have Sex with Men**

R. Rossotti<sup>1</sup>, C. Baiguera<sup>1</sup>, C. Vismara<sup>2</sup>, M. Merli<sup>1</sup>, A. Nava<sup>2</sup>, S. Chiappetta<sup>1</sup>, M.C. Moioli<sup>1</sup>, D. Fanti<sup>2</sup>, L.G. Chianura<sup>1</sup>, D. Motta<sup>1</sup>, C.F. Perno<sup>2,3</sup>, M. Puoti<sup>1</sup>

<sup>1</sup>Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, <sup>2</sup>Chemical-Clinical and Microbiological Analysis, ASST Grande Ospedale Metropolitano Niguarda, Milan, <sup>3</sup>Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan



ORAL  
POSTER

**OP 57 HCV infection in PWUD: a microelimination intervention in Rome**

C. Taibi<sup>1</sup>, I. Luzzitelli<sup>1</sup>, A.R. Garbuglia<sup>2</sup>, L. Rapisarda<sup>3</sup>, G. Monacelli<sup>3</sup>, U. Visco Comandini<sup>1</sup>, R. Lionetti<sup>1</sup>, E. Girardi<sup>4</sup>, G. D'Offizi<sup>1</sup>

<sup>1</sup>Hepatology and Infectious Disease Department, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, <sup>2</sup>Virology Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, <sup>3</sup>Service for Addictions Department, ASL RM3, Rome, <sup>4</sup>Epidemiology Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome

**OP 58 Direct-acting antiviral based treatment for HCV-infected persons who inject drugs: a multi-centre real-life study**

L. Onorato<sup>1</sup>, V. Messina<sup>1</sup>, G. Di Caprio<sup>1</sup>, A. Russo<sup>1</sup>, C. Caruso<sup>2</sup>, V. Rosato<sup>3</sup>, E. Claar<sup>3</sup>, V. Iovinella<sup>2</sup>, N. Coppola<sup>4</sup>

<sup>1</sup>Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, <sup>2</sup>Department of Internal Medicine, San Paolo Hospital, Naples, Italy, <sup>3</sup>Hepatology Unit, "Villa Betania" Evangelical Hospital, Naples, Italy, <sup>4</sup>Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania L. Vanvitelli, Naples, Italy

**OP 59 Are Non-Injecting Drug Users at risk of HCV-infection? Data from the San Patrignano cohort**

A. Boschini<sup>1</sup>, P. Piselli<sup>2</sup>, R. Poletti<sup>1</sup>, M. Begnini<sup>1</sup>, P. Ottogalli<sup>1</sup>, C. Cimaglia<sup>2</sup>, P. Parracino<sup>2</sup>, E. Girardi<sup>2</sup>

<sup>1</sup>Comunità San Patrignano (Rimini), <sup>2</sup>INMI "L. Spallanzani" IRCCS, Rome

**OP 60 Real Life DAAs in a large cohort of people who use drugs with hepatitis C virus infection in Tor Vergata Hospital in Rome: adherence, efficacy and reinfections of a key population**

T. Mulas, E. Teti, L. Foroghi, G. De Simone, L. Campogiani, L. Ferrari, C. Stingone, M. De Masi, L. Coppola, M. Compagno, M. Iannetta, L. Sarmati, M. Andreoni

Infectious Diseases Clinic, Tor Vergata Hospital, Rome, Italy

**OP 61 Effects of HCV eradication on liver function in haemophilic HIV/HCV co-infected patients**

V. Castelli<sup>1</sup>, L. Taramasso<sup>1</sup>, F. Portunato<sup>2</sup>, G. Bozzi<sup>1</sup>, A. Gori<sup>1</sup>, A. Bandera<sup>1</sup>, A. Muscatello<sup>1</sup>, M.E. Mancuso<sup>3</sup>

<sup>1</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, <sup>2</sup>Infectious Diseases Unit, Azienda Ospedaliera Universitaria Federico II, Napoli, <sup>3</sup>Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano

**OP 62 Virological patterns of HCV-patients with failure to second generation direct-acting antivirals**

M. Starace<sup>1</sup>, M. Pisaturo<sup>1</sup>, C. Minichini<sup>1</sup>, S. De Pascalis<sup>1</sup>, M. Macera<sup>1</sup>, L. Occhiello<sup>1</sup>, A. Di Fraia<sup>1</sup>, L. Alessio<sup>2</sup>, V. Messina<sup>2</sup>, E. Claar<sup>3</sup>, T. Ascione<sup>4</sup>, A. Marrone<sup>5</sup>, V. Rosato<sup>6</sup>, I. Gentile<sup>6</sup>, V. Iovinella<sup>7</sup>, L. Fontanella<sup>8</sup>, G. D'Adamo<sup>9</sup>, R. Santoro<sup>10</sup>, G.B. Gaeta<sup>1</sup>, N. Coppola<sup>1</sup>

<sup>1</sup>Infectious Diseases Unit, Department of Mental and Physical Health and Preventive Medicine, University L. Vanvitelli, Naples, Italy, <sup>2</sup>Infectious Diseases Unit, AO Caserta, Caserta, Italy, <sup>3</sup>Internal Medicine Unit, Evangelical Hospital Villa Betania Naples, Italy, <sup>4</sup>Internal Medicine Unit, University L. Vanvitelli, Marcianise (CE), Italy, <sup>5</sup>Internal Medicine, University of Campania L. Vanvitelli, <sup>6</sup>Infectious Diseases Unit, University Federico II, Naples, Italy, <sup>7</sup>Internal Medicine Unit, P.O. S.Paolo - ASL Napoli 1, Naples, Italy, <sup>8</sup>Internal Medicine Unit, AO Madonna del Buon Consiglio FATEBENEFRAELLI, Naples, Italy, <sup>9</sup>Internal Medicine Unit, P.O. Umberto I Nocera Inferiore, <sup>10</sup>Internal Medicine and Hepatology Unit, PO G. Da Prada-AOU- San Giovanni e Ruggi D'Aragona, University of Salerno

**OP 63 Advanced liver disease outcomes after Hepatitis C viral eradication according to Human Immunodeficiency Virus coinfection in PITER cohort**

M.G. Quaranta<sup>1</sup>, L. Ferrigno<sup>1</sup>, M. Monti<sup>2</sup>, R. Filomia<sup>3</sup>, E. Biliotti<sup>4</sup>, A. Iannone<sup>5</sup>, G. Migliorino<sup>6</sup>, B. Coco<sup>7</sup>, F. Morisco<sup>8</sup>, M. Vinci<sup>9</sup>, R. D'Ambrosio<sup>10</sup>, L. Chemello<sup>11</sup>, M. Massari<sup>12</sup>, D. Ieluzzi<sup>13</sup>, F.P. Russo<sup>14</sup>, P. Blanc<sup>15</sup>, G. Verucchi<sup>16</sup>, M. Puoti<sup>17</sup>, M.G. Rumi<sup>18</sup>, F. Barbaro<sup>19</sup>, T.A. Santantonio<sup>20</sup>, A. Federico<sup>21</sup>, L. Chessa<sup>22</sup>, I. Gentile<sup>23</sup>, M. Zuin<sup>24</sup>, G. Parruti<sup>25</sup>, G. Morsica<sup>26</sup>, L.A. Kondili<sup>1</sup> on behalf of PITER Collaborating Group\*

<sup>1</sup>Center for Global Health, Istituto Superiore di Sanità, Rome, <sup>2</sup>Interdepartmental Centre MASVE, University of Florence, Florence, <sup>3</sup>Division of Clinical and Molecular Hepatology, University Hospital of Messina, Messina, <sup>4</sup>Hepatology Unit, Department of Clinical Medicine, Sapienza University, Rome, <sup>5</sup>Department of Emergency and Organ Transplantation, Gastroenterology Unit, University of Bari, Bari, <sup>6</sup>Division of Infectious Diseases, San Gerardo Hospital, Monza, <sup>7</sup>Hepatology and Liver Physiopathology Laboratory and Internal Medicine, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, <sup>8</sup>Department of Clinical Medicine and Surgery, Federico II University, Naples, <sup>9</sup>Department of Hepatology and Gastroenterology, Niguarda Hospital, Milan, <sup>10</sup>Pathophysiology and Transplantation Department, Gastroenterology and Hepatology, CRC AM e A Migliavacca Center for Liver Diseases, Fondazione Ca' Granda IRCCS Ospedale Maggiore Policlinico, University of Milan, Milan, <sup>11</sup>Department of Medicine, University Hospital of Padua, Padua, <sup>12</sup>Infectious Diseases, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, <sup>13</sup>Clinical Unit of Gastroenterology, University Hospital of Verona, Verona, <sup>14</sup>Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, <sup>15</sup>Infectious Disease Unit, Santa Maria Annunziata Hospital, Florence, <sup>16</sup>Department of Medical and Surgical Sciences, Clinic of Infectious Diseases and Microbiology Unit, Alma Mater Studiorum Bologna University, Bologna, <sup>17</sup>Department of Infectious Disease, Niguarda Hospital, Milan, <sup>18</sup>Hepatology Unit, San Giuseppe Hospital, University of Milan, Milan, <sup>19</sup>Infectious and Tropical Diseases Unit, Azienda Ospedaliera di Padova, Padova, <sup>20</sup>Infectious Diseases, Ospedali Riuniti, Foggia, <sup>21</sup>Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, <sup>22</sup>Liver Unit, University Hospital, Monserrato, Cagliari, <sup>23</sup>Department of Clinical Medicine and Surgery, Federico II University, Naples, <sup>24</sup>Department of Health Sciences, San Paolo Hospital, University of Milan, Milan, <sup>25</sup>Infectious Disease Unit, Spirito Santo General Hospital, Pescara, <sup>26</sup>Department of Infectious Diseases, San Raffaele Hospital, Milan, \*available at www.progettopiter.it

**OP 64 The combination of accurate serological and virological HBV markers can help to predict the occurrence of HBV reactivation and to optimize prophylaxis duration in HBsAg-negative/anti-HBc-positive patients with oncohematological diseases**

R. Salpini<sup>1</sup>, C. Cerva<sup>2</sup>, M. Alkhatib<sup>1</sup>, L. Piermattei<sup>1</sup>, A. Battisti<sup>1</sup>, V. Malagnino<sup>2</sup>, L. Fabeni<sup>1</sup>, M.L. Cantonetti<sup>3</sup>, W. Arcese<sup>3</sup>, F. Ceccherini-Silberstein<sup>1</sup>, C.F. Perno<sup>4</sup>, M. Andreoni<sup>2</sup>, L. Sarmati<sup>2</sup>, V. Svicher<sup>1</sup>

<sup>1</sup>Department of Experimental Medicine, Tor Vergata University, Rome, Italy, <sup>2</sup>Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, Rome, Italy, <sup>3</sup>Department of Hematology, Stem Cell Transplant Unit, Tor Vergata University, Rome, Italy, <sup>4</sup>Department of Oncology and Haemato-oncology, University of Milan

**OP 65 HBV and HDV infection in immigrants living in South Italy: epidemiological and virological characteristics**

L. Onorato<sup>2</sup>, M. Pisaturo<sup>2,6</sup>, C. Sagnelli<sup>2,4</sup>, L. Alessio<sup>1,4</sup>, C. Monari<sup>1</sup>, L. Gualdieri<sup>5</sup>, C. Minichini<sup>2</sup>, G. Di Caprio<sup>1</sup>, M. Starace<sup>2</sup>, M. Caroprese<sup>1</sup>, L. Occhiello<sup>1</sup>, G. Scotto<sup>6</sup>, M. Macera<sup>2</sup>, E. Sagnelli<sup>2</sup>, N. Coppola<sup>1,2</sup>

<sup>1</sup>UOC di Malattie Infettive, AORN Sant'Anna e San Sebastiano, Caserta, <sup>2</sup>Sezione di Malattie Infettive, Dipartimento di Salute Mentale e Medicina Pubblica, Università della Campania Luigi Vanvitelli, Napoli, <sup>3</sup>Centro di Accoglienza "La tenda di Abramo", Caserta, <sup>4</sup>Centro Suore Missionarie della Carità, Napoli, <sup>5</sup>Centro per la Tutela della Salute degli Immigrati, Napoli, <sup>6</sup>Centro sociale ex canonificio Caserta, <sup>7</sup>UOC di Malattie Infettive, Foggia



ORAL  
POSTER

**OP 66 HEV infection as an emergent public health issue: is it a concern for Italian blood donors?**

L. Colagrossi<sup>1</sup>, M. Mercuri<sup>2</sup>, A. Nava<sup>2</sup>, E. Matarazzo<sup>1</sup>, D. Campisi<sup>2</sup>, C.F. Perno<sup>1,2</sup>, D. Fanti<sup>2</sup>

<sup>1</sup>Residency in Microbiology and Virology, Università degli Studi di Milano, Milan; <sup>2</sup>Chemical-clinical and Microbiological Analysis, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

**Social Science and Prevention**

Chairs: S. Babudieri (Sassari), B.M. Celesia (Catania), M.G. Di Benedetto (Catania)

**OP 67 HIV SelfTesting: a survey of self-tests availability in Italian Pharmacies**

M. Maffeo<sup>1,2</sup>, M.L. Cosmaro<sup>2</sup>, M. Kall<sup>3</sup>, S. Nash<sup>3</sup>

<sup>1</sup>Scuola di Specializzazione in Igiene e Medicina Preventiva - Università degli Studi di Milano Statale, <sup>2</sup>Fondazione Lega Italiana per la Lotta contro l'AIDS - LILA Milano, <sup>3</sup>Public Health England

**OP 68 Testing MSM in cruising venues**

D. Zagato<sup>1</sup>, A. Andolina<sup>1</sup>, L. Beltrami<sup>1</sup>, A. Bianchi<sup>1</sup>, A. Brambilla<sup>1</sup>, G. Calcagno<sup>1</sup>, D. Calzavara<sup>2</sup>, M. Carbonara<sup>2</sup>, D. Deserti<sup>2</sup>, A.J. Gallucci<sup>2</sup>, V. Gambini<sup>1</sup>, E. Garavaglia<sup>2</sup>, M. Gucciardi<sup>1</sup>, V. LaMonica<sup>1</sup>, S. Lolli<sup>1</sup>, L. Londei<sup>1</sup>, F. Maddaloni<sup>1</sup>, M. Manfredini<sup>1</sup>, G.M. Mattioli<sup>2</sup>, V. Nicotera<sup>1</sup>, D. Pennisi<sup>1</sup>, P. Peruggia<sup>1</sup>, A. Pezzotti<sup>1</sup>, M. Pierini<sup>1</sup>, C. Romero<sup>1</sup>, R. Rossotti<sup>1</sup>, A. Ruggeri<sup>2</sup>, P. Testoni<sup>1</sup>, L. Valpreda<sup>1</sup>, P. Vinti<sup>1</sup>, A. Ünlü<sup>1</sup>, M. Cernuschi<sup>1</sup>

<sup>1</sup>ASA Associazione Solidarietà AIDS, Milan, <sup>2</sup>CIG-Arcigay, Milano

**OP 69 Behavioral aspects of MSM tested in community-based settings in 5 cities**

M. Breveglieri<sup>1</sup>, P. Guarino<sup>2</sup>, A. Bignardi<sup>3</sup>, D. Pavia<sup>3</sup>, D. Calzavara<sup>4</sup>, M. Costacurta<sup>2</sup>, D. Deserti<sup>4</sup>, F. Angeli<sup>5</sup>, M. Marocco<sup>1</sup>, G. Corradini<sup>6</sup>

<sup>1</sup>Arcigay, Associazione LGBT+ Italiana, <sup>2</sup>Arcigay Padova, <sup>3</sup>Arcigay Modena, <sup>4</sup>Arcigay Milano, <sup>5</sup>Arcigay Roma, <sup>6</sup>Arcigay Verona

**OP 70 Pre-exposure prophylaxis in Modena: a wide spread of sexually transmitted infections among users attending the dedicated outpatient Clinic**

C. Rogati<sup>1</sup>, C.G. Cuomo<sup>1</sup>, A. Raimondi<sup>1</sup>, M. Tutone<sup>1</sup>, E. Bacca<sup>1</sup>, B. Beghetto<sup>1</sup>, E. Roncaglia<sup>1</sup>, G. Nardini<sup>1</sup>, V. Borghi<sup>1</sup>, G. Guaraldi<sup>1</sup>, M. Coppini<sup>1</sup>, C. Mussini<sup>1</sup>

<sup>1</sup>Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>Clinic of Dermatology, University of Modena and Reggio Emilia, Modena, Italy

**OP 71 Prevalence and risk factors for HPV anal infection in PrEP users: implications for vaccination policy**

R. Rossotti<sup>1</sup>, C. Baiguera<sup>1</sup>, A. Nava<sup>2</sup>, M. Merli<sup>1</sup>, D. Fanti<sup>2</sup>, S. Chiappetta<sup>1</sup>, M.C. Moiola<sup>1</sup>, L. Colagrossi<sup>2</sup>, L.G. Chianura<sup>1</sup>, D. Motta<sup>1</sup>, C.F. Perno<sup>2,3</sup>, M. Puoti<sup>1</sup>

<sup>1</sup>Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, <sup>2</sup>Chemical-Clinical and Microbiological Analysis, ASST Grande Ospedale Metropolitano Niguarda, Milan, <sup>3</sup>Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan

**OP 72 NEETagers for the prevention of HIV and AIDS**

V. Corallino, M. Ramadori

Anlaidis Umbria Onlus, Corciano (PG)

**OP 73 Clinical research integrated with narrative medicine to understand living and coping with HIV: TMC114F D1HTX4011 - DIAMANTE study**

A. Antinori<sup>1</sup>, A. Vergori<sup>1</sup>, D. Ripamonti<sup>2</sup>, D. Valenti<sup>3</sup>, V. Esposito<sup>3</sup>, M.A. Carle<sup>4</sup>, S. Rusconi<sup>5</sup>, E. Manzillo<sup>6</sup>, T. Pizzella<sup>6</sup>, G. Orofino<sup>7</sup>, G. Madeddu<sup>8</sup>, A. Cappuccino<sup>9</sup>, L. Reale<sup>9</sup>, M.G. Marini<sup>9</sup>, A. Uglietti<sup>10</sup>, R. Termini<sup>10</sup>, M. Portaro<sup>10</sup>, D. Mancusi<sup>10</sup>

<sup>1</sup>HIV/AIDS Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy, <sup>2</sup>Infectious Diseases Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy, <sup>3</sup>FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy, <sup>4</sup>Immunodeficiencies and Gender Infectious Diseases Unit, Department of Infectious Disease and Infectious Emergencies, Cotugno Hospital, Naples, Italy, <sup>5</sup>Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Italy, <sup>6</sup>A.O.R.N. Cotugno VIII Divisione di Malattie Infettive Napoli, Italy, <sup>7</sup>Amedeo di Savoia Hospital Unit of Infectious Diseases Torino, Italy, <sup>8</sup>University of Sassari, Department of Medical, Surgical and Experimental Sciences, Unit of Infectious Diseases Sassari Italy, <sup>9</sup>Fondazione ISTUD, Milan, Italy, <sup>10</sup>Medical Affairs Department, Infectious Diseases, Janssen-Cilag SpA, Cologno Monzese, Italy

**OP 74 Women and HIV in prison setting: a data up date from the Italian ROSE network**

E. Rastrelli<sup>1,2</sup>, R. Ranieri<sup>2,3</sup>, S. Marcellini<sup>2,4</sup>, E. Pontali<sup>2,5</sup>, R. Bergamaschi<sup>6</sup>, V. Esposito<sup>7</sup>, V. Rizzo<sup>7</sup>, A. Bascià<sup>8</sup>, M.R. Attianese<sup>9</sup>, A. Tartaglia<sup>10</sup>, F. Campanale<sup>11</sup>, L. Rapisarda<sup>12</sup>, V. Fiore<sup>13</sup>, T. Prestileo<sup>2,14</sup>, G. Leo<sup>2,15</sup>, M. Giuliano<sup>2,15</sup>, O. Mollaretti<sup>2,15</sup>, R. Marocco<sup>16</sup>, M. Pontolillo<sup>17</sup>, F. Vignale<sup>17</sup>, A. Lucarini<sup>18</sup>, G. Pugliese<sup>19</sup>, R. Giuliani<sup>3</sup>, A.M. Ialungo<sup>1,2</sup>, S. Dell'Isola<sup>1,2</sup>, L. Testa<sup>1,2</sup>, Lucania<sup>2,20</sup>, S. Babudieri<sup>2,13</sup>, G. Starnini<sup>1,2</sup>

<sup>1</sup>U.O.C. Medicina Protetto-Malattie Infettive, Ospedale Belcolle, Viterbo, <sup>2</sup>SIMSpE (Società Italiana di Medicina e Sanità Penitenziaria), <sup>3</sup>Azienda Ospedaliera Santi Paolo e Carlo Unità di Malattie Infettive, Università di Milano Unità di Malattie Infettive in Ambito Penitenziario, Milano, <sup>4</sup>Casa Circondariale Rebibbia Femminile, Roma, <sup>5</sup>Unità di Malattie Infettive, Ospedale Galliera, Genova, <sup>6</sup>Casa Circondariale Pesaro, <sup>7</sup>UOC Immunodeficienze e Malattie Infettive di Genere, Ospedale Cotugno, Napoli, <sup>8</sup>Distretto Socio Sanitaria ASL Lecce, Poliambulatorio "Cittadella della Salute", <sup>9</sup>ASL Salerno CC Salerno, <sup>10</sup>Ambulatorio Malattie Infettive ASL Foggia, <sup>11</sup>Specialistica Ambulatoriale ASL Bat, <sup>12</sup>CC Catania, <sup>13</sup>Unità di Malattie Infettive, Università di Sassari, Sassari, <sup>14</sup>ARNAS, Ospedale Civico-Benefratelli Palermo, Palermo, <sup>15</sup>Unità di Malattie Infettive, Ospedale Amedeo di Savoia, Torino Casa Circondariale "G. Panzera", <sup>16</sup>Unità di Malattie Infettive, Università La Sapienza, Ospedale S. M., Latina, <sup>17</sup>Clinica di Malattie Infettive, Dipartimento di Medicina ed Scienze dell'Invecchiamento, Università G. d'Annunzio, Chieti, <sup>18</sup>Casa Circondariale di Perugia «Capanne», <sup>19</sup>Casa Circondariale Avellino, <sup>20</sup>Reggio Calabria ASP Reggio Calabria – Presidio I.P. RC "Panzera" e "Arghilla"

**OP 75 First-year experience of an HIV clinic-based stop-smoking service**

V. Spagnuolo<sup>1,2</sup>, E. Lombardi<sup>2</sup>, A. Poli<sup>2</sup>, S. Bossolasco<sup>2</sup>, C. Raddato<sup>1</sup>, A. Castagna<sup>1,2</sup>, A. Lazzarin<sup>2</sup>, N. Gianotti<sup>2</sup>

<sup>1</sup>School of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, <sup>2</sup>Division of Infectious Diseases, San Raffaele Scientific Institute, Milan





ORAL  
POSTER

**OP 76 Psychiatric disturbances are common in PrEP users: an analysis of comorbidities and comedications in real life**

R. Rossotti, C. Baiguera, M. Colaneri, M. Merli, S. Chiappetta, M.C. Moiola, L.G. Chianura, D. Motta, M. Puoti  
Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda

**Virology and Pharmacology**

Chairs: R. Cavallo (Torino), S. Parisi (Padova)

**OP 77 The HIV-1 provirus excised by CRISPR/Cas9 may be integrated back into the cell genome in presence of the viral integrase**

M. Lai<sup>1,2</sup>, P. Quaranta<sup>1</sup>, F. Maggi<sup>1,3</sup>, M. Sgarbanti<sup>4</sup>, O. Turriziani<sup>7</sup>, G. Freer<sup>1</sup>, G. Antonelli<sup>7</sup>, J.L. Heeney<sup>2</sup>, M. Pistello<sup>1,3</sup>

<sup>1</sup>Retrovirus Center and Virology Section, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, <sup>2</sup>Laboratory of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom, <sup>3</sup>Virology Unit, Pisa University Hospital, Pisa, Italy, <sup>4</sup>National Institute of Health, Rome, Italy, <sup>5</sup>Pharmacology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy, <sup>6</sup>Hematology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy, <sup>7</sup>Laboratory of Virology and Pasteur Institute-Cenci Bolognetti Foundation, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy

**OP 78 Analysis of HIV latency establishment and maintenance in CD4 T cells stimulated with IL-15**

G.M. Butta<sup>1,2</sup>, G. Bozzi<sup>3</sup>, G. Copaloni<sup>2</sup>, G. Gallo<sup>2</sup>, M. Crosti<sup>1</sup>, M. Mancino<sup>1</sup>, L. Taramasso<sup>3,4,5</sup>, A. Muscatello<sup>3</sup>, A. Gori<sup>3,4,5</sup>, R. De Francesco<sup>1,2</sup>, A. Bandera<sup>3,4,5</sup>, L. Manganaro<sup>1,3</sup>

<sup>1</sup>INGM-Istituto Nazionale di Genetica Molecolare, Virology, Milan, Italy, <sup>2</sup>Università degli Studi di Milano, Department of Pharmacological and Biomolecular Sciences, Milan, <sup>3</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Infectious Diseases Unit, Department of Internal Medicine, Milan, Italy, <sup>4</sup>Centre for Multidisciplinary Research in Health Science (MACH), <sup>5</sup>Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

**OP 79 Phylogenetic analyses applied to the study of transmission variants and their evolution in a HIV-1 positive couple**

A. Lai<sup>1</sup>, V. Giacometti<sup>2</sup>, A. Bergna<sup>1</sup>, G.V. Zuccotti<sup>2</sup>, G. Zehender<sup>1</sup>, M. Clerici<sup>3,4</sup>, D. Trabattoni<sup>1</sup>, C. Fenizia<sup>3</sup>

<sup>1</sup>Department of Biomedical and Clinical Sciences, University of Milan, Milan, <sup>2</sup>Clinic of Pediatrics, ASST Fatebenefratelli-Sacco, Sacco Clinical Sciences Institute, Milan, <sup>3</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, <sup>4</sup>IRCCS Fondazione Don Carlo Gnocchi, Milan

**OP 80 Creation of an Italian HIV DNA Network for the validation and clinical use of HIV-1 DNA quantification assays**

I. Vicenti<sup>1</sup>, F. Dragoni<sup>1</sup>, A. Giannini<sup>1</sup>, A. Callegaro<sup>2</sup>, G. Napolitano<sup>2</sup>, O. Turriziani<sup>3</sup>, D. Di Carlo<sup>3</sup>, S. Giambenedetto<sup>4,14</sup>, F. Lombardi<sup>4</sup>, S. Belmonti<sup>4</sup>, F. Ceccherini-Silberstein<sup>5</sup>, R. Scutari<sup>5</sup>, C. Alteri<sup>5,6</sup>, A. Lai<sup>7</sup>, A. Bergna<sup>7</sup>, S. Racca<sup>8</sup>, A. Ardemagni<sup>8</sup>, A. Casabianca<sup>9</sup>, C. Orlandi<sup>9</sup>, I. Bon<sup>10</sup>, A. Bertoldi<sup>10</sup>, P. Bagnarelli<sup>11</sup>, L. Di Sante<sup>11</sup>, I. Abbate<sup>12</sup>, G. Rozera<sup>12</sup>, M.R. Capobianchi<sup>12</sup>, S. Paolucci<sup>13</sup>, G. Campanini<sup>13</sup>, F. Saladini<sup>13</sup>, M. Zazzi<sup>13</sup>

<sup>1</sup>Department of Medical Biotechnologies, University of Siena, Siena, <sup>2</sup>Microbiology and Virology Laboratory, ASST Papa Giovanni XXIII, Bergamo, <sup>3</sup>Department of Molecular Medicine, Sapienza University of Rome, Rome, <sup>4</sup>Department of Safety and Bioethics, Infectious Disease Section, Catholic University of Sacred Heart, Rome, <sup>5</sup>Department of Experimental Medicine, University of Rome Tor Vergata, Rome, <sup>6</sup>Department of Oncology and Hemato-oncology, University of Milan, Milan, <sup>7</sup>Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, <sup>8</sup>Laboratory of Microbiology and Virology, IRCCS San Raffaele Scientific Institute, Milan, <sup>9</sup>Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino, PU, <sup>10</sup>Microbiology Section, Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, University of Bologna, Bologna, <sup>11</sup>Virology Unit, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, <sup>12</sup>Virology and Biosafety Laboratories Unit, National Institute for Infectious Diseases IRCCS L. Spallanzani, Rome, <sup>13</sup>Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, <sup>14</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Infectious Disease Rome

**OP 81 Initial characterization of elements detected and quantified exclusively on the basis of LTR region by Aptima HIV-1 Quant Dx dualtarget assay in plasma of HIV-positive patients**

A. Amendola, G. Sberna, M.R. Capobianchi  
National Institute for Infectious Diseases L. Spallanzani IRCCS, Rome, Italy

**OP 82 Stable total HIV-DNA after 1 year on switch to TAF-based regimens in real world data**

C. Alteri<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, R. Scutari<sup>3</sup>, Y. Bouba<sup>3</sup>, E.S. Cannizzo<sup>4</sup>, A. Tavelli<sup>5</sup>, M. Prato<sup>6</sup>, F. Bai<sup>4</sup>, A. Antinori<sup>7</sup>, A. d'Arminio Monforte<sup>4</sup>, F. Ceccherini-Silberstein<sup>3</sup>, G. Marchetti<sup>4</sup> on behalf of Icona and TAF-Icona Study Groups

<sup>1</sup>Dept. of Oncology and Hemato-Oncology, University of Milan, Milan, Italy, <sup>2</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME) Institute for Global Health UCL, London, UK, <sup>3</sup>Dept. of Experimental Medicine, University of Tor Vergata, Rome, Italy, <sup>4</sup>Clinic of Infectious Diseases, Dept Health Sciences, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy, <sup>5</sup>Icona Foundation, Milan, Italy, <sup>6</sup>Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy, <sup>7</sup>HIV/AIDS Clinical Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy

**OP 83 HIV-1 RNA and DNA mutational load in HTE patients with MDR virus: a tool for deciding OBR?**

M.M. Santoro<sup>1</sup>, D. Armenia<sup>1,2</sup>, M.C. Bellocchi<sup>1</sup>, L. Carioti<sup>1</sup>, L. Galli<sup>3</sup>, R. Scutari<sup>1</sup>, E. Salsi<sup>4</sup>, C. Mussini<sup>5</sup>, G. Sterrantino<sup>6</sup>, L. Calza<sup>7</sup>, B. Rossetti<sup>8</sup>, M. Zazzi<sup>9</sup>, A. Castagna<sup>3,10</sup>, on behalf of the PRESTIGIO Registry Study Group

<sup>1</sup>Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, <sup>2</sup>Saint Camillus International University of Health Sciences, Rome, <sup>3</sup>Clinic of Infectious Diseases, Istituto Scientifico San Raffaele, Milano, <sup>4</sup>Azienda Ospedaliero-Universitaria Parma, <sup>5</sup>Malattie Infettive, Policlinico di Modena, Modena, <sup>6</sup>Department of Experimental and Clinical Medicine, University of Florence, <sup>7</sup>Policlinico Sant'Orsola-Malpighi, Bologna, Italy, <sup>8</sup>Azienda Ospedaliero-Universitaria Senese, Siena, Italy, <sup>9</sup>University of Siena, Siena, Italy, <sup>10</sup>Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Milano



ORAL  
POSTER

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

**OP 84 Viral tropism does not have any impact on CD4 recovery in acute HIV infection or AIDS**

*D. Vita, A. Giacomelli, L. Oreni, P. Tau, G.M. Bottani, V. Micheli, D. Mileto, L. Swenson, C. Brumme, M. Galli, S. Rusconi*  
Università degli studi di Milano, Milano

**OP 85 Antiviral effect of HIV1 tat/rev siRNA carried by nanoparticles in human CD4+ T cell line**

*F. Falasca<sup>1</sup>, F. Di Fonzo<sup>2</sup>, L. Chronopoulou<sup>2</sup>, I. Sciandra<sup>3</sup>, C. Palocci<sup>2</sup>, O. Turriziani<sup>1</sup>*  
<sup>1</sup>Department of Molecular Medicine, <sup>2</sup>Department of Chemistry, Sapienza University of Rome, Italy, <sup>3</sup>National Institute of Gastroenterology "S. de Bellis", Research Hospital, Castellana Grotte, Italy

**OP 86 A real-life experience of vaccination strategies for HBV prevention in HIV patients**

*D. Tomasoni, L. Gazzola, D. Barbanotti, A. Tavelli, F. Bai, C. Tincati, S. Cianciola, K. Reister, P. Tognetti, A. De Bona, A. d'Arminio Monforte*  
Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, Italy

**OP 87 A successful experience of an immunization program in HIV-positive adults**

*G. Chieffo, L. Maboni, M. Farinazzo, F. Franzetti, B. Menzaghi*  
ASST Valle Olona Ospedale di Busto Arsizio, Busto Arsizio (VA)

**OP 88 Plasma exchange and dolutegravir exposure. A case report**

*M. Mussa<sup>1,2</sup>, M. Sciarra<sup>1</sup>, A. Di Filippo<sup>1</sup>, R. Maserati<sup>2,3</sup>, A. Gaballo<sup>4</sup>, G. Dornini<sup>5</sup>, A. Maria Di Matteo<sup>3</sup>, P. Villani<sup>6</sup>*  
<sup>1</sup>Department of Internal Medicine – University of Pavia, Pavia, Italy, <sup>2</sup>Unit of Infectious Diseases, SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, <sup>3</sup>Unit of Infectious Diseases, IRCCS San Matteo Hospital Foundation, Pavia, Italy, <sup>4</sup>Unit of Nephrology, Dialysis and Transplantation, IRCCS San Matteo Hospital Foundation, Pavia, Italy, <sup>5</sup>Immunohaematology and Transfusion Service and Cell Therapy Unit, IRCCS San Matteo Hospital Foundation, Pavia, Italy, <sup>6</sup>Laboratory of Pharmacology and Clinical Pharmacokinetics, IRCCS San Matteo Hospital Foundation, Pavia, Italy



SCIENTIFIC  
PROGRAMME

12° CONGRESSO NAZIONALE



**Italian Conference on  
AIDS and Antiviral Research**

*Reach out  
for including all*

 12-16  
ottobre 2020  
DIGITAL EDITION

*Presidenza del Congresso*

*Massimo Clementi, Milano*

*Sandro Mattioli, Bologna*

*Cristina Mussini, Modena*

*Guido Silvestri, Atlanta*

*Marcello Tavio, Ancona*

POSTER EXHIBITION





## POSTER EXHIBITION

### Bacterial and fungal infections in immunocompromised host

- P 1 A descriptive analysis of bloodstream infections in patients living with HIV in a large Italian center**  
A. Ciccullo<sup>1</sup>, A. Dusina<sup>1</sup>, B. Fiori<sup>2,3</sup>, A. Borghetti<sup>4</sup>, T. D'Inzeo<sup>2,3</sup>, M. Sanguinetti<sup>2,3</sup>, F. Pallavicini<sup>1,4</sup>, T. Spanu<sup>2,3</sup>, S. Di Giambenedetto<sup>1,4</sup>  
<sup>1</sup>Section of Infectious Diseases, Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy, <sup>2</sup>Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Rome, Italy, <sup>3</sup>Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, <sup>4</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- P 2 Amebic abscess of the spleen with severe sepsis and bronchial fistulisation in HIV+patient: case report**  
A. Franco<sup>1</sup>, F. Acconciagioco<sup>2</sup>, L. Aprea<sup>3</sup>, R. Filippelli<sup>2</sup>, R.M. Franco<sup>1</sup>, C. Palumbo<sup>2</sup>, T. Pizzella<sup>3</sup>, M. Sardo<sup>3</sup>, F. Simioli<sup>3</sup>, E. Manzillo<sup>3</sup>  
<sup>1</sup>UOSD Profilassi Post-Esposizione - AORN "Ospedali dei Colli" - Napoli, <sup>2</sup>UOC Radiodiagnostica P.O. "Cotugno" - AORN "Ospedali dei Colli" - Napoli, <sup>3</sup>UOC Immunodeficienze e Malattie dell'Emigrazione - AORN "Ospedali dei Colli" - Napoli
- P 3 Pneumocystis jirovecii Pneumonia in HIV-negative Patients, a Frequently Overlooked Problem: Case Series from a Large Italian Center**  
G. Bozzi<sup>1</sup>, V. Morena<sup>2</sup>, A.M. Peri<sup>1</sup>, L. Taramasso<sup>1,3</sup>, R. Ungaro<sup>1</sup>, P. Bono<sup>4</sup>, A. Grancini<sup>4</sup>, A. Maraschini<sup>4</sup>, C. Matinato<sup>4</sup>, A. Gori<sup>1,3</sup>, A. Bandera<sup>1,3</sup>  
<sup>1</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy, <sup>2</sup>III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milano, Italy, <sup>3</sup>Department of Biomedical and Clinical Sciences "Luigi Sacco", Università degli Studi di Milano, Italy, <sup>4</sup>Centre for Multidisciplinary Research in Health Science (MACH), Milan, Italy, <sup>5</sup>Medical Laboratory of Clinical Chemistry and Microbiology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- P 4 Infection by Mycobacterium chimaera in two subjected undergoing cardiac surgery**  
F. Bulla<sup>1</sup>, V. Vespertini<sup>1</sup>, M. de Fazio<sup>2</sup>, T. Alcaro<sup>2</sup>, S. Nisticò<sup>2</sup>, L. Cosco<sup>1</sup>  
<sup>1</sup>S.O.C. Malattie Infettive A.O. "Pugliese-Ciaccio" Catanzaro, <sup>2</sup>S.O.C. Microbiologia A.O. "Pugliese-Ciaccio" Catanzaro
- P 5 A case of persistent relapsing abdominal mycobacterial infection requiring prolonged intravenous multi-drug treatment**  
M. Rossi, A. Soria, L. Bisi, F. Sabbatini, A. Cappelletti, P. Columpsi, S. Foresti, E. Colella, F. Iannuzzi, V. Cogliandro, G. Gustinetti, N. Squillace, P. Vitiello, N. Brianese, E. Pollastri, G. Migliorino, G. Lapadula  
Unit of Infectious Diseases, San Gerardo Hospital, ASST Monza

### Basics in viral hepatitis

- P 6 Comparison of immunoassays for quantitative serum HBsAg**  
G. Roncarati, S. Galli, A. Moroni, G. Furlini  
Operative Unit of Clinical Microbiology, St. Orsola-Malpighi University Hospital, Bologna
- P 7 Cryptic HBV replication is frequently revealed in anti-HBc positive/HBsAg negative patients with HIV infection by applying a highly sensitive digital droplet PCR assay**  
R. Salpini<sup>1</sup>, V. Malagnino<sup>2</sup>, M. Alkhatib<sup>1</sup>, T. Mulas<sup>2</sup>, L. Piermatteo<sup>1</sup>, R. Scutari<sup>1</sup>, R. Chirichello<sup>1</sup>, A. Bertoli<sup>1</sup>, K. Yu La Rosa<sup>1</sup>, M. Brugnetti<sup>1</sup>, M. Ciotti<sup>2</sup>, M. Andreoni<sup>2</sup>, C.F. Perno<sup>4</sup>, F. Ceccherini-Silberstein<sup>1</sup>, L. Sarmati<sup>1</sup>, V. Svicher<sup>1</sup>  
<sup>1</sup>Department of Experimental Medicine, Tor Vergata University, Rome, Italy, <sup>2</sup>Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, Rome, Italy, <sup>3</sup>Microbiology and Virology Unit, Tor Vergata University Hospital, Rome, Italy, <sup>4</sup>Department of Oncology and Haemato-oncology, University of Milan, Milan, Italy

### Cancers in HIV

- P 8 The multidisciplinary group for HPV related disease and STD in Azienda Ospedaliera Universitaria Pisana (AOUP) Cisanello. An opportunity for HIV and HIV at risk people**  
L. DelBono<sup>1</sup>, C. Menconi<sup>2</sup>, S. Verdenelli<sup>1</sup>, I. Marchetti<sup>3</sup>, V. Seccia<sup>4</sup>, C. Cambi<sup>4</sup>, P. Cuttano<sup>5</sup>, S. Panduri<sup>6</sup>, P. Mazzetti<sup>7</sup>, F. Maggi<sup>7</sup>, S. Esim<sup>8</sup>, A. Gallo<sup>9</sup>, A.G. Naccarato<sup>3</sup>, G. Naldini<sup>2</sup>, M. Pistello<sup>7</sup>, F. Menichetti<sup>1</sup>  
<sup>1</sup>UO Malattie Infettive AOU Pisa, <sup>2</sup>SOD Chirurgia Proctologica e Perineale AOUP, <sup>3</sup>UO Anatomia Patologica 1 AOUP, <sup>4</sup>ORL 1 Universitaria AOUP, <sup>5</sup>UO Urologia Universitaria AOUP, <sup>6</sup>UO Dermatologia Universitaria AOUP, <sup>7</sup>Virologia AOUP, <sup>8</sup>SOD Microbiologia batteriologica AOUP, <sup>9</sup>UOC Igiene e Sanità Pubblica Azienda USL Toscana Nord Ovest
- P 9 Non-AIDS-defining cancers in a cohort of HIV positive patients**  
V. Barocci, S. Mazzanti, M. Di Pietrantonio, A. Polenta, P. Mantini, F. Pallotta, S. Olivieri, B. Candelaresi, L. Brescini, G. De Iaco, A. Fiorentini, O. Cirioni, A. Giacometti  
Clinica Malattie Infettive e Tropicali, Parassitologia ed Epatiti croniche, Università Politecnica delle Marche, Ancona





## POSTER EXHIBITION

- P 10 Case report on oncopathology in HIV-infected patients**  
Z. Akhmedjanova, D. Urunova, V. Barotova, M. Khasanova, D. Akhmedjanov  
Institute of Immunology and Human Genomics, Academy of Sciences of the Republic of Uzbekistan, Tashkent; Tashkent Institute of Advanced Medical Studies, Tashkent; AIDS Center. Tashkent; University of Toronto, Toronto
- P 11 Primitive NHL of bone in an HIV patient: case-report and review of literature**  
A. Amedeo, D. Testi, G. Ferraro, G. Verucchi, P. Viale, L. Calza  
Infectious Disease Section, Alma Mater Studiorum University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy
- P 12 Alexithymia and cancer-related mortality in Human Immunodeficiency Virus-Infected Patients: An Italian Multisite Prospective Cohort Study**  
F. Vadini<sup>1</sup>, F. Sozio<sup>1</sup>, G. Madeddu<sup>3</sup>, G. De Socio<sup>4</sup>, P. Maggi<sup>5</sup>, B.M. Celesia<sup>6</sup>, G. Nunnari<sup>7</sup>, F. Vichi<sup>8</sup>, P. DiStefano<sup>1</sup>, E. Tracanna<sup>1</sup>, E. Polilli<sup>2</sup>, A. Sciacca<sup>1</sup>, E. Mazzotta<sup>9</sup>, B. Zizi<sup>3</sup>, V. Lai<sup>3</sup>, C. Bartolozzi<sup>8</sup>, M.E. Flacco<sup>10</sup>, P. Bonfanti<sup>11</sup>, F. Santilli<sup>12</sup>, L. Manzoli<sup>13</sup>, G. Parruti<sup>1</sup>; CISAI Study Group  
<sup>1</sup>Infectious Disease Unit, Pescara, <sup>2</sup>Clinical Pathology Laboratory, Pescara, <sup>3</sup>Department of Clinical and Experimental Medicine, Unit of Infectious Diseases University of Sassari, Sassari, <sup>4</sup>Infectious Diseases Unit, Santa Maria Hospital, Perugia, <sup>5</sup>Infectious Diseases Clinic, Policlinico Hospital of Bari, Bari, <sup>6</sup>Division of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital Catania, Catania, <sup>7</sup>Department of Clinical and Experimental Medicine, University of Messina, Messina, <sup>8</sup>Infectious Diseases Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, <sup>9</sup>Infectious Disease Unit, Teramo, <sup>10</sup>Local Health Unit of Pescara, Pescara, <sup>11</sup>Infectious Diseases Unit, A. Manzoni Hospital, Lecco, <sup>12</sup>Department of Medicine and Aging and Center of Aging Science and Translational Medicine, University of Chieti, Chieti, <sup>13</sup>Department of Medical Sciences, University of Ferrara
- P 13 Kaposi Sarcoma among AIDS-presenters in Modena: could it be a cluster?**  
E. Bacca<sup>1</sup>, M. Tutone<sup>1</sup>, G. Ciusa<sup>1</sup>, G. Cuomo<sup>1</sup>, A. Jary<sup>2</sup>, A.G. Marcelin<sup>2</sup>, V. Calvez<sup>2</sup>, V. Borghi<sup>1</sup>, C. Mussini<sup>1</sup>  
<sup>1</sup>Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliero Universitaria, Modena, Italy, <sup>2</sup>Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Pitié-Salpêtrière hospital, département de Virologie, Paris, France
- P 14 Oral Human Papillomavirus (HPV) detection in the context of the multidisciplinary HPV group in Azienda Ospedaliero-Universitaria Pisana (AOUP): a screening opportunity for HIV+ and other at risk-patients**  
C. Cambi<sup>1</sup>, S. Verdenelli<sup>2</sup>, L. Del Bono<sup>3</sup>, C. Menconi<sup>3</sup>, P. Mazzetti<sup>4</sup>, I. Marchetti<sup>4</sup>, G. Cuttano, E. Balestri<sup>6</sup>, F. Maggi<sup>6</sup>, S. Esin<sup>8</sup>, A. Gallo<sup>7</sup>, A.G. Naccarato<sup>4</sup>, G. Naldini<sup>5</sup>, F. Menichetti<sup>2</sup>, M. Pistello<sup>6</sup>, V. Seccia<sup>1</sup>  
<sup>1</sup>U.O. Otorinolaringoiatria Universitaria AOUP, <sup>2</sup>U.O. Malattie Infettive AOUP, <sup>3</sup>SOD Chirurgia Proctologica e Perineale AOUP, <sup>4</sup>U.O. Anatomia Patologica 1 AOUP, <sup>5</sup>U.O. Urologia Universitaria AOUP, <sup>6</sup>Virologia AOUP, <sup>7</sup>UOC Igiene e Sanità Pubblica Azienda USL Toscana Nord Ovest, <sup>8</sup>SOD Microbiologia batteriologica AOUP
- P 15 HCC Recurrence 8 years post Liver-Transplant was linked to Hepatitis Delta Reactivation in a person living with HIV**  
G. Ciusa<sup>1</sup>, G. Dolci<sup>1</sup>, J. Milic<sup>1</sup>, M. Tutone<sup>1</sup>, C. Rogati<sup>1</sup>, M. Di Gaetano<sup>1</sup>, E. Franceschini<sup>1</sup>, N. De Maria<sup>2</sup>, F. Di Benedetto<sup>3</sup>, C. Mussini<sup>1</sup>, G. Guaraldi<sup>1</sup>  
<sup>1</sup>Clinic of Infectious and Tropical Diseases, University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>Gastroenterology Unit, Department of Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy, <sup>3</sup>Epatology-Pancreato-Biliary Surgery and Liver Transplantation Unit, University of Modena and Reggio Emilia, Modena, Italy
- P 16 Epidemiological analysis from a newly established anal HPV screening ambulatory**  
M. Ridolfi, E.N. Cavallari, C. Borrazzo, L. Santinelli, G.P. Innocenti, L. Celani, G. De Girolamo, G. Ceccarelli, G. d'Ettore, C.M. Mastroianni  
Dipartimento di Sanità Pubblica e Malattie infettive, Sapienza Università di Roma, Rome

## Gender issues

- P 17 Behavioural and awareness changes in a HIV prevention program based on women empowerment in Uganda**  
G. Micheli<sup>2</sup>, C. Seguiti<sup>2</sup>, F.V. Segala<sup>2</sup>, A. Pierantozzi<sup>3</sup>, F. Opira<sup>4</sup>, S. Di Murro<sup>2</sup>, A. D'Angelillo<sup>2</sup>, T. Tabu<sup>4</sup>, M. Chiuchiarelli<sup>2</sup>, D. Faliero<sup>2</sup>, B. Odong<sup>6</sup>, R. Lukwiya<sup>4</sup>, F.S. Alo<sup>5</sup>, K. De Gaetano Donati<sup>1</sup>, A. Cingolani<sup>1,2</sup> for 'Pe Atye Kena, no longer alone' study group  
<sup>1</sup>Fondazione Policlinico A. Gemelli, IRCCS, Istituto di Clinica delle Malattie Infettive, Roma, <sup>2</sup>Università Cattolica S. Cuore, Malattie Infettive, Roma, <sup>3</sup>AIFA-Agenzia Italiana del farmaco, Roma, <sup>4</sup>Comboni Samaritans of Gulu Health Center, Gulu, Uganda, <sup>5</sup>Università Cattolica S. Cuore, Patologia Speciale Medica e Semeiotica Medica, Roma, <sup>6</sup>Medical Teams International, Kitgum, Uganda
- P 18 Therapy burdens of Italian women living with HIV - Findings from the Positive Perspectives 2 Study**  
G.M. Corbelli<sup>1</sup>, S. Marcotullio<sup>2</sup>, P. Rizzini<sup>2</sup>, P. de los Rios<sup>3</sup>, A. Appiah<sup>4</sup>  
<sup>1</sup>Plus Onlus, Bologna, Italy, <sup>2</sup>ViiV Healthcare Verona VR, Italy, <sup>3</sup>ViiV Healthcare Laval, Quebec, Canada, <sup>4</sup>ViiV Healthcare Brentford, UK
- P 19 Transgender people and HIV**  
M. Formisano<sup>1</sup>, M. Errico<sup>2</sup>, A. Giacomelli<sup>3</sup>, D. Bernacchia<sup>4</sup>, G. Casella<sup>5</sup>, A. Tosano<sup>6</sup>, L. Brogionzoli<sup>7</sup>  
<sup>1</sup>NPS Italia Onlus Vice President, Milan, <sup>2</sup>NPS Italia Onlus President, Milan, <sup>3</sup>III Infectious Diseases Unit, ASST-FBF-Sacco, Department of Biomedical and Clinical Sciences DIBIC Luigi Sacco, University of Milan, member of SIMIT, Milan, <sup>4</sup>III Infectious Diseases Unit, ASST-FBF-Sacco, Department of Biomedical and Clinical Sciences DIBIC Luigi Sacco, University of Milan, member of SIMIT, Milan, <sup>5</sup>NPS Italia Onlus Junior Researcher, Milan, <sup>6</sup>NPS Italia Onlus Senior Researcher, Milan, <sup>7</sup>NPS Italia Onlus Head Researcher, Milan



## POSTER EXHIBITION

**P 20 HIV-positive transgender people in follow-up at an Italian single tertiary care hospital in Florence: a cross-sectional study**

F. Lagi<sup>1</sup>, A. Botta<sup>1</sup>, S.T. Kiro<sup>1</sup>, M. Mazzetti<sup>2</sup>, A. Bartoloni<sup>1,2</sup>, G. Sterrantino<sup>1</sup>

<sup>1</sup>Department of Experimental and Clinical Medicine, University of Florence, Florence Italy, <sup>2</sup>Infectious and Tropical Diseases Unit, Careggi University and Hospital, Florence, Italy

**P 21 HPV and bacterial vaginal infection impact on immune system in a cohort of HIV female population under suppressive ART**

A. Carraro<sup>1</sup>, P. Nijhawan<sup>1</sup>, S. Vita<sup>2</sup>, R. Marocco<sup>2</sup>, L. Fondaco<sup>1</sup>, B. Kertusha<sup>1</sup>, L. Ansaldo<sup>1</sup>, V. Petrozza<sup>1,3</sup>, J. Cacciotti<sup>3</sup>, M. Renzelli<sup>2</sup>, C.M. Mastroianni<sup>1</sup>, M. Lichtner<sup>1,2</sup>

<sup>1</sup>Dept. Of Public health and Infection Disease, Sapienza, University of Rome, Italy, <sup>2</sup>Infectious Disease Unit, SM Goretti Hospital, Latina, <sup>3</sup>Pathological Anatomy, ICOT, Sapienza, University of Rome, Italy

## HCV elimination

**P 22 Qualitative analysis of significant clinical events in a cohort of patients after DAA treatment for chronic HCV infection after virological eradication**

M. Mazzitelli, C. Costa, V. Pisani, G. Greco, F. Serapide, V. Scaglione, R. Lionello, V. La Gamba, E.M. Trecarichi, C. Torti

Infectious and Tropical Disease Unit, "Magna Graecia University", Catanzaro, Italy

**P 23 A fast track city micro-project to eradicate HCV infection in PLWHIV**

F. Maggiolo, L. Comi, E. Di Filippo, R. Teocchi, D. Valenti, A. Callegaro, M. Rizzi

ASST Papa Giovanni XXIII, Bergamo

**P 24 A pilot intervention for HCV elimination among MSM in Rome: preliminary results**

P. Piselli<sup>1</sup>, M. Giuliani<sup>2</sup>, M. Farinella<sup>3</sup>, C. Cimaglia<sup>1</sup>, A. Latini<sup>2</sup>, F. Carduccelli<sup>3</sup>, C. Ancona<sup>2</sup>, O. Bruzzi<sup>1</sup>, G. De Carli<sup>1</sup>, R. Esvan<sup>1</sup>, F. Gili<sup>1</sup>, M. Marra<sup>3</sup>, N. Orchi<sup>1</sup>, E. Piscitelli<sup>1</sup>, S. Pittalis<sup>1</sup>, A.R. Garbuglia<sup>1</sup>, A. Amendola<sup>1</sup>, S. Meschi<sup>1</sup>, S. Cicalini<sup>1</sup>, M. De Palo<sup>1</sup>, E. Grilli<sup>1</sup>, A. Antinori<sup>1</sup>, M.R. Capobianchi<sup>1</sup>, A. Crisafuolo<sup>2</sup>, G. D'Offizi<sup>1</sup>, V. Puro<sup>1</sup>, E. Girardi<sup>1</sup>

<sup>1</sup>INMI "L. Spallanzani" IRCCS, Rome, <sup>2</sup>Istituto Dermatologico San Gallicano, IRCCS, Rome, <sup>3</sup>Circolo di Cultura Omosessuale "Mario Mieli", Rome, Italy

**P 25 HCV eradication in people living with HIV in Sassari: the final countdown?**

A. De Vito, N. Geremia, S. Malnati, V. Fiore, E. Prinic, A.A. Muredda, M.A. Seazzu, I. Maida, S. Babudieri, G. Madeddu

Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy

**P 26 Glecaprevir/Pibrentasvir and Sofosbuvir/Velpatasvir/Voxilaprevir failure in a young man with genotype 1a congenital HCV infection: a case presentation**

P. Columpsi<sup>1</sup>, A. Soria<sup>1</sup>, E. Colella<sup>1</sup>, N. Squillace<sup>1</sup>, P. Vitiello<sup>1</sup>, M. Rossi<sup>1</sup>, G. Migliorino<sup>1</sup>, S. Paolucci<sup>2</sup>, F. Baldanti<sup>2,3</sup>, G. Lapadula<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, San Gerardo Hospital, ASST Monza, <sup>2</sup>Molecular Virology Unit, Microbiology and Virology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico, San Matteo, Pavia, Italy, <sup>3</sup>Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy

**P 27 Acute hepatitis C treatment with direct antiviral agents (DAAs) in patients with solid organ cancer**

V. Bianco<sup>1</sup>, C. Dell'Isola<sup>1</sup>, F. Martucci<sup>1</sup>, B. Matteis<sup>1</sup>, G. Morelli<sup>1</sup>, P. Pierri<sup>1</sup>, R. Punzi<sup>2</sup>

<sup>1</sup>Infectious Disease Specialist, "D. Cotugno" hospital, Naples, Italy, <sup>2</sup>Head of Infectious Disease, "D. Cotugno" hospital, Naples, Italy

**P 28 How to eliminate HCV in people who inject drugs? Preliminary results of a provincial multi-targeted approach involving three different settings: addictions services, prison, outreach mobile unit for active users**

A. Soria<sup>1</sup>, E. Colella<sup>1</sup>, P. Columpsi<sup>1</sup>, E. Chiesa<sup>2</sup>, A. Cardia<sup>3</sup>, M. Bramani Araldi<sup>4</sup>, D. Leto<sup>3</sup>, G. Scaffidi<sup>4</sup>, S. Mancastropia<sup>2</sup>, C. De Ferrari<sup>3</sup>, A. Caruso<sup>4</sup>, S. Marangon<sup>2</sup>, M. Pecoraro<sup>5</sup>, B. Tinghino<sup>5</sup>, G. Galimberti<sup>2</sup>, L. Vaira<sup>6</sup>, M. Grilli<sup>7</sup>, A. Cocchini<sup>7</sup>, C. Bregamo<sup>8</sup>, R. Galizzi<sup>8</sup>, G. Marconi<sup>9</sup>, G. Migliorino<sup>1</sup>, G. Lapadula<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, San Gerardo Hospital, ASST Monza, <sup>2</sup>Addiction service (SERD) of Monza, ASST Monza, <sup>3</sup>Addiction service (SERD) of Limbiate, ASST Monza, <sup>4</sup>Addiction service (SERD) of Carate Brianza, ASST Vimercate, <sup>5</sup>Service of Alcohol disorders and new addictions (NOA) of Seregno, ASST Vimercate, <sup>6</sup>Presidio Sanitario Penitenziario, ASST Monza, <sup>7</sup>SERD Casa Circondariale Monza, <sup>8</sup>Cooperativa Lotta Contro L'Emarginazione, <sup>9</sup>UOS Raccordo della Rete Territoriale dei Servizi, ATS Brianza

**P 29 Innovative procedures for micro-elimination of HCV infection in persons who use drug (PWUD)**

M. Pisaturo<sup>2,4</sup>, V. Messina<sup>1</sup>, A. Russo<sup>1,2</sup>, E. Parente<sup>3</sup>, G. Russo<sup>3</sup>, T. Raimondo<sup>3</sup>, A. Salzillo<sup>1</sup>, F. Simeone<sup>1</sup>, L. Onorato<sup>1</sup>, G. Di Caprio<sup>1</sup>, N. Coppola<sup>1,2</sup>

<sup>1</sup>Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, <sup>2</sup>Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Italy, <sup>3</sup>SerD Teano, Piedimonte Matese (Caserta), Italy, <sup>4</sup>AORN Dei Colli, Ospedale Cotugno, Naples

**P 30 Short course therapy for chronic hepatitis C infection**

G. Stroffolini, T. Lupia, G. Cariti, L. Boglione, G. Di Perri

Amedeo di Savoia Hospital, University of Torino, department of medical science



## POSTER EXHIBITION

- P 31 DAA failure in HCV genotype 3: virological features and efficacy of re-treatment**  
*M. Pisaturo<sup>1,4</sup>, L. Occhiello<sup>1</sup>, M. Starace<sup>1</sup>, C. Minichini<sup>1</sup>, A. Di Fraia<sup>1</sup>, S. De Pascalis<sup>2</sup>, M. Macera<sup>2</sup>, V. Messina<sup>3</sup>, V. Sangiovanni<sup>4</sup>, E. Claar<sup>5</sup>, D. Precone<sup>6</sup>, G. Stornaiuolo<sup>2</sup>, M. Stanzione<sup>2</sup>, I. Gentile<sup>8</sup>, G. Brancaccio<sup>2</sup>, S. Martini<sup>9</sup>, A. Masiello<sup>10</sup>, A. Salomone Megna<sup>11</sup>, C. Coppola<sup>12</sup>, A. Federico<sup>13</sup>, E. Sagnelli<sup>1</sup>, M. Persico<sup>14</sup>, A. Galeota Lanza<sup>15</sup>, A. Marrone<sup>16</sup>, G.B. Gaeta<sup>2</sup>, N. Coppola<sup>1,3</sup>*  
<sup>1</sup>Laboratory for the identification of prognostic factors of response to the treatment against infectious diseases, University of Campania "L. Vanvitelli", Napoli, Italy, <sup>2</sup>Infectious Diseases and Viral Hepatitis, Department of Mental and Physical Health and Preventive Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, <sup>3</sup>Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, <sup>4</sup>Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, <sup>5</sup>Internal Medicine Unit, Evangelical Hospital Villa Betania Naples, Italy, <sup>6</sup>Internal Medicine Unit A.O Sarno, Sarno (SA) Campania L. Vanvitelli, & Infectious and Transplant Medicine, AORN Ospedali dei Colli- Monaldi Hospital, Naples, Italy, <sup>7</sup>Gastroenterology Unit, AOU San Giovanni di Dio Ruggi d'Aragona, Salerno Italy, <sup>8</sup>Infectious Diseases Unit, University Federico II, Naples, Italy, <sup>9</sup>HIV Unit, University of Campania L. Vanvitelli, Naples, Italy, <sup>10</sup>Infectious Diseases Unit, A.O.S.G. Moscati, Avellino Italy, <sup>11</sup>Infectious Diseases Unit, A. OG.Rummo, Benevento, <sup>12</sup>Hepatology Unit, Gragnano Hospital, Gragnano, <sup>13</sup>Internal Medicine and Hepatology Department of Clinical and Experimental Medicine, University of Campania "L. Vanvitelli", <sup>14</sup>Internal Medicine and Hepatology Unit, PO G. Da Procida-AOU- San Giovanni e Ruggi D'Aragona, University of Salerno, <sup>15</sup>Hepatology Unit, Cardarelli Hospital, Naples, Italy, <sup>16</sup>Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, University of Campania "L. Vanvitelli"
- P 32 Therapy of Hepatitis C in Prison: Experience of Systematic Treatment Program in Rome**  
*S. Rosati<sup>1</sup>, S. Lardo<sup>1</sup>, S. Marcellini<sup>2</sup>, G. Iannicelli<sup>1</sup>, P. Magrini<sup>3</sup>, C. Leonardi<sup>4</sup>, M. Zaccarelli<sup>1</sup>*  
<sup>1</sup>INMI L. Spallanzani, Rome (Italy), <sup>2</sup>Infectiologist Doctor for Rebibbia Prison, <sup>3</sup>Health Director ASL Frosinone, <sup>4</sup>Health Director ASL RM 2 for Drug Addictions and Prisons
- P 33 Five years real-life experience with direct-acting antivirals for hepatitis C in a suburban setting in Rome: a retrospective analysis**  
*L. Foroghi Biland, E. Teti, G. De Simone, T. Mulas, L. Campogiani, C. Stingone, L. Ferrari, M. De Masi, L. Coppola, M. Compagno, M. Iannetta, L. Sarmati, M. Andreoni*  
Infectious Diseases Clinic, Tor Vergata University Hospital, Rome, Italy
- P 34 Association Between Polymorphism in the Enhancer Gene and Hepatitis C Virus-induced Hepatocellular Cancer Risk**  
*G. Greco<sup>1</sup>, V. Folliero<sup>2</sup>, V. Valastro<sup>1</sup>, D. D'orio<sup>1</sup>, F. Pinto<sup>1</sup>, S.A. Maiella<sup>1</sup>, M.V. Morone<sup>1</sup>, G. Franci<sup>3</sup>, L. Rinaldi<sup>4</sup>, M. Galdiero<sup>1</sup>*  
<sup>1</sup>Department of Experimental Medicine, Section of Virology and Microbiology University of Campania "Luigi Vanvitelli", Naples, Italy, <sup>2</sup>Section of Microbiology and Virology, University Hospital Luigi Vanvitelli of Naples, Naples, Italy, <sup>3</sup>Department of medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi (SA), Italy, <sup>4</sup>Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy
- P 35 Genotyping and treatment issues with unusual 1e and 1g HCV subtypes from African subjects: report of two cases**  
*C. Caudai<sup>1</sup>, P. Pierotti<sup>2</sup>, P. Galluzzi<sup>3</sup>, B. Rossetti<sup>3</sup>, P. Blanc<sup>2</sup>, M. Zazzi<sup>4</sup>*  
<sup>1</sup>Microbiology and Virology Unit, Siena University Hospital, Siena, Italy, <sup>2</sup>Infectious Diseases Unit, S. Maria Annunziata Hospital, Florence, Italy, <sup>3</sup>Infectious Diseases Unit, Siena University Hospital, Siena, Italy, <sup>4</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy
- P 36 Feasibility and impact of HCV treatment in a HRS in Milan**  
*G. Cocca<sup>1</sup>, V. Casigliani<sup>2</sup>, T. Sebastiani<sup>1</sup>, S. Mazzilli<sup>2,3</sup>, D. Bugatti<sup>1</sup>, G. Visi<sup>2</sup>, A. Stemat<sup>4</sup>, G. Arzilli<sup>2</sup>, P. Vigezzi<sup>1</sup>, C. Nicola<sup>1</sup>, P. Selva<sup>1</sup>, C. Catani<sup>1</sup>, L. Tavoschi<sup>2</sup>, R. Ranieri<sup>4</sup>*  
<sup>1</sup>Local Harm Reduction Service, San Paolo University Hospital, Milan, Italy Department of <sup>2</sup>Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy, <sup>3</sup>Scuola Normale Superiore, Pisa, <sup>4</sup>Penitentiary Infectious Diseases Unit, San Paolo University Hospital, Milan, Italy
- P 37 An effective strategy to achieve HCV micro-elimination: HCV test and treatment into two Harm Reduction Services in Milan**  
*T. Sebastiani<sup>1</sup>, S. Mazzilli<sup>2,3</sup>, G. Cocca<sup>1</sup>, V. Casigliani<sup>2</sup>, A. Stemat<sup>4</sup>, G. Arzilli<sup>2</sup>, P. Vigezzi<sup>1</sup>, G. Visi<sup>2</sup>, D. Bugatti<sup>1</sup>, C. Nicola<sup>1</sup>, P. Selva<sup>1</sup>, C. Catani<sup>1</sup>, L. Tavoschi<sup>2</sup>, R. Ranieri<sup>4</sup>*  
<sup>1</sup>Local Harm Reduction Service, San Paolo University Hospital, Milan, Italy Department of <sup>2</sup>Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy, <sup>3</sup>Scuola Normale Superiore, Pisa, <sup>4</sup>Penitentiary Infectious Diseases Unit, San Paolo University Hospital, Milan, Italy
- P 38 Long follow up of monocyte-macrophage immuneactivation markers in HCV mono-infected patients undergoing DAA treatment**  
*B. Kertusha<sup>1</sup>, P. Nijhawan<sup>1</sup>, L. Fondaco<sup>1</sup>, A. Curtolo<sup>1</sup>, C. Mascia<sup>1</sup>, I. Pozzetto<sup>1</sup>, R. Marocco<sup>2</sup>, A. Carraro<sup>1</sup>, F. Cogliati Dezza<sup>1</sup>, V. Rossi<sup>2</sup>, T. Tieghi<sup>2</sup>, S. Vita<sup>2</sup>, C. Mastroianni<sup>1</sup>, M. Lichtner<sup>1,2</sup>*  
<sup>1</sup>Department of Public health and Infectious disease, Sapienza, University of Rome, <sup>2</sup>Infectious Disease Unit, SM Goretti Hospital Latina
- P 39 EradichiamoCi: HCV micro-eradication project among 5 psychoactive substances user services using a DAA delivery strategy**  
*P. Zuccala<sup>1</sup>, R. Marocco<sup>2</sup>, G. Di Palma<sup>2</sup>, B. Kertusha<sup>2</sup>, L. Fondaco<sup>2</sup>, M. D'Achille<sup>1</sup>, V. Rossi<sup>1</sup>, A. Mecozzi<sup>3</sup>, T. Franci<sup>3</sup>, C. De Mei<sup>4</sup>, E. Mattacchioni<sup>4</sup>, W. Ke-bebe<sup>4</sup>, G. Papa<sup>4</sup>, G. Padula<sup>5</sup>, T. Danieli<sup>6</sup>, O. Coletta<sup>6</sup>, A. Parente<sup>6</sup>, F. Aiuti<sup>7</sup>, E. Montanari<sup>7</sup>, P. Spina<sup>8</sup>, C. Paiano<sup>8</sup>, A. Veica<sup>1</sup>, M.P. Giardino<sup>5</sup>, M. Lichtner<sup>1,2</sup>*  
<sup>1</sup>UOC Infectious Disease, Ospedale S.Maria Goretti, Latina, <sup>2</sup>Sapienza University of Rome, Polo Pontino, Latina, <sup>3</sup>Hospital Pharmacy, Ospedale S.Maria Goretti, Latina, <sup>4</sup>Ser.D Latina, ASL Latina, Latina, <sup>5</sup>Ser.D Terracina, ASL Latina, Terracina, <sup>6</sup>Ser.D Formia, ASL Latina, Formia, <sup>7</sup>Ser.D Priverno, ASL Latina, Priverno, <sup>8</sup>Ser.D Aprilia, ASL Latina, Aprilia



## POSTER EXHIBITION

**P 40 Effect of direct antiviral therapy against HCV on CD4+ T cell count in patients with HIV-HCV coinfection**

*B. Pinchera, A.R. Buonomo, R. Scotto, E. Zappulo, F. Borrelli, M.R. Cotugno, G. Di Filippo, I. Gentile*

Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy

**P 41 HCV treatment in PWID: a linkage to care model in Cagliari**

*F. Pes<sup>1</sup>, C. Balestrieri<sup>1</sup>, M. Casale<sup>2</sup>, M. Buffa<sup>1</sup>, C. Guiso<sup>3</sup>, R. Altea<sup>4</sup>, O. Angioni<sup>5</sup>, L. Barca<sup>1</sup>, A. Cola<sup>2</sup>, S. Onali<sup>1</sup>, L. Chessa<sup>1,2</sup>*

<sup>1</sup>Department of Medical Sciences and Public Health; Monserrato (CA) Italy, <sup>2</sup>Liver Unit, University Hospital, Monserrato (CA) Italy, <sup>3</sup>Ser.D. via Liguria, ATS, Cagliari, Italy, <sup>4</sup>Ser.D. Via dei Valenziani, ATS, Cagliari, Italy, <sup>5</sup>Ser.D. Quartu S.E. (CA), ATS, Italy

## Hepatitis epidemiology

**P 42 Hepatitis A: has the outbreak ended?**

*E. Garlatti Costa<sup>1</sup>, P. Martelli<sup>2</sup>, R. Giacomello<sup>2</sup>, A. Berto<sup>3</sup>, A. Grembiale<sup>1</sup>, S. Grazioli<sup>1</sup>, R. De Rosa<sup>3</sup>, D. Villalta<sup>2</sup>, M. Tonizzo<sup>1</sup>*

<sup>1</sup>Department of Internal Medicine, ASFO, Pordenone, <sup>2</sup>Department of Immunology and Allergology, ASFO, Pordenone, <sup>3</sup>Department of Microbiology and Virology, ASFO, Pordenone

**P 43 Re-treatment of HCV infection following failure to DAAs: data from the SCOLTA cohort**

*L.A. Nicolini<sup>1</sup>, B. Menzaghi<sup>2</sup>, P. Bonfanti<sup>3</sup>, F. Vichi<sup>4</sup>, A. Cascio<sup>5</sup>, A. Parisini<sup>6</sup>, G. V. De Socio<sup>7</sup>, K. Falasca<sup>8</sup>, A. Di Biagio<sup>1,9</sup>*

<sup>1</sup>Infectious Diseases, Policlinico San Martino-IRCCS, Genova, Italy, <sup>2</sup>Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, Busto Arsizio, Italy, <sup>3</sup>Infectious Disease Unit, Ospedale A. Manzoni, Lecco, Italy, <sup>4</sup>Infectious Diseases Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy, <sup>5</sup>Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy, <sup>6</sup>Infectious Diseases Unit, SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, <sup>7</sup>Unit of Infectious Diseases, Department of Medicine 2, Azienda Ospedaliera di Perugia, Santa Maria Hospital, Perugia, <sup>8</sup>Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy, <sup>9</sup>Department of Health Sciences (DISSAL), University of Genoa, Genova, Italy

**P 44 HEV in Southern Italy. Still a chimera?**

*C. Dell'Isola, B.M. Matteis, F. Martucci, G. Morelli, P. Pierri, V. Bianco, R. Punzi*

Division of hepatic diseases- AORN "dei Colli" Monaldi-Cotugno-CTO, Naples

**P 45 Evaluation of early HCC occurrence rate and its risk factors in HCV patients treated with direct-acting antivirals**

*V. Valastro<sup>1</sup>, F. Foglia<sup>1</sup>, G. Greco<sup>1</sup>, D. D'orio<sup>1</sup>, F. Pinto<sup>1</sup>, S.A. Maiella<sup>1</sup>, M.V. Morone<sup>1</sup>, G. Franci<sup>2</sup>, M. Galdiero<sup>1</sup>*

<sup>1</sup>Department of Experimental. Medicine, Section of Virology and Microbiology University of Campania "Luigi Vanvitelli", Naples, Italy, <sup>2</sup>Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi (SA), Italy

## HIV and COVID

**P 46 Covid-19 in patients with HIV-1 infection: a single-centre experience in Northern Italy**

*L. Calza<sup>1</sup>, I. Bon<sup>2</sup>, V. Colangeli<sup>1</sup>, M. Borderi<sup>1</sup>, G. Beci<sup>1</sup>, F. Esposito<sup>1</sup>, L. Badia<sup>1</sup>, M. Tadolini<sup>1</sup>, M.C. Re<sup>2</sup>, P. Viale<sup>1</sup>*

<sup>1</sup>Unit of Infectious Diseases and <sup>2</sup>Unit of Microbiology, S.Orsola Hospital, University of Bologna, Bologna (Italy)

**P 47 A case of acute hepatitis C in a patient with HIV, occult HBV and SARS-CoV-2 co-infection**

*E. Garlatti Costa<sup>1</sup>, A. Grembiale<sup>1</sup>, C. Mazzaro<sup>2</sup>, A. Rosso<sup>1</sup>, A. Berto<sup>3</sup>, S. Grazioli<sup>1</sup>, O. Schioppa<sup>4</sup>, R. De Rosa<sup>3</sup>, M. Tonizzo<sup>1</sup>*

<sup>1</sup>Department of Internal Medicine, Azienda Sanitaria Friuli Occidentale (ASFO), Pordenone, Italy, <sup>2</sup>Department of Experimental Onco-Hematology, Centro Riferimento Oncologico (CRO), IRCCS, Aviano, Italy, <sup>3</sup>Department of Microbiology and Virology, Azienda Sanitaria Friuli Occidentale (ASFO), Pordenone, Italy, <sup>4</sup>Department of Oncology, Centro Riferimento Oncologico (CRO), IRCCS, Aviano, Italy

**P 48 SARS-CoV-2 infection in a highly-experienced person living with HIV**

*A. Ciccullo<sup>1,2</sup>, P. Del Giacomo<sup>1</sup>, A. Porfidia<sup>3</sup>, G. De Matteis<sup>3</sup>, R. Cianci<sup>3</sup>, F. De Vito<sup>3</sup>, A. Dusina<sup>1,2</sup>, A. Borghetti<sup>1</sup>, M. Tumbarello<sup>1,2</sup>, S. Di Giambenedetto<sup>1,2</sup>*

<sup>1</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Malattie Infettive, Rome, Italy, <sup>2</sup>Section of Infectious Diseases, Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy,

<sup>3</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Medicina Generale, Rome, Italy

**P 49 SARS-CoV-2 infection in a HIV+ patient on darunavir-based ART monotherapy: a case report**

*G.E. Recchia<sup>1</sup>, M. Ridolfi<sup>1</sup>, G. Siccardi<sup>1</sup>, F. Cogliati Dezza<sup>1</sup>, F. Alessi<sup>1</sup>, C. Pinacchio<sup>1</sup>, L. Santinelli<sup>1</sup>, G.P. Innocenti<sup>1</sup>, C. Scagnolari<sup>2</sup>, G. Ceccarelli<sup>1</sup>, G. d'Etterre<sup>1</sup>, C. Mastroianni<sup>1</sup>*

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, <sup>2</sup>Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognietti Foundation, Sapienza University, Rome, Italy





## POSTER EXHIBITION

- P 50 COVID-19 in people living with HIV (PLWH): clinical picture, viral clearance, cellular and antibody response in a case series of a reference HIV/AIDS center in a COVID Hospital in Rome**  
A. Mondì<sup>1</sup>, E. Cimini<sup>2</sup>, F. Colavita<sup>3</sup>, S. Cicalini<sup>1</sup>, C. Pinnetti<sup>1</sup>, G. Matusali<sup>3</sup>, R. Casetti<sup>2</sup>, A. Vergori<sup>1</sup>, V. Mazzotta<sup>1</sup>, R. Gagliardini<sup>1</sup>, V. Schininà<sup>4</sup>, E. Girardi<sup>5</sup>, V. Puro<sup>6</sup>, G. Ippolito<sup>7</sup>, M. Capobianchi<sup>3</sup>, C. Castilletti<sup>3</sup>, C. Agrati<sup>2</sup>, A. Antinori<sup>1</sup>  
<sup>1</sup>HIV/AIDS Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>2</sup>Cellular Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>3</sup>Laboratory of Virology, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>4</sup>Radiology Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>5</sup>Clinical Epidemiology Unit, National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy, <sup>6</sup>AIDS Reference Center - National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>7</sup>Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy
- P 51 Clinical course and viroimmunological impact of COVID-19 in HIV infected patients: a single-center report from Milan, Italy**  
A. Mastrangelo<sup>1</sup>, C. Muccini<sup>1</sup>, E. Bruzzesi<sup>1</sup>, M. Ranzenigo<sup>1</sup>, M. Chiurlo<sup>1</sup>, L. Galli<sup>2</sup>, A. Poli<sup>2</sup>, A. Castagna<sup>1,2</sup>, A. Lazzarin<sup>2</sup>, P. Cinque<sup>2</sup> on behalf of the HIV-COVID OSR Study Group<sup>2</sup> (E. Messina, A. Danise, M. Guffanti, R. dell'Acqua, S. Nozza, N. Gianotti, V. Spagnuolo, L. Fumagalli, H. Hamid, S. Bossolasco, G. Morsica, G. Gaiera, M. Cernuschi, M. Ripa, B. Castiglioni, C. Oltolini, D. Canetti, C. Tassan-Din, A. Andolina, P. Scarpellini, G. Tambussi, C. Uberti-Foppa)  
<sup>1</sup>Vita-Salute San Raffaele University, Milan, <sup>2</sup>Unit of Infectious Diseases, San Raffaele Hospital, Milan
- P 52 Management of emergency COVID-19 in prison, Monza experience**  
L.M. Vaira<sup>1</sup>, V. Costa<sup>1</sup>, M. Pitaniello<sup>2</sup>  
<sup>1</sup>Medical Prison Unit, San Gerardo Hospital, ASST-Monza, Monza, Italy, <sup>2</sup>Prison director of Monza
- P 53 Psychological impact and awareness of COVID-19 in young people with HIV**  
S. Bernardi<sup>1</sup>, E. Mozzo<sup>2</sup>, M. Di Pastena<sup>1</sup>, F. Leone<sup>3</sup>, C. Novello<sup>2</sup>, A. Oletto<sup>2</sup>, N. Cotugno<sup>4</sup>, P. Zangari<sup>4</sup>, P. Palma<sup>4</sup>, V. Santilli<sup>4</sup>, P. Palma<sup>4</sup>, O. Rampon<sup>5</sup>, C. Giaquinto<sup>2</sup>  
<sup>1</sup>DPUO Immunoinfettivologia, Ospedale Pediatrico Bambino Gesù, Roma, <sup>2</sup>Fondazione Penta, Padova, <sup>3</sup>Università degli Studi di Roma, <sup>4</sup>UOC Immunologia Clinica – DPUO, Ospedale Pediatrico Bambino Gesù, Roma, <sup>5</sup>Department of Women's and Children's Health, University of Padova
- P 54 Review of lopinavir and darunavir use in SARS-CoV-2 and HIV co-infection: is it time to find another role and another actor?**  
E. Garlatti Costa<sup>1</sup>, R. Ranieri<sup>2</sup>, G. Basaglia<sup>3</sup>, R. De Rosa<sup>3</sup>, M. Tonizzo<sup>1</sup>  
<sup>1</sup>Department of Internal Medicine, Azienda Sanitaria Friuli Occidentale, Pordenone, Italy, <sup>2</sup>Infectious Diseases Service, Penitentiary Health System, San Paolo University Hospital, Milano, Italy, <sup>3</sup>Department of Microbiology and Virology, Azienda Sanitaria Friuli Occidentale, Pordenone, Italy
- P 55 Seroprevalence of SARS-CoV2 antibodies in paediatric HIV patients**  
S. Bernardi, C. Casamento Tumeo, C. Concato, L. Coltella, S. Ranno, G. Linardos, L. Piccioni, C.F. Perno  
Bambino Gesù Children's Hospital Rome Italy

## HIV and nervous system

- P 56 Study of the types of the nervous system based on temperaments of HIV-infected patients**  
Z. Akhmedjanova<sup>1</sup>, D. Urunova<sup>2</sup>, Z. Kadyrova<sup>3</sup>  
<sup>1</sup>Institute of Human Immunology and Genomics, Tashkent, <sup>2</sup>Academy of Sciences of the Republic of Uzbekistan, Tashkent, <sup>3</sup>Tashkent Institute for Advanced Medical Studies, Tashkent
- P 57 Persistent activation of CXCL13 axis in the Cerebrospinal fluid of People Living with HIV despite Central Nervous System Viral Suppression**  
M. Trunfio<sup>1</sup>, L. Mighetto<sup>2</sup>, S. Torresan<sup>1</sup>, C. Atzori<sup>3</sup>, S. Biffi<sup>1</sup>, M. Nigra<sup>2</sup>, D. Imperiale<sup>3</sup>, S. Bonora<sup>1</sup>, G. Di Perri<sup>1</sup>, A. Calcagno<sup>1</sup>  
<sup>1</sup>Infectious Diseases unit, Amedeo di Savoia hospital, University of Torino, Torino, Italy, <sup>2</sup>Diagnostic Laboratory unit, Maria Vittoria hospital, ASL Città di Torino, Torino, Italy, <sup>3</sup>Neurology unit, Maria Vittoria hospital, ASL Città di Torino, Torino, Italy
- P 58 Limited health literacy (HL) ability and low awareness of HL difficulties in people living with HIV**  
V. Delle Donne<sup>1</sup>, N. Ciccarelli<sup>2</sup>, V. Massaroni, F. Lombardi<sup>1</sup>, C. Picarelli<sup>1</sup>, A. Borghetti, A. Emiliozzi<sup>1</sup>, A. Dusina<sup>1</sup>, A. Ciccullo<sup>1</sup>, D. Moschese<sup>1</sup>, G. Baldin<sup>1,5</sup>, D. Farinacci<sup>1</sup>, S. Di Giambenedetto<sup>1,4</sup>, M. Fabbiani<sup>3</sup>  
<sup>1</sup>Università Cattolica del Sacro Cuore, Roma Italia, Istituto di Clinica Malattie Infettive, <sup>2</sup>Dipartimento di Psicologia, Università Cattolica di Milano, <sup>3</sup>UOC Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Senese, Siena, Italy, <sup>4</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, UOC malattie infettive, <sup>5</sup>Mater Olbia Hospital, Olbia, Italy
- P 59 Evolution of cognitive performance at a 2 years follow-up in a group of HIV-infected patients**  
V. Delle Donne<sup>1</sup>, N. Ciccarelli<sup>2</sup>, V. Massaroni<sup>1</sup>, F. Lombardi<sup>1</sup>, C. Picarelli<sup>1</sup>, A. Borghetti<sup>1</sup>, A. Emiliozzi<sup>1</sup>, A. Dusina<sup>1</sup>, A. Ciccullo<sup>1</sup>, D. Moschese<sup>1</sup>, G. Baldin<sup>1,5</sup>, D. Farinacci<sup>1</sup>, S. Di Giambenedetto<sup>1,4</sup>, M. Fabbiani<sup>3</sup>  
<sup>1</sup>Università Cattolica del Sacro Cuore, Roma Italia, Istituto di Clinica Malattie Infettive, <sup>2</sup>Dipartimento di Psicologia, Università Cattolica di Milano, <sup>3</sup>UOC Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Senese, Siena, Italy, <sup>4</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, UOC malattie infettive, <sup>5</sup>Mater Olbia Hospital, Olbia, Italy



## POSTER EXHIBITION

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

- P 60 Cerebrospinal fluid viral replication and burden of resistance in HIV-1-infected people with multidrug resistance treated with Ibalizumab**  
C. Muccini<sup>1</sup>, D. Canetti<sup>2</sup>, A. Bigoloni<sup>2</sup>, V. Spagnuolo<sup>1,2</sup>, L. Galli<sup>2</sup>, A. Poli<sup>2</sup>, M. Cernuschi<sup>2</sup>, P. Cinque<sup>2</sup>, E. Boeri<sup>3</sup>, M. Sampaolo<sup>3</sup>, A. Lazzarin<sup>2</sup>, A. Castagna<sup>1,2</sup>  
<sup>1</sup>Vita-Salute San Raffaele University, Milan, Italy, <sup>2</sup>Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>3</sup>Laboratory of Microbiology and Virology, IRCCS San Raffaele, Milan, Italy
- P 61 In Vitro Effect of Efavirenz on Cultured Primary Astrocytes: Analysis of Neurotoxicity and Matrix Metalloproteinase Inhibition**  
I. Pati<sup>1</sup>, T. Latronico<sup>1</sup>, S. Milella<sup>1</sup>, A. Fasano<sup>1</sup>, F. Mengoni<sup>2</sup>, M. Lichtner<sup>3</sup>, C.M. Mastroianni<sup>2</sup>, G.M. Liuzzi<sup>1</sup>  
<sup>1</sup>Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari "A. Moro", Bari, Italy, <sup>2</sup>Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy, <sup>3</sup>Infectious Diseases Unit, Sapienza University, Latina, Italy
- P 62 Evaluation of Patient-Reported Outcomes (PROs) and cognitive performance in HIV naïve patients with advanced disease: results from the PRO-Advance study**  
A.C. Brita, C. Pinnetti, A. Vergori, G. Passavanti, P. Lorenzini, R. Gagliardini, R. Bellagamba, E. Grilli, A. Mondì, S. Grisetti, V. Mazzotta, F. Baldini, A. Giannetti, A. Antinori, S. Cicalini  
National Institute for Infectious Diseases, IRCCS, L. Spallanzani - HIV/AIDS Unit, Rome, Italy
- P 63 Cerebrospinal Fluid anti-EBV Viral Capsid Antigen IgG Production associates with poorer Performance in Attention, Memory and Executive functions domains among People living with HIV**  
M. Trunfio<sup>1</sup>, A. Sacchi<sup>2</sup>, D. Vai<sup>3</sup>, F. Pittaluga<sup>2</sup>, A. Gaviraghi<sup>1</sup>, G. Guastamacchia<sup>3</sup>, G. Di Perri<sup>1</sup>, R. Cavallo<sup>2</sup>, S. Bonora<sup>1</sup>, A. Calcagno<sup>1</sup>  
<sup>1</sup>Infectious Diseases unit, Amedeo di Savoia hospital, University of Torino, Torino, Italy, <sup>2</sup>Microbiology and Virology unit, Città della Salute e della Scienza, University of Torino, Torino, Italy, <sup>3</sup>Neurology unit, Maria Vittoria hospital, ASL Città di Torino, Torino, Italy
- P 64 Cryptococcal meningitis in a young woman HIV late presenter: a case report**  
V. Fortunato, A. Campagna, L. Iapicco, S. Madonna, R. Santoro, A. Spera, R. Verrioli, A. Masullo  
AOU "San Giovanni di Dio E Ruggi D'Aragona" Salerno

## HIV cure

- P 65 A multidisciplinary approach to imprint a successful long term adherence skill to Antiretroviral Therapy in naïve patients: background and preliminary data of a pilot project of the GLAD group**  
G.C. Orofino<sup>1</sup>, M. Guastavigna<sup>1</sup>, M.C. Tettoni<sup>2</sup>, G. Mosso<sup>1</sup>, R. Interdonato<sup>1</sup>, C. Grassone<sup>2</sup>, R. Casciaro<sup>2</sup>, G. Cinnirella<sup>3</sup>, S. Bertini<sup>3</sup>, M.E. Bersia<sup>4</sup>, F. Busso<sup>4</sup>, S. Lupo<sup>4</sup>, S. Ferrero Merlino<sup>4</sup>  
<sup>1</sup>Division A of Infectious Diseases, Amedeo di Savoia Hospital, Turin, Italy, <sup>2</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy, <sup>3</sup>Pharmacy Department, Amedeo di Savoia Hospital, Turin, Italy, <sup>4</sup>Hospital Clinical Psychology, Amedeo di Savoia Hospital, Turin, Italy
- P 66 Switching Dolutegravir/Abacavir/Lamivudine single tablet regimen (STR) to a less-costly multi-tablet regimen of Dolutegravir +Abacavir/Lamivudine (generic) in the setting of virologic suppression: data at 48 weeks**  
S. Gardin, L. Sasset, S. Cavinato, E. Di Meco, A.M. Cattelan  
Infectious Diseases Division, Azienda Ospedaliera Padova
- P 67 Complementary-alternative medicines and self prescribed drugs use in women living with HIV**  
L. Sasset<sup>1</sup>, E. Di Meco<sup>1</sup>, A. Frater<sup>1</sup>, A. Londero<sup>2</sup>, R. Luzzati<sup>3</sup>, V. Vazzoler<sup>1</sup>, A. Cattelan<sup>1</sup>  
<sup>1</sup>Infectious Diseases Division, Azienda Ospedaliera di Padova, Italy, <sup>2</sup>Infectious Diseases Division, Santa Maria della Misericordia University Hospital, Udine, Italy, <sup>3</sup>Department of Infective Diseases, University Hospital of Trieste, Italy

## HIV epidemiology and retention in care

- P 68 Availability of rapid HIV self-test in Italian pharmacies: a survey**  
P. Piselli<sup>1</sup>, C. Cimaglia<sup>1</sup>, C. Pellegrini<sup>2</sup>, C. Castelli<sup>3</sup>, V. Calvino<sup>4</sup>, S. Negri<sup>4</sup>, S. Penon<sup>5</sup>, M. Farinella<sup>6</sup>, E. Bendetti<sup>6</sup>, E. Teti<sup>7</sup>, R. Marchetti<sup>7</sup>, N. Catucci<sup>5</sup>, F. Laura<sup>2</sup>, G.M. Corbelli<sup>8</sup>, L. Solagna<sup>9</sup>, A. Riccio<sup>9</sup>, M.G. Di Benedetto<sup>5</sup>, S. Bellini<sup>5</sup>, A. Camposeragna<sup>10</sup>, M.L. Circosta<sup>2</sup>, F. Corona<sup>2</sup>, A. Caraglia<sup>11</sup>, L. Rancilio<sup>3</sup>, M. Oldrini<sup>5</sup>, E. Girardi<sup>1</sup> for the project "Linkage to Care in HIV: a further piece to the analysis of continuum of care in HIV in Italy"  
<sup>1</sup>INMI L. Spallanzani IRCCS, Rome, <sup>2</sup>CICA, <sup>3</sup>Caritas Ambrosiana, Milan, <sup>4</sup>ANLAIDS, <sup>5</sup>LILA, <sup>6</sup>Circolo Mario Mieli, Rome, <sup>7</sup>Villa Maraini Onlus, Rome, <sup>8</sup>PLUS, rete persone LGBT+ sieropositive, <sup>9</sup>NPS, <sup>10</sup>CNCA, <sup>12</sup>Minister of Health, Rome



## POSTER EXHIBITION

### P 69 Reducing Late Presenters Patients rate in Milan area (RELAPP Study): preliminary results

M. Bonfanti<sup>1</sup>, T. Quirino<sup>2</sup>, U. Restelli<sup>3</sup>, N. Astuti<sup>4</sup>, M.V. Cossu<sup>5</sup>, A. De Silvestri<sup>6</sup>, D. Croce<sup>7</sup>, G. Rizzardini<sup>8</sup>

<sup>1</sup>Centre for Research on Health Economics, Social and Health Care Management, LIUC – Università Cattaneo, Castellanza, Varese, Italy; <sup>2</sup>Freelance expert in infectious diseases; <sup>3</sup>Centre for Research on Health Economics, Social and Health Care Management, LIUC – Università Cattaneo, Castellanza, Varese, Italy; <sup>4</sup>School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; <sup>5</sup>Department of Infectious Diseases, ASST Fatebenefratelli Sacco, University Hospital; <sup>6</sup>Department of Infectious Diseases, ASST Fatebenefratelli Sacco, University Hospital; <sup>7</sup>Clinical Epidemiology and Biometrics Service - IRCCS Policlinico San Matteo Foundation; <sup>8</sup>Centre for Research on Health Economics, Social and Health Care Management, LIUC – Università Cattaneo, Castellanza, Varese, Italy; <sup>9</sup>Department of Infectious Diseases, ASST Fatebenefratelli Sacco, University Hospital; <sup>10</sup>School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

### P 70 May administering routine HIV test be useful to uncover the iceberg in a University Hospital setting? Our experience

C. Picarelli<sup>1</sup>, F. Lombardi<sup>1</sup>, A. Ciccullo<sup>1</sup>, D. Farinacci<sup>1</sup>, A. Dusina<sup>1</sup>, D. Moschese<sup>1</sup>, A. D'Angelillo<sup>1</sup>, A. Borghetti<sup>2</sup>, S. Di Giambenedetto<sup>1,2</sup>

<sup>1</sup>Università Cattolica del Sacro Cuore, Roma Italia, Istituto di Clinica Malattie Infettive, <sup>2</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, UOC malattie infettive

### P 71 High rates of lost-to-follow-up among naive HIV+ female population: real-life data from UOC "Immunodeficienze e Malattie Infettive di Genere", D. Cotugno Hospital, Naples, 2017-19

V. Rizzo<sup>1</sup>, F.M. Fusco<sup>2</sup>, M.A. Carleo<sup>1</sup>, S. Mascolo<sup>1</sup>, R. Pisapia<sup>3</sup>, P. Rosario<sup>1</sup>, V. Esposito<sup>1</sup>

<sup>1</sup>UOC Immunodeficienze e Malattie Infettive di Genere, P.O. "D. Cotugno", Azienda Ospedaliera dei Colli, Naples, Italy; <sup>2</sup>UOC Infezioni Sistemiche e dell'Immunodepresso, P.O. "D. Cotugno", Azienda Ospedaliera dei Colli, Naples, Italy; <sup>3</sup>UOC Malattie Infettive ad indirizzo Neurologico, P.O. "D. Cotugno", Azienda Ospedaliera dei Colli, Naples, Italy

### P 72 Risk Factors for Late HIV Presentation in a Tertiary Care University Hospital

C. Rovelli, L. Clerici, N.W. Delfrate, Z. Di Rosa, P.A. Grossi

University of Insubria, Varese

### P 73 Epidemiology and clinical characteristics of HIV/AIDS among foreign in Campania Region, 2008-19: which differences with Italian population?

F.M. Fusco<sup>1</sup>, A. Menna<sup>2</sup>, A. Galano<sup>2</sup>, A. Laudiero<sup>2</sup>, A. Mariniello<sup>2</sup>, M. De Cenzo<sup>2</sup>, S. Mascolo<sup>3</sup>, M. Sardo<sup>4</sup>, R. Viglietti<sup>1</sup>, G. Parrella<sup>1</sup>, O. Tambaro<sup>1</sup>, V. Iodice<sup>1</sup>, M.A. Pisaturo<sup>1</sup>, G. Di Flumeri<sup>1</sup>, E. Manzillo<sup>4</sup>, V. Esposito<sup>3</sup>, A. Chirianni<sup>1</sup>, V. Sangiovanni<sup>1</sup>

<sup>1</sup>UOC Infezioni Sistemiche e dell'Immunodepresso, P.O. "D. Cotugno", Azienda Ospedaliera dei Colli, Naples, Italy; <sup>2</sup>Servizio Ospedalizzazione Domiciliare, P.O. "D. Cotugno", Azienda Ospedaliera dei Colli, Naples, Italy; <sup>3</sup>UOC Immunodeficienze e Malattie Infettive di Genere, P.O. "D. Cotugno", Azienda Ospedaliera dei Colli, Naples, Italy; <sup>4</sup>U.O.C. Immunodeficienze e malattie dell'immigrazione, P.O. "D. Cotugno", Azienda Ospedaliera dei Colli, Naples, Italy

### P 74 The efficacy of cART regimens and retention in care in an HIV-infected cohort of naïve patients

G. Piazza<sup>1</sup>, S. Vitale<sup>1</sup>, S. Meneghetti<sup>1</sup>, L. Appolloni<sup>1</sup>, G. Pensalfine<sup>1</sup>, L. Calza<sup>2</sup>, M. Morotti<sup>1</sup>

<sup>1</sup>Clinical Pharmacy, S. Orsola-Malpighi Polyclinic, Bologna; <sup>2</sup>Infectious Disease S. Orsola-Malpighi Polyclinic, Bologna

### P 75 Characterization of HIV-1 transmission dynamics in North and Central Italy over the years 2012-2019

C. Alteri<sup>1,2</sup>, R. Scutari<sup>3</sup>, V. Costabile<sup>4</sup>, S. Carta<sup>5</sup>, L. Colagrossi<sup>5</sup>, C. Gori<sup>6</sup>, A. Bertoli<sup>3,7</sup>, N. Orchi<sup>8</sup>, G. De Carli<sup>9</sup>, S. Pittalis<sup>8</sup>, L.G. Chianura<sup>9</sup>, R. Rossotti<sup>9</sup>, V. Malagnino<sup>10</sup>, S. Ciclini<sup>11</sup>, R. Gagliardini<sup>11</sup>, A. Latini<sup>12</sup>, A. Nava<sup>1</sup>, D. Fanti<sup>1</sup>, M. Lichtner<sup>13</sup>, M.C. Moiola<sup>9</sup>, F. Ceccherini-Silberstein<sup>3</sup>, E. Girardi<sup>14</sup>, M.M. Santoro<sup>3</sup>, M. Andreoni<sup>10</sup>, M. Puoti<sup>9</sup>, A. Antinori<sup>11</sup>, C.F. Perno<sup>1,2,6</sup>

<sup>1</sup>Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy; <sup>2</sup>Chemical-clinical and Microbiological Analysis, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; <sup>3</sup>Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy; <sup>4</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; <sup>5</sup>Residency in Microbiology and Virology, University of Milan, Milan, Italy; <sup>6</sup>Laboratory of Virology, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy; <sup>7</sup>Virology Unit, University Hospital "Tor Vergata", Rome, Italy; <sup>8</sup>AIDS Reference Center, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy; <sup>9</sup>Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; <sup>10</sup>Infectious Diseases, University Hospital "Tor Vergata", Rome, Italy; <sup>11</sup>Clinical Department, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy; <sup>12</sup>Unit of Dermatology and Sexually Transmitted Diseases, San Galliciano Dermatological Institute IRCCS, Rome, Italy; <sup>13</sup>Infectious Diseases Unit, "Sapienza" University, Polo Pontino, Latina, Italy; <sup>14</sup>Clinical Epidemiology, INMI "Lazzaro Spallanzani" IRCCS, Rome, Italy

### P 76 "EXTERNA": QoL Perception in PLWHIV during ID checkup

A. Antonino<sup>1</sup>, A. Bianchi<sup>1</sup>, F. Rossi<sup>1</sup>, S. Bossolasco<sup>2</sup>, E. Messina<sup>2</sup>, M. Cernuschi<sup>1,2</sup>, L. Galli<sup>2</sup>, A. Poli<sup>2</sup>, A. Castagna<sup>2</sup>, N. Gianotti<sup>2</sup>

<sup>1</sup>ASA Milano, <sup>2</sup>San Luigi(HSR), Milano

### P 77 HIV screening in migrant population living in "ghetti" in Apulia

R. Lattanzio<sup>1,3</sup>, F. Di Gennaro<sup>1,2</sup>, A. Volpe<sup>3</sup>, D.F. Bavaro<sup>1</sup>, G. Putoto<sup>2</sup>, C. Marotta<sup>2</sup>, L. Raho<sup>3</sup>, R. Laforgia<sup>3</sup>, S. Lo Caputo<sup>4</sup>, C. Falanga<sup>5</sup>, L. Monno<sup>1</sup>, G. Angarano<sup>1</sup>, A. Saracino<sup>1</sup>

<sup>1</sup>Clinic of Infectious Diseases, University of Bari, Bari, Italy; <sup>2</sup>Research Unit, Cuamm Medici con l'Africa, Padova, Veneto, Italy; <sup>3</sup>Doctors with Africa CUAMM, Bari, Apulia, Italy; <sup>4</sup>Clinic of Infectious Diseases, University of Foggia, Foggia, Italy; <sup>5</sup>ANLAIDS Sezione Lombardia, Milan, Italy

### P 78 Geographic distribution of delayed presentation of HIV infection in HIV Emilia Romagna Surveillance System

V. Borghi<sup>1</sup>, A. Navarra<sup>2</sup>, S. Leone<sup>2</sup>, A. Degli Antoni<sup>3</sup>, E. Barchi<sup>4</sup>, L. Sighinolfi<sup>5</sup>, A. Boschi<sup>6</sup>, E. Massimiliani<sup>7</sup>, E. Girardi<sup>2</sup>, C. Mussini<sup>1</sup>

<sup>1</sup>Azienda Ospedaliera Universitaria di Modena, Modena, Italy; <sup>2</sup>Istituto Nazionale di Malattie Infettive "L. Spallanzani", I.R.C.C.S., Roma, Italy; <sup>3</sup>Azienda Ospedaliera Universitaria di Parma, Parma, Italy; <sup>4</sup>Presidio Ospedaliero Provinciale di Reggio Emilia, Reggio Emilia, Italy; <sup>5</sup>Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy; <sup>6</sup>Azienda Unità Sanitaria Locale della Romagna, Rimini, Italy; <sup>7</sup>Regione Emilia Romagna, Servizio Prevenzione Collettiva e Sanità Pubblica, Bologna, Italy

### P 79 Immunological evolution of a cohort of HIV-2 infected patients: peculiarities of an underestimated infection

B. Fumarola, G. Renis, S. Calza, S. Renzetti, I. El Hamad, C. Pezzoli, I. Izzo, M. Properzi, M. Degli Antoni, A. Celotti, A. Chiesa, P. Nasta, M. De

Francesco<sup>3</sup>, E. Quiros-Roldan, A. Caruso, F.Castelli, E. Focà  
Spedali Civili di Brescia, Brescia



## POSTER EXHIBITION

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

- P 80 HIV testing offer and services to improve linkage to Care in public services for HIV test: a survey**  
P. Piselli<sup>1</sup>, C. Cimaglia<sup>1</sup>, L. Rancilio<sup>2</sup>, P. Meli<sup>3</sup>, M. Farinella<sup>4</sup>, E. Teti<sup>5</sup>, V. Calvino<sup>6</sup>, G.M. Corbelli<sup>7</sup>, A. Camposeragna<sup>8</sup>, M. Errico<sup>9</sup>, F. von Schloesser<sup>10</sup>, M. Breveglieri<sup>11</sup>, A. Caraglia<sup>12</sup>, M. Oldrini<sup>13</sup>, E. Girardi<sup>1</sup> for the project "Linkage to Care in HIV: a further piece to the analysis of continuum of care in HIV in Italy"  
<sup>1</sup>INMI "L. Spallanzani" IRCCS, Rome, <sup>2</sup>Caritas Ambrosiana, Milan, <sup>3</sup>CICA, <sup>4</sup>Circolo Mario Mieli, Rome, <sup>5</sup>Fondazione Villa Maraini, Rome, <sup>6</sup>Anlaids, <sup>7</sup>PLUS, <sup>8</sup>CNCA, <sup>9</sup>NPS Italia, <sup>10</sup>Nadir, <sup>11</sup>Arcigay, <sup>12</sup>Minister of Health, <sup>13</sup>LILA, Milan
- P 81 Gap in care and loss to follow up due to administrative barriers among migrants living with HIV in the city of Padova**  
E. Di Meco, F. Raumer, S. Gardin, L. Sasset, S. Cavinato, A. Cattelan  
Division of Infectious Diseases, Azienda Ospedaliera di Padova, Italy
- P 82 Long-term survivors in a cohort of HIV+ patients diagnosed between 1985 and 1994: predictive factors associated with more than 25 years of survival**  
F. Cosentino, L. Anile, M. Ceccarelli, A. Marino, A. Pampaloni, D. Scuderi, M.E. Locatelli, V. Moscatt, M. Gussio, V. Boscia, F. Benanti, R.S. Grasso, A. Onorante, R. Bruno, B. Cacopardo, B.M. Celesia  
Unit of Infectious Diseases University of Catania ARNAS Garibaldi, Catania
- P 83 New diagnoses of HIV infection: what has changed in 10 years**  
T. Alessandra<sup>1</sup>, S. Ferrara<sup>2</sup>, S. Sica<sup>2</sup>, S.R. Bruno<sup>2</sup>, R. De Benedictis<sup>2</sup>, T. Santantonio<sup>2</sup>, S. Lo Caputo<sup>2</sup>  
<sup>1</sup>Malattie Infettive ASL Foggia, <sup>2</sup>Clinica Malattie Infettive, Università degli Studi di Foggia - Foggia, Italy

## HIV immunology and immune-based therapies

- P 84 Acne vulgaris as possible Immune Recovery Folliculitis driven by the lymphocyte T CD8+ immunological recovery in naïve and experienced patients**  
M. Camici<sup>1</sup>, A. Scarabello<sup>2</sup>, R. Gagliardini<sup>1</sup>, A. Antinori<sup>1</sup>  
<sup>1</sup>HIV/AIDS Clinical Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>2</sup>Dermatological Clinical Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy
- P 85 Influence of HLA haplotype on immunological recovery in HIV-infected patients**  
D. Fiordelisi, R. Casciaro, D.F. Bavaro, G. Angarano, L. Monno, A. Saracino  
Azienda Ospedaliero Universitaria Consorziale Policlinico, Bari

## HIV pathogenesis

- P 86 Oxidative Stress and gut microbiota composition in primary HIV infection**  
E.S. Cannizzo, E. Merlini, M. Allegrini, G. Ancona, C. Tincati, F. Bai, F. Gelpi, A. d'Arminio Monforte, G. Marchetti  
Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan

## HIV prevention (PrEP and PEP)

- P 87 PrEP awareness and attitudes in a survey among Italian clinicians**  
A. Ciccullo<sup>1</sup>, G. Baldin<sup>1</sup>, S. Rusconi<sup>2</sup>, G. Sterrantino<sup>3</sup>, G. Madeddu<sup>4</sup>, V. Borghi<sup>5</sup>, C. Fimiani<sup>6</sup>, I. Uccella<sup>7</sup>, E. Trearichi<sup>8</sup>, B. Rossetti<sup>9</sup>, F. Vignale<sup>10</sup>, G. d'Ettore<sup>6</sup>, M. Scuderi<sup>11</sup>, A. Latini<sup>12</sup>, S. Di Giambenedetto<sup>1,13</sup>  
<sup>1</sup>Section of Infectious Diseases, Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy, <sup>2</sup>Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy, <sup>3</sup>Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy, <sup>4</sup>Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>5</sup>Clinic of Infectious Diseases, University Hospital, University of Modena and Reggio Emilia, Modena, Italy, <sup>6</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, <sup>7</sup>UOC Malattie Infettive, Frosinone, Italy, <sup>8</sup>Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, University 'Magna Graecia', Catanzaro, Italy, <sup>9</sup>Hospital Department of Specialized and Internal Medicine, Infectious Diseases Unit, University Hospital of Siena, Siena, Italy, <sup>10</sup>Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Italy, <sup>11</sup>Unità di Malattie Infettive, Ospedale San Camillo de Lellis, Rieti, Italia, <sup>12</sup>Unit of Dermatology and Sexually Transmitted Diseases, San Gallicano Dermatological Institute IRCCS, Rome, Italy, <sup>13</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italia
- P 88 PrEP: the stories about who used the therapy**  
M. Zetti, A. Bianchi, P. Vinti  
ASA-Associazione Solidarietà Aids
- P 89 Young People Inform Young People - Speak to the students with the Peer Section of the School Project**  
R. Galipò<sup>1</sup>, E. Farinola<sup>1</sup>, A. Ferraroni<sup>1</sup>, P. Ferri<sup>1</sup>, N. Orchi<sup>2</sup>, M. Ghenzer<sup>1</sup>  
<sup>1</sup>Anlaids Lazio, Rome, <sup>2</sup>Infectious Disease Epidemiology Unit - AIDS Reference Centre, National Institute for Infectious Disease "L. Spallanzani" - IRCCS, Rome





## POSTER EXHIBITION

### P 90 Problems and difficulties in the management of a PrEP clinic

A. Franco<sup>1</sup>, L. Aprea<sup>2</sup>, R.M. Franco<sup>1</sup>, T. Pizzella<sup>2</sup>, M. Sardo<sup>2</sup>, F. Simioli<sup>2</sup>, E. Manziolo<sup>2</sup>

<sup>1</sup>UOSD Profilassi Post-Esposizione – AORN “Ospedali dei Colli” – Napoli, <sup>2</sup>UOC Immunodeficienze e Malattie dell’Emigrazione – AORN “Ospedali dei Colli - Napoli

### P 91 Post-exposure prophylaxis in real life

A. Venturelli<sup>1</sup>, M. Franzetti<sup>2</sup>, G.V. Calvino<sup>1</sup>, C. Balotta<sup>1</sup>, M. Galli<sup>3</sup>, B. Marchini<sup>1</sup>

<sup>1</sup>Anlaid Onlus, Rome, Italy, <sup>2</sup>Infectious Diseases Unit, A. Manzoni Hospital, Lecco, Italy, <sup>3</sup>Department of Biomedical and Clinical Sciences, ASST ‘Fatebenefratelli Sacco’, University Of Milan, Italy

### P 92 Determinants of drug start, schedule change and discontinuation in PrEP users

R. Rossotti, C. Baiguera, M. Merli, M. Colaneri, S. Chiappetta, M.C. Moiola, L.G. Chianura, D. Motta, M. Puoti

Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda

### P 93 No increased risk of adverse events and sexually transmitted infections in PrEP users despite the rise in condomless sex

R. Rossotti, C. Baiguera, M. Colaneri, M. Merli, S. Chiappetta, M.C. Moiola, L.G. Chianura, D. Motta, M. Puoti

Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda

### P 94 PrEP: psychological and emotional aspects

A. Bianchi<sup>1,2</sup>, A. Tavelli<sup>3</sup>, M. Lanza<sup>1</sup>, A. De Bona<sup>3</sup>, E. Suardi<sup>3</sup>, P. L. Vinti<sup>2</sup>, D. Calzavara<sup>2</sup>, A. Antonino<sup>1</sup>, F. Rossi<sup>1</sup>, G. Fracca<sup>1</sup>, D. Rossotti<sup>4</sup>, S. Bossolasco<sup>5</sup>, D. Canetta<sup>5</sup>, G. Ancona<sup>3</sup>, M. Cernuschi<sup>1,2,5</sup>

<sup>1</sup>ASA. Associazione Solidarietà AIDS, Milan, Italy, <sup>2</sup>Milano Checkpoint, Milan, <sup>3</sup>San Paolo Hospital, Milan, Italy, <sup>4</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>5</sup>San Raffaele Hospital, Milano, Italy

### P 95 PrEP use amongst MSM in Italy: data from the EMIS 2017 survey

M. Cordiali<sup>1</sup>, L. Gios<sup>1</sup>, M.L. Cosmaro<sup>2</sup>, M. Breveglieri<sup>3</sup>, F.M. Nimbi<sup>4</sup>, G.M. Corbelli<sup>5</sup>, N. Sherriff<sup>6</sup>, M. Mirandola<sup>1,6</sup>

<sup>1</sup>UOC di Malattie Infettive e Tropicali, Dipartimento di Diagnostica e Sanità Pubblica, Università di Verona / Infectious Diseases Section, Diagnostic and Public Health Department, University of Verona, <sup>2</sup>Fondazione Lega Italiana per la Lotta contro l’AIDS – LILA Milano, <sup>3</sup>Arcigay, <sup>4</sup>Dept of Dynamic and Clinical Psychology, Sapienza University of Rome, <sup>5</sup>Plus Network persone LGBT sieropositive, <sup>6</sup>School of Health Sciences, University of Brighton, Brighton, UK

### P 96 Pre-Exposure Prophylaxis (PrEP): the one-year experience of the first dedicated service of Tuscany Region in S.M. Annunziata Hospital, Florence

E. Salomoni<sup>1</sup>, F. Vichi<sup>1</sup>, F. Baragli<sup>1</sup>, G.M. Corbelli<sup>2</sup>, M.A. Di Pietro<sup>3</sup>, P. Blanc<sup>1</sup>

<sup>1</sup>Infectious Diseases Unit, S.M. Annunziata Hospital, Florence, Azienda USL Toscana centro; <sup>2</sup>Plus Association, Bologna; <sup>3</sup>Coordinator of Infectious Diseases Units of Azienda USL Toscana Centro, S. Jacopo Hospital, Pistoia

### P 97 In vitro effect of Castanea Sativa Mill. bark extract (ENC®) on HIV-1 infection: a potential microbicide

M. Tamburello<sup>1</sup>, V. D’Urbano<sup>1</sup>, M. Micucci<sup>2</sup>, R. Budriesi<sup>2</sup>, A. Bertoldi<sup>1</sup>, A. Primavera<sup>1</sup>, M.C. Re<sup>1</sup>, I. Bon<sup>1</sup>

<sup>1</sup>Microbiology Section, Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, University of Bologna, Bologna, Italy, <sup>2</sup>Pharmacy and Biotechnology Department, University of Bologna, Bologna, Italy

## HIV virology

### P 98 Undetectable versus low level HIV viremia on patients taking antiretroviral therapy

M. Nofri<sup>1</sup>, C. Papani<sup>1</sup>, G.V. De Socio<sup>2</sup>, B. Belfiori<sup>2</sup>, S. Bastianelli<sup>1</sup>, D. Francisci<sup>1</sup>

<sup>1</sup>Clinica di Malattie Infettive, Università degli Studi di Perugia, <sup>2</sup>Azienda Ospedaliera S. Maria della Misericordia, Perugia

### P 99 Quantification of total HIV-1 DNA in the peripheral blood of naïve and treated patients

L. Di Sante<sup>1</sup>, A. Costantini<sup>2</sup>, R. Longo<sup>1</sup>, A. Corsi<sup>2</sup>, P. Sestilli<sup>2</sup>, S. Caucci<sup>1</sup>, L. Brescini<sup>1</sup>, S. Menzo<sup>1</sup>, P. Bagnarelli<sup>1</sup>

<sup>1</sup>Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy, <sup>2</sup>Department of Molecular and Clinical Sciences, Polytechnic University of Marche, Ancona, Italy, <sup>3</sup>Virology Unit, Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy

### P 100 HIV2-Vpx modulation of MDDCs-CD4+ T cells HIV-1 Trans Infection

G.M. Butta<sup>1,2</sup>, R. De Francesco<sup>1,2</sup>, L. Manganaro<sup>1,3</sup>

<sup>1</sup>INGM-Istituto Nazionale di Genetica Molecolare, Milan, Italy, <sup>2</sup>Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy, <sup>3</sup>Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Infectious Diseases Unit, Department of Internal Medicine, Milan, Italy

### P 101 New potential anti-HIV agents: the antimicrobial peptide Temporin L

A. Chianese<sup>1</sup>, C. Zannella<sup>1</sup>, G. Greco<sup>1</sup>, V. Valastro<sup>1</sup>, D. D’orio<sup>1</sup>, F. Pinto<sup>1</sup>, S.A. Maiella<sup>1</sup>, M.V. Morone<sup>1</sup>, G. Franci<sup>2</sup>, P. Grieco<sup>3</sup>, M. Galdiero<sup>1</sup>

<sup>1</sup>Department of Experimental Medicine, Section of Virology and Microbiology University of Campania “Luigi Vanvitelli”, Naples, Italy, <sup>2</sup>Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Baronissi (SA), Italy, <sup>3</sup>Department of Pharmacy, University of Napoli Federico II, Naples, Italy

### P 102 Fast and sensitive qPCR assay for the concomitant quantification of bacterial 16S rDNA and HIV-1 DNA: preliminary data from blood samples of HIV-1 infected patients

C. Orlandi<sup>1</sup>, E. Merlini<sup>2</sup>, ES. Cannizzo<sup>2</sup>, G. Marchetti<sup>2</sup>, M. Magnani<sup>1</sup>, A. Casabianca<sup>1</sup>

<sup>1</sup>Department of Biomolecular Sciences, University of Urbino “Carlo Bo”, <sup>2</sup>Clinic of Infectious Diseases ASST Santi Paolo e Carlo, Department of Health Sciences-University of Milan



## POSTER EXHIBITION

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

**P 103 HIV-DNA quantification in PBMC: evaluation of two new real-time PCR commercial test**

T. Alice, M.G. Milia, E. Burdino, G. Gregori, G. Morleo, B. Simoncelli, P. Russo, E. Scuccimarra, V. Ghisetti  
Laboratory of Microbiology and Virology, ASL Città di Torino, Italy

**P 104 Influence of HIV-1 V2 domain characteristics on immunological recovery under ART**

F. Balena, D.F. Bavaro, A. Ricciardi, E. Pallara, A. Volpe, A. Lagioia, G. Angarano, L. Monno, A. Saracino  
Clinica di Malattie Infettive, Bari

**P 105 Susceptibility to HIV-1 integrase inhibitors in HIV-1 sub-subtype A6 isolates**

A. Giannini<sup>1</sup>, F. Giammarino<sup>1</sup>, A. Antonova<sup>2</sup>, E. Ozhmegova<sup>2</sup>, R. Kaiser<sup>3</sup>, F. Dragoni<sup>1</sup>, A. Boccutto<sup>1</sup>, I. Vicenti<sup>1</sup>, A. Sönnnerborg<sup>4,5</sup>, M. Bobkova<sup>2</sup>, M. Zazzi<sup>1</sup>, F. Saladini<sup>1</sup>  
<sup>1</sup>Department of Medical Biotechnologies, University of Siena, Italy, <sup>2</sup>Gamaleya National Research Center of Epidemiology and Microbiology, Moscow, Russian Federation, <sup>3</sup>Institute of Virology, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Germany, <sup>4</sup>Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Sweden, <sup>5</sup>Department of Medicine Huddinge, Division of Infectious Diseases, Karolinska Institutet, Sweden

**P 106 Residual phenotypic susceptibility to second generation NNRTI in multidrug resistant HIV-1 from the PRESTIGIO Registry**

F. Saladini<sup>1</sup>, F. Giammarino<sup>1</sup>, F. Maggiolo<sup>2</sup>, M. Ferrara<sup>3</sup>, G. Cenderello<sup>4</sup>, B.M. Celesia<sup>5</sup>, F. Martellotta<sup>6</sup>, V. Spagnuolo<sup>7</sup>, G.M. Corbelli<sup>8</sup>, N. Gianotti<sup>9</sup>, M.M. Santoro<sup>10</sup>, S. Rusconi<sup>11</sup>, M. Zazzi<sup>1</sup>, A. Castagna<sup>7,9</sup>, for the PRESTIGIO STUDY GROUP  
<sup>1</sup>University of Siena, Siena, Italy, <sup>2</sup>Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy, <sup>3</sup>Amedeo di Savoia Hospital, Torino, Italy, <sup>4</sup>Galliera Hospital, Genoa, Italy, <sup>5</sup>Garibaldi Hospital, Catania, Italy, <sup>6</sup>Centro di riferimento oncologico, Aviano, Italy, <sup>7</sup>San Raffaele Vita-Salute University, Milan, Italy, <sup>8</sup>Plus, Bologna, Italy, <sup>9</sup>San Raffaele Scientific Institute, Milan, Italy, <sup>10</sup>University of Rome Tor Vergata, Rome, Italy, <sup>11</sup>DIBIC Luigi Sacco, University of Milan, Italy

**P 107 In vitro activity of Islatravir against HIV-1 mutants harboring multiple NRTI resistance mutations**

F. Giammarino<sup>1</sup>, F. Saladini<sup>1</sup>, M. Tavia<sup>2</sup>, A.M. Cattelan<sup>3</sup>, B. Menzaghi<sup>4</sup>, E. Garlassi<sup>5</sup>, F. Ortu<sup>6</sup>, G.M. Corbelli<sup>7</sup>, A. Poli<sup>8</sup>, M.M. Santoro<sup>9</sup>, M. Zazzi<sup>1</sup>, A. Castagna<sup>8,10</sup>, for the PRESTIGIO STUDY GROUP  
<sup>1</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, <sup>2</sup>Infectious Diseases Unit, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy, <sup>3</sup>Unit of Infectious Diseases, Department of Internal Medicine, Azienda Ospedaliero-Universitaria di Padova, Padova, Italy, <sup>4</sup>Busto Arsizio Hospital, ASST Valle Olona, Infectious Diseases, Busto Arsizio, Italy, <sup>5</sup>Infectious Disease Unit, Arcispedale Santa Maria Nuova, Azienda USL-IRCCS, Reggio Emilia, Italy, <sup>6</sup>Immunology Department, AOU Cagliari, Italy, <sup>7</sup>PLUS, Bologna, Italy, <sup>8</sup>Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>9</sup>Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, <sup>10</sup>San Raffaele Vita-Salute University, Milan, Italy

**P 108 Does HLA-C binding stability affect HIV-1 infection?**

S. Mutascio, A. Bonomini, C. Stefani, D. Gibellini, M.G. Romanelli, D. Zipeto  
University of Verona

**P 109 Genotypic Resistance test in rapid ART era**

M. Rizzo<sup>1</sup>, L. Montemurro<sup>1</sup>, M.R. Lipsi<sup>2</sup>, I.R. Bottalico<sup>1</sup>, J.F. Fiore<sup>1</sup>, S. Ferrara<sup>1</sup>, S. Lo Caputo<sup>1</sup>, T.A. Santantonio<sup>1</sup>  
<sup>1</sup>Clinica Malattie Infettive, Università degli Studi di Foggia - Foggia, Italy, <sup>2</sup>Il Laboratorio analisi sezione Biologia Molecolare AOU Ospedali Riuniti di Foggia

## HIV-associated tuberculosis

**P 110 Tuberculous and non tuberculous mycobacterial extra-pulmonary infections in HIV**

F. Bulla<sup>1</sup>, P. Scerbo<sup>1</sup>, S. Nisticò<sup>2</sup>, L. Cosco<sup>1</sup>  
<sup>1</sup>S.O.C. Malattie Infettive A.O. "Pugliese-Ciaccio" Catanzaro, <sup>2</sup>S.O.C. Microbiologia A.O. "Pugliese-Ciaccio" Catanzaro

## Issues on antiretroviral therapy

**P 111 Short-Cycle Therapy comprising a lamivudine and dolutegravir regimen of 5 days on and 2 off in a small cohort of suppressed HIV-infected patients**

M. Lanzafame<sup>1</sup>, D. Luise<sup>2</sup>, S. Rizzardo<sup>2</sup>, L. Lambertenghi<sup>2</sup>, G. Be<sup>2</sup>, L. Motta<sup>2</sup>, D. Piacentini<sup>2</sup>, M. Cordioli<sup>2</sup>, E. Lattuada<sup>2</sup>  
<sup>1</sup>Unità Semplice Organizzativa "Diagnosi e Terapia dell'infezione da HIV", Ospedale Policlinico "G.B. Rossi", Verona, <sup>2</sup>Unità Complessa di Malattie Infettive, Ospedale Policlinico "G.B. Rossi", Verona

**P 112 Are 2-drug regimens with lamivudine plus boosted-PI still a feasible option in the era of integrase inhibitors? A multicenter analysis**

A. Ciccullo<sup>1</sup>, G. Baldin<sup>1,2</sup>, V. Borghi<sup>3</sup>, M. Colafigli<sup>4</sup>, G. Sterrantino<sup>5</sup>, A. Latini<sup>4</sup>, C. Mussini<sup>3</sup>, S. Di Giambenedetto<sup>1,6</sup>  
<sup>1</sup>Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy, <sup>2</sup>Mater Olbia Hospital, Olbia, Italy, <sup>3</sup>Azienda Ospedaliero Universitaria di Modena, Clinica Malattie Infettive e Tropicali, Modena, Italy, <sup>4</sup>Infectious Dermatology and Allergology Unit, S. Galliciano Institute IRCCS, Rome, Italy, <sup>5</sup>Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy, <sup>6</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy



## POSTER EXHIBITION

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 **DIGITAL EDITION**

- P 113 HIV-DNA decay in ART-naïve patients starting a DTG-based dual vs triple therapy**  
*F. Lombardi<sup>1</sup>, R. Scutari<sup>2</sup>, S. Belmonti<sup>1</sup>, C. Stingone<sup>3</sup>, A. Ciccullo<sup>1</sup>, V. Svicher<sup>3</sup>, A. Borghetti<sup>4</sup>, L. Sarmati<sup>3</sup>, G. Baldin<sup>1</sup>, C. Alteri<sup>5</sup>, M. Fabbiani<sup>6</sup>, C. F. Perno<sup>5</sup>, M. Andreoni<sup>3</sup>, S. Di Giambenedetto<sup>1,4</sup>, F. Ceccherini-Silberstein<sup>3</sup>*  
<sup>1</sup>Università Cattolica del Sacro Cuore, Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive, Rome, Italy, <sup>2</sup>Department of Experimental Medicine, Tor Vergata University, Rome, Italy, <sup>3</sup>Department of System Medicine, Clinical Infectious Diseases, Tor Vergata University, Rome, Italy, <sup>4</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, UOC malattie infettive, <sup>5</sup>Department of Oncology and Hemato-oncology, University of Milan, Italy, <sup>6</sup>UOC Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Senese
- P 114 Side effects detected in HIV-positive patients depending on the ART regimen**  
*Z. Akhmedjanova<sup>1</sup>, D. Karimov<sup>2</sup>, D. Urunova<sup>3</sup>, M. Mirhoshimov<sup>4</sup>, D. Akhmedjanov<sup>5</sup>*  
<sup>1</sup>Institute of Immunology and Genomics of the Academy of Sciences of the Republic of Uzbekistan, Tashkent, <sup>2</sup>Tashkent Medical Academy, Tashkent, <sup>3</sup>Tashkent Institute for Advanced Training of Physicians, Tashkent, <sup>4</sup>Tashkent Pediatric Medical Institute, Tashkent, <sup>5</sup>The University of Toronto, Toronto
- P 115 Safety and tolerability of tenofovir alafenamide (TAF) on bone mineralization and renal function in a cohort of young adults with HIV infection**  
*A. Manzo<sup>1</sup>, S. Lazzarin<sup>1</sup>, K. Maruca<sup>2</sup>, L. Legramandi<sup>3</sup>, E. Longoni<sup>1</sup>, P. Erba<sup>1</sup>, F.W. Basile<sup>1</sup>, G.V. Zuccotti<sup>4</sup>, S. Mora<sup>2</sup>, V. Giacomet<sup>1</sup>*  
<sup>1</sup>University of Milan, Italy, Paediatric Infectious Disease Unit, ASST-FBF-SACCO, Milan, Italy, <sup>2</sup>IRCCS San Raffaele Scientific Institute, Laboratory of Paediatric Endocrinology, Milan, Italy, <sup>3</sup>Unit of Statistics – Laboratory of Methodology for Clinical Research, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, <sup>4</sup>University of Milan, Italy, Children Hospital V. Buzzi, ASST-FBF-SACCO, Milan, Italy
- P 116 A rare case of acute tubular necrosis tenofovir alafenamide-related**  
*M. Pontolillo, L. Caiazzo, L. Piscitani, A. Auricchio, C. Ucciferri, F. Vignale, K. Falasca, J. Vecchiet*  
Clinic of Infectious Diseases, "G. d'Annunzio" University Chieti-Pescara, Chieti, Italy, Nephrology Department, "G. d'Annunzio" University Chieti-Pescara, Chieti, Italy, Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy
- P 117 New cases of diabetes dolutegravir-associated in HIV patients: a case series**  
*V. Cogliandro, G. Lapadula, N. Squillace, A. Soria, P. Vitello, M. Rossi, E. Colella, P. Columpsi, G.M. Migliorino*  
ASST Monza, Ospedale San Gerardo, Unità Operativa di Malattie Infettive, Monza
- P 118 Reduced Bone catabolism and inflammation in patients switching to TAF-containing cART**  
*E.S. Cannizzo<sup>1</sup>, A. Cozzi-Leprì<sup>2</sup>, F. Ceccherini S.<sup>3</sup>, R. Scutari<sup>3</sup>, C. Alteri<sup>4</sup>, A. Tavelli<sup>5</sup>, D. Bernacchia<sup>6</sup>, E. Merlini<sup>7</sup>, A. Castagna<sup>7</sup>, A. Antinori<sup>8</sup>, A. d'Arminio Monforte<sup>1</sup>, G. Marchetti<sup>1</sup> on behalf of Icona and TAF-Icona Study Groups*  
<sup>1</sup>Clinic of Infectious Diseases, Dept Health Sciences, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy, <sup>2</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME) Institute for Global Health UCL, London, UK, <sup>3</sup>Dept of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>4</sup>Dept of Oncology and Hemato-Oncology, University of Milan, Milan, Italy, <sup>5</sup>Icona Foundation, Milan, Italy, <sup>6</sup>Infectious Diseases Unit, ASST FBF-Sacco, DIBIC "L. Sacco", University of Milan, Milan, Italy, <sup>7</sup>Division of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, <sup>8</sup>HIV/AIDS Clinical Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy
- P 119 Viral outcome on tailored treatment strategy saving cost saving antiretroviral (ARV)**  
*S.T. Kiro<sup>1</sup>, P. Nizzoli<sup>2</sup>, M. Pittorru<sup>3</sup>, L. Rabatti<sup>3</sup>, M.G. Colao<sup>4</sup>, D. Bartolozzi<sup>2</sup>*  
<sup>1</sup>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, <sup>2</sup>Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy, <sup>3</sup>Local health pharmaceutical department of Central Tuscany, <sup>4</sup>Microbiology and Virology laboratory, Careggi University Hospital, Florence, Italy
- P 120 The need for reducing both ARV and medicine-taking burdens among Italian PLHIV - Findings from the Positive Perspectives 2 Study**  
*G.M. Corbelli<sup>1</sup>, S. Marcotullio<sup>2</sup>, P. Rizzini<sup>2</sup>, P. de los Rios<sup>3</sup>, A. Appiah<sup>4</sup>*  
<sup>1</sup>Plus Onlus, Bologna, Italy, <sup>2</sup>ViV Healthcare Verona VR, Italy, <sup>3</sup>ViV Healthcare Laval, Quebec, Canada, <sup>4</sup>ViV Healthcare Brentford, UK
- P 121 Switch to darunavir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-infected patients not receiving protease inhibitors based regimens**  
*M. Ranzenigo<sup>1,2</sup>, N. Gianotti<sup>2</sup>, L. Galli<sup>2</sup>, A. Poli<sup>2</sup>, A. Mastrangelo<sup>1,2</sup>, C. Muccini<sup>1,2</sup>, E. Bruzzesi<sup>1,2</sup>, M. Chiurlo<sup>1,2</sup>, S. Nozza<sup>2</sup>, S. Bossolasco<sup>2</sup>, V. Spagnuolo<sup>2</sup>, D. Mancusi<sup>3</sup>, R. Termini<sup>3</sup>, E. Carini<sup>2</sup>, A. Lazzarin<sup>2</sup>, A. Castagna<sup>1,2</sup>*  
<sup>1</sup>Vita-Salute San Raffaele University, Milan, Italy, <sup>2</sup>Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>3</sup>Medical Affairs Department, Infectious Disease & PAH, Janssen-Cilag SpA, Cologno Monzese
- P 122 Nevirapine-based therapy in the twenty-first century: still an effective and safe long-term choice**  
*S. Casolari<sup>1</sup>, G. Fabbri<sup>1</sup>, P. Tatarelli<sup>1</sup>, M. Fantini<sup>2</sup>, E. Fabbri<sup>2</sup>, V. Sambri<sup>3</sup>, P. Bassi<sup>1</sup>*  
<sup>1</sup>Infectious Diseases Unit, Santa Maria delle Croci Hospital, Ravenna, AUSL Romagna, Italy, <sup>2</sup>Clinical and organizational research unit, AUSL Romagna, Italy, <sup>3</sup>Unit of Microbiology, The Great Romagna Hub Laboratory, Pievesestino, Forlì-Cesena, Italy
- P 123 Switch to dual therapy (3tc+dtg or rpv+dtg) in a cohort of people living with HIV: experience from real life**  
*F. Paciosi, E. Schiaroli, G.V. De Socio, S. Bastianelli, S. Pierucci, C. Busti, D. Francisci*  
Unit of Infectious Diseases, Department of Medicine, University of Perugia, Perugia, Italy
- P 124 Changes in lipid profile and subclinical atherosclerosis after switching to tenofovir alafenamide (TAF) containing antiretroviral regimens in people living with HIV**  
*M. Spaziante<sup>1</sup>, E. Biliotti<sup>1</sup>, G. Conci<sup>2</sup>, G. Iaiani<sup>1</sup>, M. Santori<sup>1</sup>, F. Tamburini<sup>1</sup>, F. Ruffi<sup>1</sup>, R. Esvan<sup>1</sup>, C. Letizia<sup>2</sup>, P. Rucci<sup>3</sup>, G. Taliani<sup>1</sup>*  
<sup>1</sup>Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy, <sup>2</sup>Unit of Secondary Hypertension, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, <sup>3</sup>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy



## POSTER EXHIBITION

- P 125 An early proactive switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/T/TAF) is effective in maintaining virologic control, reducing low level viral replication and continuing immunological recovery in patients with a primary HIV-1 infection (PHI). An interim analysis of a phase IV clinical trial (ESTER study)**  
M. Camici<sup>1</sup>, C. Pinnetti<sup>1</sup>, R. Gagliardini<sup>1</sup>, A. Amendola<sup>2</sup>, I. Abbate<sup>2</sup>, G. Rozera<sup>2</sup>, G. Passavanti<sup>1</sup>, A. Brita<sup>1</sup>, S. Ottou<sup>1</sup>, A. Vergori<sup>1</sup>, M.M. Plazzi<sup>1</sup>, R. Bellagamba<sup>1</sup>, S. Cicalini<sup>1</sup>, M.R. Capobianchi<sup>2</sup>, A. Antinori<sup>1</sup>, A. Mondì<sup>1</sup>  
<sup>1</sup>HIV/AIDS Clinical Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>2</sup>Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy
- P 126 Efficacy of dolutegravir versus darunavir in first-line regimens according to resistance mutations and viral subtype**  
A. Borghetti<sup>3</sup>, C. Picarelli<sup>2</sup>, A. Ciccullo<sup>2</sup>, V. Borghi<sup>3</sup>, P. Laghetti<sup>4</sup>, S. Rusconi<sup>5,6</sup>, L. Monno<sup>7</sup>, W. Gennari<sup>3</sup>, F. Maggiolo<sup>8</sup>, B. Bruzzone<sup>9</sup>, I. Vicenti<sup>10</sup>, A. Callegaro<sup>11</sup>, A. Di Biagio<sup>12</sup>, M. Zazzi<sup>10</sup>, S. Di Giambenedetto<sup>1,2</sup>  
<sup>1</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, UOC malattie infettive, <sup>2</sup>Università Cattolica del Sacro Cuore, Roma Italia, Istituto di Clinica Malattie Infettive, <sup>3</sup>Clinica delle Malattie Infettive e Tropicali dell'Università di Modena e Reggio Emilia, Modena, Italy, <sup>4</sup>Microbiologia e Virologia, Università degli Studi di Bari, Bari, Italy, <sup>5</sup>III Infectious Disease Unit, ASST-FBF-Sacco, Milan, Italy, <sup>6</sup>Department of Biomedical and Clinical Sciences DIBIC L. Sacco, University of Milan, Milan, Italy, <sup>7</sup>Clinica Malattie Infettive, Università degli Studi di Bari, Bari, Italy, <sup>8</sup>Infectious Diseases Unit, Ospedali Riuniti, Bergamo, Italy, <sup>9</sup>Hygiene Unit, Policlinico San Martino Hospital, Genoa, Italy, <sup>10</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, <sup>11</sup>Microbiology and Virology Unit, Bergamo Hospital, Bergamo, Italy, <sup>12</sup>Infectious Diseases Clinic, Policlinico San Martino Hospital, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
- P 127 Switch to dolutegravir-based dual therapy: outcomes in ART-experienced patients**  
G. Tagliaferri, G. Mulè, L. Gazzola, T. Bini, G. Marchetti, A. d'Arminio Monforte  
University of Milan, San Paolo Hospital, Milan
- P 128 Evaluation of efficacy and durability of raltegravir once-daily: real-life data from an Italian Center**  
A. Emiliozzi<sup>1,2</sup>, A. Dusina<sup>1</sup>, D. Farinacci<sup>1</sup>, A. D'Angelillo<sup>1</sup>, A. Ciccullo<sup>1</sup>, D. Moschese<sup>1</sup>, C. Picarelli<sup>1</sup>, G. Baldin<sup>1</sup>, S. Lamonica<sup>1</sup>, F. Lombardi<sup>1</sup>, A. Borghetti<sup>3</sup>, S. Di Giambenedetto<sup>1,3</sup>  
<sup>1</sup>Università Cattolica del Sacro Cuore, Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive, Roma, Italy, <sup>2</sup>UOC Malattie Infettive e Tropicali, Dipartimento di Biotechnologie Mediche, Università di Siena, Siena, Italy, <sup>3</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, UOC Malattie Infettive
- P 129 Impact on CD4 count and CD4/CD8 ratio of 3 different integrase inhibitor-based regimens in naïve and experienced patients**  
V. Moscatt<sup>1</sup>, M. Ceccarelli<sup>1</sup>, R. Bruno<sup>1</sup>, A. Pampaloni<sup>1</sup>, A. Marino<sup>1</sup>, M.E. Locatelli<sup>1</sup>, F. Cosentino<sup>1</sup>, V. Boscia<sup>1</sup>, G. Bruno<sup>1</sup>, M. Gussio<sup>1</sup>, B. Busà<sup>2</sup>, G. Nunnari<sup>3</sup>, B. Cacopardo<sup>1</sup>, B.M. Celesia<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases University of Catania ARNAS Garibaldi, Catania, <sup>2</sup>Unit of Hospital Pharmacy ARNAS Garibaldi, Catania, <sup>3</sup>Unit of Infectious Diseases University of Messina Policlinico Universitario G. Martino, Messina
- P 130 Alteration of serum lipid profiles in HIV/HCV co-infected patients under treatment with HAART/DAAs combined therapy**  
A.M. Spera<sup>1</sup>, V. Fortunato<sup>2</sup>, S. Madonna<sup>2</sup>, A. d'Agostino<sup>4</sup>, R. Santoro<sup>2</sup>, G. Galasso<sup>3</sup>, A. Masullo<sup>2</sup>, P. Pagliano<sup>1</sup>  
<sup>1</sup>Infectious Disease Department - University Hospital OO RR San Giovanni di Dio e Ruggi d'Aragona (SA), <sup>2</sup>Infectious Disease Department - OO RR San Giovanni di Dio e Ruggi d'Aragona (SA), <sup>3</sup>Cardiology Department - University Hospital OO RR San Giovanni di Dio e Ruggi d'Aragona (SA), <sup>4</sup>Medical Student - University Hospital OO RR San Giovanni di Dio e Ruggi d'Aragona (SA)
- P 131 Plasma viral load decay in first-time INSTI-users. A comparison between raltegravir, elvitegravir/cobicistat and dolutegravir**  
M. Ceccarelli<sup>1</sup>, V. Moscatt<sup>1</sup>, E. Venanzi Rullo<sup>2,3</sup>, G. Nunnari<sup>2</sup>, F. Cosentino<sup>1</sup>, A. Marino<sup>1</sup>, A. Pampaloni<sup>1</sup>, D. Scuderi<sup>1</sup>, R. Bruno<sup>1</sup>, B. Cacopardo<sup>1</sup>, B.M. Celesia<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases University of Catania ARNAS Garibaldi, Catania, <sup>2</sup>Unit of Infectious Diseases, University of Messina, Policlinico Universitario "G. Martino", Messina, <sup>3</sup>University of Pennsylvania, Philadelphia, US
- P 132 Metabolic profile changes after switching from a PI- to an INI-based regimen in the maintenance treatment of HIV infection**  
Z. Pasquini<sup>1,2</sup>, A. Polenta<sup>1,2</sup>, M. Malandrino<sup>1</sup>, B. Canovari<sup>2</sup>, E. Orsetti<sup>3</sup>, F. Mecozzi<sup>3</sup>, A. Mataloni<sup>4</sup>, G. Amadio<sup>3</sup>, O. Cirioni<sup>1</sup>, A. Costantini<sup>4</sup>, M. Tavio<sup>4</sup>, A. Giacometti<sup>1</sup>, F. Barchiesi<sup>1,2</sup>  
<sup>1</sup>Infectious Diseases Clinic, Department of Biological Sciences and Public Health, Marche Polytechnic University, Ancona, Italy, <sup>2</sup>Infectious Diseases Unit, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy, <sup>3</sup>Unit of Infective diseases, Hospital of Fermo, Italy, <sup>4</sup>Clinical Immunology Unit, Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy, <sup>5</sup>Division of Infectious Diseases, Azienda Ospedaliera Universitaria Ospedali Riuniti, Ancona, Italy
- P 133 Evaluation of lipid profile in HIV naïve patients, treated by TAF-based regimens**  
S. Martini<sup>1</sup>, P. Maggi<sup>1</sup>, C. Gervasoni<sup>2</sup>, L. Onorato<sup>1</sup>, S. Ferrara<sup>3</sup>, L. Alessio<sup>4</sup>, C. Bellacosa<sup>5</sup>, V. Esposito<sup>6</sup>, G. Di Filippo<sup>7</sup>, A. Masiello<sup>8</sup>, A. Maddaloni<sup>9</sup>, R. Santoro<sup>10</sup>, G. D'Alessio<sup>11</sup>, S.R. Bruno<sup>3</sup>, V. Rizzo<sup>6</sup>, S. Parente<sup>7</sup>, A. Iodice<sup>4</sup>, N. Coppola<sup>1,4</sup>  
<sup>1</sup>Infectious Disease, University of Campania, Luigi Vanvitelli, <sup>2</sup>ASST FBF Sacco di Milano, <sup>3</sup>University of studies of Foggia, <sup>4</sup>AORN Sant'Anna e San Sebastiano di Caserta, <sup>5</sup>University of studies of Bari, <sup>6</sup>IV Division AORN dei Colli, <sup>7</sup>University Federico II of Naples, <sup>8</sup>AO San Giuseppe Moscati of Avellino, <sup>9</sup>VII Divisione AORN dei Colli, <sup>10</sup>AOU San Giovanni di Dio e Ruggi d'Aragona of Salerno, <sup>11</sup>AORN San Pio of Benevento





## Management and treatment of viral hepatitis

### P 134 Younger Age, Male Gender and HCC presence are Associated to anti HCV-DAA failure

U. Visco-Comandini, Italy, R. Lionetti, Italy, C. Taibi, Italy, M. Zaccarelli, Italy, A. Vergori, Italy, M.R. Capobianchi, Italy, A.R. Garbuglia, Italy, G. D'Offizi, Italy

Infectious Disease and Hepatology Division. National Institute for Infectious Diseases Lazzaro Spallanzani, Rome Italy

### P 135 Reactivation of occult HBV infection in HIV patients treated with direct-acting antivirals for chronic hepatitis C: a retrospective study

V. Guardigni<sup>1</sup>, B. Granozzi<sup>1</sup>, L. Badia<sup>1</sup>, S. Galli<sup>2</sup>, G. Piazza<sup>3</sup>, I. Bon<sup>2</sup>, P. Viale<sup>1</sup>, M.C. Re<sup>2</sup>, G. Verucchi<sup>1</sup>

<sup>1</sup>Department of Medical and Surgical Sciences, University of Bologna, Italy, <sup>2</sup>Department of Specialistic, Diagnostic and Experimental Medicine, University of Bologna, Italy, <sup>3</sup>Clinical Pharmacy, S. Orsola-Malpighi Polyclinic, Bologna, Italy

### P 136 DAA failure in HCV genotype not 1: virological features and efficacy of re-treatment

L. Occhiello<sup>1</sup>, M. Pisaturo<sup>1</sup>, M. Starace<sup>1</sup>, C. Minichini<sup>1</sup>, A. Di Fraia<sup>1</sup>, S. De Pascalis<sup>2</sup>, M. Macera<sup>2</sup>, V. Messina<sup>3</sup>, V. Sangiovanni<sup>4</sup>, E. Claar<sup>5</sup>, D. Precone<sup>6</sup>, G. Stornaiuolo<sup>2</sup>, M. Stanzione<sup>2</sup>, I. Gentile<sup>8</sup>, G. Brancaccio<sup>2</sup>, S. Martini<sup>9</sup>, A. Masiello<sup>10</sup>, A. Salomone Megna<sup>11</sup>, C. Coppola<sup>12</sup>, A. Federico<sup>13</sup>, E. Sagnelli<sup>1</sup>, M. Persico<sup>14</sup>, A. Galeota Lanza<sup>15</sup>, A. Marrone<sup>16</sup>, G.B. Gaeta<sup>2</sup>, N. Coppola<sup>1,3</sup>

<sup>1</sup>Laboratory for the identification of prognostic factors of response to the treatment against infectious diseases, University of Campania "L. Vanvitelli", Napoli, Italy, <sup>2</sup>Infectious Diseases and Viral Hepatitis, Department of Mental and Physical Health and Preventive Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, <sup>3</sup>Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, <sup>4</sup>Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, <sup>5</sup>Internal Medicine Unit, Evangelical Hospital Villa Betania Naples, Italy, <sup>6</sup>Internal Medicine Unit A.O. Sarno, Sarno (SA) Campania L. Vanvitelli, & Infectious and Transplant Medicine, AORN Ospedali dei Colli- Monaldi Hospital, Naples, Italy, <sup>7</sup>Gastroenterology Unit, AOU San Giovanni di Dio Ruggi d'Aragona, Salerno Italy, <sup>8</sup>Infectious Diseases Unit, University Federico II, Naples, Italy, <sup>9</sup>HIV Unit, University of Campania L. Vanvitelli, Naples, Italy, <sup>10</sup>Infectious Diseases Unit, A.O. S.G. Moscati, Avellino Italy, <sup>11</sup>Infectious Diseases Unit, A. O. G. Rummo, Benevento, <sup>12</sup>Hepatology Unit, Gragnano Hospital, Gragnano, <sup>13</sup>Internal Medicine and Hepatology Department of Clinical and Experimental Medicine, University of Campania "L. Vanvitelli", <sup>14</sup>Internal Medicine and Hepatology Unit, PO G. Da Procida-AOU- San Giovanni e Ruggi D'Aragona, University of Salerno, <sup>15</sup>Hepatology Unit, Cardarelli Hospital, Naples, Italy, <sup>16</sup>Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, University of Campania "L. Vanvitelli"

### P 137 Virological features and efficacy of re-treatment in HCV patients: a real experience in Southern Italy

C. Minichini<sup>1</sup>, M. Pisaturo<sup>1</sup>, M. Starace<sup>1</sup>, A. Di Fraia<sup>1</sup>, S. De Pascalis<sup>2</sup>, M. Macera<sup>2</sup>, V. Messina<sup>3</sup>, V. Sangiovanni<sup>4</sup>, E. Claar<sup>5</sup>, D. Precone<sup>6</sup>, G. Stornaiuolo<sup>2</sup>, M. Stanzione<sup>2</sup>, I. Gentile<sup>8</sup>, G. Brancaccio<sup>2</sup>, S. Martini<sup>9</sup>, A. Masiello<sup>10</sup>, A. Salomone Megna<sup>11</sup>, C. Coppola<sup>12</sup>, A. Federico<sup>13</sup>, E. Sagnelli<sup>1</sup>, M. Persico<sup>14</sup>, A. Galeota Lanza<sup>15</sup>, A. Marrone<sup>16</sup>, G.B. Gaeta<sup>2</sup>, N. Coppola<sup>1,3</sup>

<sup>1</sup>Laboratory for the identification of prognostic factors of response to the treatment against infectious diseases, University of Campania "L. Vanvitelli", Napoli, Italy, <sup>2</sup>Infectious Diseases and Viral Hepatitis, Department of Mental and Physical Health and Preventive Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, <sup>3</sup>Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, <sup>4</sup>Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, <sup>5</sup>Internal Medicine Unit, Evangelical Hospital Villa Betania Naples, Italy, <sup>6</sup>Internal Medicine Unit A.O. Sarno, Sarno (SA) Campania L. Vanvitelli, & Infectious and Transplant Medicine, AORN Ospedali dei Colli- Monaldi Hospital, Naples, Italy, <sup>7</sup>Gastroenterology Unit, AOU San Giovanni di Dio Ruggi d'Aragona, Salerno Italy, <sup>8</sup>Infectious Diseases Unit, University Federico II, Naples, Italy, <sup>9</sup>HIV Unit, University of Campania L. Vanvitelli, Naples, Italy, <sup>10</sup>Infectious Diseases Unit, A.O. S.G. Moscati, Avellino Italy, <sup>11</sup>Infectious Diseases Unit, A. O. G. Rummo, Benevento, <sup>12</sup>Hepatology Unit, Gragnano Hospital, Gragnano, <sup>13</sup>Internal Medicine and Hepatology Department of Clinical and Experimental Medicine, University of Campania "L. Vanvitelli", <sup>14</sup>Internal Medicine and Hepatology Unit, PO G. Da Procida-AOU- San Giovanni e Ruggi D'Aragona, University of Salerno, <sup>15</sup>Hepatology Unit, Cardarelli Hospital, Naples, Italy, <sup>16</sup>Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, University of Campania "L. Vanvitelli"

### P 138 Overall survival at 3, 5 and 10 years of HIV-positive patients who underwent liver transplantation at the University Hospital of Ancona

V. Iencinella<sup>1</sup>, S. Castelletti<sup>1</sup>, R. Del Gobbo<sup>1</sup>, A. Marigliano<sup>1</sup>, A. Mataloni<sup>1</sup>, A. Riva<sup>1</sup>, S. Staffolani<sup>1</sup>, L. Brescini<sup>2</sup>, A. Fiorentini<sup>2</sup>, D. Nicolini<sup>3</sup>, M. Vivarelli<sup>3</sup>, P. Barbadoro<sup>4</sup>, M. Tavio<sup>5</sup>

<sup>1</sup>Malattie Infettive Emergenti e degli Immunodepressi - Ospedali Riuniti di Ancona, <sup>2</sup>Clinica di Malattie Infettive tropicali, parassitologia, epatiti croniche - Ospedali Riuniti di Ancona, <sup>3</sup>Clinica di chirurgia epatobiliare, pancreatica e dei trapianti - Ospedali Riuniti di Ancona, <sup>4</sup>SOD Igiene Ospedaliera - Ospedali Riuniti di Ancona, <sup>5</sup>Malattie Infettive Emergenti e degli Immunodepressi - Ospedali Riuniti di Ancona

### P 139 Viro-immunological and histological characterization of a case of HBV-related hepatitis with immune reconstitution inflammatory syndrome after treatment initiation for HBV/HIV-1 co-infection with bicitegravir/emtricitabine/tenofovir alafenamide

M. Iannetta<sup>1</sup>, L. Campogiani<sup>1</sup>, A. Crea<sup>1</sup>, A. Di Lorenzo<sup>1</sup>, E. Teti<sup>1</sup>, V. Malagnino<sup>1</sup>, C. Cerva<sup>1</sup>, G. Palmieri<sup>2</sup>, C. Cimino<sup>2</sup>, V. Svicher<sup>3</sup>, L. Piermatteo<sup>3</sup>, R. Salpini<sup>3</sup>, M.A. Zingaropoli<sup>4</sup>, M.R. Ciardi<sup>4</sup>, C.M. Mastroianni<sup>4</sup>, M. Andreoni<sup>1</sup>, L. Sarmati<sup>1</sup>

<sup>1</sup>Department of System Medicine, Tor Vergata University, Rome, Italy, <sup>2</sup>Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy, <sup>3</sup>Department of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy, <sup>4</sup>Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy

### P 140 Indirect hyperbilirubinemia and jaundice during chronic hepatitis C in an HIV-infected patient treated with glecaprevir/pibrentasvir (GLE/PIB) and antiretroviral therapy (ART). The first reported case in Italy

A. Mastroianni<sup>1</sup>, S. Greco<sup>1</sup>, G. Apuzzo<sup>1</sup>, S. De Santis<sup>1</sup>, V. Vangeli<sup>1</sup>, G. Guadagnino<sup>1</sup>, M.V. Mauro<sup>2</sup>, S. Bonora<sup>3</sup>, A. De Nicolò<sup>4</sup>, A. D'Avolio<sup>4</sup>

<sup>1</sup>UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Cosenza, Cosenza, <sup>2</sup>UOC Microbiologia e Virologia, Azienda Ospedaliera di Cosenza, Cosenza, <sup>3</sup>Clinica delle Malattie Infettive, Università degli Studi di Torino, Torino, <sup>4</sup>Laboratorio di Farmacologia e Farmacogenetica, TDM Unit, Università degli Studi di Torino, Torino

### P 141 Current management of hepatitis B in sclerosis patients treated with disease-modify therapies

P. Pasculli<sup>1</sup>, M.A. Zingaropoli<sup>1</sup>, M. Iannetta<sup>2</sup>, V. Perri<sup>1</sup>, F. Pauri<sup>3</sup>, M. Altieri<sup>3</sup>, A. Conte<sup>4</sup>, C.M. Mastroianni<sup>1</sup>, M.R. Ciardi<sup>1</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, <sup>2</sup>Department of System Medicine, Tor Vergata University of Rome, Rome, Italy, <sup>3</sup>Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy, <sup>4</sup>IRCCS Neuromed, Pozzilli (IS), Italy



## POSTER EXHIBITION

### Management of HIV infection

**P 142 Effect of 12-week physical activity program on sarcopenia measures in people living with HIV**

M. Bonato<sup>1</sup>, F. Turrini<sup>2</sup>, L. Galli<sup>2</sup>, G. Banfi<sup>1,2</sup>, P. Cinque<sup>2</sup>

<sup>1</sup>IRCCS Istituto Ortopedico Galeazzi, Milan Italy, <sup>2</sup>IRCCS, San Raffaele Scientific Institute, Milan, Italy, <sup>3</sup>Vita-Salute San Raffaele University, Milan, Italy

**P 143 Reasons for starting D/C/F/TAF and characteristics of patients enrolled in an Italian non-interventional study: the DIAMANTE (TMC114FD1HTX4011) study**

A. Antinori<sup>1</sup>, A. Vergori<sup>1</sup>, G. Rizzardini<sup>2</sup>, M.V. Cossu<sup>2</sup>, A. Cascio<sup>3</sup>, M. Trizzino<sup>3</sup>, M. Andreoni<sup>4</sup>, V. Malagnino<sup>4</sup>, A. Lazzarin<sup>5</sup>, A. Castagna<sup>5,6</sup>, F. Castelli<sup>7</sup>, E. Focà<sup>8</sup>, A. Uglietti<sup>9</sup>, R. Termini<sup>9</sup>, M. Portaro<sup>9</sup>, D. Mancusi<sup>9</sup>

<sup>1</sup>HIV/AIDS Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy, <sup>2</sup>1st Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milano, Italy, <sup>3</sup>Infectious Diseases Clinic, AOU Policlinico "P.Giaccone", Palermo - Italy, <sup>4</sup>Infectious Diseases Clinic, Fondazione Policlinico Tor Vergata University Hospital, Rome, Italy, <sup>5</sup>IRCCS San Raffaele Scientific Institute, Department of Infectious Diseases, Milan, Italy, <sup>6</sup>Università Vita-Salute San Raffaele, Milan, Italy, <sup>7</sup>University of Brescia and Spedali Civili General Hospital Department of Infectious and Tropical Diseases Brescia Italy, <sup>8</sup>Janssen-Cilag SpA, Medical Affairs Department, Infectious Diseases, Cologno Monzese, Italy

**P 144 HIV-1 DNA quantification: Comparative analysis and validation of two commercial qPCR assays**

E. Omiccioli<sup>1</sup>, E. Carloni<sup>1</sup>, C. Orlandi<sup>2</sup>, I. Bon<sup>3</sup>, A. Bertoldi<sup>3</sup>, B. Canovari<sup>4</sup>, Z. Pasquini<sup>4,5</sup>, F. Barchiesi<sup>4,5</sup>, V. Ceppetelli<sup>1</sup>, S. Cicerano<sup>1</sup>, A. Casabianca<sup>2</sup>, M. Magnani<sup>2</sup>

<sup>1</sup>Diatheva srl, Cartoceto, Fano (PU), <sup>2</sup>Dipartimento di Scienze Biomolecolari, Università di Urbino "Carlo Bo", Urbino (PU), <sup>3</sup>Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (BO), <sup>4</sup>Malattie Infettive, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro (PU), <sup>5</sup>Dipartimento di Scienze Biomediche e Sanità Pubblica, Università Politecnica delle Marche, Clinica Malattie Infettive Ospedali Riuniti di Ancona (AN)

**P 145 Intestinal Alkaline Phosphatase levels in HIV infected patients**

F. D'Andrea<sup>1</sup>, C. Micali<sup>1</sup>, M.G. Coco<sup>1</sup>, L. Marletta<sup>1</sup>, D. Larnè<sup>1</sup>, I.A. Paolucci<sup>2</sup>, M.R. Lo Presti<sup>2</sup>, P. Mondello<sup>2</sup>, P. Scordo<sup>2</sup>, D. Maranto<sup>2</sup>, E. Venanzi Rullo<sup>1</sup>, M. Ceccarelli<sup>3</sup>, G.F. Pellicanò<sup>4</sup>, G. Nunnari<sup>1</sup>

<sup>1</sup>Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Messina, Italia, <sup>2</sup>UOC di Malattie Infettive - AOU G. Martino Policlinico di Messina, <sup>3</sup>Dipartimento di Medicina Clinica e Sperimentale, ARNAS Garibaldi, Catania, <sup>4</sup>Dipartimento di Patologia Umana dell'Adulto e dell'Età Evolutiva "Gaetano Barresi", Università degli Studi di Messina, Italia

**P 146 Diagnostic performance of different screening strategies for the prevention of HPV-related anal cancer**

E.N. Cavallari, L. Santinelli, G.P. Innocenti, G. De Girolamo, M. Ridolfi, C. Pinacchio, L. Celani, G. Ceccarelli, C.M. Mastroianni, G. d'Ettore

Department of Public Health and Infectious Diseases University of Rome "Sapienza", Rome

**P 147 Syphilis in newly HIV-1 diagnosed from 2010 to 2019: a single center report**

I.F. Bottalico, M.L. D'Errico, S. Sica, S. Ferrara, J.R. Fiore, S. Lo Caputo, S. Santantonio

Clinica Malattie Infettive, Università degli Studi di Foggia - Foggia, Italy

### Non infectious comorbidities in HIV

**P 148 3TC+DTG versus FTC/TAF plus an integrase inhibitor: comparing changes in bone mineral density**

A. Ciccullo<sup>1</sup>, G. Baldin<sup>1,2</sup>, V. Borghi<sup>3</sup>, A.P. Lassandro<sup>1</sup>, D. Farinacci<sup>1</sup>, G. Guaraldi<sup>3</sup>, C. Mussini<sup>3</sup>, S. Di Giambenedetto<sup>1,4</sup>

<sup>1</sup>Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy, <sup>2</sup>Mater Olbia Hospital, Olbia, Italy, <sup>3</sup>Azienda Ospedaliero Universitaria di Modena, Clinica Malattie Infettive e Tropicali, Modena, Italy, <sup>4</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

**P 149 HTA analysis of glatiramer and neuroprotection in HIV-related comorbidities**

F. Ferrara<sup>1</sup>, C. Pelliccia<sup>2</sup>

<sup>1</sup>USL Umbria1, Perugia, <sup>2</sup>USL Umbria2, Foligno (PG)

**P 150 Low Vitamin D concentration is associated with NAFLD and metabolic syndrome in HIV-1-infected patients on combination antiretroviral therapy**

L. Calza<sup>1</sup>, V. Colangeli<sup>1</sup>, M. Borderi<sup>1</sup>, D. Testi<sup>1</sup>, A. Amedeo<sup>1</sup>, I. Bon<sup>2</sup>, M.C. Re<sup>2</sup>, P. Viale<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, <sup>2</sup>Unit of Microbiology, Policlinico S.Orsola, Università di Bologna

**P 151 Cardiovascular disease risk markers in a small cohort of HIV-infected patients switched from abacavir/lamivudine/dolutegravir to lamivudine plus dolutegravir**

G. Be<sup>2</sup>, D. Luise<sup>2</sup>, S. Rizzardo<sup>2</sup>, L. Lambertenghi<sup>2</sup>, L. Motta<sup>2</sup>, D. Piacentini<sup>2</sup>, E. Lattuada<sup>2</sup>, D. Gibellini<sup>3</sup>, E. Tacconelli<sup>2</sup>, M. Lanzafame<sup>1</sup>

<sup>1</sup>Unità Semplice Organizzativa "Diagnosi e Terapia dell'infezione da HIV", Ospedale Policlinico "G.B. Rossi", Verona, <sup>2</sup>Unità Complessa di Malattie Infettive, Ospedale Policlinico "G.B. Rossi", Verona, <sup>3</sup>Sezione di Microbiologia, Dipartimento Diagnostica e Sanità Pubblica, Università di Verona



## POSTER EXHIBITION

- P 152 Prevalence and incidence of Hepatic Steatosis in SCOLTA cohort**  
N. Squillace<sup>1</sup>, E. Ricci<sup>2</sup>, G. Orofino<sup>3</sup>, B. Menzaghi<sup>4</sup>, M. Nofri<sup>5</sup>, A. Di Biagio<sup>6</sup>, B.M. Celesia<sup>7</sup>, G. Pellicanò<sup>8</sup>, G. Madeddu<sup>9</sup>, C. Molteni<sup>10</sup>, R. Gulminetti<sup>11</sup>, S. Rusconi<sup>12</sup>, F. Vichi<sup>13</sup>, L. Valsecchi<sup>14</sup>, E. Sarchi<sup>15</sup>, P. Bonfanti<sup>9</sup>  
<sup>1</sup>Infectious Diseases Clinic, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, <sup>2</sup>Fondazione ASIA, Milan, Italy, <sup>3</sup>Unit of Infectious Diseases, "Divisione A", Amedeo di Savoia Hospital, Torino, Italy, <sup>4</sup>Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, Busto Arsizio, Italy, <sup>5</sup>Clinica di Malattie Infettive, Ospedale "Santa Maria della Misericordia" e Università di Perugia, Perugia, Italy, <sup>6</sup>Infectious Diseases Clinic, Dept. of Health Sciences, University of Genoa, San Martino Hospital-IRCCS, Genoa, Italy, <sup>7</sup>Unit of Infectious Diseases University of Catania ARNAS Garibaldi, Catania, Italy, <sup>8</sup>Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", Unit of Infectious Diseases, University of Messina, Messina, Italy, <sup>9</sup>Unit of Infectious and Tropical Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>10</sup>Infectious Disease Unit, Ospedale A. Manzoni, Lecco, Italy, <sup>11</sup>Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo -University of Pavia, Italy, <sup>12</sup>Infectious Diseases Unit, DIBIC "Luigi Sacco", University of Milan, Italy, <sup>13</sup>Infectious Diseases Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy, <sup>14</sup>1st Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy, <sup>15</sup>Infectious Diseases Department, SS Antonio, Biagio, Cesare Arrigo Hospital, Alessandria, Italy
- P 153 Factors associated with immunosenescence during early adulthood in HIV-infected patients after durable efficient cART**  
M. Properzi<sup>1</sup>, S. Paghera<sup>2</sup>, L. Imberti<sup>2</sup>, I. El Hamad<sup>1</sup>, E. Focà<sup>1</sup>, M.C. Pezzoli<sup>1</sup>, I. Izzo<sup>1</sup>, A. Celotti<sup>1</sup>, P. Nasta<sup>1</sup>, B. Fumarola<sup>1</sup>, M. Degli Antoni<sup>1</sup>, A. Chiesa<sup>1</sup>, F. Castelli<sup>1</sup>, E. Quiros-Roldan<sup>1</sup>  
<sup>1</sup>Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Brescia, Italy, <sup>2</sup>Centro di Ricerca Emato-oncologica ALL (CREA), Diagnostic Department, ASST Spedali Civili di Brescia, Italy
- P 154 Metabolic changes in HIV-infected patients who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: a randomized study (Be-OnE Study)**  
M. Chiurlo<sup>2</sup>, N. Gianotti<sup>1</sup>, L. Galli<sup>1</sup>, A. Poli<sup>1</sup>, L. Della Torre<sup>1</sup>, C. Vinci<sup>1</sup>, E. Carini<sup>1</sup>, S. Nozza<sup>1</sup>, V. Spagnuolo<sup>1,2</sup>, C. Muccini<sup>2</sup>, M. Ranzenigo<sup>2</sup>, A. Lazzarin<sup>1</sup>, A. Castagna<sup>1,2</sup>  
<sup>1</sup>IRCCS Ospedale San Raffaele, Milano, <sup>2</sup>Università Vita-Salute San Raffaele, Milano
- P 155 A structured smoking cessation intervention in a single centre in patients living with HIV**  
E. Riguccini<sup>1</sup>, M. Nofri<sup>1</sup>, F. Paciosi<sup>1</sup>, M.B. Pasticci<sup>1</sup>, M. Dell'Omo<sup>2</sup>, E. Angelucci<sup>2</sup>, D. Francisci<sup>1</sup>, G.V. De Socio<sup>1</sup>  
<sup>1</sup>Clinica di Malattie Infettive, Ospedale "Santa Maria della Misericordia" e Università di Perugia, Perugia, Italy, <sup>2</sup>Sezione di Medicina del Lavoro, Malattie Respiratorie e Tossicologia Professionale ed Ambientale, Ospedale "Santa Maria della Misericordia" e Università di Perugia, Perugia, Italy
- P 156 Physical activity levels in HIV+ cohort of Pavia**  
S. Ludovisi<sup>1</sup>, A. Di Filippo<sup>1,2</sup>, E. Asperges<sup>1,2</sup>, R. Maserati<sup>2</sup>, S. Novati<sup>2</sup>, R. Bruno<sup>1,2</sup>, M. Mondelli<sup>1,2</sup>  
<sup>1</sup>Università degli Studi di Pavia, <sup>2</sup>Fondazione IRCCS Policlinico San Matteo
- P 157 Machine learning vs Knowledge based approach in health outcomes' prediction in HIV**  
G. Guaraldi<sup>1</sup>, D. Ferrari<sup>1,2</sup>, J. Milic<sup>1,3</sup>, A. Caselgrandi<sup>1</sup>, A. Malagoli<sup>1</sup>, M. Orsini<sup>4</sup>, F. D'Imprima<sup>1</sup>, M. Mancini<sup>1</sup>, M. Cesari<sup>5</sup>, R. Martoglia<sup>2</sup>, G. Lui<sup>6</sup>, M. Bloch<sup>7</sup>, C. Mussini<sup>1</sup>, P. Missier<sup>8</sup>, F. Mandreoli<sup>2</sup>  
<sup>1</sup>Modena HIV Metabolic Clinic, University of Modena and Reggio Emilia, Italy, <sup>2</sup>Department of Mathematics, University of Modena and Reggio Emilia, Italy, <sup>3</sup>Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy, <sup>4</sup>DataRiver Srl, Italy, <sup>5</sup>Geriatric Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, <sup>6</sup>Faculty of Medicine, The Chinese University of Hong Kong, <sup>7</sup>Holdsworth House Medical Practice, Sydney, NSW, Australia, <sup>8</sup>School of Computing, Newcastle University, Newcastle upon Tyne, UK
- P 158 Use of two drugs regimens (2DR) in a cohort of HIV-infected geriatric patients (GEPO cohort)**  
S. Nozza<sup>1</sup>, S. Calza<sup>2</sup>, G. Guaraldi<sup>3</sup>, S. Renzetti<sup>3</sup>, A. Riva<sup>4</sup>, G. De Socio<sup>5</sup>, S. Piconi<sup>6</sup>, G. Orofino<sup>7</sup>, G. Madeddu<sup>8</sup>, G. Di Perri<sup>9</sup>, A.M. Cattelan<sup>10</sup>, A. Celotti<sup>11</sup>, B.M. Celesia<sup>12</sup>, A. Calcagno<sup>9</sup>, E. Focà<sup>10</sup>  
<sup>1</sup>Department of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy, <sup>2</sup>Unit of Biostatistics and Biomathematics & Unit of Bioinformatics, Department of Molecular and Translational Medicine, Università degli Studi di Brescia - Italy, <sup>3</sup>University of Modena and Reggio Emilia, Department of Mother, Child and Adult Medicine and Surgical Science, Infectious Disease Clinic, Modena, Italy, <sup>4</sup>3rd Division of Infectious Diseases, University of Milano, Ospedale L. Sacco, Milano, Italy, <sup>5</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy, <sup>6</sup>1st Division of Infectious Diseases Unit, University of Milano, Ospedale L. Sacco, Milano, Italy, <sup>7</sup>Unit of Infectious Diseases, "Divisione A", Ospedale Amedeo di Savoia, ASLTO2, Torino, Italy, <sup>8</sup>Infectious and Tropical Diseases Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>9</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, <sup>10</sup>Unit of Infectious Diseases, Department of Internal Medicine, Azienda Ospedaliero-Universitaria di Padova, Padova, Italy, <sup>11</sup>Department of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy, <sup>12</sup>Department of Clinical and Molecular Biomedicine, Division of Infectious Diseases, University of Catania, ARNAS Garibaldi, Catania, Italy
- P 159 Poor concordance between liver stiffness and non-invasive fibrosis scores in HIV-1 monoinfected virologically suppressed patients**  
V. Borgo<sup>1,2</sup>, A. Emiliozzi<sup>2</sup>, M. Colaneri<sup>3</sup>, G. Zanelli<sup>1,2</sup>, M. d'Alessandro<sup>4</sup>, D. Motta<sup>3</sup>, F. Montagnani<sup>1,2</sup>, M.C. Moiola<sup>3</sup>, C. Baiguera<sup>3</sup>, M. Puoti<sup>3</sup>, M. Fabbiani<sup>1</sup>, B. Rossetti<sup>1</sup>  
<sup>1</sup>Infectious Diseases Unit, Siena University Hospital, Siena, Italy, <sup>2</sup>Department of Medical Biotechnologies, University of Siena, Italy, <sup>3</sup>Infectious Diseases Unit, Niguarda Hospital, Milan, <sup>4</sup>Respiratory Diseases and Lung Transplant Unit, Department of Medical and Surgical Sciences and Neurosciences, Siena University Hospital
- P 160 Obesity and overweight among people living with HIV in the province of Pavia: a cross-sectional study**  
A. Di Filippo<sup>1,2</sup>, S. Ludovisi<sup>1</sup>, E. Asperges<sup>1,2</sup>, S. Novati<sup>2</sup>, R. Maserati<sup>2</sup>, R. Bruno<sup>1,2</sup>, U.M. Mondelli<sup>1,2</sup>  
<sup>1</sup>University of Pavia, Pavia, Italy, <sup>2</sup>Fondazione IRCCS Policlinico "San Matteo", Pavia, Italy
- P 161 Evaluation of resting energy expenditure and body mass composition in a cohort of HIV infected patients on antiretroviral treatment**  
P. Vitiello<sup>1</sup>, C. Bertoni<sup>2</sup>, N. Squillace<sup>1</sup>, M. Rossi<sup>1</sup>, F. Sabbatini<sup>1</sup>, P. Columpsi<sup>1</sup>, A. Soria<sup>1</sup>, E. Colella<sup>1</sup>, M.G. Migliorino<sup>1</sup>, G. Lapadula<sup>1</sup>  
<sup>1</sup>Infectious Diseases Unit, S. Gerardo University Hospital, Monza, <sup>2</sup>Medical School, Bicocca University, Milan



## POSTER EXHIBITION

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

### P 162 Archi-Prevalent project. A National Register of color-Doppler ultrasonography of the epi-aortic vessels in Patients Living with HIV

S. Martini<sup>1</sup>, S. Ferrara<sup>2</sup>, C. Bellacosa<sup>3</sup>, B.M. Cesia<sup>4</sup>, A. Tartaglia<sup>2</sup>, P. Maggi<sup>1</sup>

<sup>1</sup>Università degli studi della Campania, Luigi Vanvitelli, <sup>2</sup>Università degli studi di Foggia, <sup>3</sup>Università degli Studi di Bari, <sup>4</sup>Università di Catania ARNAS Garibaldi

## Pediatric, adolescent, maternal, fetal aspects

### P 163 Rethinking the necessity of intrapartum zidovudine administration. A small case series from a single centre in the north of Italy

A. Di Biagio<sup>1,2</sup>, F. Briano<sup>2</sup>, R. Pincino<sup>2</sup>, N. Cusini<sup>3</sup>, D. Gerbaldo<sup>4</sup>, A. Allodi<sup>5</sup>, M. Bassetti<sup>1,2</sup>

<sup>1</sup>Infectious Diseases Unit, Policlinico San Martino Hospital, Genoa, <sup>2</sup>Department of Health Sciences (DISSAL), University of Genoa, <sup>3</sup>Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, <sup>4</sup>Department of Obstetrics and Gynecology, Policlinico San Martino Hospital, Genoa, <sup>5</sup>Neonatal Unit, Policlinico San Martino Hospital, Genoa

## Pharmacology, pharmacogenomics and drug interactions

### P 164 Antiviral activity of 1-(41-chlorophenyl)-4-(42-methylphenyl)-5,6,7,8-tetrahydro-2a,4a-diazacyclopenta[cd] azulene-2-carboxylic acid derivatives

S. Demchenko<sup>1</sup>, Yu. Fedchenkova<sup>2</sup>, O. Bagreeva<sup>2</sup>, A. Demchenko<sup>2</sup>

<sup>1</sup>Institute of Pharmacology and Toxicology of National Academy of Medical Sciences Ukraine, Kyiv, Ukraine, <sup>2</sup>Nizhyn Mykola Gogol State University, Nizhyn, Ukraine

### P 165 Antiviral activity of 6-(4-methylbenzyl)-3-arylamino-4H-[1,2,4]triazin-5-one derivatives against yellow fever

E. Novodvorskyi, I. Komarov

Institute of High Technologies Taras Shevchenko National University of Kyiv, Kyiv, Ukraine

### P 166 Dolutegravir, emtricitabine/tenofovir alafenamide fumarate absorption in a gastrectomized HIV-positive patient

C. Alcantarini, M. Ferrara, M. Tettoni, F. Lipani, S. Biffi, A. Di Stefano, M. Trunfio, A. Lazzaro, V. Avataneo, J. Cusato, A. De Nicolò, A. D'Avolio, A. Calcagno, G. Di Perri, S. Bonora

Unit of Infectious Diseases, Department of Medical Sciences, University of Turin

## Social and behavioural science, marginalized groups, community aspects and community surveys

### P 167 A survey as a chance of education on U=U in Italian general population

A. Perziano<sup>1</sup>, S. Patrucco<sup>1</sup>, G. Orofino<sup>2</sup>, P. Altini<sup>3</sup>, G.L. Ciperio<sup>1</sup>, C. Owen<sup>4</sup>

<sup>1</sup>Arcobaleno AIDS ODV, Torino, <sup>2</sup>Ospedale Amedeo di Savoia, Arcobaleno AIDS ODV, Torino, <sup>3</sup>Dipartimento di Scienze della Sanità Pubblica e Pediatriche, Arcobaleno AIDS ODV, Torino, <sup>4</sup>Dipartimento di Lingue e Letterature Straniere e Culture Moderne, Arcobaleno AIDS ODV, Torino

### P 168 Development and management of a web-based system able to collect and analyse data about self-diagnostics HIV test - ULISSE

C. Falanga, D. Mainieri, S. Negri

Anlaids Sezione Lombarda, Milan

### P 169 HIV prescriptive trend 2018 vs 2019 in a teaching hospital in Rome

G. Gambarelli<sup>1</sup>, R. De Feo<sup>1</sup>, R. Lobello<sup>1</sup>, C. Bolettieri<sup>1</sup>, L. Fiorito<sup>2</sup>, G. Gambarelli<sup>3</sup>

<sup>1</sup>A.O.U. Policlinico Umberto Primo Roma, <sup>2</sup>Università La Sapienza Uniroma1, <sup>3</sup>Ospedale S. Eugenio ASL Roma 2

### P 170 HAARTisticamente An unusual fashion show

A. Infante

Policlinico Tor Vergata di Roma

### P 171 "La prevenzione va in tournée" a social experiment and on the field experience on HIV/STIs and social integration

S. Nasta<sup>1</sup>, C. Nicoara<sup>2</sup>, M. Oddo<sup>3</sup>

<sup>1</sup>TrinArt ONLUS, Castellammare Del Golfo, <sup>2</sup>NPS ONLUS Sicily, Palermo, <sup>3</sup>Università degli Studi di Palermo, Palermo





## POSTER EXHIBITION

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

- P 172 Mono-symptomatic therapeutical group for Chemsex users - an ongoing experience**  
G. Fracca, M. Manfredini  
Asa Milano Onlus, Milano
- P 173 HIV rapid testing outside healthcare facilities: diagnostic and educational tool**  
P. Meli<sup>1</sup>, M. Messina<sup>2</sup>, P. Pesenti Bolognini<sup>3</sup>, M. Arlati<sup>4</sup>, M. Gotti<sup>5</sup>, R. Carissoli<sup>6</sup>, F. Maggiolo<sup>6</sup>  
<sup>1</sup>Caritas Bergamasca & Comunità Emmaus, <sup>2</sup>Consiglio di Rappresentanza dei Sindaci & Assessorato alle Politiche Sociali del Comune di Bergamo, <sup>3</sup>Croce Rossa Italiana - Comitato di Bergamo OdV, <sup>4</sup>ARCIGAY & Cives ARCIGAY Bergamo, <sup>5</sup>Associazione La Melarancia, <sup>6</sup>ASST Papa Giovanni XXIII, Bergamo
- P 174 Changes in causes of death of people living with HIV in a large teaching hospital in Rome**  
D. Farinacci<sup>1</sup>, A. Ciccullo<sup>1</sup>, A. Dusina<sup>1</sup>, A. D'Angelillo<sup>1</sup>, D. Moschese<sup>1</sup>, C. Picarelli<sup>1</sup>, A. Borghetti<sup>2</sup>, S. Di Giambenedetto<sup>1,2</sup>  
<sup>1</sup>Istituto di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, <sup>2</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
- P 175 The PLWH perception of long acting injectable therapy**  
F. von Schloesser, A. Bove, L. Giacomi, D. Osorio, M. Martini  
NADIR onlus, Rome
- P 176 Cohort observational study and HIV brochure in a teaching hospital in Rome**  
G. Gambarelli<sup>1</sup>, R. Lobello<sup>1</sup>, R. De Feo<sup>1</sup>, C. Bolettieri<sup>1</sup>, L. Fiorito<sup>2</sup>, G. Gambarelli<sup>3</sup>  
<sup>1</sup>Azienda Universitaria Policlinico Umberto 1, Roma, <sup>2</sup>Uniroma1 La Sapienza, Roma, <sup>3</sup>Ospedale S.Eugenio ASL Roma 2, Roma
- P 177 HIV Self-Testing in Italy: a usability survey of clients using self-tests at two community organisations**  
M. Maffeo<sup>1,2</sup>, M.L. Cosmaro<sup>2</sup>, M. Kall<sup>3</sup>, S. Nash<sup>3</sup>  
<sup>1</sup>Scuola di Specializzazione in Igiene e Medicina Preventiva - Università degli Studi Milano Statale, <sup>2</sup>Fondazione Lega Italiana per la Lotta contro l'AIDS - LILA Milano, <sup>3</sup>Public Health England
- P 178 Counselling and HIV rapid test for marginalized groups: data from an Emilia-Romagna Region project\***  
D. Segala<sup>1</sup>, A. Zannini<sup>2</sup>, B. Cantarelli<sup>3</sup>, A. Giannini<sup>4</sup>, G. Mattei<sup>4</sup>, R. Cultrera<sup>5</sup>, L. Sighinolfi<sup>1</sup>  
<sup>1</sup>Infectious Disease Dept. Ferrara, <sup>2</sup>Addiction treatment service-AUSL Reggio Emilia, <sup>3</sup>Addiction treatment service -AUSL Parma, <sup>4</sup>Prevention and Public Health Dept. Regione Emilia Romagna, <sup>5</sup>Infectious Disease Clinic Ferrara  
\*Regional project DGR 1698/2015
- P 179 School and HIV. Cognitive and Emotional aspects for effective communication**  
F. Rossi, A. Bianchi, M. Manfredini, D. Pennisi, D. Zagato, M. Pierini, R. Repposi, E. Garavaglia, M. Cernuschi  
ASA ONLUS -Associazione Solidarietà AIDS- Milano
- P 180 Sardinia, first ever institutional Hiv testing and TasP promotion campaign: the communication strategy of Lila Cagliari team**  
S. Campus, G. Dessi, B. Mocchi, A. Pontis  
Lila Cagliari, Cagliari
- P 181 "TEST WITH THE STAR": a pre-counselling "dog assistance" pilot project during HIV-HCV screening campaign "1st December World AIDS Day. Communities make the difference. Union makes the difference! HIV LATINA CHALLENGE 2019. U = U"**  
V. Belvisi<sup>1</sup>, G. Stella<sup>2</sup>, R. Marocco<sup>1</sup>, V.S. Mercurio<sup>1</sup>, B. Kertusha<sup>1,2</sup>, L. Fondaco<sup>1,2</sup>, A. Curtolo<sup>1,2</sup>, P. Zuccalà<sup>1,2</sup>, A. Carraro<sup>1,2</sup>, M. D'Achille<sup>1</sup>, V. Rossi<sup>1</sup>, M. Lichtner<sup>1,2</sup>  
<sup>1</sup>Infectious Diseases Unit, S.M. Goretti Hospital, Latina, <sup>2</sup>"Sapienza" University, Rome, <sup>3</sup>"Star Golden" E.N.C.I - F.C.I. Golden Retriever Breeding Centre, Nemi
- P 182 Test, condom and chems: how the habits of people in Milan change. A test experience in a premise**  
A. Bianchi<sup>1</sup>, F.M. Esposito<sup>1</sup>, G. Fissore<sup>1</sup>, A. Antonino<sup>1</sup>, G. Fracca<sup>1</sup>, M. Lanza<sup>1</sup>, F. Rossi<sup>1</sup>, R. Repposi<sup>1</sup>, P. Testoni<sup>1</sup>, D. Zagato<sup>1</sup>, S. Bossolasco<sup>2</sup>, M. Cernuschi<sup>1,2</sup>  
<sup>1</sup>ASA, Associazione Solidarietà AIDS Onlus, Milan, Italy, <sup>2</sup>San Raffaele Hospital, Milan, Italy
- P 183 Coming out surrealista**  
A. Infante, L. Caponera  
Policlinico Tor Vergata di Roma
- P 184 App as tool for Prevention among students: the launch of a new counselling service about HIV/STIs promoted by Anlaids Onlus**  
M. Pedretti<sup>1</sup>, E. Zambon<sup>2</sup>, A. Chinelli<sup>3</sup>, A. Venturini<sup>4</sup>, R. Galipò<sup>5</sup>, V. Calvino<sup>6</sup>, B. Marchini<sup>7</sup>  
<sup>1</sup>Anlaids Lombardia, Milano, <sup>2</sup>Anlaids Lombardia, Milano, <sup>3</sup>Anlaids Liguria, Genova, <sup>4</sup>Anlaids Liguria, Genova, <sup>5</sup>Anlaids Lazio, Roma, <sup>6</sup>Anlaids Onlus, Roma, <sup>7</sup>Anlaids Onlus, Roma
- P 185 PrEP between desire and needing: 2020 update**  
D. Pavia<sup>1</sup>, L. Gozzi<sup>1</sup>, A. Toscano<sup>1</sup>, E. Bacca<sup>1,2</sup>, G. Cuomo<sup>1,2</sup>, A. Bignardi<sup>3</sup>  
<sup>1</sup>Arcigay Modena "Matthew Shepard" (ODV), Modena, Italy, <sup>2</sup>Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliero Universitaria, Modena, Italy, <sup>3</sup>Arcigay APS, Bologna, Italy



## POSTER EXHIBITION

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

- P 186 Free anonymous HIV Testing and linkage to care activities: data from the Milano Check Point**  
*D. Calzavara<sup>1,2</sup>, A. Tavelli<sup>1,3</sup>, A. De Bona<sup>1,3</sup>, R. Rossotti<sup>1,2,4</sup>, D. De Cia<sup>1,5</sup>, I. Gotti<sup>1,5</sup>, M. Massa<sup>1,5</sup>, C. Raddato<sup>1,6</sup>, R. Repossi<sup>1,7</sup>, J. C. Ritchie<sup>1,2</sup>, D. Savarino<sup>1,8</sup>, A. Soldano<sup>1,2</sup>, A. d'Arminio Monforte<sup>1,3</sup>, L. Cosmaro<sup>1,8</sup>, M. Cernuschi<sup>1,6,7</sup> for the Milano Checkpoint group*  
<sup>1</sup>Associazione Milano Check Point, Milan, Italy, <sup>2</sup>Centro d'Iniziativa Gay – Arcigay Milano Onlus, Milan, Italy, <sup>3</sup>Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Italy, <sup>4</sup>Infectious Disease Department ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>5</sup>Anlaidi Sezione Lombardia, Milan, Italy, <sup>6</sup>Department of Infectious Diseases, San Raffaele Scientific Institute, Italy, <sup>7</sup>ASA - Associazione Solidarietà AIDS Onlus, Milan, Italy, <sup>8</sup>Fondazione LILA Milano Onlus, Milano
- P 187 Pleasure and sociality as drivers of chemsex among Italian gay men living with HIV**  
*C. Di Felicianantonio*  
Manchester Metropolitan University & University of Leicester (UK)
- P 188 The multidisciplinary (MD) HPV group in Azienda Ospedaliera Universitaria Pisana (AOUP). Impact of HIV-HPV synergy. Preliminary data analysis**  
*P. Mazzetti<sup>1</sup>, E. Balestri<sup>1</sup>, S. Verdenelli<sup>2</sup>, L. DelBono<sup>2</sup>, C. Menconi<sup>3</sup>, I. Marchetti<sup>4</sup>, V. Seccia<sup>5</sup>, C. Cambi<sup>5</sup>, P. Cattano<sup>6</sup>, F. Maggi<sup>1</sup>, S. Esin<sup>7</sup>, A. Gallo<sup>8</sup>, A.G. Naccarato<sup>4</sup>, G. Naldini<sup>3</sup>, F. Menichetti<sup>2</sup>, M. Pistello<sup>1</sup>*  
<sup>1</sup>Virologia AOUP; <sup>2</sup>UO Malattie Infettive AOU Pisa, <sup>3</sup>SOD Chirurgia Proctologica e Perineale AOUP, <sup>4</sup>UO Anatomia Patologica 1 AOUP, <sup>5</sup>ORL 1 Universitaria AOUP, <sup>6</sup>UO Urologia Universitaria AOUP, <sup>7</sup>SOD Microbiologia batteriologica AOUP, <sup>8</sup>UOC Igiene e Sanità Pubblica Azienda USL Toscana Nord Ovest
- P 189 HIV and STIs amongst MSM in Italy: data from the EMIS 2017 survey**  
*M. Cordioli<sup>1</sup>, L. Gios<sup>1</sup>, M.L. Cosmaro<sup>2</sup>, M. Breveglieri<sup>3</sup>, F.M. Nimbi<sup>4</sup>, G.M. Corbelli<sup>5</sup>, N. Sherriff<sup>6</sup>, M. Mirandola<sup>1,6</sup>*  
<sup>1</sup>UOC di Malattie Infettive e Tropicali, Dipartimento di Diagnostica e Sanità Pubblica, Università di Verona / Infectious Diseases Section, Diagnostics and Public Health Department, University of Verona, <sup>2</sup>Fondazione Lega Italiana per la Lotta contro l'AIDS – LILA Milano, <sup>3</sup>Arcigay, <sup>4</sup>Dept of Dynamic and Clinical Psychology, Sapienza University of Rome, <sup>5</sup>Plus Network persone LGBT sieropositive, <sup>6</sup>School of Health Sciences, University of Brighton, Brighton, UK
- P 190 Never Infected. Perception of the Risk of HIV Infection in Case of Undetectable Virus**  
*F. Corbisiero<sup>1</sup>, C. Urciuoli<sup>1</sup>, E. Zito<sup>1</sup>, M. Cotugno<sup>2</sup>, F. Borrelli<sup>2</sup>, G. Di Filippo<sup>2</sup>*  
<sup>1</sup>Dipartimento di Scienze Sociali dell'Università degli studi di Napoli Federico II, Naples, <sup>2</sup>Unità Ospedaliera Complesse Malattie Infettive Azienda Ospedaliera Universitaria Federico II, Naples
- P 191 Linkage to care in HIV: the point of view of people with recent diagnosis**  
*P. Piselli<sup>1</sup>, C. Cimaglia<sup>1</sup>, L. Rancilio<sup>2</sup>, P. Meli<sup>3</sup>, M. Farinella<sup>4</sup>, E. Teti<sup>5</sup>, V. Calvino<sup>6</sup>, G.M. Corbelli<sup>7</sup>, M. Stagnitta<sup>8</sup>, M. Errico<sup>9</sup>, F. von Schloesser<sup>10</sup>, M. Breviglieri<sup>11</sup>, A. Caraglia<sup>12</sup>, M. Oldrini<sup>13</sup>, E. Girardi<sup>1</sup> for the project "Linkage to Care in HIV: a further piece to the analysis of continuum of care in HIV in Italy"*  
<sup>1</sup>INMI "L. Spallanzani" IRCCS, Rome, <sup>2</sup>Caritas Ambrosiana, Milan, <sup>3</sup>CICA, <sup>4</sup>Circolo Mario Mieli, Rome, <sup>5</sup>Fondazione Villa Maraini, Rome, <sup>6</sup>Anlaidi, <sup>7</sup>PLUS, rete persone LGBT+ sieropositive, <sup>8</sup>CNCA, <sup>9</sup>NPS Italia, <sup>10</sup>Nadir, <sup>11</sup>Arcigay, <sup>12</sup>Minister of Health, <sup>13</sup>LILA, Milan
- P 192 AIDS and other sexually transmitted diseases: what do young people know? – a Cross Sectional Study**  
*S. Francescon, L. Pisano, A. Zanovello, F. Lacarbonara, D. Gregori, M. Martinato*  
Servizio Clinical Trials e Biometria - Università degli Studi di Padova, Padova PD
- P 193 Prevalence and risk factors associated with new diagnosis of STI in individuals attending an in-hospital STI clinic**  
*G. Mulé, D. Tesoro, L. Gazzola, A. Tavelli, G. Ancona, S. Cianciola, P. Tonietti, K. Reister, R. Castoldi, M. Allegrini, A. De Bona, A. d'Arminio Monforte*  
Department of Health Science, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, Italy
- P 194 SRHR Sensitization and Education activities from Medical Students**  
*E. Clemente, M. Garbarini*  
Anlaidi, Milan; Fondazione The Bridge, Milan; HIV Coalition, Milan
- P 195 "Senza la C" - HCV diagnosis and treatment for people who inject drugs in a community-based setting: results from an experience in Bologna**  
*B. Granozzi<sup>2</sup>, L. Badia<sup>2</sup>, D. Testi<sup>2</sup>, E. Rosselli Del Turco<sup>2</sup>, V. Guardigni<sup>2</sup>, G.M. Corbelli<sup>1</sup>, S. Mattioli<sup>1</sup>, G. Verucchi<sup>2</sup>, P. Viale<sup>2</sup>, S. Pieralli<sup>3</sup>*  
<sup>1</sup>Plus onlus, Bologna, <sup>2</sup>Policlinico S. Orsola-Malpighi - Dipartimento di Malattie infettive, Bologna, <sup>3</sup>Open Group, Bologna
- P 196 WE TEST - National community-based HIV prevention program**  
*R. Dartenuc<sup>1</sup>, D. Zagato<sup>2</sup>*  
<sup>1</sup>ARCO - Associazione Ricreativa Circoli Omosessuali, <sup>2</sup>ASA - Associazione Solidarietà AIDS Milano



## POSTER EXHIBITION

12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research

12-16 ottobre 2020 DIGITAL EDITION

### Vaccines

- P 197 Anti-body response to pneumococcal vaccination in HIV patient after supplementation with probiotic**  
M. Pontalillo, A. Auricchio, L. Caiazza, A. Brandimarte, K. Falasca, C. Ucciferri, F. Vignale, J. Vecchiet  
Clinic of Infectious Diseases, "G. d'Annunzio" University Chieti-Pescara, Chieti, Italy
- P 198 Adherence to the influenza vaccination campaign: experience of a large clinical center**  
D. Moschese<sup>1</sup>, A. Ciccullo<sup>1</sup>, A. Borghetti<sup>2</sup>, F. Lombardi<sup>1</sup>, A. Dusina<sup>1</sup>, C. Picarelli<sup>1</sup>, D. Farinacci<sup>1</sup>, A. D'Angelillo<sup>1</sup>, E. Visconti<sup>1,2</sup>, E. Tamburrini<sup>1,2</sup>, S. Di Giambenedetto<sup>1,2</sup>  
<sup>1</sup>Sezione di Malattie Infettive - Dipartimento di Sicurezza e Bioetica - Università Cattolica del Sacro Cuore, Roma, Italia, <sup>2</sup>UOC di Malattie Infettive - Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Roma, Italia
- P 199 HPV oral infection and clearance in Men who have Sex with Men and Transgender Women undergoing nonavalent vaccination: preliminary results from an interventional study**  
R. Rossotti<sup>1</sup>, A. Nava<sup>2</sup>, M.C. Moiola<sup>1</sup>, C. Baiguera<sup>1</sup>, D. Fanti<sup>2</sup>, M. Merli<sup>1</sup>, M. Cernuschi<sup>2</sup>, L. Colagrossi<sup>2</sup>, S. Bossolasco<sup>3</sup>, A. Tamburini<sup>4</sup>, C.F. Perno<sup>2,5</sup>, M. Puoti<sup>1</sup>  
<sup>1</sup>Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, <sup>2</sup>Chemical-Clinical and Microbiological Analysis, ASST Grande Ospedale Metropolitano Niguarda, Milan, <sup>3</sup>Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, <sup>4</sup>Gastrointestinal Surgery, IRCCS San Raffaele Scientific Institute, Milan, <sup>5</sup>Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan
- P 200 Immunization status in a pediatric transplanted cohort: the Federico II teaching hospital experience**  
C. Resnati<sup>1,2</sup>, F. Di Dato<sup>3</sup>, F. Manco<sup>1</sup>, R. Iorio<sup>3</sup>, M. Cataldi<sup>1</sup>  
<sup>1</sup>Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Università degli Studi di Napoli Federico II, Napoli, <sup>2</sup>Scuola di Specializzazione in Farmacologia e Tossicologia Clinica; Università degli Studi della Campania "L. Vanvitelli", Napoli, <sup>3</sup>Dipartimento di Scienze Mediche Traslazionali, Sezione di Pediatria, Università degli Studi di Napoli Federico II, Napoli
- P 201 Vaccination knowledge, attitudes and practices in patients with HIV: a cross-sectional survey**  
G. Orofino<sup>1</sup>, C. Alcantarini<sup>2</sup>, F. Bert<sup>4</sup>, E. Boietti<sup>3</sup>, A. Corradi<sup>3</sup>, M. Farenga<sup>1</sup>, M.R. Gualano<sup>1</sup>, S. Rousset<sup>1</sup>, S. Carosella<sup>1</sup>, M. Guastavigna<sup>1</sup>, M.C. Tettoni<sup>2</sup>, G. Voglino<sup>3</sup>, R. Siliquini<sup>3</sup>  
<sup>1</sup>Division A of Infectious Diseases, Amedeo di Savoia Hospital, Turin, Italy, <sup>2</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy, <sup>3</sup>Department of Public Health Sciences, University of Turin, Turin, Italy, <sup>4</sup>Molinetto Hospital, City of Health and Science of Turin, Turin, Italy
- P 202 Success rate and evolution of immunological parameter over first vaccination against HBV with Fendrix® in People Living with HIV**  
C. Davoli, M. Mazzitelli, G. Greco, F. Serapide, P. Fusco, V. La Gamba, R. Lionello, V. Scaglione, C. Costa, V. Pisani, E.M. Trecarichi, C. Torti  
Infectious and Tropical Disease Unit, "Magna Graecia University", Catanzaro, Italy
- P 203 Organization of a dedicated vaccination service for HIV-positive patients, Pre-Exposure Prophylaxis (PrEP) users, and patients in care for sexually transmitted infections (STIs): the experience of S.M. Annunziata Hospital, Florence**  
E. Salomoni<sup>1</sup>, P. Zagli<sup>2</sup>, F. Vichi<sup>1</sup>, A. Degli Esposti<sup>1</sup>, P. Pierotti<sup>1</sup>, F. Baragli<sup>1</sup>, S. Esperti<sup>1</sup>, P. Blanc<sup>1</sup>  
<sup>1</sup>S.O.C. Malattie Infettive 1, Ospedale Santa Maria Annunziata, Firenze - Azienda USL Toscana Centro, <sup>2</sup>U.O. Assistenza Sanitaria, Dipartimento della Prevenzione - Azienda USL Toscana Centro



12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research  
12-16 ottobre 2020 **DIGITAL EDITION**

Reach out  
for including all

# ICAR 2020 SPECIAL AWARDS

The work of young researchers continues to be widely recognized by ICAR, always attentive to the progress of knowledge. The 12<sup>th</sup> edition of ICAR Congress therefore aims to reward young investigators through the following awards:



## ICAR-CROI Awards 2020

This year the absolute winners among the young Italian investigators who deserved to present their work at CROI 2020 will win:

**1 Award of 1.000,00** for the best work in **Clinical**

**1 Award of 1.000,00** for the best work in **Basic Science**

**Winners will be announced during the ICAR 2020 Special Awards Session, scheduled in Plenary Room, on Friday October 16, from 18.20.**



## ICAR 2020 Scientific Committee Awards

The 12<sup>th</sup> ICAR Chairs and Scientific Secretariat will recognize the “**Scientific Committee Awards**”, the ICAR awards for the best abstracts sent by young researchers:

**3 Awards** of 1.000,00 each one for the best abstracts sent by young researchers in for the topics **Clinical (1), Basic Science (1) and Social Science (1)**.

**Winners will be announced during the ICAR 2020 Special Awards Session, scheduled in Plenary Room, on Friday October 16, from 18.20.**



## SIMIT Special Awards

The 12<sup>th</sup> ICAR Chairs, Scientific Secretariat and Organizing Secretariat wish to thank SIMIT for the Special Awards addressed to Young Investigators:

**5 Awards** of €1.000,00 each for the best abstracts accepted as **Oral Communications** in **Clinical HIV (3 Awards), Clinical HCV (1 Award), Virology and Immunopathogenesis (1 Award)**, presented by young Investigators (under 45 aa), regularly registered to SIMIT for years 2019 and 2020.

**Abstracts will be selected by a dedicated SIMIT Commission and winners will be announced during the ICAR 2020 Special Awards Session, scheduled in Plenary Room, on Friday October 16, from 18.20.**





12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research  
12-16 ottobre 2020 **DIGITAL EDITION**

*Reach out  
for including all*

## ICAR FOR PARTICIPANTS



### ICAR 2020 Virtual lobby for a direct access to:

Meeting Rooms, Community Village, Booths, Hospitality Suite, Congress bag and all services for participants



12° CONGRESSO NAZIONALE  
Italian Conference on AIDS and Antiviral Research  
12-16 ottobre 2020 **DIGITAL EDITION**

Reach out  
for including all

## ICAR FOR PARTICIPANTS



### RaccontART HIV

The art competition launched by ICAR to students who are invited to present their views on HIV/AIDS through various forms of expression. During the Conference Opening Session, the winners will be awarded by the Jury composed of leading representatives of the national cultural world, ICAR Scientific Coordinators and Patients' Community.

*Realizzato con il contributo di Janssen*



### La App di ICAR 2020

The art competition launched by ICAR to students who are invited to present their views on HIV/AIDS through various forms of expression. Designed to facilitate participation in ICAR 2020 and to respond to request for effective and high-performance digital tools and supports. Two simple steps to access:

1. **Download the ICAR App for free** from the main markets (Apple Store and Google Play) "Minimum system requirements required for the App: Android 7.0 and iOS 10"
2. **Login App:** enter your personal login credentials (username e password) sent to you by the Organizing Secretariat Effetti

*Realizzato con il contributo di Janssen*



### Virtual Community Village

A specific virtual area dedicated to the Community Village: a meeting point for all the participants to visit the booths of HIV/AIDS and Hepatitis patient associations.

*Con la sponsorizzazione non condizionante di Theratechnologies*





12° CONGRESSO NAZIONALE  
**Italian Conference on AIDS and Antiviral Research**  
12-16 ottobre 2020 **DIGITAL EDITION**

Reach out  
for including all

## ICAR FOR PARTICIPANTS



### Poster-4-you

A free service for selected posters' Authors to create their own posters and record their own comments. Posters can be downloaded at the virtual booth Gilead Sciences.

*Con la sponsorizzazione non condizionante di Gilead Sciences*



### Digital Abstract Book

All registered participants can download the ICAR Digital Abstract Book at the virtual booth ViiV Healthcare: it contains all accepted abstracts.

*Con il supporto incondizionato di ViiV Healthcare*



### ICAR Journal

Four special editions of ICAR Daily Journal, the real-time newspaper of the Congress" (from Tuesday to Friday), in the form of articles, interviews and highlights from the different sessions and from the voice of Opinion Leaders.

It's published daily in digital version on the Congress portal [www.icar2020.it](http://www.icar2020.it) and notified to all participants

*Con la sponsorizzazione non condizionante di Gilead Sciences*



### ICAR On-Demand and Web Repository

After the Congress, the ICAR official website ([www.icar2020.it](http://www.icar2020.it)) will publish the podcasts with the audio-video recorded sessions and the web repository with abstracts, presentations, oral communications, accepted posters.

*Con la sponsorizzazione non condizionante di Gilead Sciences*



*Reach out  
for including all*

## THANKS TO THE SPONSORS

The Chairs, the Scientific Secretariat and CME Provider wish to thank the following Companies for the support given to the Congress, as unrestricted educational grants:

---

### PLATINUM



---

### GOLD



---

### SILVER



---

### OTHER







12° CONGRESSO NAZIONALE



Italian Conference on  
AIDS and Antiviral Research

Provider e Segreteria Organizzativa

**Effetti srl**

Via G.B. Giorgini 16, 20151 Milano

Tel. +39 02 3343281

Fax +39 02 38002105

icar2020@effetti.it

@ICARcongress



[www.icar2020.it](http://www.icar2020.it)

Seguici su:   #ICAR2020